{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "b638d7fe-b105-4c91-9223-8ee7c2ab515a",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "[NbConvertApp] Converting notebook trials_to_graph.ipynb to script\n",
      "[NbConvertApp] Writing 22171 bytes to trials_to_graph.py\n"
     ]
    }
   ],
   "source": [
    "from geopy.geocoders import Nominatim\n",
    "from geopy.extra.rate_limiter import RateLimiter\n",
    "import hashlib, json, os\n",
    "from IPython.display import HTML\n",
    "from collections import defaultdict\n",
    "import requests, time\n",
    "import folium, json, hashlib\n",
    "from folium.plugins import MarkerCluster\n",
    "import datetime\n",
    "from trials_to_graph import convert_and_render"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "87765d40-eff5-406f-bd0e-8445742a9827",
   "metadata": {},
   "outputs": [],
   "source": [
    "run_date = datetime.date.today().strftime(\"%Y-%m-%d\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "b37417f1-762c-4423-87b1-ba3e9eb779ed",
   "metadata": {},
   "outputs": [],
   "source": [
    "_GEOCODER = None\n",
    "_CACHE_PATH = os.path.expanduser(\"~/.ctgov_geocode_cache.json\")\n",
    "try:\n",
    "    with open(_CACHE_PATH, \"r\") as f:\n",
    "        _GEO_CACHE = json.load(f)\n",
    "except:\n",
    "    _GEO_CACHE = {}\n",
    "\n",
    "def _save_cache():\n",
    "    try:\n",
    "        with open(_CACHE_PATH, \"w\") as f:\n",
    "            json.dump(_GEO_CACHE, f)\n",
    "    except:\n",
    "        pass\n",
    "\n",
    "def _geocoder():\n",
    "    global _GEOCODER\n",
    "    if _GEOCODER is None:\n",
    "        # Nominatim requires a unique user_agent; use something identifiable\n",
    "        _GEOCODER = Nominatim(user_agent=\"ctgov_mapper_tim_robinson/1.0\")\n",
    "        # be gentle: 1 call per second\n",
    "        _GEOCODER.rate_limiter = RateLimiter(_GEOCODER.geocode, min_delay_seconds=1)\n",
    "    return _GEOCODER\n",
    "\n",
    "def geocode_addr(addr_dict):\n",
    "    \"\"\"\n",
    "    addr_dict: {\"facility\": \"...\", \"city\":\"...\", \"state\":\"...\", \"country\":\"...\"}\n",
    "    Returns (lat, lon) or (None, None)\n",
    "    \"\"\"\n",
    "    parts = [\n",
    "        addr_dict.get(\"facility\"),\n",
    "        addr_dict.get(\"city\"),\n",
    "        addr_dict.get(\"state\"),\n",
    "        addr_dict.get(\"country\"),\n",
    "    ]\n",
    "    q = \", \".join([p for p in parts if p])\n",
    "    if not q:\n",
    "        return None, None\n",
    "\n",
    "    key = hashlib.sha1(q.encode(\"utf-8\")).hexdigest()\n",
    "    if key in _GEO_CACHE:\n",
    "        return _GEO_CACHE[key]\n",
    "\n",
    "    try:\n",
    "        loc = _geocoder().rate_limiter(q)\n",
    "        if loc:\n",
    "            res = (loc.latitude, loc.longitude)\n",
    "        else:\n",
    "            res = (None, None)\n",
    "        _GEO_CACHE[key] = res\n",
    "        _save_cache()\n",
    "        return res\n",
    "    except Exception:\n",
    "        return None, None\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "892a4962-886f-4865-938f-b3c53ae9aed7",
   "metadata": {},
   "outputs": [],
   "source": [
    "BASE = \"https://clinicaltrials.gov/api/v2/studies\"\n",
    "\n",
    "# keep this list tight; add fields only as you use them\n",
    "FIELDS = [\n",
    "  \"protocolSection.identificationModule.nctId\",\n",
    "  \"protocolSection.identificationModule.briefTitle\",\n",
    "  \"protocolSection.statusModule.overallStatus\",\n",
    "  \"protocolSection.designModule.studyType\",\n",
    "  \"protocolSection.designModule.phases\",\n",
    "  \"protocolSection.statusModule.startDateStruct\",\n",
    "  \"protocolSection.statusModule.completionDateStruct\",\n",
    "  \"protocolSection.conditionsModule.conditions\",\n",
    "  \"protocolSection.armsInterventionsModule.interventions\",\n",
    "  \"protocolSection.sponsorCollaboratorsModule.leadSponsor\",\n",
    "  \"protocolSection.contactsLocationsModule.locations\",\n",
    "  \"protocolSection.eligibilityModule.eligibilityCriteria\"\n",
    "]\n",
    "\n",
    "def fetch_studies_by_condition(cond_term: str, page_size=100, max_pages=50):\n",
    "  \"\"\"\n",
    "  Use the v2 structured condition filter (query.cond),\n",
    "  so only studies that *list* this disease as a condition are returned.\n",
    "  \"\"\"\n",
    "  token = None\n",
    "  for _ in range(max_pages):\n",
    "    params = {\n",
    "      \"format\": \"json\",\n",
    "      \"pageSize\": page_size,\n",
    "      \"fields\": \",\".join(FIELDS),\n",
    "      \"query.cond\": cond_term,     # <- key change here\n",
    "      \"countTotal\": \"true\"\n",
    "    }\n",
    "    if token:\n",
    "      params[\"pageToken\"] = token\n",
    "\n",
    "    r = requests.get(BASE, params=params, timeout=30)\n",
    "    r.raise_for_status()\n",
    "    data = r.json()\n",
    "\n",
    "    for study in data.get(\"studies\", []):\n",
    "      yield study\n",
    "\n",
    "    token = data.get(\"nextPageToken\")\n",
    "    if not token:\n",
    "      break\n",
    "    time.sleep(0.2)  # be polite\n",
    "\n",
    "def _extract_addr_geo(loc: dict):\n",
    "  \"\"\"Resilient extraction for address + geoPoint from a locations item.\"\"\"\n",
    "  if not isinstance(loc, dict):\n",
    "    return {}, {}\n",
    "  facility = loc.get(\"facility\")\n",
    "  location = facility.get(\"location\") if isinstance(facility, dict) else None\n",
    "  if not isinstance(location, dict):\n",
    "    location = loc.get(\"location\") if isinstance(loc.get(\"location\"), dict) else {}\n",
    "  addr = location.get(\"address\") if isinstance(location.get(\"address\"), dict) else {}\n",
    "  geo  = location.get(\"geoPoint\") if isinstance(location.get(\"geoPoint\"), dict) else {}\n",
    "  if not geo and isinstance(loc.get(\"geoPoint\"), dict):\n",
    "    geo = loc[\"geoPoint\"]\n",
    "  return addr, geo\n",
    "\n",
    "def to_features(study, enable_geocoding=True):\n",
    "    ps   = study.get(\"protocolSection\", {}) or {}\n",
    "    idm  = ps.get(\"identificationModule\", {}) or {}\n",
    "    stat = ps.get(\"statusModule\", {}) or {}\n",
    "    des  = ps.get(\"designModule\", {}) or {}\n",
    "    cond = ps.get(\"conditionsModule\", {}) or {}\n",
    "    arms = ps.get(\"armsInterventionsModule\", {}) or {}\n",
    "    spon = ps.get(\"sponsorCollaboratorsModule\", {}) or {}\n",
    "    locs = (ps.get(\"contactsLocationsModule\", {}) or {}).get(\"locations\") or []\n",
    "\n",
    "    nct    = idm.get(\"nctId\")\n",
    "    title  = idm.get(\"briefTitle\") or idm.get(\"officialTitle\")\n",
    "    status = stat.get(\"overallStatus\")\n",
    "    phases = des.get(\"phases\") or []\n",
    "    conds  = cond.get(\"conditions\") or []\n",
    "    inters = arms.get(\"interventions\") or []\n",
    "    sponsor = (spon.get(\"leadSponsor\") or {}).get(\"name\")\n",
    "\n",
    "    for loc in locs:\n",
    "        if not isinstance(loc, dict):\n",
    "            continue\n",
    "        # address + geo extraction\n",
    "        facility = loc.get(\"facility\")\n",
    "        location = facility.get(\"location\") if isinstance(facility, dict) else None\n",
    "        if not isinstance(location, dict):\n",
    "            location = loc.get(\"location\") if isinstance(loc.get(\"location\"), dict) else {}\n",
    "        addr = location.get(\"address\") if isinstance(location.get(\"address\"), dict) else {}\n",
    "        geo  = location.get(\"geoPoint\") if isinstance(location.get(\"geoPoint\"), dict) else {}\n",
    "        if not geo and isinstance(loc.get(\"geoPoint\"), dict):\n",
    "            geo = loc[\"geoPoint\"]\n",
    "\n",
    "        lat, lon = geo.get(\"lat\"), geo.get(\"lon\")\n",
    "\n",
    "        # if no geoPoint, try geocoding from address (facility/city/state/country)\n",
    "        addr_out = {\n",
    "            \"facility\": (loc.get(\"facility\") or {}).get(\"name\") if isinstance(loc.get(\"facility\"), dict) else None,\n",
    "            \"city\": addr.get(\"city\"),\n",
    "            \"state\": addr.get(\"state\"),\n",
    "            \"country\": addr.get(\"country\"),\n",
    "        }\n",
    "        if (lat is None or lon is None) and enable_geocoding:\n",
    "            lat, lon = geocode_addr(addr_out)\n",
    "\n",
    "        if lat is None or lon is None:\n",
    "            continue  # still nothing, skip\n",
    "\n",
    "        yield {\n",
    "            \"type\": \"Feature\",\n",
    "            \"geometry\": {\"type\": \"Point\", \"coordinates\": [float(lon), float(lat)]},\n",
    "            \"properties\": {\n",
    "                \"nctId\": nct,\n",
    "                \"title\": title,\n",
    "                \"status\": status,\n",
    "                \"phases\": phases,\n",
    "                \"conditions\": conds,\n",
    "                \"interventions\": inters,\n",
    "                \"sponsor\": sponsor,\n",
    "                \"address\": addr_out,\n",
    "                \"url\": f\"https://clinicaltrials.gov/study/{nct}\",\n",
    "            },\n",
    "        }\n",
    "\n",
    "\n",
    "def run(disease_term: str):\n",
    "    disease_lc = disease_term.lower()\n",
    "    features = []\n",
    "    allowed_status = {\"NOT_YET_RECRUITING\", \"RECRUITING\", \"ACTIVE_NOT_RECRUITING\"}\n",
    "\n",
    "    for s in fetch_studies_by_condition(disease_term):\n",
    "        ps = s.get(\"protocolSection\", {}) or {}\n",
    "\n",
    "        # --- Filter: must be Interventional ---\n",
    "        design = ps.get(\"designModule\", {}) or {}\n",
    "        if design.get(\"studyType\", \"\").upper() != \"INTERVENTIONAL\":\n",
    "            continue\n",
    "\n",
    "        # --- Filter: trial status ---\n",
    "        status = (ps.get(\"statusModule\", {}) or {}).get(\"overallStatus\", \"\").upper()\n",
    "        if status not in allowed_status:\n",
    "            continue\n",
    "\n",
    "        # --- Filter: disease must be in structured conditions ---\n",
    "        conds = (ps.get(\"conditionsModule\") or {}).get(\"conditions\") or []\n",
    "        if not any(disease_lc in (c or \"\").lower() for c in conds):\n",
    "            continue\n",
    "\n",
    "        # --- Optional extra guard against exclusion-only mentions ---\n",
    "        elig_text = ((ps.get(\"eligibilityModule\") or {}).get(\"eligibilityCriteria\") or \"\").lower()\n",
    "        if \"exclusion\" in elig_text and disease_lc in elig_text and not conds:\n",
    "            continue\n",
    "\n",
    "        features.extend(list(to_features(s)))\n",
    "\n",
    "    return {\"type\": \"FeatureCollection\", \"features\": features}\n",
    "\n",
    "\n",
    "def run_multi(disease_terms):\n",
    "    \"\"\"\n",
    "    Build one FeatureCollection for multiple diseases.\n",
    "    - Calls your existing `run(disease)` for each term\n",
    "    - Dedupes sites by (nctId, lon, lat)\n",
    "    - Adds `properties[\"diseases\"]` listing which disease(s) the site belongs to\n",
    "    \"\"\"\n",
    "    per = []\n",
    "    for d in disease_terms:\n",
    "        fc = run(d)  # <-- uses your current run() unchanged\n",
    "        per.append((d, fc))\n",
    "\n",
    "    by_key = {}  # (nctId, lon, lat) -> feature\n",
    "    for disease, fc in per:\n",
    "        for feat in fc[\"features\"]:\n",
    "            props = feat[\"properties\"]\n",
    "            geom = feat[\"geometry\"]\n",
    "            nct = props.get(\"nctId\")\n",
    "            lon, lat = geom[\"coordinates\"]\n",
    "            key = (nct, float(lon), float(lat))\n",
    "            if key not in by_key:\n",
    "                # clone + add diseases list\n",
    "                new_props = dict(props)\n",
    "                new_props[\"diseases\"] = [disease]\n",
    "                by_key[key] = {\n",
    "                    \"type\": \"Feature\",\n",
    "                    \"geometry\": geom,\n",
    "                    \"properties\": new_props\n",
    "                }\n",
    "            else:\n",
    "                # append disease (dedup)\n",
    "                dl = by_key[key][\"properties\"].setdefault(\"diseases\", [])\n",
    "                if disease not in dl:\n",
    "                    dl.append(disease)\n",
    "\n",
    "    return {\"type\": \"FeatureCollection\", \"features\": list(by_key.values())}\n",
    "\n",
    "\n",
    "def nct_color(nctId: str) -> str:\n",
    "    \"\"\"Return a hex color string derived from the NCT ID.\"\"\"\n",
    "    if not nctId:\n",
    "        return \"#000000\"  # default black\n",
    "    # Hash the ID → use first 6 hex digits as color\n",
    "    h = hashlib.md5(nctId.encode(\"utf-8\")).hexdigest()\n",
    "    return \"#\" + h[:6]\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "43ff1997-0384-4e96-b1ce-36cba0381e23",
   "metadata": {},
   "outputs": [],
   "source": [
    "import folium, json, hashlib, datetime\n",
    "from folium.plugins import MarkerCluster\n",
    "\n",
    "def nct_color(nctId: str) -> str:\n",
    "    if not nctId:\n",
    "        return \"#000000\"\n",
    "    h = hashlib.md5(nctId.encode(\"utf-8\")).hexdigest()\n",
    "    return \"#\" + h[:6]\n",
    "\n",
    "def _intervention_names(interventions):\n",
    "    names = []\n",
    "    if isinstance(interventions, list):\n",
    "        for it in interventions:\n",
    "            if isinstance(it, dict):\n",
    "                name = it.get(\"name\")\n",
    "                if name:\n",
    "                    names.append(name.strip())\n",
    "            elif isinstance(it, str):\n",
    "                names.append(it.strip())\n",
    "    seen, uniq = set(), []\n",
    "    for n in names:\n",
    "        if n and n.lower() not in seen:\n",
    "            uniq.append(n); seen.add(n.lower())\n",
    "    return \"; \".join(uniq) if uniq else \"Intervention: n/a\"\n",
    "\n",
    "def make_map_with_cluster_chart(feature_collection, outfile=\"trials_map.html\"):\n",
    "    feats = feature_collection.get(\"features\", [])\n",
    "    if not feats:\n",
    "        raise ValueError(\"No geocoded locations.\")\n",
    "\n",
    "    # Payload the browser will render/control entirely\n",
    "    points = []          # [{lat,lng,nct,color,title,status,phases,interventions,sponsor,address,url,diseases:[]}]\n",
    "    nct_color_map = {}   # keep for consistent coloring per NCT\n",
    "\n",
    "    for f in feats:\n",
    "        lon, lat = f[\"geometry\"][\"coordinates\"]\n",
    "        p = f[\"properties\"]\n",
    "        nct = p[\"nctId\"]\n",
    "        color = nct_color_map.setdefault(nct, nct_color(nct))\n",
    "        points.append({\n",
    "            \"lat\": float(lat),\n",
    "            \"lng\": float(lon),\n",
    "            \"nct\": nct,\n",
    "            \"color\": color,\n",
    "            \"title\": p.get(\"title\") or \"\",\n",
    "            \"status\": p.get(\"status\") or \"\",\n",
    "            \"phases\": p.get(\"phases\") or [],\n",
    "            \"interventions\": _intervention_names(p.get(\"interventions\")),\n",
    "            \"sponsor\": p.get(\"sponsor\") or \"\",\n",
    "            \"address\": \", \".join([x for x in [p.get(\"address\", {}).get(\"city\"),\n",
    "                                              p.get(\"address\", {}).get(\"state\"),\n",
    "                                              p.get(\"address\", {}).get(\"country\")] if x]),\n",
    "            \"url\": p.get(\"url\") or \"\",\n",
    "            \"diseases\": p.get(\"diseases\") or []  # [] in single-disease mode, list in run_multi\n",
    "        })\n",
    "\n",
    "    # Bare map (no Python-side markers)\n",
    "    m = folium.Map(location=[20, 0], zoom_start=2)\n",
    "\n",
    "    # Force Folium to include Leaflet.markercluster assets\n",
    "    MarkerCluster().add_to(m)\n",
    "\n",
    "    map_var = m.get_name()\n",
    "    js_points = json.dumps(points)\n",
    "    run_date = datetime.datetime.now().strftime(\"%Y-%m-%d %H:%M\")\n",
    "\n",
    "    html_js = f\"\"\"\n",
    "    <style>\n",
    "      #nct-panel {{\n",
    "        position:absolute; top:10px; right:10px; z-index:9999;\n",
    "        background:white; padding:8px 10px; width:520px; max-height:420px;\n",
    "        box-shadow:0 2px 8px rgba(0,0,0,0.2); border-radius:8px; font-family:sans-serif; overflow:auto;\n",
    "      }}\n",
    "      #nct-panel h4 {{ margin:0 0 6px 0; font-size:14px; }}\n",
    "      .legend-note {{ font-size:11px; color:#666; margin-bottom:6px; }}\n",
    "      #nct-presets {{ display:flex; flex-wrap:wrap; gap:8px; margin:6px 0 6px 0; }}\n",
    "      #nct-presets .preset {{ padding:4px 8px; font-size:12px; }}\n",
    "      #disease-filters {{ display:flex; flex-wrap:wrap; gap:10px; margin: 6px 0 8px 0; }}\n",
    "      #disease-filters label {{ font-size:12px; user-select:none; }}\n",
    "      .bar-row {{ display:flex; align-items:center; gap:8px; margin:6px 0; }}\n",
    "      .bar-label {{ width:160px; font-size:12px; white-space:nowrap; overflow:hidden; text-overflow:ellipsis; }}\n",
    "      .bar-track {{ position:relative; flex:1; background:#f0f0f0; height:14px; border-radius:7px; overflow:hidden; }}\n",
    "      .bar-global {{ position:absolute; left:0; top:0; height:14px; opacity:.35; }}\n",
    "      .bar-local {{ position:absolute; left:0; top:0; height:14px; }}\n",
    "      .bar-count {{ width:90px; text-align:right; font-size:12px; color:#333; }}\n",
    "      /* sticky footer stays visible at panel bottom */\n",
    "      #nct-footer {{\n",
    "        position: sticky; bottom: 0; left: 0;\n",
    "        background: white; padding-top: 4px;\n",
    "        font-size: 11px; color: #999; margin-top: 6px;\n",
    "      }}\n",
    "    </style>\n",
    "\n",
    "    <div id=\"nct-panel\" class=\"leaflet-control\">\n",
    "      <h4>Sites per NCT (cluster vs global)</h4>\n",
    "      <div class=\"legend-note\">Solid = selected diseases in current area • Faint = total worldwide (selected diseases)</div>\n",
    "\n",
    "      <div id=\"nct-presets\">\n",
    "        <button class=\"preset\" data-diseases='[\"Parkinson Disease\"]'>Parkinson’s</button>\n",
    "        <button class=\"preset\" data-diseases='[\"Multiple System Atrophy\"]'>MSA</button>\n",
    "        <button class=\"preset\" data-diseases='[\"Lewy Body Disease\"]'>LBD</button>\n",
    "        <button class=\"preset\" data-diseases=\"ALL\">All</button>\n",
    "      </div>\n",
    "\n",
    "      <div id=\"disease-filters\"></div>\n",
    "      <div id=\"nct-rows\"></div>\n",
    "      <div id=\"nct-footer\">Analysis run: {run_date}</div>\n",
    "    </div>\n",
    "\n",
    "    <script>\n",
    "    (function(){{\n",
    "      var MAP_NAME = \"{map_var}\";\n",
    "      var DATA = {js_points};  // array of points with all needed meta\n",
    "\n",
    "      function initWhenReady(tries){{\n",
    "        var map = window[MAP_NAME];\n",
    "        if (!map || !map.getContainer) {{\n",
    "          if ((tries||0) < 200) return setTimeout(function(){{initWhenReady((tries||0)+1)}}, 50);\n",
    "          return;\n",
    "        }}\n",
    "\n",
    "        // Panel into map\n",
    "        var panel = document.getElementById('nct-panel');\n",
    "        var mapContainer = map.getContainer();\n",
    "        if (panel.parentNode !== mapContainer) mapContainer.appendChild(panel);\n",
    "\n",
    "        // Build cluster group & markers (in JS, so we fully control them)\n",
    "        var clusterGroup = L.markerClusterGroup();\n",
    "        map.addLayer(clusterGroup);\n",
    "\n",
    "        // Build marker registry\n",
    "        var MARKERS = []; // each: {{ marker, nct, lat, lng, diseases, color }}\n",
    "        DATA.forEach(function(p){{\n",
    "          var m = L.circleMarker([p.lat, p.lng], {{\n",
    "            radius: 6, color: p.color, fillColor: p.color, fillOpacity: 0.85\n",
    "          }});\n",
    "          var phases = (p.phases || []).join(', ');\n",
    "          var html = '<b>' + (p.title||'') + '</b><br>'\n",
    "                   + 'NCT: <a href=\"' + (p.url||'#') + '\" target=\"_blank\">' + p.nct + '</a><br>'\n",
    "                   + 'Status: ' + (p.status||'') + ' | Phase: ' + (phases||'') + '<br>'\n",
    "                   + 'Interventions: ' + (p.interventions||'n/a') + '<br>'\n",
    "                   + 'Sponsor: ' + (p.sponsor||'—') + '<br>'\n",
    "                   + (p.address||'');\n",
    "          m.bindPopup(html, {{maxWidth:350}});\n",
    "          MARKERS.push({{ marker:m, nct:p.nct, lat:p.lat, lng:p.lng, diseases:(p.diseases||[]), color:p.color }});\n",
    "        }});\n",
    "\n",
    "        // Add all markers initially\n",
    "        MARKERS.forEach(function(r){{ clusterGroup.addLayer(r.marker); }});\n",
    "\n",
    "        // ==== Disease selection UI ====\n",
    "        // Universe of diseases\n",
    "        var ALL_DISEASES = [];\n",
    "        (function(){{\n",
    "          var seen = new Set();\n",
    "          DATA.forEach(function(p){{\n",
    "            (p.diseases||[]).forEach(function(d){{ if(!seen.has(d)){{seen.add(d); ALL_DISEASES.push(d);}} }});\n",
    "          }});\n",
    "          ALL_DISEASES.sort();\n",
    "        }})();\n",
    "        var sel = new Set(ALL_DISEASES);\n",
    "\n",
    "        // Checkboxes\n",
    "        var df = document.getElementById('disease-filters');\n",
    "        df.innerHTML = '';\n",
    "        ALL_DISEASES.forEach(function(d){{\n",
    "          var id = 'dchk_' + d.replace(/\\\\W+/g,'_');\n",
    "          var label = document.createElement('label');\n",
    "          label.innerHTML = '<input type=\"checkbox\" id=\"'+id+'\" '+(sel.has(d)?'checked':'')+'> ' + d;\n",
    "          df.appendChild(label);\n",
    "          label.querySelector('input').addEventListener('change', function(e){{\n",
    "            if (e.target.checked) sel.add(d); else sel.delete(d);\n",
    "            applyMarkerFilter();\n",
    "            rerender(currentBounds());\n",
    "          }});\n",
    "        }});\n",
    "\n",
    "        // Presets\n",
    "        function setSelectionTo(listOrAll){{\n",
    "          sel.clear();\n",
    "          if (listOrAll === \"ALL\") ALL_DISEASES.forEach(function(d){{ sel.add(d); }});\n",
    "          else (listOrAll||[]).forEach(function(d){{ sel.add(d); }});\n",
    "          // sync UI\n",
    "          ALL_DISEASES.forEach(function(d){{\n",
    "            var id = 'dchk_' + d.replace(/\\\\W+/g,'_');\n",
    "            var el = document.getElementById(id);\n",
    "            if (el) el.checked = sel.has(d);\n",
    "          }});\n",
    "          applyMarkerFilter();\n",
    "          rerender(currentBounds());\n",
    "        }}\n",
    "        document.querySelectorAll('#nct-presets .preset').forEach(function(btn){{\n",
    "          btn.addEventListener('click', function(){{\n",
    "            var val = btn.getAttribute('data-diseases');\n",
    "            if (val === 'ALL') return setSelectionTo('ALL');\n",
    "            try {{ setSelectionTo(JSON.parse(val)); }} catch(e) {{}}\n",
    "          }});\n",
    "        }});\n",
    "\n",
    "        // ==== Filtering + chart logic ====\n",
    "        function markerIncluded(rec){{\n",
    "          if (!ALL_DISEASES.length) return true; // single-disease mode\n",
    "          var ds = rec.diseases || [];\n",
    "          for (var i=0;i<ds.length;i++) if (sel.has(ds[i])) return true;\n",
    "          return false;\n",
    "        }}\n",
    "        function applyMarkerFilter(){{\n",
    "          MARKERS.forEach(function(rec){{\n",
    "            var has = clusterGroup.hasLayer(rec.marker);\n",
    "            var should = markerIncluded(rec);\n",
    "            if (should && !has) clusterGroup.addLayer(rec.marker);\n",
    "            else if (!should && has) clusterGroup.removeLayer(rec.marker);\n",
    "          }});\n",
    "        }}\n",
    "\n",
    "        function withinBounds(lat, lng, bounds) {{\n",
    "          return bounds.contains(L.latLng(lat, lng));\n",
    "        }}\n",
    "        function currentBounds(){{\n",
    "          return map.getBounds ? map.getBounds() : L.latLngBounds([[-90,-180],[90,180]]);\n",
    "        }}\n",
    "\n",
    "        function localCounts(bounds){{\n",
    "          var counts = {{}};\n",
    "          MARKERS.forEach(function(r){{\n",
    "            if (!markerIncluded(r)) return;\n",
    "            if (!bounds || withinBounds(r.lat, r.lng, bounds)) {{\n",
    "              counts[r.nct] = (counts[r.nct]||0) + 1;\n",
    "            }}\n",
    "          }});\n",
    "          return counts;\n",
    "        }}\n",
    "        function globalCountsSelected(){{\n",
    "          var counts = {{}};\n",
    "          MARKERS.forEach(function(r){{\n",
    "            if (!markerIncluded(r)) return;\n",
    "            counts[r.nct] = (counts[r.nct]||0) + 1;\n",
    "          }});\n",
    "          return counts;\n",
    "        }}\n",
    "\n",
    "        function renderBars(local){{\n",
    "          var cont = document.getElementById('nct-rows');\n",
    "          cont.innerHTML = '';\n",
    "          var globalSel = globalCountsSelected();\n",
    "\n",
    "          var keys = Object.keys(local);\n",
    "          if (!keys.length) {{\n",
    "            cont.innerHTML = '<div style=\"color:#666;font-size:12px;\">No sites in selection for chosen diseases.</div>';\n",
    "            return;\n",
    "          }}\n",
    "\n",
    "          keys.sort(function(a,b){{\n",
    "            if (local[b] !== local[a]) return local[b] - local[a];\n",
    "            return (globalSel[b]||0) - (globalSel[a]||0);\n",
    "          }});\n",
    "\n",
    "          var maxG = 1;\n",
    "          keys.forEach(function(k){{ maxG = Math.max(maxG, globalSel[k]||0); }});\n",
    "          keys.forEach(function(nct){{\n",
    "            var g = globalSel[nct] || 0;\n",
    "            var l = local[nct] || 0;\n",
    "            var rec = MARKERS.find(function(r){{return r.nct===nct;}});\n",
    "            var color = (rec && rec.color) ? rec.color : '#888';\n",
    "            var gPct = Math.max(4, Math.round(100 * g / (maxG||1)));\n",
    "            var lPct = Math.min(gPct, Math.round(gPct * (l / (g||1))));\n",
    "\n",
    "            var row = document.createElement('div'); row.className = 'bar-row';\n",
    "\n",
    "            var label = document.createElement('div'); label.className = 'bar-label';\n",
    "            label.textContent = nct;\n",
    "            var any = DATA.find(function(p){{return p.nct===nct;}});\n",
    "            label.title = (any && any.interventions) ? any.interventions : 'Intervention: n/a';\n",
    "\n",
    "            var track = document.createElement('div'); track.className = 'bar-track';\n",
    "            track.title = label.title;\n",
    "\n",
    "            var gdiv = document.createElement('div'); gdiv.className='bar-global';\n",
    "            gdiv.style.width = gPct + '%'; gdiv.style.background = color;\n",
    "            var ldiv = document.createElement('div'); ldiv.className='bar-local';\n",
    "            ldiv.style.width = lPct + '%'; ldiv.style.background = color;\n",
    "\n",
    "            var cnt = document.createElement('div'); cnt.className='bar-count';\n",
    "            cnt.textContent = l + ' / ' + g;\n",
    "\n",
    "            track.appendChild(gdiv); track.appendChild(ldiv);\n",
    "            row.appendChild(label); row.appendChild(track); row.appendChild(cnt);\n",
    "            cont.appendChild(row);\n",
    "          }});\n",
    "        }}\n",
    "\n",
    "        function rerender(bounds){{ renderBars(localCounts(bounds)); }}\n",
    "\n",
    "        // Initial sync\n",
    "        applyMarkerFilter();\n",
    "        rerender(L.latLngBounds([[-90,-180],[90,180]]));\n",
    "\n",
    "        // Cluster click → render for that area\n",
    "        clusterGroup.on('clusterclick', function(e){{\n",
    "          rerender(e.layer.getBounds());\n",
    "        }});\n",
    "      }}\n",
    "      initWhenReady(0);\n",
    "    }})();\n",
    "    </script>\n",
    "    \"\"\"\n",
    "\n",
    "    m.get_root().html.add_child(folium.Element(html_js))\n",
    "    m.save(outfile)\n",
    "    return m\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "44ef4e43-d61e-42fb-b88b-64749d136363",
   "metadata": {},
   "outputs": [],
   "source": [
    "# m = make_map_with_cluster_chart(fc, outfile=\"C:\\\\Users\\\\robin\\\\Programs\\\\Proteinopathy\\\\reveal.js\\\\trials_map.html\")\n",
    "# m  # inline"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "38382700-3b90-47fd-88f8-c005fb6cb170",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div style=\"width:100%;\"><div style=\"position:relative;width:100%;height:0;padding-bottom:60%;\"><span style=\"color:#565656\">Make this Notebook Trusted to load map: File -> Trust Notebook</span><iframe srcdoc=\"&lt;!DOCTYPE html&gt;\n",
       "&lt;html&gt;\n",
       "&lt;head&gt;\n",
       "    \n",
       "    &lt;meta http-equiv=&quot;content-type&quot; content=&quot;text/html; charset=UTF-8&quot; /&gt;\n",
       "    &lt;script src=&quot;https://cdn.jsdelivr.net/npm/leaflet@1.9.3/dist/leaflet.js&quot;&gt;&lt;/script&gt;\n",
       "    &lt;script src=&quot;https://code.jquery.com/jquery-3.7.1.min.js&quot;&gt;&lt;/script&gt;\n",
       "    &lt;script src=&quot;https://cdn.jsdelivr.net/npm/bootstrap@5.2.2/dist/js/bootstrap.bundle.min.js&quot;&gt;&lt;/script&gt;\n",
       "    &lt;script src=&quot;https://cdnjs.cloudflare.com/ajax/libs/Leaflet.awesome-markers/2.0.2/leaflet.awesome-markers.js&quot;&gt;&lt;/script&gt;\n",
       "    &lt;link rel=&quot;stylesheet&quot; href=&quot;https://cdn.jsdelivr.net/npm/leaflet@1.9.3/dist/leaflet.css&quot;/&gt;\n",
       "    &lt;link rel=&quot;stylesheet&quot; href=&quot;https://cdn.jsdelivr.net/npm/bootstrap@5.2.2/dist/css/bootstrap.min.css&quot;/&gt;\n",
       "    &lt;link rel=&quot;stylesheet&quot; href=&quot;https://netdna.bootstrapcdn.com/bootstrap/3.0.0/css/bootstrap-glyphicons.css&quot;/&gt;\n",
       "    &lt;link rel=&quot;stylesheet&quot; href=&quot;https://cdn.jsdelivr.net/npm/@fortawesome/fontawesome-free@6.2.0/css/all.min.css&quot;/&gt;\n",
       "    &lt;link rel=&quot;stylesheet&quot; href=&quot;https://cdnjs.cloudflare.com/ajax/libs/Leaflet.awesome-markers/2.0.2/leaflet.awesome-markers.css&quot;/&gt;\n",
       "    &lt;link rel=&quot;stylesheet&quot; href=&quot;https://cdn.jsdelivr.net/gh/python-visualization/folium/folium/templates/leaflet.awesome.rotate.min.css&quot;/&gt;\n",
       "    \n",
       "            &lt;meta name=&quot;viewport&quot; content=&quot;width=device-width,\n",
       "                initial-scale=1.0, maximum-scale=1.0, user-scalable=no&quot; /&gt;\n",
       "            &lt;style&gt;\n",
       "                #map_0a345331d60a7f95c66cb029a2f6d1e5 {\n",
       "                    position: relative;\n",
       "                    width: 100.0%;\n",
       "                    height: 100.0%;\n",
       "                    left: 0.0%;\n",
       "                    top: 0.0%;\n",
       "                }\n",
       "                .leaflet-container { font-size: 1rem; }\n",
       "            &lt;/style&gt;\n",
       "\n",
       "            &lt;style&gt;html, body {\n",
       "                width: 100%;\n",
       "                height: 100%;\n",
       "                margin: 0;\n",
       "                padding: 0;\n",
       "            }\n",
       "            &lt;/style&gt;\n",
       "\n",
       "            &lt;style&gt;#map {\n",
       "                position:absolute;\n",
       "                top:0;\n",
       "                bottom:0;\n",
       "                right:0;\n",
       "                left:0;\n",
       "                }\n",
       "            &lt;/style&gt;\n",
       "\n",
       "            &lt;script&gt;\n",
       "                L_NO_TOUCH = false;\n",
       "                L_DISABLE_3D = false;\n",
       "            &lt;/script&gt;\n",
       "\n",
       "        \n",
       "    &lt;script src=&quot;https://cdnjs.cloudflare.com/ajax/libs/leaflet.markercluster/1.1.0/leaflet.markercluster.js&quot;&gt;&lt;/script&gt;\n",
       "    &lt;link rel=&quot;stylesheet&quot; href=&quot;https://cdnjs.cloudflare.com/ajax/libs/leaflet.markercluster/1.1.0/MarkerCluster.css&quot;/&gt;\n",
       "    &lt;link rel=&quot;stylesheet&quot; href=&quot;https://cdnjs.cloudflare.com/ajax/libs/leaflet.markercluster/1.1.0/MarkerCluster.Default.css&quot;/&gt;\n",
       "&lt;/head&gt;\n",
       "&lt;body&gt;\n",
       "    \n",
       "    \n",
       "    &lt;style&gt;\n",
       "      #nct-panel {\n",
       "        position:absolute; top:10px; right:10px; z-index:9999;\n",
       "        background:white; padding:8px 10px; width:520px; max-height:420px;\n",
       "        box-shadow:0 2px 8px rgba(0,0,0,0.2); border-radius:8px; font-family:sans-serif; overflow:auto;\n",
       "      }\n",
       "      #nct-panel h4 { margin:0 0 6px 0; font-size:14px; }\n",
       "      .legend-note { font-size:11px; color:#666; margin-bottom:6px; }\n",
       "      #nct-presets { display:flex; flex-wrap:wrap; gap:8px; margin:6px 0 6px 0; }\n",
       "      #nct-presets .preset { padding:4px 8px; font-size:12px; }\n",
       "      #disease-filters { display:flex; flex-wrap:wrap; gap:10px; margin: 6px 0 8px 0; }\n",
       "      #disease-filters label { font-size:12px; user-select:none; }\n",
       "      .bar-row { display:flex; align-items:center; gap:8px; margin:6px 0; }\n",
       "      .bar-label { width:160px; font-size:12px; white-space:nowrap; overflow:hidden; text-overflow:ellipsis; }\n",
       "      .bar-track { position:relative; flex:1; background:#f0f0f0; height:14px; border-radius:7px; overflow:hidden; }\n",
       "      .bar-global { position:absolute; left:0; top:0; height:14px; opacity:.35; }\n",
       "      .bar-local { position:absolute; left:0; top:0; height:14px; }\n",
       "      .bar-count { width:90px; text-align:right; font-size:12px; color:#333; }\n",
       "      /* sticky footer stays visible at panel bottom */\n",
       "      #nct-footer {\n",
       "        position: sticky; bottom: 0; left: 0;\n",
       "        background: white; padding-top: 4px;\n",
       "        font-size: 11px; color: #999; margin-top: 6px;\n",
       "      }\n",
       "    &lt;/style&gt;\n",
       "\n",
       "    &lt;div id=&quot;nct-panel&quot; class=&quot;leaflet-control&quot;&gt;\n",
       "      &lt;h4&gt;Sites per NCT (cluster vs global)&lt;/h4&gt;\n",
       "      &lt;div class=&quot;legend-note&quot;&gt;Solid = selected diseases in current area • Faint = total worldwide (selected diseases)&lt;/div&gt;\n",
       "\n",
       "      &lt;div id=&quot;nct-presets&quot;&gt;\n",
       "        &lt;button class=&quot;preset&quot; data-diseases=&#x27;[&quot;Parkinson Disease&quot;]&#x27;&gt;Parkinson’s&lt;/button&gt;\n",
       "        &lt;button class=&quot;preset&quot; data-diseases=&#x27;[&quot;Multiple System Atrophy&quot;]&#x27;&gt;MSA&lt;/button&gt;\n",
       "        &lt;button class=&quot;preset&quot; data-diseases=&#x27;[&quot;Lewy Body Disease&quot;]&#x27;&gt;LBD&lt;/button&gt;\n",
       "        &lt;button class=&quot;preset&quot; data-diseases=&quot;ALL&quot;&gt;All&lt;/button&gt;\n",
       "      &lt;/div&gt;\n",
       "\n",
       "      &lt;div id=&quot;disease-filters&quot;&gt;&lt;/div&gt;\n",
       "      &lt;div id=&quot;nct-rows&quot;&gt;&lt;/div&gt;\n",
       "      &lt;div id=&quot;nct-footer&quot;&gt;Analysis run: 2025-09-12 14:33&lt;/div&gt;\n",
       "    &lt;/div&gt;\n",
       "\n",
       "    &lt;script&gt;\n",
       "    (function(){\n",
       "      var MAP_NAME = &quot;map_0a345331d60a7f95c66cb029a2f6d1e5&quot;;\n",
       "      var DATA = [{&quot;lat&quot;: 49.9, &quot;lng&quot;: 2.3, &quot;nct&quot;: &quot;NCT04794634&quot;, &quot;color&quot;: &quot;#185d4d&quot;, &quot;title&quot;: &quot;Relationship Between Alzheimer Disease and Diminution of the Three Macular Nervous Retinal Layers&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Optical coherence tomography (OCT); Optical coherence tomograpohy angiography (OCTA)&quot;, &quot;sponsor&quot;: &quot;Centre Hospitalier Universitaire, Amiens&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04794634&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;]}, {&quot;lat&quot;: 42.98339, &quot;lng&quot;: -81.23304, &quot;nct&quot;: &quot;NCT04405596&quot;, &quot;color&quot;: &quot;#846716&quot;, &quot;title&quot;: &quot;Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Ambroxol Hydrochloride; Placebo&quot;, &quot;sponsor&quot;: &quot;London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph&#x27;s&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04405596&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;]}, {&quot;lat&quot;: 30.29365, &quot;lng&quot;: 120.16142, &quot;nct&quot;: &quot;NCT05518409&quot;, &quot;color&quot;: &quot;#070967&quot;, &quot;title&quot;: &quot;Immunohistochemical Study of Neurodegenerative Diseases&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Detection of cytof in peripheral PBMC; Donepezil for patients with AD and DLB&quot;, &quot;sponsor&quot;: &quot;First Affiliated Hospital of Zhejiang University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05518409&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;]}, {&quot;lat&quot;: -22.90642, &quot;lng&quot;: -43.18223, &quot;nct&quot;: &quot;NCT06733714&quot;, &quot;color&quot;: &quot;#926b95&quot;, &quot;title&quot;: &quot;Association of Transcranial Alternating Current Stimulation with Digital Cognitive Training for Cognitive Remediation in Older Adults&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Transcranial Alternating Current Stimulation; Digital Cognitive Training&quot;, &quot;sponsor&quot;: &quot;Universidade Federal do Rio de Janeiro&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06733714&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;]}, {&quot;lat&quot;: 49.19522, &quot;lng&quot;: 16.60796, &quot;nct&quot;: &quot;NCT05847985&quot;, &quot;color&quot;: &quot;#8cee60&quot;, &quot;title&quot;: &quot;Language and Lewy Body Diseases: Sentence Comprehension Problems and Modifying Noninvasive Brain Stimulation Treatment&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;transcranial direct current stimulation (tDCS)&quot;, &quot;sponsor&quot;: &quot;Masaryk University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05847985&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;]}, {&quot;lat&quot;: 53.55014, &quot;lng&quot;: -113.46871, &quot;nct&quot;: &quot;NCT04706910&quot;, &quot;color&quot;: &quot;#f37e39&quot;, &quot;title&quot;: &quot;18F-DOPA II - PET Imaging Optimization&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;18F-DOPA; Furosemide Injection&quot;, &quot;sponsor&quot;: &quot;University of Alberta&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04706910&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;, &quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.14149, &quot;lng&quot;: -73.3579, &quot;nct&quot;: &quot;NCT02795052&quot;, &quot;color&quot;: &quot;#14033b&quot;, &quot;title&quot;: &quot;Neurologic Stem Cell Treatment Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Intravenous and Intranasal BMSC&quot;, &quot;sponsor&quot;: &quot;MD Stem Cells&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT02795052&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 26.27119, &quot;lng&quot;: -80.2706, &quot;nct&quot;: &quot;NCT02795052&quot;, &quot;color&quot;: &quot;#14033b&quot;, &quot;title&quot;: &quot;Neurologic Stem Cell Treatment Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Intravenous and Intranasal BMSC&quot;, &quot;sponsor&quot;: &quot;MD Stem Cells&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT02795052&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 25.07725, &quot;lng&quot;: 55.30927, &quot;nct&quot;: &quot;NCT02795052&quot;, &quot;color&quot;: &quot;#14033b&quot;, &quot;title&quot;: &quot;Neurologic Stem Cell Treatment Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Intravenous and Intranasal BMSC&quot;, &quot;sponsor&quot;: &quot;MD Stem Cells&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT02795052&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 29.65163, &quot;lng&quot;: -82.32483, &quot;nct&quot;: &quot;NCT05014971&quot;, &quot;color&quot;: &quot;#184c72&quot;, &quot;title&quot;: &quot;Telehealth in Lewy Body Dementia&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Tele-neurohub&quot;, &quot;sponsor&quot;: &quot;University of Florida&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05014971&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;, &quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.31344, &quot;lng&quot;: 5.01391, &quot;nct&quot;: &quot;NCT06439355&quot;, &quot;color&quot;: &quot;#1535d4&quot;, &quot;title&quot;: &quot;Single-center Study of Gustation in Idiopathic Parkinson&#x27;s Disease and Lewy Body Disease Using Gustatory Evoked Potential Analysis&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Fasting blood test; Subject interview; Motor assessment; Neurocognitive assessment; Nutritional assessment; Taste tests&quot;, &quot;sponsor&quot;: &quot;Centre Hospitalier Universitaire Dijon&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06439355&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;]}, {&quot;lat&quot;: 33.50921, &quot;lng&quot;: -111.89903, &quot;nct&quot;: &quot;NCT04148391&quot;, &quot;color&quot;: &quot;#8d106c&quot;, &quot;title&quot;: &quot;NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson&#x27;s Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo Oral Capsule; NYX-458&quot;, &quot;sponsor&quot;: &quot;Aptinyx&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04148391&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;, &quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.74773, &quot;lng&quot;: -119.77237, &quot;nct&quot;: &quot;NCT04148391&quot;, &quot;color&quot;: &quot;#8d106c&quot;, &quot;title&quot;: &quot;NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson&#x27;s Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo Oral Capsule; NYX-458&quot;, &quot;sponsor&quot;: &quot;Aptinyx&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04148391&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;, &quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 34.26945, &quot;lng&quot;: -118.78148, &quot;nct&quot;: &quot;NCT04148391&quot;, &quot;color&quot;: &quot;#8d106c&quot;, &quot;title&quot;: &quot;NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson&#x27;s Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo Oral Capsule; NYX-458&quot;, &quot;sponsor&quot;: &quot;Aptinyx&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04148391&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;, &quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.35869, &quot;lng&quot;: -80.0831, &quot;nct&quot;: &quot;NCT04148391&quot;, &quot;color&quot;: &quot;#8d106c&quot;, &quot;title&quot;: &quot;NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson&#x27;s Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo Oral Capsule; NYX-458&quot;, &quot;sponsor&quot;: &quot;Aptinyx&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04148391&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;, &quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 27.49893, &quot;lng&quot;: -82.57482, &quot;nct&quot;: &quot;NCT04148391&quot;, &quot;color&quot;: &quot;#8d106c&quot;, &quot;title&quot;: &quot;NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson&#x27;s Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo Oral Capsule; NYX-458&quot;, &quot;sponsor&quot;: &quot;Aptinyx&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04148391&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;, &quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 25.77427, &quot;lng&quot;: -80.19366, &quot;nct&quot;: &quot;NCT04148391&quot;, &quot;color&quot;: &quot;#8d106c&quot;, &quot;title&quot;: &quot;NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson&#x27;s Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo Oral Capsule; NYX-458&quot;, &quot;sponsor&quot;: &quot;Aptinyx&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04148391&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;, &quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 25.90871, &quot;lng&quot;: -80.30866, &quot;nct&quot;: &quot;NCT04148391&quot;, &quot;color&quot;: &quot;#8d106c&quot;, &quot;title&quot;: &quot;NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson&#x27;s Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo Oral Capsule; NYX-458&quot;, &quot;sponsor&quot;: &quot;Aptinyx&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04148391&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;, &quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 28.53834, &quot;lng&quot;: -81.37924, &quot;nct&quot;: &quot;NCT04148391&quot;, &quot;color&quot;: &quot;#8d106c&quot;, &quot;title&quot;: &quot;NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson&#x27;s Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo Oral Capsule; NYX-458&quot;, &quot;sponsor&quot;: &quot;Aptinyx&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04148391&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;, &quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.97617, &quot;lng&quot;: -82.09064, &quot;nct&quot;: &quot;NCT04148391&quot;, &quot;color&quot;: &quot;#8d106c&quot;, &quot;title&quot;: &quot;NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson&#x27;s Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo Oral Capsule; NYX-458&quot;, &quot;sponsor&quot;: &quot;Aptinyx&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04148391&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;, &quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.13832, &quot;lng&quot;: -80.99561, &quot;nct&quot;: &quot;NCT04148391&quot;, &quot;color&quot;: &quot;#8d106c&quot;, &quot;title&quot;: &quot;NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson&#x27;s Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo Oral Capsule; NYX-458&quot;, &quot;sponsor&quot;: &quot;Aptinyx&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04148391&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;, &quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.13397, &quot;lng&quot;: -80.1131, &quot;nct&quot;: &quot;NCT04148391&quot;, &quot;color&quot;: &quot;#8d106c&quot;, &quot;title&quot;: &quot;NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson&#x27;s Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo Oral Capsule; NYX-458&quot;, &quot;sponsor&quot;: &quot;Aptinyx&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04148391&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;, &quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.77483, &quot;lng&quot;: -84.29631, &quot;nct&quot;: &quot;NCT04148391&quot;, &quot;color&quot;: &quot;#8d106c&quot;, &quot;title&quot;: &quot;NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson&#x27;s Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo Oral Capsule; NYX-458&quot;, &quot;sponsor&quot;: &quot;Aptinyx&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04148391&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;, &quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.48531, &quot;lng&quot;: -83.37716, &quot;nct&quot;: &quot;NCT04148391&quot;, &quot;color&quot;: &quot;#8d106c&quot;, &quot;title&quot;: &quot;NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson&#x27;s Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo Oral Capsule; NYX-458&quot;, &quot;sponsor&quot;: &quot;Aptinyx&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04148391&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;, &quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.00969, &quot;lng&quot;: -93.34912, &quot;nct&quot;: &quot;NCT04148391&quot;, &quot;color&quot;: &quot;#8d106c&quot;, &quot;title&quot;: &quot;NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson&#x27;s Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo Oral Capsule; NYX-458&quot;, &quot;sponsor&quot;: &quot;Aptinyx&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04148391&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;, &quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.95373, &quot;lng&quot;: -74.19792, &quot;nct&quot;: &quot;NCT04148391&quot;, &quot;color&quot;: &quot;#8d106c&quot;, &quot;title&quot;: &quot;NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson&#x27;s Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo Oral Capsule; NYX-458&quot;, &quot;sponsor&quot;: &quot;Aptinyx&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04148391&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;, &quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.70037, &quot;lng&quot;: -73.92097, &quot;nct&quot;: &quot;NCT04148391&quot;, &quot;color&quot;: &quot;#8d106c&quot;, &quot;title&quot;: &quot;NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson&#x27;s Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo Oral Capsule; NYX-458&quot;, &quot;sponsor&quot;: &quot;Aptinyx&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04148391&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;, &quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 35.60095, &quot;lng&quot;: -82.55402, &quot;nct&quot;: &quot;NCT04148391&quot;, &quot;color&quot;: &quot;#8d106c&quot;, &quot;title&quot;: &quot;NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson&#x27;s Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo Oral Capsule; NYX-458&quot;, &quot;sponsor&quot;: &quot;Aptinyx&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04148391&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;, &quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.75895, &quot;lng&quot;: -84.19161, &quot;nct&quot;: &quot;NCT04148391&quot;, &quot;color&quot;: &quot;#8d106c&quot;, &quot;title&quot;: &quot;NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson&#x27;s Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo Oral Capsule; NYX-458&quot;, &quot;sponsor&quot;: &quot;Aptinyx&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04148391&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;, &quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.15398, &quot;lng&quot;: -95.99277, &quot;nct&quot;: &quot;NCT04148391&quot;, &quot;color&quot;: &quot;#8d106c&quot;, &quot;title&quot;: &quot;NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson&#x27;s Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo Oral Capsule; NYX-458&quot;, &quot;sponsor&quot;: &quot;Aptinyx&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04148391&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;, &quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 30.50826, &quot;lng&quot;: -97.6789, &quot;nct&quot;: &quot;NCT04148391&quot;, &quot;color&quot;: &quot;#8d106c&quot;, &quot;title&quot;: &quot;NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson&#x27;s Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo Oral Capsule; NYX-458&quot;, &quot;sponsor&quot;: &quot;Aptinyx&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04148391&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;, &quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.61968, &quot;lng&quot;: -95.63495, &quot;nct&quot;: &quot;NCT04148391&quot;, &quot;color&quot;: &quot;#8d106c&quot;, &quot;title&quot;: &quot;NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson&#x27;s Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo Oral Capsule; NYX-458&quot;, &quot;sponsor&quot;: &quot;Aptinyx&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04148391&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;, &quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.61038, &quot;lng&quot;: -122.20068, &quot;nct&quot;: &quot;NCT04148391&quot;, &quot;color&quot;: &quot;#8d106c&quot;, &quot;title&quot;: &quot;NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson&#x27;s Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo Oral Capsule; NYX-458&quot;, &quot;sponsor&quot;: &quot;Aptinyx&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04148391&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;, &quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.65966, &quot;lng&quot;: -117.42908, &quot;nct&quot;: &quot;NCT04148391&quot;, &quot;color&quot;: &quot;#8d106c&quot;, &quot;title&quot;: &quot;NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson&#x27;s Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo Oral Capsule; NYX-458&quot;, &quot;sponsor&quot;: &quot;Aptinyx&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04148391&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;, &quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 56.2428, &quot;lng&quot;: 12.86219, &quot;nct&quot;: &quot;NCT03174938&quot;, &quot;color&quot;: &quot;#a6b73c&quot;, &quot;title&quot;: &quot;The Swedish BioFINDER 2 Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Flutemetamol F18 Injection; [18F]-RO6958948; Elecsys (Roche) Abeta42, Ttau and Ptau; Lumipulse (Fujirebio) Abeta42, Ttau and Ptau&quot;, &quot;sponsor&quot;: &quot;Skane University Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03174938&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;, &quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 55.60587, &quot;lng&quot;: 13.00073, &quot;nct&quot;: &quot;NCT03174938&quot;, &quot;color&quot;: &quot;#a6b73c&quot;, &quot;title&quot;: &quot;The Swedish BioFINDER 2 Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Flutemetamol F18 Injection; [18F]-RO6958948; Elecsys (Roche) Abeta42, Ttau and Ptau; Lumipulse (Fujirebio) Abeta42, Ttau and Ptau&quot;, &quot;sponsor&quot;: &quot;Skane University Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03174938&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;, &quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 43.73718, &quot;lng&quot;: 7.42145, &quot;nct&quot;: &quot;NCT06785948&quot;, &quot;color&quot;: &quot;#b276a3&quot;, &quot;title&quot;: &quot;tDCS Effect on Psychotic Symptoms in Dementia With Lewy Bodies (DLB), and Impacts on Caregiver Burden&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;active-tDCS; Sham-tDCS&quot;, &quot;sponsor&quot;: &quot;Association de Recherche Bibliographique pour les Neurosciences&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06785948&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;]}, {&quot;lat&quot;: 47.60621, &quot;lng&quot;: -122.33207, &quot;nct&quot;: &quot;NCT05596760&quot;, &quot;color&quot;: &quot;#5ea085&quot;, &quot;title&quot;: &quot;Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Jumpstart Guide&quot;, &quot;sponsor&quot;: &quot;University of Washington&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05596760&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;]}, {&quot;lat&quot;: 40.71427, &quot;lng&quot;: -74.00597, &quot;nct&quot;: &quot;NCT06221202&quot;, &quot;color&quot;: &quot;#18e436&quot;, &quot;title&quot;: &quot;Stories in the Moment: Dance Program for People Living With Dementia&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Stories in the Moment Dance Program - Online&quot;, &quot;sponsor&quot;: &quot;DanceStream Projects&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06221202&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;]}, {&quot;lat&quot;: 48.85341, &quot;lng&quot;: 2.3488, &quot;nct&quot;: &quot;NCT04389437&quot;, &quot;color&quot;: &quot;#dd451e&quot;, &quot;title&quot;: &quot;OCT-Angiography and Adaptive Optics in Patients With Memory Impairment&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Ophthalmological exam; Blood pressure measurement&quot;, &quot;sponsor&quot;: &quot;Fondation Ophtalmologique Adolphe de Rothschild&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04389437&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;]}, {&quot;lat&quot;: 41.85003, &quot;lng&quot;: -87.65005, &quot;nct&quot;: &quot;NCT06389032&quot;, &quot;color&quot;: &quot;#e0cfde&quot;, &quot;title&quot;: &quot;PERSEVERE: Peer Mentor Support and Caregiver Education in Lewy Body Dementia&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Peer Mentor Support and Caregiver Education; Caregiver Education&quot;, &quot;sponsor&quot;: &quot;Rush University Medical Center&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06389032&quot;, &quot;diseases&quot;: [&quot;Lewy Body Disease&quot;, &quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.06733, &quot;lng&quot;: 15.44197, &quot;nct&quot;: &quot;NCT06403280&quot;, &quot;color&quot;: &quot;#a90147&quot;, &quot;title&quot;: &quot;The Effect of Alcohol on Common Tremor Syndromes&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Alcoholic drink; Placebo drink&quot;, &quot;sponsor&quot;: &quot;Medical University of Graz&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06403280&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.01384, &quot;lng&quot;: 28.94966, &quot;nct&quot;: &quot;NCT06416722&quot;, &quot;color&quot;: &quot;#95c491&quot;, &quot;title&quot;: &quot;Telerehabilitation Dual-Task Training for Parkinson&#x27;s: A Multidimensional Evaluation&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Cognitive-Motor Dual Task Activities; Motor-Motor Dual Task Activities; Cognitive-Motor &amp; Motor-Motor Dual Task Activities&quot;, &quot;sponsor&quot;: &quot;Fenerbahce University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06416722&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 32.78306, &quot;lng&quot;: -96.80667, &quot;nct&quot;: &quot;NCT04957095&quot;, &quot;color&quot;: &quot;#8960a0&quot;, &quot;title&quot;: &quot;Motor Network Physiology&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Apomorphine Injectable Solution; Subcortical Stimulation&quot;, &quot;sponsor&quot;: &quot;University of Texas Southwestern Medical Center&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04957095&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.58528, &quot;lng&quot;: -1.98396, &quot;nct&quot;: &quot;NCT05973565&quot;, &quot;color&quot;: &quot;#09a1c1&quot;, &quot;title&quot;: &quot;The Effects of a Single Session of Rhythmic Movement Program on Selected Biopsychological Parameters in PD Patients&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Musicokinetic Training&quot;, &quot;sponsor&quot;: &quot;University of Wolverhampton&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05973565&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.2, &quot;lng&quot;: 0.11667, &quot;nct&quot;: &quot;NCT06430151&quot;, &quot;color&quot;: &quot;#b8d673&quot;, &quot;title&quot;: &quot;Useability and Acceptability of the CUE1 Device in Older People With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;CUE1&quot;, &quot;sponsor&quot;: &quot;Dr Alistair Mackett&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06430151&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.11109, &quot;lng&quot;: -1.67431, &quot;nct&quot;: &quot;NCT06080659&quot;, &quot;color&quot;: &quot;#290d6b&quot;, &quot;title&quot;: &quot;Network-based BiOmarker Discovery of Neurodegenerative Diseases Using Multimodal Connectivity&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;fMRI; CONFMEM&quot;, &quot;sponsor&quot;: &quot;Rennes University Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06080659&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.8425, &quot;lng&quot;: 5.85278, &quot;nct&quot;: &quot;NCT05551377&quot;, &quot;color&quot;: &quot;#5f4870&quot;, &quot;title&quot;: &quot;Head-up Tilt Sleeping to Alleviate Orthostatic Hypotension, Supine Hypertension and Nocturia in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Head-up tilt sleeping&quot;, &quot;sponsor&quot;: &quot;Radboud University Medical Center&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05551377&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.15833, &quot;lng&quot;: 4.49306, &quot;nct&quot;: &quot;NCT05551377&quot;, &quot;color&quot;: &quot;#5f4870&quot;, &quot;title&quot;: &quot;Head-up Tilt Sleeping to Alleviate Orthostatic Hypotension, Supine Hypertension and Nocturia in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Head-up tilt sleeping&quot;, &quot;sponsor&quot;: &quot;Radboud University Medical Center&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05551377&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 35.9132, &quot;lng&quot;: -79.05584, &quot;nct&quot;: &quot;NCT05864157&quot;, &quot;color&quot;: &quot;#3c6efa&quot;, &quot;title&quot;: &quot;Targeted Motor Learning to Improve Gait for Individuals With Parkinson Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Gait training without rhythmic auditory cues; TRAC; dTRAC&quot;, &quot;sponsor&quot;: &quot;University of North Carolina, Chapel Hill&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05864157&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: -23.5475, &quot;lng&quot;: -46.63611, &quot;nct&quot;: &quot;NCT06957405&quot;, &quot;color&quot;: &quot;#c4bc4d&quot;, &quot;title&quot;: &quot;Remote Mental Practice for Freezing of Gait in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;MPPG (Mental and Physical Practice Group); PPG (Physical Practice Group)&quot;, &quot;sponsor&quot;: &quot;University of Sao Paulo General Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06957405&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 44.84124, &quot;lng&quot;: -0.58046, &quot;nct&quot;: &quot;NCT05433441&quot;, &quot;color&quot;: &quot;#f17e6c&quot;, &quot;title&quot;: &quot;Evaluation of the Effectiveness of the Parkinson Specialized Teams Intervention&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;ESPark Intervention&quot;, &quot;sponsor&quot;: &quot;University Hospital, Bordeaux&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05433441&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.63391, &quot;lng&quot;: 3.05512, &quot;nct&quot;: &quot;NCT05433441&quot;, &quot;color&quot;: &quot;#f17e6c&quot;, &quot;title&quot;: &quot;Evaluation of the Effectiveness of the Parkinson Specialized Teams Intervention&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;ESPark Intervention&quot;, &quot;sponsor&quot;: &quot;University Hospital, Bordeaux&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05433441&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.83362, &quot;lng&quot;: 1.24759, &quot;nct&quot;: &quot;NCT05433441&quot;, &quot;color&quot;: &quot;#f17e6c&quot;, &quot;title&quot;: &quot;Evaluation of the Effectiveness of the Parkinson Specialized Teams Intervention&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;ESPark Intervention&quot;, &quot;sponsor&quot;: &quot;University Hospital, Bordeaux&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05433441&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 46.58261, &quot;lng&quot;: 0.34348, &quot;nct&quot;: &quot;NCT05433441&quot;, &quot;color&quot;: &quot;#f17e6c&quot;, &quot;title&quot;: &quot;Evaluation of the Effectiveness of the Parkinson Specialized Teams Intervention&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;ESPark Intervention&quot;, &quot;sponsor&quot;: &quot;University Hospital, Bordeaux&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05433441&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 30.29365, &quot;lng&quot;: 120.16142, &quot;nct&quot;: &quot;NCT06821529&quot;, &quot;color&quot;: &quot;#66edc3&quot;, &quot;title&quot;: &quot;Stereotactic Intracerebral Injection of IPSC-DAPs in Patients with Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;ICA07 therapy&quot;, &quot;sponsor&quot;: &quot;iCamuno Biotherapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06821529&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.4165, &quot;lng&quot;: -3.70256, &quot;nct&quot;: &quot;NCT05699694&quot;, &quot;color&quot;: &quot;#f2311c&quot;, &quot;title&quot;: &quot;Clinical Study on the Efficacy of Natural Stem Cell Mobilizers on Parkinson Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;StemRegen product&quot;, &quot;sponsor&quot;: &quot;Sociedad Espa\\u00f1ola de Medicina Regenerativa y Terapia Celular&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05699694&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 31.76904, &quot;lng&quot;: 35.21633, &quot;nct&quot;: &quot;NCT06193421&quot;, &quot;color&quot;: &quot;#af3a7a&quot;, &quot;title&quot;: &quot;High-Dose Ambroxol in GBA1-Related Parkinson&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Ambroxol Hydrochloride&quot;, &quot;sponsor&quot;: &quot;Agyany Pharma LTD&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06193421&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.37403, &quot;lng&quot;: 4.88969, &quot;nct&quot;: &quot;NCT06223399&quot;, &quot;color&quot;: &quot;#095914&quot;, &quot;title&quot;: &quot;DBS Imaging-based vs. Threshold Assessment-based Programming&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Imaging-based programming; Threshold assessment-based programming&quot;, &quot;sponsor&quot;: &quot;Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06223399&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 49.40768, &quot;lng&quot;: 8.69079, &quot;nct&quot;: &quot;NCT06580977&quot;, &quot;color&quot;: &quot;#e4f724&quot;, &quot;title&quot;: &quot;Exploring the Effects of Exercise on Memory and Cognition in Parkinson\\u00b4s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;cardiovascular training; stretching&quot;, &quot;sponsor&quot;: &quot;Heidelberg University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06580977&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 34.05223, &quot;lng&quot;: -118.24368, &quot;nct&quot;: &quot;NCT03775096&quot;, &quot;color&quot;: &quot;#c8597c&quot;, &quot;title&quot;: &quot;Adrenergic Blockers for Cardiac Changes in Early Parkinson&#x27;s Disease (Protocol 53136)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Carvedilol&quot;, &quot;sponsor&quot;: &quot;Michele Tagliati, MD&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03775096&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 31.86389, &quot;lng&quot;: 117.28083, &quot;nct&quot;: &quot;NCT06978920&quot;, &quot;color&quot;: &quot;#313b70&quot;, &quot;title&quot;: &quot;A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;Allogeneic dopaminergic neural precursor cell(NCR201)&quot;, &quot;sponsor&quot;: &quot;Nuwacell Biotechnologies Co., Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06978920&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: -32.88946, &quot;lng&quot;: -68.84582, &quot;nct&quot;: &quot;NCT06629389&quot;, &quot;color&quot;: &quot;#e71032&quot;, &quot;title&quot;: &quot;Clinical Trial with Cannabidiol (Kanbis\\u00ae) for Parkinson Disease Symptoms&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Cannabidiol 100 mg/ml; cannabidiol 300 mg/ml; Cannabidiol 400 mg/ml; Placebo&quot;, &quot;sponsor&quot;: &quot;Laboratorio Elea Phoenix S.A.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06629389&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.77483, &quot;lng&quot;: -84.29631, &quot;nct&quot;: &quot;NCT06088355&quot;, &quot;color&quot;: &quot;#5463d4&quot;, &quot;title&quot;: &quot;Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;HV-PDAE: High Volume Partnered Dance Aerobic Exercise; MV-PDAE: Moderate Volume Partnered Dance Aerobic Exercise; MV-WALK: Moderate Volume Walking&quot;, &quot;sponsor&quot;: &quot;VA Office of Research and Development&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06088355&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.8425, &quot;lng&quot;: 5.85278, &quot;nct&quot;: &quot;NCT06669455&quot;, &quot;color&quot;: &quot;#a793dc&quot;, &quot;title&quot;: &quot;An Integrated and Personalized Lifestyle Approach for People with Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Personalized and combined lifestyle approach&quot;, &quot;sponsor&quot;: &quot;Radboud University Medical Center&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06669455&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.51142, &quot;lng&quot;: 14.06252, &quot;nct&quot;: &quot;NCT06297538&quot;, &quot;color&quot;: &quot;#5033cc&quot;, &quot;title&quot;: &quot;Parkinson&#x27;s Disease and Gamma-transcranial Alternating Current Stimulation&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;gamma transcranial alternating current stimulation (tACS); sham transcranial alternating current stimulation (tACS)&quot;, &quot;sponsor&quot;: &quot;Neuromed IRCCS&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06297538&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 31.3141, &quot;lng&quot;: 34.62025, &quot;nct&quot;: &quot;NCT06730074&quot;, &quot;color&quot;: &quot;#5ad50b&quot;, &quot;title&quot;: &quot;A Novel Robotic System for Motor-cognitive Exercise for Patients With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Using a gamified rehabilitation system in a sitting position involving robots and music for the benefit of individuals with Parkinson&#x27;s disease (PD)&quot;, &quot;sponsor&quot;: &quot;Adi Negev-Nahalat Eran&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06730074&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.85341, &quot;lng&quot;: 2.3488, &quot;nct&quot;: &quot;NCT02800460&quot;, &quot;color&quot;: &quot;#c47948&quot;, &quot;title&quot;: &quot;New Approaches in MRI at 3T Dedicated to Targeting Subthalamic Nucleus on Parkinsonian Patients&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;fMRI-3T&quot;, &quot;sponsor&quot;: &quot;Institut National de la Sant\\u00e9 Et de la Recherche M\\u00e9dicale, France&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT02800460&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.70918, &quot;lng&quot;: -117.95367, &quot;nct&quot;: &quot;NCT06822517&quot;, &quot;color&quot;: &quot;#905d0c&quot;, &quot;title&quot;: &quot;A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;VENT-02; Placebo&quot;, &quot;sponsor&quot;: &quot;Ventus Therapeutics U.S., Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06822517&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.33939, &quot;lng&quot;: -121.89496, &quot;nct&quot;: &quot;NCT06822517&quot;, &quot;color&quot;: &quot;#905d0c&quot;, &quot;title&quot;: &quot;A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;VENT-02; Placebo&quot;, &quot;sponsor&quot;: &quot;Ventus Therapeutics U.S., Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06822517&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 34.19731, &quot;lng&quot;: -118.64398, &quot;nct&quot;: &quot;NCT06822517&quot;, &quot;color&quot;: &quot;#905d0c&quot;, &quot;title&quot;: &quot;A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;VENT-02; Placebo&quot;, &quot;sponsor&quot;: &quot;Ventus Therapeutics U.S., Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06822517&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.64777, &quot;lng&quot;: -104.98776, &quot;nct&quot;: &quot;NCT06822517&quot;, &quot;color&quot;: &quot;#905d0c&quot;, &quot;title&quot;: &quot;A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;VENT-02; Placebo&quot;, &quot;sponsor&quot;: &quot;Ventus Therapeutics U.S., Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06822517&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 25.95648, &quot;lng&quot;: -80.13921, &quot;nct&quot;: &quot;NCT06822517&quot;, &quot;color&quot;: &quot;#905d0c&quot;, &quot;title&quot;: &quot;A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;VENT-02; Placebo&quot;, &quot;sponsor&quot;: &quot;Ventus Therapeutics U.S., Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06822517&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.35869, &quot;lng&quot;: -80.0831, &quot;nct&quot;: &quot;NCT06822517&quot;, &quot;color&quot;: &quot;#905d0c&quot;, &quot;title&quot;: &quot;A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;VENT-02; Placebo&quot;, &quot;sponsor&quot;: &quot;Ventus Therapeutics U.S., Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06822517&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 25.72149, &quot;lng&quot;: -80.26838, &quot;nct&quot;: &quot;NCT06822517&quot;, &quot;color&quot;: &quot;#905d0c&quot;, &quot;title&quot;: &quot;A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;VENT-02; Placebo&quot;, &quot;sponsor&quot;: &quot;Ventus Therapeutics U.S., Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06822517&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.27119, &quot;lng&quot;: -80.2706, &quot;nct&quot;: &quot;NCT06822517&quot;, &quot;color&quot;: &quot;#905d0c&quot;, &quot;title&quot;: &quot;A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;VENT-02; Placebo&quot;, &quot;sponsor&quot;: &quot;Ventus Therapeutics U.S., Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06822517&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 25.5783, &quot;lng&quot;: -80.3377, &quot;nct&quot;: &quot;NCT06822517&quot;, &quot;color&quot;: &quot;#905d0c&quot;, &quot;title&quot;: &quot;A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;VENT-02; Placebo&quot;, &quot;sponsor&quot;: &quot;Ventus Therapeutics U.S., Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06822517&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.21081, &quot;lng&quot;: -81.02283, &quot;nct&quot;: &quot;NCT06822517&quot;, &quot;color&quot;: &quot;#905d0c&quot;, &quot;title&quot;: &quot;A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;VENT-02; Placebo&quot;, &quot;sponsor&quot;: &quot;Ventus Therapeutics U.S., Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06822517&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 25.81954, &quot;lng&quot;: -80.35533, &quot;nct&quot;: &quot;NCT06822517&quot;, &quot;color&quot;: &quot;#905d0c&quot;, &quot;title&quot;: &quot;A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;VENT-02; Placebo&quot;, &quot;sponsor&quot;: &quot;Ventus Therapeutics U.S., Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06822517&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 30.33218, &quot;lng&quot;: -81.65565, &quot;nct&quot;: &quot;NCT06822517&quot;, &quot;color&quot;: &quot;#905d0c&quot;, &quot;title&quot;: &quot;A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;VENT-02; Placebo&quot;, &quot;sponsor&quot;: &quot;Ventus Therapeutics U.S., Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06822517&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 28.62778, &quot;lng&quot;: -81.36312, &quot;nct&quot;: &quot;NCT06822517&quot;, &quot;color&quot;: &quot;#905d0c&quot;, &quot;title&quot;: &quot;A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;VENT-02; Placebo&quot;, &quot;sponsor&quot;: &quot;Ventus Therapeutics U.S., Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06822517&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 25.77427, &quot;lng&quot;: -80.19366, &quot;nct&quot;: &quot;NCT06822517&quot;, &quot;color&quot;: &quot;#905d0c&quot;, &quot;title&quot;: &quot;A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;VENT-02; Placebo&quot;, &quot;sponsor&quot;: &quot;Ventus Therapeutics U.S., Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06822517&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 28.6, &quot;lng&quot;: -81.33924, &quot;nct&quot;: &quot;NCT06822517&quot;, &quot;color&quot;: &quot;#905d0c&quot;, &quot;title&quot;: &quot;A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;VENT-02; Placebo&quot;, &quot;sponsor&quot;: &quot;Ventus Therapeutics U.S., Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06822517&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.57814, &quot;lng&quot;: -70.32172, &quot;nct&quot;: &quot;NCT06822517&quot;, &quot;color&quot;: &quot;#905d0c&quot;, &quot;title&quot;: &quot;A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;VENT-02; Placebo&quot;, &quot;sponsor&quot;: &quot;Ventus Therapeutics U.S., Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06822517&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.48531, &quot;lng&quot;: -83.37716, &quot;nct&quot;: &quot;NCT06822517&quot;, &quot;color&quot;: &quot;#905d0c&quot;, &quot;title&quot;: &quot;A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;VENT-02; Placebo&quot;, &quot;sponsor&quot;: &quot;Ventus Therapeutics U.S., Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06822517&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.12067, &quot;lng&quot;: -75.11795, &quot;nct&quot;: &quot;NCT06822517&quot;, &quot;color&quot;: &quot;#905d0c&quot;, &quot;title&quot;: &quot;A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;VENT-02; Placebo&quot;, &quot;sponsor&quot;: &quot;Ventus Therapeutics U.S., Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06822517&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 35.14953, &quot;lng&quot;: -90.04898, &quot;nct&quot;: &quot;NCT06822517&quot;, &quot;color&quot;: &quot;#905d0c&quot;, &quot;title&quot;: &quot;A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;VENT-02; Placebo&quot;, &quot;sponsor&quot;: &quot;Ventus Therapeutics U.S., Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06822517&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.96911, &quot;lng&quot;: -95.69717, &quot;nct&quot;: &quot;NCT06822517&quot;, &quot;color&quot;: &quot;#905d0c&quot;, &quot;title&quot;: &quot;A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;VENT-02; Placebo&quot;, &quot;sponsor&quot;: &quot;Ventus Therapeutics U.S., Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06822517&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 30.50826, &quot;lng&quot;: -97.6789, &quot;nct&quot;: &quot;NCT06822517&quot;, &quot;color&quot;: &quot;#905d0c&quot;, &quot;title&quot;: &quot;A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;VENT-02; Placebo&quot;, &quot;sponsor&quot;: &quot;Ventus Therapeutics U.S., Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06822517&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.65966, &quot;lng&quot;: -117.42908, &quot;nct&quot;: &quot;NCT06822517&quot;, &quot;color&quot;: &quot;#905d0c&quot;, &quot;title&quot;: &quot;A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;VENT-02; Placebo&quot;, &quot;sponsor&quot;: &quot;Ventus Therapeutics U.S., Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06822517&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.50921, &quot;lng&quot;: -111.89903, &quot;nct&quot;: &quot;NCT05424276&quot;, &quot;color&quot;: &quot;#cc0556&quot;, &quot;title&quot;: &quot;A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;IkT-148009; Placebo&quot;, &quot;sponsor&quot;: &quot;ABLi Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05424276&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 34.74648, &quot;lng&quot;: -92.28959, &quot;nct&quot;: &quot;NCT05424276&quot;, &quot;color&quot;: &quot;#cc0556&quot;, &quot;title&quot;: &quot;A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;IkT-148009; Placebo&quot;, &quot;sponsor&quot;: &quot;ABLi Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05424276&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 34.20112, &quot;lng&quot;: -118.53647, &quot;nct&quot;: &quot;NCT05424276&quot;, &quot;color&quot;: &quot;#cc0556&quot;, &quot;title&quot;: &quot;A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;IkT-148009; Placebo&quot;, &quot;sponsor&quot;: &quot;ABLi Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05424276&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.05343, &quot;lng&quot;: -73.53873, &quot;nct&quot;: &quot;NCT05424276&quot;, &quot;color&quot;: &quot;#cc0556&quot;, &quot;title&quot;: &quot;A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;IkT-148009; Placebo&quot;, &quot;sponsor&quot;: &quot;ABLi Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05424276&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.35869, &quot;lng&quot;: -80.0831, &quot;nct&quot;: &quot;NCT05424276&quot;, &quot;color&quot;: &quot;#cc0556&quot;, &quot;title&quot;: &quot;A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;IkT-148009; Placebo&quot;, &quot;sponsor&quot;: &quot;ABLi Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05424276&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 25.77427, &quot;lng&quot;: -80.19366, &quot;nct&quot;: &quot;NCT05424276&quot;, &quot;color&quot;: &quot;#cc0556&quot;, &quot;title&quot;: &quot;A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;IkT-148009; Placebo&quot;, &quot;sponsor&quot;: &quot;ABLi Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05424276&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.14234, &quot;lng&quot;: -81.79596, &quot;nct&quot;: &quot;NCT05424276&quot;, &quot;color&quot;: &quot;#cc0556&quot;, &quot;title&quot;: &quot;A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;IkT-148009; Placebo&quot;, &quot;sponsor&quot;: &quot;ABLi Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05424276&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 27.94752, &quot;lng&quot;: -82.45843, &quot;nct&quot;: &quot;NCT05424276&quot;, &quot;color&quot;: &quot;#cc0556&quot;, &quot;title&quot;: &quot;A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;IkT-148009; Placebo&quot;, &quot;sponsor&quot;: &quot;ABLi Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05424276&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.06538, &quot;lng&quot;: -71.24783, &quot;nct&quot;: &quot;NCT05424276&quot;, &quot;color&quot;: &quot;#cc0556&quot;, &quot;title&quot;: &quot;A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;IkT-148009; Placebo&quot;, &quot;sponsor&quot;: &quot;ABLi Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05424276&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.59177, &quot;lng&quot;: -70.94115, &quot;nct&quot;: &quot;NCT05424276&quot;, &quot;color&quot;: &quot;#cc0556&quot;, &quot;title&quot;: &quot;A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;IkT-148009; Placebo&quot;, &quot;sponsor&quot;: &quot;ABLi Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05424276&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.48531, &quot;lng&quot;: -83.37716, &quot;nct&quot;: &quot;NCT05424276&quot;, &quot;color&quot;: &quot;#cc0556&quot;, &quot;title&quot;: &quot;A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;IkT-148009; Placebo&quot;, &quot;sponsor&quot;: &quot;ABLi Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05424276&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.00969, &quot;lng&quot;: -93.34912, &quot;nct&quot;: &quot;NCT05424276&quot;, &quot;color&quot;: &quot;#cc0556&quot;, &quot;title&quot;: &quot;A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;IkT-148009; Placebo&quot;, &quot;sponsor&quot;: &quot;ABLi Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05424276&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.29039, &quot;lng&quot;: -74.01764, &quot;nct&quot;: &quot;NCT05424276&quot;, &quot;color&quot;: &quot;#cc0556&quot;, &quot;title&quot;: &quot;A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;IkT-148009; Placebo&quot;, &quot;sponsor&quot;: &quot;ABLi Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05424276&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 35.99403, &quot;lng&quot;: -78.89862, &quot;nct&quot;: &quot;NCT05424276&quot;, &quot;color&quot;: &quot;#cc0556&quot;, &quot;title&quot;: &quot;A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;IkT-148009; Placebo&quot;, &quot;sponsor&quot;: &quot;ABLi Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05424276&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 35.7721, &quot;lng&quot;: -78.63861, &quot;nct&quot;: &quot;NCT05424276&quot;, &quot;color&quot;: &quot;#cc0556&quot;, &quot;title&quot;: &quot;A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;IkT-148009; Placebo&quot;, &quot;sponsor&quot;: &quot;ABLi Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05424276&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.96118, &quot;lng&quot;: -82.99879, &quot;nct&quot;: &quot;NCT05424276&quot;, &quot;color&quot;: &quot;#cc0556&quot;, &quot;title&quot;: &quot;A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;IkT-148009; Placebo&quot;, &quot;sponsor&quot;: &quot;ABLi Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05424276&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.15398, &quot;lng&quot;: -95.99277, &quot;nct&quot;: &quot;NCT05424276&quot;, &quot;color&quot;: &quot;#cc0556&quot;, &quot;title&quot;: &quot;A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;IkT-148009; Placebo&quot;, &quot;sponsor&quot;: &quot;ABLi Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05424276&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.52345, &quot;lng&quot;: -122.67621, &quot;nct&quot;: &quot;NCT05424276&quot;, &quot;color&quot;: &quot;#cc0556&quot;, &quot;title&quot;: &quot;A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;IkT-148009; Placebo&quot;, &quot;sponsor&quot;: &quot;ABLi Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05424276&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 32.37896, &quot;lng&quot;: -80.69265, &quot;nct&quot;: &quot;NCT05424276&quot;, &quot;color&quot;: &quot;#cc0556&quot;, &quot;title&quot;: &quot;A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;IkT-148009; Placebo&quot;, &quot;sponsor&quot;: &quot;ABLi Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05424276&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 35.14953, &quot;lng&quot;: -90.04898, &quot;nct&quot;: &quot;NCT05424276&quot;, &quot;color&quot;: &quot;#cc0556&quot;, &quot;title&quot;: &quot;A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;IkT-148009; Placebo&quot;, &quot;sponsor&quot;: &quot;ABLi Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05424276&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.16589, &quot;lng&quot;: -86.78444, &quot;nct&quot;: &quot;NCT05424276&quot;, &quot;color&quot;: &quot;#cc0556&quot;, &quot;title&quot;: &quot;A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;IkT-148009; Placebo&quot;, &quot;sponsor&quot;: &quot;ABLi Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05424276&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.15067, &quot;lng&quot;: -96.82361, &quot;nct&quot;: &quot;NCT05424276&quot;, &quot;color&quot;: &quot;#cc0556&quot;, &quot;title&quot;: &quot;A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;IkT-148009; Placebo&quot;, &quot;sponsor&quot;: &quot;ABLi Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05424276&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.76328, &quot;lng&quot;: -95.36327, &quot;nct&quot;: &quot;NCT05424276&quot;, &quot;color&quot;: &quot;#cc0556&quot;, &quot;title&quot;: &quot;A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;IkT-148009; Placebo&quot;, &quot;sponsor&quot;: &quot;ABLi Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05424276&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 30.50826, &quot;lng&quot;: -97.6789, &quot;nct&quot;: &quot;NCT05424276&quot;, &quot;color&quot;: &quot;#cc0556&quot;, &quot;title&quot;: &quot;A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;IkT-148009; Placebo&quot;, &quot;sponsor&quot;: &quot;ABLi Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05424276&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.68149, &quot;lng&quot;: -122.20874, &quot;nct&quot;: &quot;NCT05424276&quot;, &quot;color&quot;: &quot;#cc0556&quot;, &quot;title&quot;: &quot;A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;IkT-148009; Placebo&quot;, &quot;sponsor&quot;: &quot;ABLi Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05424276&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.07305, &quot;lng&quot;: -89.40123, &quot;nct&quot;: &quot;NCT05424276&quot;, &quot;color&quot;: &quot;#cc0556&quot;, &quot;title&quot;: &quot;A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;IkT-148009; Placebo&quot;, &quot;sponsor&quot;: &quot;ABLi Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05424276&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.0389, &quot;lng&quot;: -87.90647, &quot;nct&quot;: &quot;NCT05424276&quot;, &quot;color&quot;: &quot;#cc0556&quot;, &quot;title&quot;: &quot;A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;IkT-148009; Placebo&quot;, &quot;sponsor&quot;: &quot;ABLi Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05424276&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.71982, &quot;lng&quot;: -72.83204, &quot;nct&quot;: &quot;NCT06954662&quot;, &quot;color&quot;: &quot;#0ca507&quot;, &quot;title&quot;: &quot;A Targeted Amino Acid Supplement for People With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;EARLY_PHASE1&quot;], &quot;interventions&quot;: &quot;Amino acid supplement; Whey Protein Supplement; Isonitrogenous Placebo Supplement&quot;, &quot;sponsor&quot;: &quot;UConn Health&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06954662&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 35.99403, &quot;lng&quot;: -78.89862, &quot;nct&quot;: &quot;NCT06618157&quot;, &quot;color&quot;: &quot;#7a30f1&quot;, &quot;title&quot;: &quot;Connectomic Guided DBS for Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Cerebellothalamic optimized deep brain stimulation; Pallidothalamic optimized deep brain stimulation; No deep brain stimulation; Usual care deep brain stimulation&quot;, &quot;sponsor&quot;: &quot;Duke University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06618157&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.15478, &quot;lng&quot;: -77.61556, &quot;nct&quot;: &quot;NCT05222386&quot;, &quot;color&quot;: &quot;#c0473a&quot;, &quot;title&quot;: &quot;Community Outreach for Palliative Engagement -- Parkinson Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Parkinson Disease Standard Care; Online Community-Supported Palliative Care&quot;, &quot;sponsor&quot;: &quot;University of Rochester&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05222386&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 42.35843, &quot;lng&quot;: -71.12589, &quot;nct&quot;: &quot;NCT06602544&quot;, &quot;color&quot;: &quot;#011a3e&quot;, &quot;title&quot;: &quot;Robotic Apparel to Prevent Freezing of Gait in Parkinson Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Robotic Apparel&quot;, &quot;sponsor&quot;: &quot;Harvard Medical School (HMS and HSDM)&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06602544&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.35843, &quot;lng&quot;: -71.05977, &quot;nct&quot;: &quot;NCT06602544&quot;, &quot;color&quot;: &quot;#011a3e&quot;, &quot;title&quot;: &quot;Robotic Apparel to Prevent Freezing of Gait in Parkinson Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Robotic Apparel&quot;, &quot;sponsor&quot;: &quot;Harvard Medical School (HMS and HSDM)&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06602544&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.9075, &quot;lng&quot;: 116.39723, &quot;nct&quot;: &quot;NCT06919822&quot;, &quot;color&quot;: &quot;#638a20&quot;, &quot;title&quot;: &quot;SCAN Electrical Stimulation for Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Personalized SCAN Electrical Stimulation&quot;, &quot;sponsor&quot;: &quot;Changping Laboratory&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06919822&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 25.05306, &quot;lng&quot;: 121.52639, &quot;nct&quot;: &quot;NCT05960331&quot;, &quot;color&quot;: &quot;#1db19d&quot;, &quot;title&quot;: &quot;Influence of Autonomy on Motor Learning in People With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Autonomy supported learning; Practice with predetermined feedback&quot;, &quot;sponsor&quot;: &quot;National Taiwan University Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05960331&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 38.19394, &quot;lng&quot;: 15.55256, &quot;nct&quot;: &quot;NCT06838975&quot;, &quot;color&quot;: &quot;#6e31c1&quot;, &quot;title&quot;: &quot;Virtual Reality Rehabilitation for Cognitive, Emotional, and Motor Recovery in Neurological Disorders&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;VR Training; traditional cognitive and motor rehabilitation following standard clinical practices&quot;, &quot;sponsor&quot;: &quot;IRCCS Centro Neurolesi Bonino Pulejo&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06838975&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 25.05306, &quot;lng&quot;: 121.52639, &quot;nct&quot;: &quot;NCT06476912&quot;, &quot;color&quot;: &quot;#c43119&quot;, &quot;title&quot;: &quot;Balance Exercise and Vagus Nerve Stimulation on Weight-shifting Control and Ambulation in Parkinson Disease and Anxiety&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;weight-shifting exercise&quot;, &quot;sponsor&quot;: &quot;National Taiwan University Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06476912&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.37403, &quot;lng&quot;: 4.88969, &quot;nct&quot;: &quot;NCT06416345&quot;, &quot;color&quot;: &quot;#816b85&quot;, &quot;title&quot;: &quot;Cue2Walk, Cost-effectiveness of Automated Freezing Detection and Provision of External Cues in Comparison to Usual Care in People With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Cue2Walk; Usual Care&quot;, &quot;sponsor&quot;: &quot;Amsterdam UMC, location VUmc&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06416345&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.16589, &quot;lng&quot;: -86.78444, &quot;nct&quot;: &quot;NCT05933681&quot;, &quot;color&quot;: &quot;#2ce865&quot;, &quot;title&quot;: &quot;Neurophysiology Biomarkers of Cognitive Impairment Associated With Deep Brain Stimulation&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Neural recordings and stimulation&quot;, &quot;sponsor&quot;: &quot;Vanderbilt University Medical Center&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05933681&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 38.19394, &quot;lng&quot;: 15.55256, &quot;nct&quot;: &quot;NCT07066137&quot;, &quot;color&quot;: &quot;#3b1190&quot;, &quot;title&quot;: &quot;Motor Learning in Health and Movement Disorders: Role of Physical Activity and Advanced Devices&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;CAREN; Control group&quot;, &quot;sponsor&quot;: &quot;IRCCS Centro Neurolesi Bonino Pulejo&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07066137&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 31.86389, &quot;lng&quot;: 117.28083, &quot;nct&quot;: &quot;NCT07118956&quot;, &quot;color&quot;: &quot;#7d6bfb&quot;, &quot;title&quot;: &quot;Respiratory-gated Transcutaneous Auricular Vagus Nerve Stimulation for Improving Apathy in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Active RAVANS; Sham RAVANS&quot;, &quot;sponsor&quot;: &quot;Anhui Medical University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07118956&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 22.61626, &quot;lng&quot;: 120.31333, &quot;nct&quot;: &quot;NCT06548256&quot;, &quot;color&quot;: &quot;#247b7c&quot;, &quot;title&quot;: &quot;The Clinical Application of Clostridium Butyricum Miyairisan for Motor and Non-motor Symptoms in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Miyarisan-BM (Clostridium Butyricum Miyairi)&quot;, &quot;sponsor&quot;: &quot;Kaohsiung Medical University Chung-Ho Memorial Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06548256&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.77493, &quot;lng&quot;: -122.41942, &quot;nct&quot;: &quot;NCT05065151&quot;, &quot;color&quot;: &quot;#f782e5&quot;, &quot;title&quot;: &quot;Understanding Motivation in Parkinson&#x27;s Patients Through Neurophysiology&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Stimulation on; Stimulation off; Decision Making Task&quot;, &quot;sponsor&quot;: &quot;University of California, San Francisco&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05065151&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: -33.45694, &quot;lng&quot;: -70.64827, &quot;nct&quot;: &quot;NCT06584383&quot;, &quot;color&quot;: &quot;#1ac126&quot;, &quot;title&quot;: &quot;A Prospective, Randomized, Controlled Trial to Test Safety and Effectiveness of Unilateral Exablate MR-guided Focused Ultrasound Subthalamotomy in Patients With Early-Stage Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Exablate MRgFUS subthalamotomy; Best Medical Treatment&quot;, &quot;sponsor&quot;: &quot;InSightec&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06584383&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 54.32133, &quot;lng&quot;: 10.13489, &quot;nct&quot;: &quot;NCT06584383&quot;, &quot;color&quot;: &quot;#1ac126&quot;, &quot;title&quot;: &quot;A Prospective, Randomized, Controlled Trial to Test Safety and Effectiveness of Unilateral Exablate MR-guided Focused Ultrasound Subthalamotomy in Patients With Early-Stage Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Exablate MRgFUS subthalamotomy; Best Medical Treatment&quot;, &quot;sponsor&quot;: &quot;InSightec&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06584383&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.32234, &quot;lng&quot;: -3.86496, &quot;nct&quot;: &quot;NCT06584383&quot;, &quot;color&quot;: &quot;#1ac126&quot;, &quot;title&quot;: &quot;A Prospective, Randomized, Controlled Trial to Test Safety and Effectiveness of Unilateral Exablate MR-guided Focused Ultrasound Subthalamotomy in Patients With Early-Stage Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Exablate MRgFUS subthalamotomy; Best Medical Treatment&quot;, &quot;sponsor&quot;: &quot;InSightec&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06584383&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.81687, &quot;lng&quot;: -1.64323, &quot;nct&quot;: &quot;NCT06584383&quot;, &quot;color&quot;: &quot;#1ac126&quot;, &quot;title&quot;: &quot;A Prospective, Randomized, Controlled Trial to Test Safety and Effectiveness of Unilateral Exablate MR-guided Focused Ultrasound Subthalamotomy in Patients With Early-Stage Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Exablate MRgFUS subthalamotomy; Best Medical Treatment&quot;, &quot;sponsor&quot;: &quot;InSightec&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06584383&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.29038, &quot;lng&quot;: -76.61219, &quot;nct&quot;: &quot;NCT05824728&quot;, &quot;color&quot;: &quot;#68e843&quot;, &quot;title&quot;: &quot;Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson&#x27;s Disease Related Psychosis&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;AGB101&quot;, &quot;sponsor&quot;: &quot;Johns Hopkins University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05824728&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.01384, &quot;lng&quot;: 28.94966, &quot;nct&quot;: &quot;NCT06490809&quot;, &quot;color&quot;: &quot;#5de9d7&quot;, &quot;title&quot;: &quot;Minimal Clinically Important Difference of the Box and Block Test in Parkinson&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Physiotherapy&quot;, &quot;sponsor&quot;: &quot;Emre \\u015eenocak&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06490809&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.77493, &quot;lng&quot;: -122.41942, &quot;nct&quot;: &quot;NCT04675398&quot;, &quot;color&quot;: &quot;#213ffc&quot;, &quot;title&quot;: &quot;Adaptive Deep Brain Stimulation to Improve Motor and Gait Functions in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Summit RC+S&quot;, &quot;sponsor&quot;: &quot;Doris Wang, MD, PhD&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04675398&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: -23.5475, &quot;lng&quot;: -46.63611, &quot;nct&quot;: &quot;NCT05008289&quot;, &quot;color&quot;: &quot;#75834c&quot;, &quot;title&quot;: &quot;Effects of Magnetic Stimulation of the Dorsal Spinal Cord on Gait in Patients With Parkinson\\u00b4s Disease and Deep Brain Stimulation&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Magnetic transcutaneous spinal cord stimulation; Transcutaneous electrical nerve stimulation&quot;, &quot;sponsor&quot;: &quot;University of Sao Paulo General Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05008289&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.60426, &quot;lng&quot;: 1.44367, &quot;nct&quot;: &quot;NCT06885541&quot;, &quot;color&quot;: &quot;#af86b1&quot;, &quot;title&quot;: &quot;Detection of Internal Tremors by Oscillometry in Parkinson&#x27;s Patient&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Detection of objective internal tremors&quot;, &quot;sponsor&quot;: &quot;University Hospital, Toulouse&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06885541&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.61968, &quot;lng&quot;: -95.63495, &quot;nct&quot;: &quot;NCT04995081&quot;, &quot;color&quot;: &quot;#840034&quot;, &quot;title&quot;: &quot;Clinical Trial for Parkinson&#x27;s Disease Using Allogeneic HB-adMSCs (Early and Moderate PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Biological/Vaccine: Allogeneic HB-adMSCs; Placebo&quot;, &quot;sponsor&quot;: &quot;Hope Biosciences Stem Cell Research Foundation&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04995081&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.4165, &quot;lng&quot;: -3.70256, &quot;nct&quot;: &quot;NCT07095400&quot;, &quot;color&quot;: &quot;#fa5046&quot;, &quot;title&quot;: &quot;Evaluation of Functional and Biochemical Effectiveness of a Strength Training Protocol in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;strength training&quot;, &quot;sponsor&quot;: &quot;Universidad Villanueva&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07095400&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.35843, &quot;lng&quot;: -71.05977, &quot;nct&quot;: &quot;NCT04286308&quot;, &quot;color&quot;: &quot;#843e8c&quot;, &quot;title&quot;: &quot;Cortical-Basal Ganglia Speech Networks&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;electrophysiological data collection&quot;, &quot;sponsor&quot;: &quot;Massachusetts General Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04286308&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 34.05223, &quot;lng&quot;: -118.24368, &quot;nct&quot;: &quot;NCT05307055&quot;, &quot;color&quot;: &quot;#52fccb&quot;, &quot;title&quot;: &quot;Evaluation of Neurocognitive Changes in Parkinson&#x27;s Disease After Low Frequency Burst Stimulation&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;STN DBS - Theta Burst; STN DBS - Gamma&quot;, &quot;sponsor&quot;: &quot;University of Southern California&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05307055&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.37403, &quot;lng&quot;: 4.88969, &quot;nct&quot;: &quot;NCT05357638&quot;, &quot;color&quot;: &quot;#545ddc&quot;, &quot;title&quot;: &quot;Physical Training for People With Parkinson&#x27;s Disease and Multiple Sclerosis: Effect on Mind and Body&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;High Intensity Interval Training (HIIT); Continuous Aerobic Training (CAT); Movement Advice&quot;, &quot;sponsor&quot;: &quot;Amsterdam UMC, location VUmc&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05357638&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.05089, &quot;lng&quot;: 13.73832, &quot;nct&quot;: &quot;NCT04329676&quot;, &quot;color&quot;: &quot;#6e0a6d&quot;, &quot;title&quot;: &quot;directSTIM Deep Brain Stimulation System Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Deep Brain Stimulation&quot;, &quot;sponsor&quot;: &quot;Aleva Neurotherapeutics SA&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04329676&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.9959, &quot;lng&quot;: 7.85222, &quot;nct&quot;: &quot;NCT04329676&quot;, &quot;color&quot;: &quot;#6e0a6d&quot;, &quot;title&quot;: &quot;directSTIM Deep Brain Stimulation System Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Deep Brain Stimulation&quot;, &quot;sponsor&quot;: &quot;Aleva Neurotherapeutics SA&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04329676&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 53.55073, &quot;lng&quot;: 9.99302, &quot;nct&quot;: &quot;NCT04329676&quot;, &quot;color&quot;: &quot;#6e0a6d&quot;, &quot;title&quot;: &quot;directSTIM Deep Brain Stimulation System Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Deep Brain Stimulation&quot;, &quot;sponsor&quot;: &quot;Aleva Neurotherapeutics SA&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04329676&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.37052, &quot;lng&quot;: 9.73322, &quot;nct&quot;: &quot;NCT04329676&quot;, &quot;color&quot;: &quot;#6e0a6d&quot;, &quot;title&quot;: &quot;directSTIM Deep Brain Stimulation System Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Deep Brain Stimulation&quot;, &quot;sponsor&quot;: &quot;Aleva Neurotherapeutics SA&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04329676&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 54.32133, &quot;lng&quot;: 10.13489, &quot;nct&quot;: &quot;NCT04329676&quot;, &quot;color&quot;: &quot;#6e0a6d&quot;, &quot;title&quot;: &quot;directSTIM Deep Brain Stimulation System Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Deep Brain Stimulation&quot;, &quot;sponsor&quot;: &quot;Aleva Neurotherapeutics SA&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04329676&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.96236, &quot;lng&quot;: 7.62571, &quot;nct&quot;: &quot;NCT04329676&quot;, &quot;color&quot;: &quot;#6e0a6d&quot;, &quot;title&quot;: &quot;directSTIM Deep Brain Stimulation System Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Deep Brain Stimulation&quot;, &quot;sponsor&quot;: &quot;Aleva Neurotherapeutics SA&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04329676&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.70643, &quot;lng&quot;: -79.39864, &quot;nct&quot;: &quot;NCT04946812&quot;, &quot;color&quot;: &quot;#8ce8e1&quot;, &quot;title&quot;: &quot;Split-belt Treadmill Training to Rehabilitate Freezing of Gait and Balance in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Split-belt treadmill training&quot;, &quot;sponsor&quot;: &quot;University of Toronto&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04946812&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.9075, &quot;lng&quot;: 116.39723, &quot;nct&quot;: &quot;NCT07028632&quot;, &quot;color&quot;: &quot;#a90763&quot;, &quot;title&quot;: &quot;The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Human Dopaminergic Progenitor Cells&quot;, &quot;sponsor&quot;: &quot;iRegene Therapeutics Co., Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07028632&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.80307, &quot;lng&quot;: -118.07256, &quot;nct&quot;: &quot;NCT06809400&quot;, &quot;color&quot;: &quot;#3d658d&quot;, &quot;title&quot;: &quot;A Study of LY4006896 in Healthy Participants and Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;LY4006896; Placebo&quot;, &quot;sponsor&quot;: &quot;Eli Lilly and Company&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06809400&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 28.62778, &quot;lng&quot;: -81.36312, &quot;nct&quot;: &quot;NCT06809400&quot;, &quot;color&quot;: &quot;#3d658d&quot;, &quot;title&quot;: &quot;A Study of LY4006896 in Healthy Participants and Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;LY4006896; Placebo&quot;, &quot;sponsor&quot;: &quot;Eli Lilly and Company&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06809400&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.14234, &quot;lng&quot;: -81.79596, &quot;nct&quot;: &quot;NCT06809400&quot;, &quot;color&quot;: &quot;#3d658d&quot;, &quot;title&quot;: &quot;A Study of LY4006896 in Healthy Participants and Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;LY4006896; Placebo&quot;, &quot;sponsor&quot;: &quot;Eli Lilly and Company&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06809400&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 28.53834, &quot;lng&quot;: -81.37924, &quot;nct&quot;: &quot;NCT06809400&quot;, &quot;color&quot;: &quot;#3d658d&quot;, &quot;title&quot;: &quot;A Study of LY4006896 in Healthy Participants and Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;LY4006896; Placebo&quot;, &quot;sponsor&quot;: &quot;Eli Lilly and Company&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06809400&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 28.93408, &quot;lng&quot;: -81.95994, &quot;nct&quot;: &quot;NCT06809400&quot;, &quot;color&quot;: &quot;#3d658d&quot;, &quot;title&quot;: &quot;A Study of LY4006896 in Healthy Participants and Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;LY4006896; Placebo&quot;, &quot;sponsor&quot;: &quot;Eli Lilly and Company&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06809400&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.77483, &quot;lng&quot;: -84.29631, &quot;nct&quot;: &quot;NCT06809400&quot;, &quot;color&quot;: &quot;#3d658d&quot;, &quot;title&quot;: &quot;A Study of LY4006896 in Healthy Participants and Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;LY4006896; Placebo&quot;, &quot;sponsor&quot;: &quot;Eli Lilly and Company&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06809400&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.48531, &quot;lng&quot;: -83.37716, &quot;nct&quot;: &quot;NCT06809400&quot;, &quot;color&quot;: &quot;#3d658d&quot;, &quot;title&quot;: &quot;A Study of LY4006896 in Healthy Participants and Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;LY4006896; Placebo&quot;, &quot;sponsor&quot;: &quot;Eli Lilly and Company&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06809400&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 30.26715, &quot;lng&quot;: -97.74306, &quot;nct&quot;: &quot;NCT06809400&quot;, &quot;color&quot;: &quot;#3d658d&quot;, &quot;title&quot;: &quot;A Study of LY4006896 in Healthy Participants and Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;LY4006896; Placebo&quot;, &quot;sponsor&quot;: &quot;Eli Lilly and Company&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06809400&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.68149, &quot;lng&quot;: -122.20874, &quot;nct&quot;: &quot;NCT06809400&quot;, &quot;color&quot;: &quot;#3d658d&quot;, &quot;title&quot;: &quot;A Study of LY4006896 in Healthy Participants and Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;LY4006896; Placebo&quot;, &quot;sponsor&quot;: &quot;Eli Lilly and Company&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06809400&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.1956, &quot;lng&quot;: 131.37829, &quot;nct&quot;: &quot;NCT06809400&quot;, &quot;color&quot;: &quot;#3d658d&quot;, &quot;title&quot;: &quot;A Study of LY4006896 in Healthy Participants and Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;LY4006896; Placebo&quot;, &quot;sponsor&quot;: &quot;Eli Lilly and Company&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06809400&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 35.65583, &quot;lng&quot;: 139.32389, &quot;nct&quot;: &quot;NCT06809400&quot;, &quot;color&quot;: &quot;#3d658d&quot;, &quot;title&quot;: &quot;A Study of LY4006896 in Healthy Participants and Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;LY4006896; Placebo&quot;, &quot;sponsor&quot;: &quot;Eli Lilly and Company&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06809400&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.46427, &quot;lng&quot;: 9.18951, &quot;nct&quot;: &quot;NCT04635436&quot;, &quot;color&quot;: &quot;#db1c30&quot;, &quot;title&quot;: &quot;Efficacy of Split Gait in the Treatment of Dynamic Asymmetries in Subjects With Pathologic Claudication&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Split-belt treadmill walking.&quot;, &quot;sponsor&quot;: &quot;Istituto Auxologico Italiano&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04635436&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 23.7104, &quot;lng&quot;: 90.40744, &quot;nct&quot;: &quot;NCT05959044&quot;, &quot;color&quot;: &quot;#857b4c&quot;, &quot;title&quot;: &quot;Effect of Folic Acid in Levodopa Treated Parkinson&#x27;s Disease Patients&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Folic Acid Tablet; Placebo&quot;, &quot;sponsor&quot;: &quot;Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05959044&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.85003, &quot;lng&quot;: -87.65005, &quot;nct&quot;: &quot;NCT05862649&quot;, &quot;color&quot;: &quot;#c82231&quot;, &quot;title&quot;: &quot;Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;NeuraLight&quot;, &quot;sponsor&quot;: &quot;NeuraLight&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05862649&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.20686, &quot;lng&quot;: -8.41996, &quot;nct&quot;: &quot;NCT05862649&quot;, &quot;color&quot;: &quot;#c82231&quot;, &quot;title&quot;: &quot;Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;NeuraLight&quot;, &quot;sponsor&quot;: &quot;NeuraLight&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05862649&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.38283, &quot;lng&quot;: -5.97317, &quot;nct&quot;: &quot;NCT05862649&quot;, &quot;color&quot;: &quot;#c82231&quot;, &quot;title&quot;: &quot;Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;NeuraLight&quot;, &quot;sponsor&quot;: &quot;NeuraLight&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05862649&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.36667, &quot;lng&quot;: 8.55, &quot;nct&quot;: &quot;NCT05862649&quot;, &quot;color&quot;: &quot;#c82231&quot;, &quot;title&quot;: &quot;Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;NeuraLight&quot;, &quot;sponsor&quot;: &quot;NeuraLight&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05862649&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.75222, &quot;lng&quot;: -1.25596, &quot;nct&quot;: &quot;NCT05862649&quot;, &quot;color&quot;: &quot;#c82231&quot;, &quot;title&quot;: &quot;Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;NeuraLight&quot;, &quot;sponsor&quot;: &quot;NeuraLight&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05862649&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 32.06167, &quot;lng&quot;: 118.77778, &quot;nct&quot;: &quot;NCT05850598&quot;, &quot;color&quot;: &quot;#cfd1d7&quot;, &quot;title&quot;: &quot;Effect of rTMS of the Cerebellum on Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;sham rTMS; active rTMS&quot;, &quot;sponsor&quot;: &quot;Jiangsu Province Nanjing Brain Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05850598&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.98376, &quot;lng&quot;: 23.72784, &quot;nct&quot;: &quot;NCT06220084&quot;, &quot;color&quot;: &quot;#9b543e&quot;, &quot;title&quot;: &quot;The UPbeating GReek Application of DancE in Parkinson&#x27;s Disease Clinical Trial&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Dance for PD\\u00ae&quot;, &quot;sponsor&quot;: &quot;University of West Attica&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06220084&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.76328, &quot;lng&quot;: -95.36327, &quot;nct&quot;: &quot;NCT06991335&quot;, &quot;color&quot;: &quot;#fd2400&quot;, &quot;title&quot;: &quot;VC/VS for Apathy in PD&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Deep Brain Stimulation&quot;, &quot;sponsor&quot;: &quot;Nora Vanegas&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06991335&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.19205, &quot;lng&quot;: 9.15917, &quot;nct&quot;: &quot;NCT04876339&quot;, &quot;color&quot;: &quot;#0ae23a&quot;, &quot;title&quot;: &quot;Sonification Techniques for Gait Training&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Gait rehabilitation with \\&quot;sonification\\&quot;; Standard gait rehabilitation (without sonification)&quot;, &quot;sponsor&quot;: &quot;Istituti Clinici Scientifici Maugeri SpA&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04876339&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.47391, &quot;lng&quot;: -0.37966, &quot;nct&quot;: &quot;NCT04788693&quot;, &quot;color&quot;: &quot;#559ede&quot;, &quot;title&quot;: &quot;Effects of Gait Rehabilitation With Motor Imagery in People With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Physical rehabilitation of gait with motor imagery; Physical rehabilitation of gait without motor imagery&quot;, &quot;sponsor&quot;: &quot;University of Valencia&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04788693&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.42411, &quot;lng&quot;: -122.16608, &quot;nct&quot;: &quot;NCT04043403&quot;, &quot;color&quot;: &quot;#3c99a2&quot;, &quot;title&quot;: &quot;Bilateral Closed Loop Deep Brain Stimulation for Freezing of Gait Using Neural and Kinematic Feedback&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Open Loop DBS; Adaptive (Closed Loop) DBS; Intermittent Open Loop DBS&quot;, &quot;sponsor&quot;: &quot;Stanford University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04043403&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 49.24966, &quot;lng&quot;: -123.11934, &quot;nct&quot;: &quot;NCT04784494&quot;, &quot;color&quot;: &quot;#479043&quot;, &quot;title&quot;: &quot;MST for Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Magnetic Seizure Theapy (MagPro XP MST)&quot;, &quot;sponsor&quot;: &quot;University of British Columbia&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04784494&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.12753, &quot;lng&quot;: -87.82895, &quot;nct&quot;: &quot;NCT07127120&quot;, &quot;color&quot;: &quot;#5155a3&quot;, &quot;title&quot;: &quot;Open Label Single Arm Prebiotic Pilot Trial SR001&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Prebiotic fiber blend&quot;, &quot;sponsor&quot;: &quot;Sorridi Therapeutics&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07127120&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.16589, &quot;lng&quot;: -86.78444, &quot;nct&quot;: &quot;NCT04768101&quot;, &quot;color&quot;: &quot;#b4fa03&quot;, &quot;title&quot;: &quot;Quantitative Imaging of Brain Glymphatic Function in Humans&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;EARLY_PHASE1&quot;], &quot;interventions&quot;: &quot;[11C]-PIB&quot;, &quot;sponsor&quot;: &quot;Vanderbilt University Medical Center&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04768101&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.89797, &quot;lng&quot;: -8.47061, &quot;nct&quot;: &quot;NCT06192628&quot;, &quot;color&quot;: &quot;#39e23c&quot;, &quot;title&quot;: &quot;Behavioural Change Techniques for Physical Activity and Exercise Adherence Among People With Parkinson&#x27;s&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Parkinson&#x27;s Exercise and Education Programme; Parkinson&#x27;s Exercise and Education Programme and Behavioural Change&quot;, &quot;sponsor&quot;: &quot;University College Cork&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06192628&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 32.08088, &quot;lng&quot;: 34.78057, &quot;nct&quot;: &quot;NCT07105787&quot;, &quot;color&quot;: &quot;#b0fb15&quot;, &quot;title&quot;: &quot;Steps Against the Burden of Parkinson&#x27;s Disease - TelAviv/Bologna&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;SDTT + VR triggered adaptations; Speed-dependent treadmill training (SDTT)&quot;, &quot;sponsor&quot;: &quot;University of Kiel&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07105787&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 44.49381, &quot;lng&quot;: 11.33875, &quot;nct&quot;: &quot;NCT07105787&quot;, &quot;color&quot;: &quot;#b0fb15&quot;, &quot;title&quot;: &quot;Steps Against the Burden of Parkinson&#x27;s Disease - TelAviv/Bologna&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;SDTT + VR triggered adaptations; Speed-dependent treadmill training (SDTT)&quot;, &quot;sponsor&quot;: &quot;University of Kiel&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07105787&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 38.72509, &quot;lng&quot;: -9.1498, &quot;nct&quot;: &quot;NCT06094309&quot;, &quot;color&quot;: &quot;#25b1f8&quot;, &quot;title&quot;: &quot;Effectiveness of Botulinum Toxin in Freezing of Gate in Parkinson&#x27;s Disease Walking in Parkinson&#x27;s Disease.&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Botulinum toxin type A injection&quot;, &quot;sponsor&quot;: &quot;Centro Hospitalar de Lisboa Central&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06094309&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.8425, &quot;lng&quot;: 5.85278, &quot;nct&quot;: &quot;NCT06193252&quot;, &quot;color&quot;: &quot;#2ad21a&quot;, &quot;title&quot;: &quot;Slow-SPEED-NL: Slowing Parkinson&#x27;s Early Through Exercise Dosage-Netherlands&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Increase of physical activity volume and intensity with the use of a motivational smartphone application&quot;, &quot;sponsor&quot;: &quot;Radboud University Medical Center&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06193252&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.29038, &quot;lng&quot;: -76.61219, &quot;nct&quot;: &quot;NCT06997484&quot;, &quot;color&quot;: &quot;#e4d84f&quot;, &quot;title&quot;: &quot;First-in-Human Single and Multiple Dose of HL-400&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;HL-400; Placebo&quot;, &quot;sponsor&quot;: &quot;Highlightll Pharmaceutical (USA) LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06997484&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.50921, &quot;lng&quot;: -111.89903, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 36.06258, &quot;lng&quot;: -94.15743, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 34.74648, &quot;lng&quot;: -92.28959, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 37.87159, &quot;lng&quot;: -122.27275, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 33.70918, &quot;lng&quot;: -117.95367, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 33.66946, &quot;lng&quot;: -117.82311, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 34.04835, &quot;lng&quot;: -117.26115, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 34.05223, &quot;lng&quot;: -118.24368, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 37.22661, &quot;lng&quot;: -121.97468, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 37.44188, &quot;lng&quot;: -122.14302, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 33.95335, &quot;lng&quot;: -117.39616, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 38.58157, &quot;lng&quot;: -121.4944, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 37.77493, &quot;lng&quot;: -122.41942, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 39.72943, &quot;lng&quot;: -104.83192, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 39.06387, &quot;lng&quot;: -108.55065, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 41.71982, &quot;lng&quot;: -72.83204, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 41.76371, &quot;lng&quot;: -72.68509, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 29.65163, &quot;lng&quot;: -82.32483, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 30.33218, &quot;lng&quot;: -81.65565, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 25.77427, &quot;lng&quot;: -80.19366, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 33.749, &quot;lng&quot;: -84.38798, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 33.47097, &quot;lng&quot;: -81.97484, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 21.30694, &quot;lng&quot;: -157.85833, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 41.85003, &quot;lng&quot;: -87.65005, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 41.85364, &quot;lng&quot;: -87.8395, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 39.11417, &quot;lng&quot;: -94.62746, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 37.98869, &quot;lng&quot;: -84.47772, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 29.95465, &quot;lng&quot;: -90.07507, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 42.35843, &quot;lng&quot;: -71.05977, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 42.73698, &quot;lng&quot;: -84.48387, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 42.48531, &quot;lng&quot;: -83.37716, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 44.02163, &quot;lng&quot;: -92.4699, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 43.64229, &quot;lng&quot;: -72.25176, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 42.65258, &quot;lng&quot;: -73.75623, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.94149, &quot;lng&quot;: -73.10594, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.86232, &quot;lng&quot;: -73.63374, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.80066, &quot;lng&quot;: -73.72846, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.79788, &quot;lng&quot;: -73.69957, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.71427, &quot;lng&quot;: -74.00597, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 43.15478, &quot;lng&quot;: -77.61556, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.92565, &quot;lng&quot;: -73.14094, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 35.99403, &quot;lng&quot;: -78.89862, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 36.09986, &quot;lng&quot;: -80.24422, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 39.12711, &quot;lng&quot;: -84.51439, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 41.4995, &quot;lng&quot;: -81.69541, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 39.96118, &quot;lng&quot;: -82.99879, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 45.52345, &quot;lng&quot;: -122.67621, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 39.95238, &quot;lng&quot;: -75.16362, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.44062, &quot;lng&quot;: -79.99589, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.00289, &quot;lng&quot;: -75.27074, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 32.77632, &quot;lng&quot;: -79.93275, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 35.14953, &quot;lng&quot;: -90.04898, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 36.16589, &quot;lng&quot;: -86.78444, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 32.78306, &quot;lng&quot;: -96.80667, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 29.76328, &quot;lng&quot;: -95.36327, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 29.42412, &quot;lng&quot;: -98.49363, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.66689, &quot;lng&quot;: -111.88799, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.76078, &quot;lng&quot;: -111.89105, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 44.47588, &quot;lng&quot;: -73.21207, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 47.68149, &quot;lng&quot;: -122.20874, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 43.07305, &quot;lng&quot;: -89.40123, &quot;nct&quot;: &quot;NCT03924414&quot;, &quot;color&quot;: &quot;#a36837&quot;, &quot;title&quot;: &quot;Trial of Parkinson&#x27;s And Zoledronic Acid&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Zoledronic Acid 5Mg/Bag 100Ml Inj; Placebo&quot;, &quot;sponsor&quot;: &quot;California Pacific Medical Center Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03924414&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 30.00944, &quot;lng&quot;: 31.20861, &quot;nct&quot;: &quot;NCT06104072&quot;, &quot;color&quot;: &quot;#749778&quot;, &quot;title&quot;: &quot;Effect of Adding Computerized Cognitive Training on Balance, Locomotion and Cognition in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;REHACOM Software; A Designed Physical Therapy Program&quot;, &quot;sponsor&quot;: &quot;Engy Badreldin Saleh Moustafa, PhD&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06104072&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.4995, &quot;lng&quot;: -81.69541, &quot;nct&quot;: &quot;NCT06013956&quot;, &quot;color&quot;: &quot;#a79cf5&quot;, &quot;title&quot;: &quot;Personalized Real-Time DBS and PD Mechanisms&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Neurostimulation; Carbidopa 25/Levodopa 100Mg Tab&quot;, &quot;sponsor&quot;: &quot;David Escobar&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06013956&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.8425, &quot;lng&quot;: 5.85278, &quot;nct&quot;: &quot;NCT06142448&quot;, &quot;color&quot;: &quot;#7fb660&quot;, &quot;title&quot;: &quot;The Effect of Compensation Strategies on Gait Impairment in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Cueing app&quot;, &quot;sponsor&quot;: &quot;Radboud University Medical Center&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06142448&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 31.22222, &quot;lng&quot;: 121.45806, &quot;nct&quot;: &quot;NCT05382858&quot;, &quot;color&quot;: &quot;#17f64e&quot;, &quot;title&quot;: &quot;PSA Versus STN DBS for TD-PD&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Deep brain stimulation&quot;, &quot;sponsor&quot;: &quot;Ruijin Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05382858&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.68372, &quot;lng&quot;: -75.74966, &quot;nct&quot;: &quot;NCT06916260&quot;, &quot;color&quot;: &quot;#f6da85&quot;, &quot;title&quot;: &quot;Light Therapy Intervention in Individuals With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Red Light (PDT); Placebo&quot;, &quot;sponsor&quot;: &quot;University of Delaware&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06916260&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.08804, &quot;lng&quot;: 14.42076, &quot;nct&quot;: &quot;NCT06893055&quot;, &quot;color&quot;: &quot;#b8b7f7&quot;, &quot;title&quot;: &quot;Strength-Endurance Circuit Training in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Strength-Endurance Training; Endurance Training&quot;, &quot;sponsor&quot;: &quot;General University Hospital, Prague&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06893055&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 32.71571, &quot;lng&quot;: -117.16472, &quot;nct&quot;: &quot;NCT05400174&quot;, &quot;color&quot;: &quot;#691a35&quot;, &quot;title&quot;: &quot;Blood Pressure Effects on Cognition and Brain Blood Flow in PD&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Tilt table (upright position)&quot;, &quot;sponsor&quot;: &quot;University of California, San Diego&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05400174&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.44838, &quot;lng&quot;: -112.07404, &quot;nct&quot;: &quot;NCT05766813&quot;, &quot;color&quot;: &quot;#6adfaf&quot;, &quot;title&quot;: &quot;Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lenrispodun; Placebo&quot;, &quot;sponsor&quot;: &quot;Intra-Cellular Therapies, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05766813&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.50921, &quot;lng&quot;: -111.89903, &quot;nct&quot;: &quot;NCT05766813&quot;, &quot;color&quot;: &quot;#6adfaf&quot;, &quot;title&quot;: &quot;Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lenrispodun; Placebo&quot;, &quot;sponsor&quot;: &quot;Intra-Cellular Therapies, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05766813&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.66946, &quot;lng&quot;: -117.82311, &quot;nct&quot;: &quot;NCT05766813&quot;, &quot;color&quot;: &quot;#6adfaf&quot;, &quot;title&quot;: &quot;Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lenrispodun; Placebo&quot;, &quot;sponsor&quot;: &quot;Intra-Cellular Therapies, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05766813&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 34.04835, &quot;lng&quot;: -117.26115, &quot;nct&quot;: &quot;NCT05766813&quot;, &quot;color&quot;: &quot;#6adfaf&quot;, &quot;title&quot;: &quot;Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lenrispodun; Placebo&quot;, &quot;sponsor&quot;: &quot;Intra-Cellular Therapies, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05766813&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 28.66111, &quot;lng&quot;: -81.36562, &quot;nct&quot;: &quot;NCT05766813&quot;, &quot;color&quot;: &quot;#6adfaf&quot;, &quot;title&quot;: &quot;Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lenrispodun; Placebo&quot;, &quot;sponsor&quot;: &quot;Intra-Cellular Therapies, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05766813&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.35869, &quot;lng&quot;: -80.0831, &quot;nct&quot;: &quot;NCT05766813&quot;, &quot;color&quot;: &quot;#6adfaf&quot;, &quot;title&quot;: &quot;Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lenrispodun; Placebo&quot;, &quot;sponsor&quot;: &quot;Intra-Cellular Therapies, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05766813&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.27119, &quot;lng&quot;: -80.2706, &quot;nct&quot;: &quot;NCT05766813&quot;, &quot;color&quot;: &quot;#6adfaf&quot;, &quot;title&quot;: &quot;Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lenrispodun; Placebo&quot;, &quot;sponsor&quot;: &quot;Intra-Cellular Therapies, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05766813&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 25.9812, &quot;lng&quot;: -80.14838, &quot;nct&quot;: &quot;NCT05766813&quot;, &quot;color&quot;: &quot;#6adfaf&quot;, &quot;title&quot;: &quot;Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lenrispodun; Placebo&quot;, &quot;sponsor&quot;: &quot;Intra-Cellular Therapies, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05766813&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 28.62778, &quot;lng&quot;: -81.36312, &quot;nct&quot;: &quot;NCT05766813&quot;, &quot;color&quot;: &quot;#6adfaf&quot;, &quot;title&quot;: &quot;Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lenrispodun; Placebo&quot;, &quot;sponsor&quot;: &quot;Intra-Cellular Therapies, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05766813&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 25.77427, &quot;lng&quot;: -80.19366, &quot;nct&quot;: &quot;NCT05766813&quot;, &quot;color&quot;: &quot;#6adfaf&quot;, &quot;title&quot;: &quot;Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lenrispodun; Placebo&quot;, &quot;sponsor&quot;: &quot;Intra-Cellular Therapies, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05766813&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.1872, &quot;lng&quot;: -82.14009, &quot;nct&quot;: &quot;NCT05766813&quot;, &quot;color&quot;: &quot;#6adfaf&quot;, &quot;title&quot;: &quot;Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lenrispodun; Placebo&quot;, &quot;sponsor&quot;: &quot;Intra-Cellular Therapies, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05766813&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 28.53834, &quot;lng&quot;: -81.37924, &quot;nct&quot;: &quot;NCT05766813&quot;, &quot;color&quot;: &quot;#6adfaf&quot;, &quot;title&quot;: &quot;Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lenrispodun; Placebo&quot;, &quot;sponsor&quot;: &quot;Intra-Cellular Therapies, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05766813&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.13832, &quot;lng&quot;: -80.99561, &quot;nct&quot;: &quot;NCT05766813&quot;, &quot;color&quot;: &quot;#6adfaf&quot;, &quot;title&quot;: &quot;Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lenrispodun; Placebo&quot;, &quot;sponsor&quot;: &quot;Intra-Cellular Therapies, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05766813&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 27.94752, &quot;lng&quot;: -82.45843, &quot;nct&quot;: &quot;NCT05766813&quot;, &quot;color&quot;: &quot;#6adfaf&quot;, &quot;title&quot;: &quot;Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lenrispodun; Placebo&quot;, &quot;sponsor&quot;: &quot;Intra-Cellular Therapies, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05766813&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.47097, &quot;lng&quot;: -81.97484, &quot;nct&quot;: &quot;NCT05766813&quot;, &quot;color&quot;: &quot;#6adfaf&quot;, &quot;title&quot;: &quot;Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lenrispodun; Placebo&quot;, &quot;sponsor&quot;: &quot;Intra-Cellular Therapies, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05766813&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.77483, &quot;lng&quot;: -84.29631, &quot;nct&quot;: &quot;NCT05766813&quot;, &quot;color&quot;: &quot;#6adfaf&quot;, &quot;title&quot;: &quot;Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lenrispodun; Placebo&quot;, &quot;sponsor&quot;: &quot;Intra-Cellular Therapies, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05766813&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.11417, &quot;lng&quot;: -94.62746, &quot;nct&quot;: &quot;NCT05766813&quot;, &quot;color&quot;: &quot;#6adfaf&quot;, &quot;title&quot;: &quot;Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lenrispodun; Placebo&quot;, &quot;sponsor&quot;: &quot;Intra-Cellular Therapies, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05766813&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.48531, &quot;lng&quot;: -83.37716, &quot;nct&quot;: &quot;NCT05766813&quot;, &quot;color&quot;: &quot;#6adfaf&quot;, &quot;title&quot;: &quot;Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lenrispodun; Placebo&quot;, &quot;sponsor&quot;: &quot;Intra-Cellular Therapies, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05766813&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.00969, &quot;lng&quot;: -93.34912, &quot;nct&quot;: &quot;NCT05766813&quot;, &quot;color&quot;: &quot;#6adfaf&quot;, &quot;title&quot;: &quot;Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lenrispodun; Placebo&quot;, &quot;sponsor&quot;: &quot;Intra-Cellular Therapies, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05766813&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.65258, &quot;lng&quot;: -73.75623, &quot;nct&quot;: &quot;NCT05766813&quot;, &quot;color&quot;: &quot;#6adfaf&quot;, &quot;title&quot;: &quot;Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lenrispodun; Placebo&quot;, &quot;sponsor&quot;: &quot;Intra-Cellular Therapies, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05766813&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 34.92487, &quot;lng&quot;: -81.02508, &quot;nct&quot;: &quot;NCT05766813&quot;, &quot;color&quot;: &quot;#6adfaf&quot;, &quot;title&quot;: &quot;Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lenrispodun; Placebo&quot;, &quot;sponsor&quot;: &quot;Intra-Cellular Therapies, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05766813&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 35.14953, &quot;lng&quot;: -90.04898, &quot;nct&quot;: &quot;NCT05766813&quot;, &quot;color&quot;: &quot;#6adfaf&quot;, &quot;title&quot;: &quot;Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lenrispodun; Placebo&quot;, &quot;sponsor&quot;: &quot;Intra-Cellular Therapies, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05766813&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 30.26715, &quot;lng&quot;: -97.74306, &quot;nct&quot;: &quot;NCT05766813&quot;, &quot;color&quot;: &quot;#6adfaf&quot;, &quot;title&quot;: &quot;Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lenrispodun; Placebo&quot;, &quot;sponsor&quot;: &quot;Intra-Cellular Therapies, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05766813&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 32.78306, &quot;lng&quot;: -96.80667, &quot;nct&quot;: &quot;NCT05766813&quot;, &quot;color&quot;: &quot;#6adfaf&quot;, &quot;title&quot;: &quot;Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lenrispodun; Placebo&quot;, &quot;sponsor&quot;: &quot;Intra-Cellular Therapies, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05766813&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 30.63269, &quot;lng&quot;: -97.67723, &quot;nct&quot;: &quot;NCT05766813&quot;, &quot;color&quot;: &quot;#6adfaf&quot;, &quot;title&quot;: &quot;Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lenrispodun; Placebo&quot;, &quot;sponsor&quot;: &quot;Intra-Cellular Therapies, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05766813&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 38.88233, &quot;lng&quot;: -77.17109, &quot;nct&quot;: &quot;NCT05766813&quot;, &quot;color&quot;: &quot;#6adfaf&quot;, &quot;title&quot;: &quot;Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lenrispodun; Placebo&quot;, &quot;sponsor&quot;: &quot;Intra-Cellular Therapies, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05766813&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.59264, &quot;lng&quot;: -78.61611, &quot;nct&quot;: &quot;NCT05766813&quot;, &quot;color&quot;: &quot;#6adfaf&quot;, &quot;title&quot;: &quot;Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lenrispodun; Placebo&quot;, &quot;sponsor&quot;: &quot;Intra-Cellular Therapies, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05766813&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.68149, &quot;lng&quot;: -122.20874, &quot;nct&quot;: &quot;NCT05766813&quot;, &quot;color&quot;: &quot;#6adfaf&quot;, &quot;title&quot;: &quot;Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lenrispodun; Placebo&quot;, &quot;sponsor&quot;: &quot;Intra-Cellular Therapies, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05766813&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.65966, &quot;lng&quot;: -117.42908, &quot;nct&quot;: &quot;NCT05766813&quot;, &quot;color&quot;: &quot;#6adfaf&quot;, &quot;title&quot;: &quot;Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lenrispodun; Placebo&quot;, &quot;sponsor&quot;: &quot;Intra-Cellular Therapies, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05766813&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.0389, &quot;lng&quot;: -87.90647, &quot;nct&quot;: &quot;NCT05766813&quot;, &quot;color&quot;: &quot;#6adfaf&quot;, &quot;title&quot;: &quot;Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lenrispodun; Placebo&quot;, &quot;sponsor&quot;: &quot;Intra-Cellular Therapies, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05766813&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 32.06167, &quot;lng&quot;: 118.77778, &quot;nct&quot;: &quot;NCT06409338&quot;, &quot;color&quot;: &quot;#73180d&quot;, &quot;title&quot;: &quot;Research on the Brain Mechanism of taVNS in Regulating PD Motor Symptoms&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Transcutaneous auricular vagus nerve stimulation (active\\uff09; Transcutaneous auricular vagus nerve stimulation (sham\\uff09&quot;, &quot;sponsor&quot;: &quot;The First Affiliated Hospital with Nanjing Medical University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06409338&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.42587, &quot;lng&quot;: -86.90807, &quot;nct&quot;: &quot;NCT06638944&quot;, &quot;color&quot;: &quot;#ebc7d5&quot;, &quot;title&quot;: &quot;Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;In-person sEMG-biofeedback; Remote sEMG-biofeedback; Standard-of-care treatment&quot;, &quot;sponsor&quot;: &quot;Purdue University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06638944&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.44188, &quot;lng&quot;: -122.14302, &quot;nct&quot;: &quot;NCT04728295&quot;, &quot;color&quot;: &quot;#b4f42b&quot;, &quot;title&quot;: &quot;Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Exablate 4000&quot;, &quot;sponsor&quot;: &quot;InSightec&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04728295&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.46146, &quot;lng&quot;: -80.07282, &quot;nct&quot;: &quot;NCT04728295&quot;, &quot;color&quot;: &quot;#b4f42b&quot;, &quot;title&quot;: &quot;Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Exablate 4000&quot;, &quot;sponsor&quot;: &quot;InSightec&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04728295&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.85003, &quot;lng&quot;: -87.65005, &quot;nct&quot;: &quot;NCT04728295&quot;, &quot;color&quot;: &quot;#b4f42b&quot;, &quot;title&quot;: &quot;Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Exablate 4000&quot;, &quot;sponsor&quot;: &quot;InSightec&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04728295&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.29038, &quot;lng&quot;: -76.61219, &quot;nct&quot;: &quot;NCT04728295&quot;, &quot;color&quot;: &quot;#b4f42b&quot;, &quot;title&quot;: &quot;Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Exablate 4000&quot;, &quot;sponsor&quot;: &quot;InSightec&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04728295&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.71427, &quot;lng&quot;: -74.00597, &quot;nct&quot;: &quot;NCT04728295&quot;, &quot;color&quot;: &quot;#b4f42b&quot;, &quot;title&quot;: &quot;Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Exablate 4000&quot;, &quot;sponsor&quot;: &quot;InSightec&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04728295&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.4165, &quot;lng&quot;: -3.70256, &quot;nct&quot;: &quot;NCT04728295&quot;, &quot;color&quot;: &quot;#b4f42b&quot;, &quot;title&quot;: &quot;Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Exablate 4000&quot;, &quot;sponsor&quot;: &quot;InSightec&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04728295&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.81687, &quot;lng&quot;: -1.64323, &quot;nct&quot;: &quot;NCT04728295&quot;, &quot;color&quot;: &quot;#b4f42b&quot;, &quot;title&quot;: &quot;Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Exablate 4000&quot;, &quot;sponsor&quot;: &quot;InSightec&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04728295&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 24.05533, &quot;lng&quot;: 120.4335, &quot;nct&quot;: &quot;NCT04728295&quot;, &quot;color&quot;: &quot;#b4f42b&quot;, &quot;title&quot;: &quot;Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Exablate 4000&quot;, &quot;sponsor&quot;: &quot;InSightec&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04728295&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: -33.91439, &quot;lng&quot;: 151.24895, &quot;nct&quot;: &quot;NCT07057219&quot;, &quot;color&quot;: &quot;#807321&quot;, &quot;title&quot;: &quot;Steps Against the Burden of Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Exercise&quot;, &quot;sponsor&quot;: &quot;The University of New South Wales&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07057219&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.52066, &quot;lng&quot;: -86.80249, &quot;nct&quot;: &quot;NCT03305588&quot;, &quot;color&quot;: &quot;#5e845f&quot;, &quot;title&quot;: &quot;RAD 1601: EDGE Radiosurgery for Intractable Essential Tremor and Tremor-Dominant Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Unframed Virtual Cone&quot;, &quot;sponsor&quot;: &quot;University of Alabama at Birmingham&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03305588&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.27756, &quot;lng&quot;: -83.74088, &quot;nct&quot;: &quot;NCT06679374&quot;, &quot;color&quot;: &quot;#14adf3&quot;, &quot;title&quot;: &quot;Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo; Varenicline&quot;, &quot;sponsor&quot;: &quot;Vikas Kotagal&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06679374&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 9.93388, &quot;lng&quot;: -84.08489, &quot;nct&quot;: &quot;NCT06141317&quot;, &quot;color&quot;: &quot;#27451c&quot;, &quot;title&quot;: &quot;Randomized Clinical Trial in Parkinson&#x27;s Disease Patients Using Pluripotent Adipose Stem Cells (PASCs)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;PASC transplantation (25 million PASCs/patient); Control&quot;, &quot;sponsor&quot;: &quot;ClusterXStem-Costa Rica&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06141317&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.60426, &quot;lng&quot;: 1.44367, &quot;nct&quot;: &quot;NCT05910008&quot;, &quot;color&quot;: &quot;#85f98c&quot;, &quot;title&quot;: &quot;O-ARM Stereotactic Imaging in Deep Brain Stimulation for Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;O-Arm Stereotactic imaging; Standard Stereotactic imaging&quot;, &quot;sponsor&quot;: &quot;University Hospital, Toulouse&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05910008&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 44.84124, &quot;lng&quot;: -0.58046, &quot;nct&quot;: &quot;NCT06438419&quot;, &quot;color&quot;: &quot;#e69180&quot;, &quot;title&quot;: &quot;Parkinsonism-Related Oscillations in the Cortico-Basal Ganglia-Thalamic Network During Movement: Beyond the Frequency Range&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Electrophysiological recordings&quot;, &quot;sponsor&quot;: &quot;University Hospital, Bordeaux&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06438419&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 49.86988, &quot;lng&quot;: 2.2434, &quot;nct&quot;: &quot;NCT06799923&quot;, &quot;color&quot;: &quot;#511a12&quot;, &quot;title&quot;: &quot;Possibilities of Use MRI-Guided Laser Interstitial Thermal Therapy in Medically Intractable Tremor&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;laser electrode&quot;, &quot;sponsor&quot;: &quot;Centre Hospitalier Universitaire, Amiens&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06799923&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.68372, &quot;lng&quot;: -75.74966, &quot;nct&quot;: &quot;NCT04616508&quot;, &quot;color&quot;: &quot;#2ffd06&quot;, &quot;title&quot;: &quot;Online Motor Control in People With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;motor control assessment&quot;, &quot;sponsor&quot;: &quot;University of Delaware&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04616508&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.52345, &quot;lng&quot;: -122.67621, &quot;nct&quot;: &quot;NCT05881460&quot;, &quot;color&quot;: &quot;#bdbf7b&quot;, &quot;title&quot;: &quot;Vibrotactile Coordinated Reset: a Non-invasive Treatment for Parkinson&#x27;s Disease 2&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Active vibrotactile coordinated reset; Sham vibrotactile coordinated reset&quot;, &quot;sponsor&quot;: &quot;Synergic Medical Technologies, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05881460&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.9075, &quot;lng&quot;: 116.39723, &quot;nct&quot;: &quot;NCT07044973&quot;, &quot;color&quot;: &quot;#350d5e&quot;, &quot;title&quot;: &quot;VIM+PTT MRgFUS for PD&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Transcranial focused ultrasound thalamotomy&quot;, &quot;sponsor&quot;: &quot;Chinese PLA General Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07044973&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 34.14251, &quot;lng&quot;: -118.25508, &quot;nct&quot;: &quot;NCT05670782&quot;, &quot;color&quot;: &quot;#9e226e&quot;, &quot;title&quot;: &quot;A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants with Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;KM-819; Placebo&quot;, &quot;sponsor&quot;: &quot;FAScinate Therapeutics Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05670782&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 32.71571, &quot;lng&quot;: -117.16472, &quot;nct&quot;: &quot;NCT05670782&quot;, &quot;color&quot;: &quot;#9e226e&quot;, &quot;title&quot;: &quot;A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants with Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;KM-819; Placebo&quot;, &quot;sponsor&quot;: &quot;FAScinate Therapeutics Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05670782&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.48948, &quot;lng&quot;: -83.14465, &quot;nct&quot;: &quot;NCT05670782&quot;, &quot;color&quot;: &quot;#9e226e&quot;, &quot;title&quot;: &quot;A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants with Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;KM-819; Placebo&quot;, &quot;sponsor&quot;: &quot;FAScinate Therapeutics Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05670782&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.03399, &quot;lng&quot;: -73.76291, &quot;nct&quot;: &quot;NCT04564495&quot;, &quot;color&quot;: &quot;#84898b&quot;, &quot;title&quot;: &quot;Home Based Tele-exercise for People With Chronic Neurological Impairments&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Seated exercise&quot;, &quot;sponsor&quot;: &quot;Burke Medical Research Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04564495&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 17.12096, &quot;lng&quot;: -61.84329, &quot;nct&quot;: &quot;NCT05152394&quot;, &quot;color&quot;: &quot;#9e3153&quot;, &quot;title&quot;: &quot;Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Exosomes for Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;AlloEx&quot;, &quot;sponsor&quot;: &quot;The Foundation for Orthopaedics and Regenerative Medicine&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05152394&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: -8.05389, &quot;lng&quot;: -34.88111, &quot;nct&quot;: &quot;NCT06856941&quot;, &quot;color&quot;: &quot;#d9683e&quot;, &quot;title&quot;: &quot;CsDCS on Functional Mobility in Parkinsons Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;cerebello-spinal direct current stimulation; sham cerebello-spinal direct current stimulation&quot;, &quot;sponsor&quot;: &quot;Universidade Federal de Pernambuco&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06856941&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 32.84727, &quot;lng&quot;: -117.2742, &quot;nct&quot;: &quot;NCT03616145&quot;, &quot;color&quot;: &quot;#8d74d4&quot;, &quot;title&quot;: &quot;Effects of Osteopathic Manipulative Treatment (OMT) on Gait Biomechanics in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Osteopathic Manipulative Treatment (OMT); Light Touch&quot;, &quot;sponsor&quot;: &quot;University of California, San Diego&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03616145&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 24.80361, &quot;lng&quot;: 120.96861, &quot;nct&quot;: &quot;NCT06536478&quot;, &quot;color&quot;: &quot;#b08bc7&quot;, &quot;title&quot;: &quot;The Effect of Exercise Intervention on Posture, Trunk Flexibility and Spine Function in Patients With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;exercise; education&quot;, &quot;sponsor&quot;: &quot;National Taiwan University Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06536478&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.50921, &quot;lng&quot;: -111.89903, &quot;nct&quot;: &quot;NCT04127578&quot;, &quot;color&quot;: &quot;#9e7bac&quot;, &quot;title&quot;: &quot;Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson&#x27;s Disease With at Least One GBA1 Mutation (PROPEL)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;LY3884961; Methylprednisolone; Sirolimus&quot;, &quot;sponsor&quot;: &quot;Prevail Therapeutics&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04127578&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.55391, &quot;lng&quot;: -117.21392, &quot;nct&quot;: &quot;NCT04127578&quot;, &quot;color&quot;: &quot;#9e7bac&quot;, &quot;title&quot;: &quot;Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson&#x27;s Disease With at Least One GBA1 Mutation (PROPEL)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;LY3884961; Methylprednisolone; Sirolimus&quot;, &quot;sponsor&quot;: &quot;Prevail Therapeutics&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04127578&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.64777, &quot;lng&quot;: -104.98776, &quot;nct&quot;: &quot;NCT04127578&quot;, &quot;color&quot;: &quot;#9e7bac&quot;, &quot;title&quot;: &quot;Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson&#x27;s Disease With at Least One GBA1 Mutation (PROPEL)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;LY3884961; Methylprednisolone; Sirolimus&quot;, &quot;sponsor&quot;: &quot;Prevail Therapeutics&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04127578&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 28.62778, &quot;lng&quot;: -81.36312, &quot;nct&quot;: &quot;NCT04127578&quot;, &quot;color&quot;: &quot;#9e7bac&quot;, &quot;title&quot;: &quot;Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson&#x27;s Disease With at Least One GBA1 Mutation (PROPEL)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;LY3884961; Methylprednisolone; Sirolimus&quot;, &quot;sponsor&quot;: &quot;Prevail Therapeutics&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04127578&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 28.53834, &quot;lng&quot;: -81.37924, &quot;nct&quot;: &quot;NCT04127578&quot;, &quot;color&quot;: &quot;#9e7bac&quot;, &quot;title&quot;: &quot;Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson&#x27;s Disease With at Least One GBA1 Mutation (PROPEL)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;LY3884961; Methylprednisolone; Sirolimus&quot;, &quot;sponsor&quot;: &quot;Prevail Therapeutics&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04127578&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.85003, &quot;lng&quot;: -87.65005, &quot;nct&quot;: &quot;NCT04127578&quot;, &quot;color&quot;: &quot;#9e7bac&quot;, &quot;title&quot;: &quot;Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson&#x27;s Disease With at Least One GBA1 Mutation (PROPEL)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;LY3884961; Methylprednisolone; Sirolimus&quot;, &quot;sponsor&quot;: &quot;Prevail Therapeutics&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04127578&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 44.02163, &quot;lng&quot;: -92.4699, &quot;nct&quot;: &quot;NCT04127578&quot;, &quot;color&quot;: &quot;#9e7bac&quot;, &quot;title&quot;: &quot;Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson&#x27;s Disease With at Least One GBA1 Mutation (PROPEL)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;LY3884961; Methylprednisolone; Sirolimus&quot;, &quot;sponsor&quot;: &quot;Prevail Therapeutics&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04127578&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.71427, &quot;lng&quot;: -74.00597, &quot;nct&quot;: &quot;NCT04127578&quot;, &quot;color&quot;: &quot;#9e7bac&quot;, &quot;title&quot;: &quot;Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson&#x27;s Disease With at Least One GBA1 Mutation (PROPEL)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;LY3884961; Methylprednisolone; Sirolimus&quot;, &quot;sponsor&quot;: &quot;Prevail Therapeutics&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04127578&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.95238, &quot;lng&quot;: -75.16362, &quot;nct&quot;: &quot;NCT04127578&quot;, &quot;color&quot;: &quot;#9e7bac&quot;, &quot;title&quot;: &quot;Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson&#x27;s Disease With at Least One GBA1 Mutation (PROPEL)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;LY3884961; Methylprednisolone; Sirolimus&quot;, &quot;sponsor&quot;: &quot;Prevail Therapeutics&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04127578&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.16589, &quot;lng&quot;: -86.78444, &quot;nct&quot;: &quot;NCT04127578&quot;, &quot;color&quot;: &quot;#9e7bac&quot;, &quot;title&quot;: &quot;Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson&#x27;s Disease With at Least One GBA1 Mutation (PROPEL)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;LY3884961; Methylprednisolone; Sirolimus&quot;, &quot;sponsor&quot;: &quot;Prevail Therapeutics&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04127578&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 31.76904, &quot;lng&quot;: 35.21633, &quot;nct&quot;: &quot;NCT04127578&quot;, &quot;color&quot;: &quot;#9e7bac&quot;, &quot;title&quot;: &quot;Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson&#x27;s Disease With at Least One GBA1 Mutation (PROPEL)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;LY3884961; Methylprednisolone; Sirolimus&quot;, &quot;sponsor&quot;: &quot;Prevail Therapeutics&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04127578&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 32.08227, &quot;lng&quot;: 34.81065, &quot;nct&quot;: &quot;NCT04127578&quot;, &quot;color&quot;: &quot;#9e7bac&quot;, &quot;title&quot;: &quot;Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson&#x27;s Disease With at Least One GBA1 Mutation (PROPEL)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;LY3884961; Methylprednisolone; Sirolimus&quot;, &quot;sponsor&quot;: &quot;Prevail Therapeutics&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04127578&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 32.08088, &quot;lng&quot;: 34.78057, &quot;nct&quot;: &quot;NCT04127578&quot;, &quot;color&quot;: &quot;#9e7bac&quot;, &quot;title&quot;: &quot;Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson&#x27;s Disease With at Least One GBA1 Mutation (PROPEL)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;LY3884961; Methylprednisolone; Sirolimus&quot;, &quot;sponsor&quot;: &quot;Prevail Therapeutics&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04127578&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.85003, &quot;lng&quot;: -87.65005, &quot;nct&quot;: &quot;NCT05076565&quot;, &quot;color&quot;: &quot;#9c8860&quot;, &quot;title&quot;: &quot;Wearable Airbag Technology to Mitigate Falls in Individuals With High Fall Risk&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Airbag Belt Fall Protection System&quot;, &quot;sponsor&quot;: &quot;Shirley Ryan AbilityLab&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05076565&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 32.77632, &quot;lng&quot;: -79.93275, &quot;nct&quot;: &quot;NCT06994728&quot;, &quot;color&quot;: &quot;#3a5b18&quot;, &quot;title&quot;: &quot;Correlation of STN-DBS Induced Visuospatial Changes and Freezing of Gait&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Left STN-DBS on, right STN-DBS off first; Right STN-DBS on, left STN-DBS off first&quot;, &quot;sponsor&quot;: &quot;Medical University of South Carolina&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06994728&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 30.00944, &quot;lng&quot;: 31.20861, &quot;nct&quot;: &quot;NCT06646510&quot;, &quot;color&quot;: &quot;#189988&quot;, &quot;title&quot;: &quot;Effect of Sensory Electrical Stimulation on Resting Tremors in Patients with Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;traditional exercises; sensory electrical stimulation&quot;, &quot;sponsor&quot;: &quot;Cairo University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06646510&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.37403, &quot;lng&quot;: 4.88969, &quot;nct&quot;: &quot;NCT06932692&quot;, &quot;color&quot;: &quot;#a2c79e&quot;, &quot;title&quot;: &quot;The BRAINMAP-DBS Study: BRain Network AnalysIs usiNg 7-Tesla MRI and MAgnetoencephalograPhy for Deep Brain Stimulation&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;magnetoencephalography&quot;, &quot;sponsor&quot;: &quot;Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06932692&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.72943, &quot;lng&quot;: -104.83192, &quot;nct&quot;: &quot;NCT06778135&quot;, &quot;color&quot;: &quot;#017676&quot;, &quot;title&quot;: &quot;Neocortical Microarchitecture of Executive Function&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Temporary implatation of large-scale intracranial electrode.; brain electrode&quot;, &quot;sponsor&quot;: &quot;University of Colorado, Denver&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06778135&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.90982, &quot;lng&quot;: 2.45012, &quot;nct&quot;: &quot;NCT04265209&quot;, &quot;color&quot;: &quot;#be880d&quot;, &quot;title&quot;: &quot;[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson&#x27;s Diseases and Essential Tremor&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;SPECT; PET&quot;, &quot;sponsor&quot;: &quot;Zionexa&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04265209&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 44.84124, &quot;lng&quot;: -0.58046, &quot;nct&quot;: &quot;NCT04265209&quot;, &quot;color&quot;: &quot;#be880d&quot;, &quot;title&quot;: &quot;[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson&#x27;s Diseases and Essential Tremor&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;SPECT; PET&quot;, &quot;sponsor&quot;: &quot;Zionexa&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04265209&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.77969, &quot;lng&quot;: 3.08682, &quot;nct&quot;: &quot;NCT04265209&quot;, &quot;color&quot;: &quot;#be880d&quot;, &quot;title&quot;: &quot;[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson&#x27;s Diseases and Essential Tremor&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;SPECT; PET&quot;, &quot;sponsor&quot;: &quot;Zionexa&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04265209&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.79266, &quot;lng&quot;: 2.46569, &quot;nct&quot;: &quot;NCT04265209&quot;, &quot;color&quot;: &quot;#be880d&quot;, &quot;title&quot;: &quot;[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson&#x27;s Diseases and Essential Tremor&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;SPECT; PET&quot;, &quot;sponsor&quot;: &quot;Zionexa&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04265209&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.31344, &quot;lng&quot;: 5.01391, &quot;nct&quot;: &quot;NCT04265209&quot;, &quot;color&quot;: &quot;#be880d&quot;, &quot;title&quot;: &quot;[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson&#x27;s Diseases and Essential Tremor&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;SPECT; PET&quot;, &quot;sponsor&quot;: &quot;Zionexa&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04265209&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.63391, &quot;lng&quot;: 3.05512, &quot;nct&quot;: &quot;NCT04265209&quot;, &quot;color&quot;: &quot;#be880d&quot;, &quot;title&quot;: &quot;[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson&#x27;s Diseases and Essential Tremor&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;SPECT; PET&quot;, &quot;sponsor&quot;: &quot;Zionexa&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04265209&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.74906, &quot;lng&quot;: 4.84789, &quot;nct&quot;: &quot;NCT04265209&quot;, &quot;color&quot;: &quot;#be880d&quot;, &quot;title&quot;: &quot;[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson&#x27;s Diseases and Essential Tremor&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;SPECT; PET&quot;, &quot;sponsor&quot;: &quot;Zionexa&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04265209&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.29695, &quot;lng&quot;: 5.38107, &quot;nct&quot;: &quot;NCT04265209&quot;, &quot;color&quot;: &quot;#be880d&quot;, &quot;title&quot;: &quot;[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson&#x27;s Diseases and Essential Tremor&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;SPECT; PET&quot;, &quot;sponsor&quot;: &quot;Zionexa&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04265209&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.68439, &quot;lng&quot;: 6.18496, &quot;nct&quot;: &quot;NCT04265209&quot;, &quot;color&quot;: &quot;#be880d&quot;, &quot;title&quot;: &quot;[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson&#x27;s Diseases and Essential Tremor&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;SPECT; PET&quot;, &quot;sponsor&quot;: &quot;Zionexa&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04265209&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.21725, &quot;lng&quot;: -1.55336, &quot;nct&quot;: &quot;NCT04265209&quot;, &quot;color&quot;: &quot;#be880d&quot;, &quot;title&quot;: &quot;[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson&#x27;s Diseases and Essential Tremor&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;SPECT; PET&quot;, &quot;sponsor&quot;: &quot;Zionexa&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04265209&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.83665, &quot;lng&quot;: 4.35788, &quot;nct&quot;: &quot;NCT04265209&quot;, &quot;color&quot;: &quot;#be880d&quot;, &quot;title&quot;: &quot;[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson&#x27;s Diseases and Essential Tremor&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;SPECT; PET&quot;, &quot;sponsor&quot;: &quot;Zionexa&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04265209&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.85341, &quot;lng&quot;: 2.3488, &quot;nct&quot;: &quot;NCT04265209&quot;, &quot;color&quot;: &quot;#be880d&quot;, &quot;title&quot;: &quot;[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson&#x27;s Diseases and Essential Tremor&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;SPECT; PET&quot;, &quot;sponsor&quot;: &quot;Zionexa&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04265209&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.11109, &quot;lng&quot;: -1.67431, &quot;nct&quot;: &quot;NCT04265209&quot;, &quot;color&quot;: &quot;#be880d&quot;, &quot;title&quot;: &quot;[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson&#x27;s Diseases and Essential Tremor&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;SPECT; PET&quot;, &quot;sponsor&quot;: &quot;Zionexa&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04265209&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.58392, &quot;lng&quot;: 7.74553, &quot;nct&quot;: &quot;NCT04265209&quot;, &quot;color&quot;: &quot;#be880d&quot;, &quot;title&quot;: &quot;[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson&#x27;s Diseases and Essential Tremor&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;SPECT; PET&quot;, &quot;sponsor&quot;: &quot;Zionexa&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04265209&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.60426, &quot;lng&quot;: 1.44367, &quot;nct&quot;: &quot;NCT04265209&quot;, &quot;color&quot;: &quot;#be880d&quot;, &quot;title&quot;: &quot;[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson&#x27;s Diseases and Essential Tremor&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;SPECT; PET&quot;, &quot;sponsor&quot;: &quot;Zionexa&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04265209&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.39484, &quot;lng&quot;: 0.70398, &quot;nct&quot;: &quot;NCT04265209&quot;, &quot;color&quot;: &quot;#be880d&quot;, &quot;title&quot;: &quot;[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson&#x27;s Diseases and Essential Tremor&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;SPECT; PET&quot;, &quot;sponsor&quot;: &quot;Zionexa&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04265209&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 46.20222, &quot;lng&quot;: 6.14569, &quot;nct&quot;: &quot;NCT05220449&quot;, &quot;color&quot;: &quot;#f03e43&quot;, &quot;title&quot;: &quot;Re-Orchestration of Interregional Oscillatory Activity to Promote Visual Recovery&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Cross-frequency dual-site tACS&quot;, &quot;sponsor&quot;: &quot;Ecole Polytechnique F\\u00e9d\\u00e9rale de Lausanne&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05220449&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.38879, &quot;lng&quot;: 2.15899, &quot;nct&quot;: &quot;NCT07105384&quot;, &quot;color&quot;: &quot;#1386bc&quot;, &quot;title&quot;: &quot;Quantification Tools for a Novel Tau PET Marker in a Rare Neurological Disease: 18F-PI-2620 in Progressive Supranuclear Palsy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Radiotracer&quot;, &quot;sponsor&quot;: &quot;Fundacion Clinic per a la Recerca Biom\\u00e9dica&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07105384&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: -30.03283, &quot;lng&quot;: -51.23019, &quot;nct&quot;: &quot;NCT06921122&quot;, &quot;color&quot;: &quot;#922768&quot;, &quot;title&quot;: &quot;Use Of A Tongue Strength Training Device And Its Relationship With Speech In Patients With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;IOWA ORAL PERFORMANCE INSTRUMENT; Placebo Group - Without Treatment&quot;, &quot;sponsor&quot;: &quot;Hospital de Clinicas de Porto Alegre&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06921122&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.91987, &quot;lng&quot;: 32.85427, &quot;nct&quot;: &quot;NCT06017336&quot;, &quot;color&quot;: &quot;#57adb3&quot;, &quot;title&quot;: &quot;Effects of Inspiratory Muscle Training in Patients With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Inspiratory Muscle Training Group; Control Group (breathing exercises)&quot;, &quot;sponsor&quot;: &quot;Gazi University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06017336&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.56995, &quot;lng&quot;: -73.692, &quot;nct&quot;: &quot;NCT04558879&quot;, &quot;color&quot;: &quot;#a4872a&quot;, &quot;title&quot;: &quot;Exercise and Sleep in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;CT; RT&quot;, &quot;sponsor&quot;: &quot;McGill University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04558879&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 38.62727, &quot;lng&quot;: -90.19789, &quot;nct&quot;: &quot;NCT04474379&quot;, &quot;color&quot;: &quot;#87f8f1&quot;, &quot;title&quot;: &quot;Everyday Memory Impairment in PD-related Cognitive Decline&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Strategy Training (Time- and Event- Based)&quot;, &quot;sponsor&quot;: &quot;Washington University School of Medicine&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04474379&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.8425, &quot;lng&quot;: 5.85278, &quot;nct&quot;: &quot;NCT04848077&quot;, &quot;color&quot;: &quot;#b355a8&quot;, &quot;title&quot;: &quot;STEPWISE Parkinson: A Smartphone Based Exercise Solution for Patients With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Step count increase with the use of a motivational smartphone application&quot;, &quot;sponsor&quot;: &quot;Radboud University Medical Center&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04848077&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.87959, &quot;lng&quot;: 4.70093, &quot;nct&quot;: &quot;NCT04269577&quot;, &quot;color&quot;: &quot;#29042c&quot;, &quot;title&quot;: &quot;Motor Learning in Parkinson&#x27;s Disease: Underlying Effective Connectivity and Influential Factors&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;SSP training&quot;, &quot;sponsor&quot;: &quot;KU Leuven&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04269577&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.15478, &quot;lng&quot;: -77.61556, &quot;nct&quot;: &quot;NCT04453033&quot;, &quot;color&quot;: &quot;#63438e&quot;, &quot;title&quot;: &quot;DB RCT for Specialized Phototherapy in Parkinson&#x27;s Disease.&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Celeste Specialized Phototherapy Device&quot;, &quot;sponsor&quot;: &quot;PhotoPharmics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04453033&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 46.87719, &quot;lng&quot;: -96.7898, &quot;nct&quot;: &quot;NCT03191916&quot;, &quot;color&quot;: &quot;#aac4b9&quot;, &quot;title&quot;: &quot;Transcranial Direct Current Stimulation for Cognitive Improvement in Parkinson&#x27;s Patients&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;transcranial direct current stimulation; Sham (for transcranial direct current stimulation)&quot;, &quot;sponsor&quot;: &quot;Sanford Health&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03191916&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.57515, &quot;lng&quot;: 0.18582, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 53.48095, &quot;lng&quot;: -2.23743, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 54.66079, &quot;lng&quot;: -5.66802, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.62783, &quot;lng&quot;: 1.29834, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 55.95206, &quot;lng&quot;: -3.19648, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 56.02246, &quot;lng&quot;: -3.82872, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.3751, &quot;lng&quot;: -2.36172, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 57.14369, &quot;lng&quot;: -2.09814, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 53.55, &quot;lng&quot;: -1.48333, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.72048, &quot;lng&quot;: -1.8795, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.50583, &quot;lng&quot;: -3.57722, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.45523, &quot;lng&quot;: -2.59665, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 53.6, &quot;lng&quot;: -2.3, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.92277, &quot;lng&quot;: -1.47663, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 56.46913, &quot;lng&quot;: -2.97489, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 54.96209, &quot;lng&quot;: -1.60168, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.86568, &quot;lng&quot;: -2.2431, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 53.79648, &quot;lng&quot;: -1.54785, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.6386, &quot;lng&quot;: -1.13169, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 53.41058, &quot;lng&quot;: -2.97794, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.50853, &quot;lng&quot;: -0.12574, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 54.57623, &quot;lng&quot;: -1.23483, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 54.21804, &quot;lng&quot;: -5.88979, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.58774, &quot;lng&quot;: -2.99835, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.75222, &quot;lng&quot;: -1.25596, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.57364, &quot;lng&quot;: -0.24777, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.37153, &quot;lng&quot;: -4.14305, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 53.76282, &quot;lng&quot;: -2.70452, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.45625, &quot;lng&quot;: -0.97113, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 53.48771, &quot;lng&quot;: -2.29042, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 54.56848, &quot;lng&quot;: -1.3187, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.01494, &quot;lng&quot;: -3.10293, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 53.54296, &quot;lng&quot;: -2.63706, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 53.04664, &quot;lng&quot;: -2.99132, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.94159, &quot;lng&quot;: -2.63211, &quot;nct&quot;: &quot;NCT04226248&quot;, &quot;color&quot;: &quot;#94dbbe&quot;, &quot;title&quot;: &quot;CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson&#x27;s Disease)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Rivastigmine Transdermal System; Placebo Transdermal System&quot;, &quot;sponsor&quot;: &quot;University of Bristol&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04226248&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 22.27832, &quot;lng&quot;: 114.17469, &quot;nct&quot;: &quot;NCT05524961&quot;, &quot;color&quot;: &quot;#14134f&quot;, &quot;title&quot;: &quot;Bright Light Therapy for Non-motor Symptoms in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Bright light therapy; Inactivated negative ion generator&quot;, &quot;sponsor&quot;: &quot;Chinese University of Hong Kong&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05524961&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.42411, &quot;lng&quot;: -122.16608, &quot;nct&quot;: &quot;NCT06029686&quot;, &quot;color&quot;: &quot;#511036&quot;, &quot;title&quot;: &quot;Vibrotactile Coordinated Reset for Parkinson&#x27;s Patients of a More Variable Population&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Stanford Glove&quot;, &quot;sponsor&quot;: &quot;Stanford University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06029686&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.62953, &quot;lng&quot;: -79.9559, &quot;nct&quot;: &quot;NCT06237868&quot;, &quot;color&quot;: &quot;#35cb57&quot;, &quot;title&quot;: &quot;rTMS Over the Dorsolateral Prefrontal Cortex for the Treatment of Impulse Control Disorders in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;rTMS Active; rTMS Sham&quot;, &quot;sponsor&quot;: &quot;West Virginia University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06237868&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.46427, &quot;lng&quot;: 9.18951, &quot;nct&quot;: &quot;NCT05799690&quot;, &quot;color&quot;: &quot;#2d116c&quot;, &quot;title&quot;: &quot;Comparison of Different Rehabilitation Protocols in Parkinson&#x27;s Disease With Postural Instability and Gait Disorders&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Gait and balance training with dual-task + action observation and motor imagery (six weeks); Gait and balance training with dual-task (six weeks); Gait and balance training with dual-task + action observation and motor imagery (twelve weeks: 6 + 6); Gait and balance training with dual-task (twelve weeks: 6 +6)&quot;, &quot;sponsor&quot;: &quot;Prof. Massimo Filippi&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05799690&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.43854, &quot;lng&quot;: 10.9938, &quot;nct&quot;: &quot;NCT05799690&quot;, &quot;color&quot;: &quot;#2d116c&quot;, &quot;title&quot;: &quot;Comparison of Different Rehabilitation Protocols in Parkinson&#x27;s Disease With Postural Instability and Gait Disorders&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Gait and balance training with dual-task + action observation and motor imagery (six weeks); Gait and balance training with dual-task (six weeks); Gait and balance training with dual-task + action observation and motor imagery (twelve weeks: 6 + 6); Gait and balance training with dual-task (twelve weeks: 6 +6)&quot;, &quot;sponsor&quot;: &quot;Prof. Massimo Filippi&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05799690&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.52345, &quot;lng&quot;: -122.67621, &quot;nct&quot;: &quot;NCT04897256&quot;, &quot;color&quot;: &quot;#210769&quot;, &quot;title&quot;: &quot;Mobility in Daily Life and Falls in Parkinson&#x27;s Disease: Potential for Rehabilitation&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;TURN-IT exercise program&quot;, &quot;sponsor&quot;: &quot;Oregon Health and Science University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04897256&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 38.58157, &quot;lng&quot;: -121.4944, &quot;nct&quot;: &quot;NCT03741920&quot;, &quot;color&quot;: &quot;#f98be2&quot;, &quot;title&quot;: &quot;Evaluation of the Personal KinetiGraph\\u2122 (PKG\\u2122) to Improve Insight Into Parkinson&#x27;s Disease Status&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Personal KinetiGraph\\u2122 (PKG\\u2122)&quot;, &quot;sponsor&quot;: &quot;Global Kinetics Corporation&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03741920&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 32.71571, &quot;lng&quot;: -117.16472, &quot;nct&quot;: &quot;NCT03741920&quot;, &quot;color&quot;: &quot;#f98be2&quot;, &quot;title&quot;: &quot;Evaluation of the Personal KinetiGraph\\u2122 (PKG\\u2122) to Improve Insight Into Parkinson&#x27;s Disease Status&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Personal KinetiGraph\\u2122 (PKG\\u2122)&quot;, &quot;sponsor&quot;: &quot;Global Kinetics Corporation&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03741920&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.35869, &quot;lng&quot;: -80.0831, &quot;nct&quot;: &quot;NCT03741920&quot;, &quot;color&quot;: &quot;#f98be2&quot;, &quot;title&quot;: &quot;Evaluation of the Personal KinetiGraph\\u2122 (PKG\\u2122) to Improve Insight Into Parkinson&#x27;s Disease Status&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Personal KinetiGraph\\u2122 (PKG\\u2122)&quot;, &quot;sponsor&quot;: &quot;Global Kinetics Corporation&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03741920&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.65163, &quot;lng&quot;: -82.32483, &quot;nct&quot;: &quot;NCT03741920&quot;, &quot;color&quot;: &quot;#f98be2&quot;, &quot;title&quot;: &quot;Evaluation of the Personal KinetiGraph\\u2122 (PKG\\u2122) to Improve Insight Into Parkinson&#x27;s Disease Status&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Personal KinetiGraph\\u2122 (PKG\\u2122)&quot;, &quot;sponsor&quot;: &quot;Global Kinetics Corporation&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03741920&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 25.77427, &quot;lng&quot;: -80.19366, &quot;nct&quot;: &quot;NCT03741920&quot;, &quot;color&quot;: &quot;#f98be2&quot;, &quot;title&quot;: &quot;Evaluation of the Personal KinetiGraph\\u2122 (PKG\\u2122) to Improve Insight Into Parkinson&#x27;s Disease Status&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Personal KinetiGraph\\u2122 (PKG\\u2122)&quot;, &quot;sponsor&quot;: &quot;Global Kinetics Corporation&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03741920&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 27.94752, &quot;lng&quot;: -82.45843, &quot;nct&quot;: &quot;NCT03741920&quot;, &quot;color&quot;: &quot;#f98be2&quot;, &quot;title&quot;: &quot;Evaluation of the Personal KinetiGraph\\u2122 (PKG\\u2122) to Improve Insight Into Parkinson&#x27;s Disease Status&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Personal KinetiGraph\\u2122 (PKG\\u2122)&quot;, &quot;sponsor&quot;: &quot;Global Kinetics Corporation&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03741920&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.11417, &quot;lng&quot;: -94.62746, &quot;nct&quot;: &quot;NCT03741920&quot;, &quot;color&quot;: &quot;#f98be2&quot;, &quot;title&quot;: &quot;Evaluation of the Personal KinetiGraph\\u2122 (PKG\\u2122) to Improve Insight Into Parkinson&#x27;s Disease Status&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Personal KinetiGraph\\u2122 (PKG\\u2122)&quot;, &quot;sponsor&quot;: &quot;Global Kinetics Corporation&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03741920&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.29038, &quot;lng&quot;: -76.61219, &quot;nct&quot;: &quot;NCT03741920&quot;, &quot;color&quot;: &quot;#f98be2&quot;, &quot;title&quot;: &quot;Evaluation of the Personal KinetiGraph\\u2122 (PKG\\u2122) to Improve Insight Into Parkinson&#x27;s Disease Status&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Personal KinetiGraph\\u2122 (PKG\\u2122)&quot;, &quot;sponsor&quot;: &quot;Global Kinetics Corporation&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03741920&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.73698, &quot;lng&quot;: -84.48387, &quot;nct&quot;: &quot;NCT03741920&quot;, &quot;color&quot;: &quot;#f98be2&quot;, &quot;title&quot;: &quot;Evaluation of the Personal KinetiGraph\\u2122 (PKG\\u2122) to Improve Insight Into Parkinson&#x27;s Disease Status&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Personal KinetiGraph\\u2122 (PKG\\u2122)&quot;, &quot;sponsor&quot;: &quot;Global Kinetics Corporation&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03741920&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.80066, &quot;lng&quot;: -73.72846, &quot;nct&quot;: &quot;NCT03741920&quot;, &quot;color&quot;: &quot;#f98be2&quot;, &quot;title&quot;: &quot;Evaluation of the Personal KinetiGraph\\u2122 (PKG\\u2122) to Improve Insight Into Parkinson&#x27;s Disease Status&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Personal KinetiGraph\\u2122 (PKG\\u2122)&quot;, &quot;sponsor&quot;: &quot;Global Kinetics Corporation&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03741920&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.71427, &quot;lng&quot;: -74.00597, &quot;nct&quot;: &quot;NCT03741920&quot;, &quot;color&quot;: &quot;#f98be2&quot;, &quot;title&quot;: &quot;Evaluation of the Personal KinetiGraph\\u2122 (PKG\\u2122) to Improve Insight Into Parkinson&#x27;s Disease Status&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Personal KinetiGraph\\u2122 (PKG\\u2122)&quot;, &quot;sponsor&quot;: &quot;Global Kinetics Corporation&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03741920&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.76328, &quot;lng&quot;: -95.36327, &quot;nct&quot;: &quot;NCT03741920&quot;, &quot;color&quot;: &quot;#f98be2&quot;, &quot;title&quot;: &quot;Evaluation of the Personal KinetiGraph\\u2122 (PKG\\u2122) to Improve Insight Into Parkinson&#x27;s Disease Status&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Personal KinetiGraph\\u2122 (PKG\\u2122)&quot;, &quot;sponsor&quot;: &quot;Global Kinetics Corporation&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03741920&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: -22.88333, &quot;lng&quot;: -43.10361, &quot;nct&quot;: &quot;NCT06912997&quot;, &quot;color&quot;: &quot;#451aae&quot;, &quot;title&quot;: &quot;Effects of Inspiratory Muscle Training on Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Exercise; Sham Comparator&quot;, &quot;sponsor&quot;: &quot;Universidade Federal Fluminense&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06912997&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.52066, &quot;lng&quot;: -86.80249, &quot;nct&quot;: &quot;NCT03457493&quot;, &quot;color&quot;: &quot;#f2a5f7&quot;, &quot;title&quot;: &quot;The University of Alabama At Birmingham (UAB) Neuroinflammation in Parkinson&#x27;s Disease-TSPO- Positron Emission Tomography (PET) Substudy&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;DPA-714-PET/MRI; 5-year Follow-up DPA-714-PET/MRI; DPA-714 Metabolite Analysis&quot;, &quot;sponsor&quot;: &quot;University of Alabama at Birmingham&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03457493&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.72943, &quot;lng&quot;: -104.83192, &quot;nct&quot;: &quot;NCT04796506&quot;, &quot;color&quot;: &quot;#2a817a&quot;, &quot;title&quot;: &quot;Slow Wave Sleep As a Biomarker of Rehabilitation-induced Cognitive Improvement in PD&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Progressive Resistance Training (PRT); Delayed Exercise Training (DE); Endurance Training (ET)&quot;, &quot;sponsor&quot;: &quot;University of Colorado, Denver&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04796506&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.35843, &quot;lng&quot;: -71.05977, &quot;nct&quot;: &quot;NCT06804668&quot;, &quot;color&quot;: &quot;#a35ca9&quot;, &quot;title&quot;: &quot;Safety and Feasibility of Tele-supervised Home-based Transcranial Direct Current Stimulation in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;tDCS&quot;, &quot;sponsor&quot;: &quot;Brigham and Women&#x27;s Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06804668&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 44.39071, &quot;lng&quot;: 7.54828, &quot;nct&quot;: &quot;NCT06052280&quot;, &quot;color&quot;: &quot;#5277f8&quot;, &quot;title&quot;: &quot;Pilot Study: Parkinson&#x27;s Conventional Physiotherapy vs Home-based Telerehabilitation&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Telerehabilitation exercise program; Home self-exercise program&quot;, &quot;sponsor&quot;: &quot;Azienda Sanitaria Locale CN1 Cuneo&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06052280&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.44838, &quot;lng&quot;: -112.07404, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.59754, &quot;lng&quot;: -112.27182, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 34.05223, &quot;lng&quot;: -118.24368, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 34.14778, &quot;lng&quot;: -118.14452, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.77493, &quot;lng&quot;: -122.41942, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.72943, &quot;lng&quot;: -104.83192, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.64777, &quot;lng&quot;: -104.98776, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.30815, &quot;lng&quot;: -72.92816, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.35869, &quot;lng&quot;: -80.0831, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 25.77427, &quot;lng&quot;: -80.19366, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 28.53834, &quot;lng&quot;: -81.37924, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 27.94752, &quot;lng&quot;: -82.45843, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 21.30694, &quot;lng&quot;: -157.85833, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.85003, &quot;lng&quot;: -87.65005, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.11417, &quot;lng&quot;: -94.62746, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.35843, &quot;lng&quot;: -71.05977, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.48531, &quot;lng&quot;: -83.37716, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.71427, &quot;lng&quot;: -74.00597, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 35.99403, &quot;lng&quot;: -78.89862, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.4995, &quot;lng&quot;: -81.69541, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.95238, &quot;lng&quot;: -75.16362, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 32.77632, &quot;lng&quot;: -79.93275, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 35.15565, &quot;lng&quot;: -89.7762, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.76328, &quot;lng&quot;: -95.36327, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 30.50826, &quot;lng&quot;: -97.6789, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.55376, &quot;lng&quot;: -77.46026, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.68149, &quot;lng&quot;: -122.20874, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.65966, &quot;lng&quot;: -117.42908, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.26266, &quot;lng&quot;: 11.39454, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.20849, &quot;lng&quot;: 16.37208, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.05011, &quot;lng&quot;: -114.08529, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 44.64269, &quot;lng&quot;: -63.57688, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.70643, &quot;lng&quot;: -79.39864, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.50884, &quot;lng&quot;: -73.58781, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.9075, &quot;lng&quot;: 116.39723, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 30.66667, &quot;lng&quot;: 104.06667, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.29695, &quot;lng&quot;: 5.38107, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.60426, &quot;lng&quot;: 1.44367, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.61093, &quot;lng&quot;: 3.87635, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.11109, &quot;lng&quot;: -1.67431, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.77969, &quot;lng&quot;: 3.08682, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.73865, &quot;lng&quot;: 4.91303, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.85341, &quot;lng&quot;: 2.3488, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.52266, &quot;lng&quot;: 9.05222, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.39841, &quot;lng&quot;: 9.99155, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.13743, &quot;lng&quot;: 11.57549, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 49.79391, &quot;lng&quot;: 9.95121, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.31667, &quot;lng&quot;: 9.5, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.80904, &quot;lng&quot;: 8.77069, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.37052, &quot;lng&quot;: 9.73322, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.48165, &quot;lng&quot;: 7.21648, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.22172, &quot;lng&quot;: 6.77616, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.05089, &quot;lng&quot;: 13.73832, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 53.86893, &quot;lng&quot;: 10.68729, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 32.08707, &quot;lng&quot;: 34.88747, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 32.08227, &quot;lng&quot;: 34.81065, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 32.08088, &quot;lng&quot;: 34.78057, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 44.49381, &quot;lng&quot;: 11.33875, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.53558, &quot;lng&quot;: 10.21472, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.49223, &quot;lng&quot;: 15.07041, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.34827, &quot;lng&quot;: 14.16494, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.78235, &quot;lng&quot;: 12.59836, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.87618, &quot;lng&quot;: 14.5195, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.70853, &quot;lng&quot;: 10.4036, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 44.99364, &quot;lng&quot;: 11.10642, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 34.69379, &quot;lng&quot;: 135.50107, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 38.26667, &quot;lng&quot;: 140.86667, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 35.6895, &quot;lng&quot;: 139.69171, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.37403, &quot;lng&quot;: 4.88969, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.8425, &quot;lng&quot;: 5.85278, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.5125, &quot;lng&quot;: 6.09444, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.03437, &quot;lng&quot;: 19.21037, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.22977, &quot;lng&quot;: 21.01178, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 53.1235, &quot;lng&quot;: 18.00762, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.2597, &quot;lng&quot;: 19.02173, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.47063, &quot;lng&quot;: 2.08611, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.81687, &quot;lng&quot;: -1.64323, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.37135, &quot;lng&quot;: -8.396, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.29639, &quot;lng&quot;: -2.98813, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.38879, &quot;lng&quot;: 2.15899, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.31283, &quot;lng&quot;: -1.97499, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.4165, &quot;lng&quot;: -3.70256, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.38283, &quot;lng&quot;: -5.97317, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.37153, &quot;lng&quot;: -4.14305, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.50853, &quot;lng&quot;: -0.12574, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 53.48771, &quot;lng&quot;: -2.29042, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 55.78924, &quot;lng&quot;: -3.99187, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 54.97328, &quot;lng&quot;: -1.61396, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.48142, &quot;lng&quot;: -1.89983, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 56.46913, &quot;lng&quot;: -2.97489, &quot;nct&quot;: &quot;NCT05348785&quot;, &quot;color&quot;: &quot;#a69e06&quot;, &quot;title&quot;: &quot;A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson&#x27;s Disease in Adults Between the Ages of 30 and 80&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Biogen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05348785&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 44.97997, &quot;lng&quot;: -93.26384, &quot;nct&quot;: &quot;NCT06692920&quot;, &quot;color&quot;: &quot;#e5eb88&quot;, &quot;title&quot;: &quot;Characterizing the Pathophysiological Role of the Pallido-thalamocortical Motor Pathway in Parkinson&#x27;s Disease.&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;DBS stimulation&quot;, &quot;sponsor&quot;: &quot;University of Minnesota&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06692920&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.61674, &quot;lng&quot;: 0.62218, &quot;nct&quot;: &quot;NCT06444685&quot;, &quot;color&quot;: &quot;#8962fe&quot;, &quot;title&quot;: &quot;Effects of Table Tennis for People With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Exercise and cognitive training interventino&quot;, &quot;sponsor&quot;: &quot;Universitat de Lleida&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06444685&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 28.4853, &quot;lng&quot;: -16.32014, &quot;nct&quot;: &quot;NCT06853262&quot;, &quot;color&quot;: &quot;#84da5a&quot;, &quot;title&quot;: &quot;Manual Therapy in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Manual Therapy Protocol; Sham Manual Protocol&quot;, &quot;sponsor&quot;: &quot;University of La Laguna&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06853262&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.75222, &quot;lng&quot;: -1.25596, &quot;nct&quot;: &quot;NCT06485986&quot;, &quot;color&quot;: &quot;#29bb96&quot;, &quot;title&quot;: &quot;Frontosubthalamic Networks in Parkinson&#x27;s Disease.&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;DBS on/off&quot;, &quot;sponsor&quot;: &quot;University of Oxford&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06485986&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 31.22222, &quot;lng&quot;: 121.45806, &quot;nct&quot;: &quot;NCT07157345&quot;, &quot;color&quot;: &quot;#e95b92&quot;, &quot;title&quot;: &quot;Testing if PDR-001 Can Safely and Effectively Remove Harmful Brain Protein in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;PDR001&quot;, &quot;sponsor&quot;: &quot;Ruijin Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07157345&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 34.05223, &quot;lng&quot;: -118.24368, &quot;nct&quot;: &quot;NCT05109364&quot;, &quot;color&quot;: &quot;#eda021&quot;, &quot;title&quot;: &quot;Terazosin and Parkinson&#x27;s Disease Extension Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Terazosin therapy&quot;, &quot;sponsor&quot;: &quot;Cedars-Sinai Medical Center&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05109364&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.64229, &quot;lng&quot;: -72.25176, &quot;nct&quot;: &quot;NCT06260228&quot;, &quot;color&quot;: &quot;#1ea6ff&quot;, &quot;title&quot;: &quot;HOme-Based Self-management and COgnitive Training CHanges Lives (HOBSCOTCH)-Parkinson&#x27;s Disease (HOBSCOTCH-Parkinson&#x27;s)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;HOme-Based Self-management and COgnitive Training CHanges lives (HOBSCOTCH)&quot;, &quot;sponsor&quot;: &quot;Dartmouth-Hitchcock Medical Center&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06260228&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.01384, &quot;lng&quot;: 28.94966, &quot;nct&quot;: &quot;NCT07068217&quot;, &quot;color&quot;: &quot;#527a93&quot;, &quot;title&quot;: &quot;Effect of Metronome-Based Structured Rhythmic Exercise Program on Freezing and Gait Parameters in Parkinson Disease&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Exercise&quot;, &quot;sponsor&quot;: &quot;Medipol University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07068217&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.36667, &quot;lng&quot;: 8.55, &quot;nct&quot;: &quot;NCT05101161&quot;, &quot;color&quot;: &quot;#ba9ba4&quot;, &quot;title&quot;: &quot;Neurofeedback Using Implanted Deep Brain Stimulation Electrodes&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Neurofeedback&quot;, &quot;sponsor&quot;: &quot;ETH Zurich&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05101161&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.70643, &quot;lng&quot;: -79.39864, &quot;nct&quot;: &quot;NCT04953637&quot;, &quot;color&quot;: &quot;#8d0c93&quot;, &quot;title&quot;: &quot;Physiotherapy and Deep Brain Stimulation in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Physiotherapy&quot;, &quot;sponsor&quot;: &quot;University of Toronto&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04953637&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.52066, &quot;lng&quot;: -86.80249, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.44838, &quot;lng&quot;: -112.07404, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 34.74648, &quot;lng&quot;: -92.28959, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.70918, &quot;lng&quot;: -117.95367, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.74773, &quot;lng&quot;: -119.77237, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 34.05223, &quot;lng&quot;: -118.24368, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 34.14778, &quot;lng&quot;: -118.14452, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 34.20112, &quot;lng&quot;: -118.53647, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.64777, &quot;lng&quot;: -104.98776, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 25.96537, &quot;lng&quot;: -80.14282, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.35869, &quot;lng&quot;: -80.0831, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.27119, &quot;lng&quot;: -80.2706, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 28.62778, &quot;lng&quot;: -81.36312, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.14234, &quot;lng&quot;: -81.79596, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.1872, &quot;lng&quot;: -82.14009, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.97617, &quot;lng&quot;: -82.09064, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.13832, &quot;lng&quot;: -80.99561, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 27.94752, &quot;lng&quot;: -82.45843, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 28.6, &quot;lng&quot;: -81.33924, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.47097, &quot;lng&quot;: -81.97484, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.85003, &quot;lng&quot;: -87.65005, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.8617, &quot;lng&quot;: -88.1609, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.11417, &quot;lng&quot;: -94.62746, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.98869, &quot;lng&quot;: -84.47772, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.57814, &quot;lng&quot;: -70.32172, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.35843, &quot;lng&quot;: -71.05977, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.70704, &quot;lng&quot;: -71.16311, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.73698, &quot;lng&quot;: -84.48387, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.56891, &quot;lng&quot;: -83.38356, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.17497, &quot;lng&quot;: -115.13722, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.92595, &quot;lng&quot;: -75.11962, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.65258, &quot;lng&quot;: -73.75623, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.04812, &quot;lng&quot;: -76.14742, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 35.60095, &quot;lng&quot;: -82.55402, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 35.99403, &quot;lng&quot;: -78.89862, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.12711, &quot;lng&quot;: -84.51439, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.4995, &quot;lng&quot;: -81.69541, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.96118, &quot;lng&quot;: -82.99879, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.75895, &quot;lng&quot;: -84.19161, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.66394, &quot;lng&quot;: -83.55521, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.95238, &quot;lng&quot;: -75.16362, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 35.14953, &quot;lng&quot;: -90.04898, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 30.63269, &quot;lng&quot;: -97.67723, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.76328, &quot;lng&quot;: -95.36327, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.57786, &quot;lng&quot;: -101.85517, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 30.50826, &quot;lng&quot;: -97.6789, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 44.47588, &quot;lng&quot;: -73.21207, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.55376, &quot;lng&quot;: -77.46026, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.85293, &quot;lng&quot;: -75.97799, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.68149, &quot;lng&quot;: -122.20874, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.65966, &quot;lng&quot;: -117.42908, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: -33.43218, &quot;lng&quot;: 151.38972, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: -33.9681, &quot;lng&quot;: 151.13564, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: -33.86785, &quot;lng&quot;: 151.20732, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: -27.48855, &quot;lng&quot;: 153.03655, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: -37.91667, &quot;lng&quot;: 145.11667, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: -37.78333, &quot;lng&quot;: 144.95, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.41791, &quot;lng&quot;: 24.61666, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.69751, &quot;lng&quot;: 23.32415, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.41117, &quot;lng&quot;: -75.69812, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.70643, &quot;lng&quot;: -79.39864, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.00161, &quot;lng&quot;: 16.22303, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.08804, &quot;lng&quot;: 14.42076, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.16284, &quot;lng&quot;: 16.27488, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.73865, &quot;lng&quot;: 4.91303, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.79266, &quot;lng&quot;: 2.46569, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.68439, &quot;lng&quot;: 6.18496, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.17869, &quot;lng&quot;: 5.71479, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.83665, &quot;lng&quot;: 4.35788, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.58392, &quot;lng&quot;: 7.74553, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.60426, &quot;lng&quot;: 1.44367, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.22683, &quot;lng&quot;: 8.61816, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.88029, &quot;lng&quot;: 12.08187, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.16196, &quot;lng&quot;: 12.17942, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.60698, &quot;lng&quot;: 13.31243, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.96236, &quot;lng&quot;: 7.62571, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.52437, &quot;lng&quot;: 13.41053, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.48165, &quot;lng&quot;: 7.21648, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.13743, &quot;lng&quot;: 11.57549, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.85684, &quot;lng&quot;: 11.72677, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.49835, &quot;lng&quot;: 19.04045, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 46.07617, &quot;lng&quot;: 18.22814, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.59247, &quot;lng&quot;: 18.38099, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 32.08227, &quot;lng&quot;: 34.81065, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 32.81303, &quot;lng&quot;: 34.99928, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 32.08707, &quot;lng&quot;: 34.88747, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 31.99866, &quot;lng&quot;: 34.94559, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 32.08088, &quot;lng&quot;: 34.78057, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.78235, &quot;lng&quot;: 12.59836, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.89193, &quot;lng&quot;: 12.51133, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 44.88856, &quot;lng&quot;: 11.99138, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.40797, &quot;lng&quot;: 11.88586, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.60717, &quot;lng&quot;: 13.5103, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.48581, &quot;lng&quot;: 13.82835, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.70853, &quot;lng&quot;: 10.4036, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.06143, &quot;lng&quot;: 19.93658, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.2597, &quot;lng&quot;: 19.02173, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.25058, &quot;lng&quot;: 22.57009, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.22977, &quot;lng&quot;: 21.01178, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.32738, &quot;lng&quot;: 19.02901, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 53.1235, &quot;lng&quot;: 18.00762, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 44.80401, &quot;lng&quot;: 20.46513, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 38.26218, &quot;lng&quot;: -0.70107, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.38879, &quot;lng&quot;: 2.15899, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.4165, &quot;lng&quot;: -3.70256, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.38283, &quot;lng&quot;: -5.97317, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.31283, &quot;lng&quot;: -1.97499, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.81687, &quot;lng&quot;: -1.64323, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.56667, &quot;lng&quot;: 2.01667, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.47391, &quot;lng&quot;: -0.37966, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.46664, &quot;lng&quot;: 35.04066, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 49.83826, &quot;lng&quot;: 24.02324, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 49.84639, &quot;lng&quot;: 37.71861, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.85167, &quot;lng&quot;: 35.11714, &quot;nct&quot;: &quot;NCT04760769&quot;, &quot;color&quot;: &quot;#d3e26a&quot;, &quot;title&quot;: &quot;Open-label Trial in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Tavapadon&quot;, &quot;sponsor&quot;: &quot;AbbVie&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04760769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.9075, &quot;lng&quot;: 116.39723, &quot;nct&quot;: &quot;NCT06012461&quot;, &quot;color&quot;: &quot;#23ee3a&quot;, &quot;title&quot;: &quot;Closed-loop DBS in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Closed-loop DBS stimulation for 24 hours; Open-loop DBS stimulation for 24 hours; Closed-loop DBS stimulation for 72 hours; Open-loop DBS stimulation for 72 hours&quot;, &quot;sponsor&quot;: &quot;Tsinghua University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06012461&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 49.24966, &quot;lng&quot;: -123.11934, &quot;nct&quot;: &quot;NCT06259708&quot;, &quot;color&quot;: &quot;#2d913c&quot;, &quot;title&quot;: &quot;Using Low Intensity Focused Ultrasound to Modulate Deep Brain Areas for Tremor Control in Parkinson&#x27;s Disease Patients.&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Low intensity focused ultrasound&quot;, &quot;sponsor&quot;: &quot;University of British Columbia&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06259708&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.48522, &quot;lng&quot;: -122.23635, &quot;nct&quot;: &quot;NCT05292794&quot;, &quot;color&quot;: &quot;#3edcb2&quot;, &quot;title&quot;: &quot;Use of CereGate Therapy for Freezing of Gait in PD&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;CereGate Software; BSN cDBS Programmer; BSN Burst Programmer&quot;, &quot;sponsor&quot;: &quot;CereGate Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05292794&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.72943, &quot;lng&quot;: -104.83192, &quot;nct&quot;: &quot;NCT05292794&quot;, &quot;color&quot;: &quot;#3edcb2&quot;, &quot;title&quot;: &quot;Use of CereGate Therapy for Freezing of Gait in PD&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;CereGate Software; BSN cDBS Programmer; BSN Burst Programmer&quot;, &quot;sponsor&quot;: &quot;CereGate Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05292794&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 25.77427, &quot;lng&quot;: -80.19366, &quot;nct&quot;: &quot;NCT05292794&quot;, &quot;color&quot;: &quot;#3edcb2&quot;, &quot;title&quot;: &quot;Use of CereGate Therapy for Freezing of Gait in PD&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;CereGate Software; BSN cDBS Programmer; BSN Burst Programmer&quot;, &quot;sponsor&quot;: &quot;CereGate Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05292794&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.85003, &quot;lng&quot;: -87.65005, &quot;nct&quot;: &quot;NCT05292794&quot;, &quot;color&quot;: &quot;#3edcb2&quot;, &quot;title&quot;: &quot;Use of CereGate Therapy for Freezing of Gait in PD&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;CereGate Software; BSN cDBS Programmer; BSN Burst Programmer&quot;, &quot;sponsor&quot;: &quot;CereGate Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05292794&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.09986, &quot;lng&quot;: -80.24422, &quot;nct&quot;: &quot;NCT05292794&quot;, &quot;color&quot;: &quot;#3edcb2&quot;, &quot;title&quot;: &quot;Use of CereGate Therapy for Freezing of Gait in PD&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;CereGate Software; BSN cDBS Programmer; BSN Burst Programmer&quot;, &quot;sponsor&quot;: &quot;CereGate Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05292794&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.16589, &quot;lng&quot;: -86.78444, &quot;nct&quot;: &quot;NCT05292794&quot;, &quot;color&quot;: &quot;#3edcb2&quot;, &quot;title&quot;: &quot;Use of CereGate Therapy for Freezing of Gait in PD&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;CereGate Software; BSN cDBS Programmer; BSN Burst Programmer&quot;, &quot;sponsor&quot;: &quot;CereGate Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05292794&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.60621, &quot;lng&quot;: -122.33207, &quot;nct&quot;: &quot;NCT05292794&quot;, &quot;color&quot;: &quot;#3edcb2&quot;, &quot;title&quot;: &quot;Use of CereGate Therapy for Freezing of Gait in PD&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;CereGate Software; BSN cDBS Programmer; BSN Burst Programmer&quot;, &quot;sponsor&quot;: &quot;CereGate Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05292794&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 58.46151, &quot;lng&quot;: 8.77253, &quot;nct&quot;: &quot;NCT03568968&quot;, &quot;color&quot;: &quot;#bacbae&quot;, &quot;title&quot;: &quot;A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Nicotinamide Riboside; Placebo&quot;, &quot;sponsor&quot;: &quot;Haukeland University Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03568968&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 60.39299, &quot;lng&quot;: 5.32415, &quot;nct&quot;: &quot;NCT03568968&quot;, &quot;color&quot;: &quot;#bacbae&quot;, &quot;title&quot;: &quot;A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Nicotinamide Riboside; Placebo&quot;, &quot;sponsor&quot;: &quot;Haukeland University Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03568968&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 59.91273, &quot;lng&quot;: 10.74609, &quot;nct&quot;: &quot;NCT03568968&quot;, &quot;color&quot;: &quot;#bacbae&quot;, &quot;title&quot;: &quot;A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Nicotinamide Riboside; Placebo&quot;, &quot;sponsor&quot;: &quot;Haukeland University Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03568968&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 59.74389, &quot;lng&quot;: 10.20449, &quot;nct&quot;: &quot;NCT03568968&quot;, &quot;color&quot;: &quot;#bacbae&quot;, &quot;title&quot;: &quot;A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Nicotinamide Riboside; Placebo&quot;, &quot;sponsor&quot;: &quot;Haukeland University Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03568968&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 61.45217, &quot;lng&quot;: 5.85717, &quot;nct&quot;: &quot;NCT03568968&quot;, &quot;color&quot;: &quot;#bacbae&quot;, &quot;title&quot;: &quot;A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Nicotinamide Riboside; Placebo&quot;, &quot;sponsor&quot;: &quot;Haukeland University Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03568968&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 59.41378, &quot;lng&quot;: 5.268, &quot;nct&quot;: &quot;NCT03568968&quot;, &quot;color&quot;: &quot;#bacbae&quot;, &quot;title&quot;: &quot;A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Nicotinamide Riboside; Placebo&quot;, &quot;sponsor&quot;: &quot;Haukeland University Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03568968&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 62.73752, &quot;lng&quot;: 7.15912, &quot;nct&quot;: &quot;NCT03568968&quot;, &quot;color&quot;: &quot;#bacbae&quot;, &quot;title&quot;: &quot;A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Nicotinamide Riboside; Placebo&quot;, &quot;sponsor&quot;: &quot;Haukeland University Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03568968&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.56995, &quot;lng&quot;: -73.692, &quot;nct&quot;: &quot;NCT05644327&quot;, &quot;color&quot;: &quot;#6d40b4&quot;, &quot;title&quot;: &quot;Exercise to Improve Sleep in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Cardiovascular training (CT); Resistance training (RT); Multimodal training (MT)&quot;, &quot;sponsor&quot;: &quot;McGill University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05644327&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.50884, &quot;lng&quot;: -73.58781, &quot;nct&quot;: &quot;NCT05644327&quot;, &quot;color&quot;: &quot;#6d40b4&quot;, &quot;title&quot;: &quot;Exercise to Improve Sleep in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Cardiovascular training (CT); Resistance training (RT); Multimodal training (MT)&quot;, &quot;sponsor&quot;: &quot;McGill University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05644327&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: -33.87939, &quot;lng&quot;: 151.21925, &quot;nct&quot;: &quot;NCT06732180&quot;, &quot;color&quot;: &quot;#8b18ef&quot;, &quot;title&quot;: &quot;Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;GT-02287&quot;, &quot;sponsor&quot;: &quot;Gain Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06732180&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: -33.9681, &quot;lng&quot;: 151.13564, &quot;nct&quot;: &quot;NCT06732180&quot;, &quot;color&quot;: &quot;#8b18ef&quot;, &quot;title&quot;: &quot;Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;GT-02287&quot;, &quot;sponsor&quot;: &quot;Gain Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06732180&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: -33.80383, &quot;lng&quot;: 150.98768, &quot;nct&quot;: &quot;NCT06732180&quot;, &quot;color&quot;: &quot;#8b18ef&quot;, &quot;title&quot;: &quot;Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;GT-02287&quot;, &quot;sponsor&quot;: &quot;Gain Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06732180&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: -27.48855, &quot;lng&quot;: 153.03655, &quot;nct&quot;: &quot;NCT06732180&quot;, &quot;color&quot;: &quot;#8b18ef&quot;, &quot;title&quot;: &quot;Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;GT-02287&quot;, &quot;sponsor&quot;: &quot;Gain Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06732180&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: -34.92866, &quot;lng&quot;: 138.59863, &quot;nct&quot;: &quot;NCT06732180&quot;, &quot;color&quot;: &quot;#8b18ef&quot;, &quot;title&quot;: &quot;Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;GT-02287&quot;, &quot;sponsor&quot;: &quot;Gain Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06732180&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: -37.814, &quot;lng&quot;: 144.96332, &quot;nct&quot;: &quot;NCT06732180&quot;, &quot;color&quot;: &quot;#8b18ef&quot;, &quot;title&quot;: &quot;Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;GT-02287&quot;, &quot;sponsor&quot;: &quot;Gain Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06732180&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: -37.78333, &quot;lng&quot;: 144.95, &quot;nct&quot;: &quot;NCT06732180&quot;, &quot;color&quot;: &quot;#8b18ef&quot;, &quot;title&quot;: &quot;Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;GT-02287&quot;, &quot;sponsor&quot;: &quot;Gain Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06732180&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 49.02012, &quot;lng&quot;: -0.63238, &quot;nct&quot;: &quot;NCT07063810&quot;, &quot;color&quot;: &quot;#a21a58&quot;, &quot;title&quot;: &quot;NEO-REEDUC - Mixed Reality for Motor Rehabilitation: a Prospective, Multicenter, Controlled, Randomized, Open Study.&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Mixed Reality Rehabilitation&quot;, &quot;sponsor&quot;: &quot;Slb Pharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07063810&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 49.21088, &quot;lng&quot;: -0.30653, &quot;nct&quot;: &quot;NCT07063810&quot;, &quot;color&quot;: &quot;#a21a58&quot;, &quot;title&quot;: &quot;NEO-REEDUC - Mixed Reality for Motor Rehabilitation: a Prospective, Multicenter, Controlled, Randomized, Open Study.&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Mixed Reality Rehabilitation&quot;, &quot;sponsor&quot;: &quot;Slb Pharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07063810&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 49.01096, &quot;lng&quot;: 1.0873, &quot;nct&quot;: &quot;NCT07063810&quot;, &quot;color&quot;: &quot;#a21a58&quot;, &quot;title&quot;: &quot;NEO-REEDUC - Mixed Reality for Motor Rehabilitation: a Prospective, Multicenter, Controlled, Randomized, Open Study.&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Mixed Reality Rehabilitation&quot;, &quot;sponsor&quot;: &quot;Slb Pharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07063810&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.60426, &quot;lng&quot;: 1.44367, &quot;nct&quot;: &quot;NCT06008704&quot;, &quot;color&quot;: &quot;#fad364&quot;, &quot;title&quot;: &quot;Pain in Parkinson&#x27;s Disease: Exploration of the Serotonin System in Positron Emission Tomography (PET [18F]-MPPF)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Clinical assessment; Pain characteristics assessment; MRI; Thermotest; UPDRS-III Scale; [18F]-MPPF PET scan&quot;, &quot;sponsor&quot;: &quot;University Hospital, Toulouse&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06008704&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.93333, &quot;lng&quot;: 6.95, &quot;nct&quot;: &quot;NCT06561919&quot;, &quot;color&quot;: &quot;#0c0674&quot;, &quot;title&quot;: &quot;STIMPulseControl Ancillary Speech Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper; best medical treatment for management of impulse control in Parkinson\\u00b4s disease according to widely accepted expert consensus paper&quot;, &quot;sponsor&quot;: &quot;Steffen Paschen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06561919&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.05089, &quot;lng&quot;: 13.73832, &quot;nct&quot;: &quot;NCT06561919&quot;, &quot;color&quot;: &quot;#0c0674&quot;, &quot;title&quot;: &quot;STIMPulseControl Ancillary Speech Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper; best medical treatment for management of impulse control in Parkinson\\u00b4s disease according to widely accepted expert consensus paper&quot;, &quot;sponsor&quot;: &quot;Steffen Paschen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06561919&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.22172, &quot;lng&quot;: 6.77616, &quot;nct&quot;: &quot;NCT06561919&quot;, &quot;color&quot;: &quot;#0c0674&quot;, &quot;title&quot;: &quot;STIMPulseControl Ancillary Speech Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper; best medical treatment for management of impulse control in Parkinson\\u00b4s disease according to widely accepted expert consensus paper&quot;, &quot;sponsor&quot;: &quot;Steffen Paschen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06561919&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 53.55073, &quot;lng&quot;: 9.99302, &quot;nct&quot;: &quot;NCT06561919&quot;, &quot;color&quot;: &quot;#0c0674&quot;, &quot;title&quot;: &quot;STIMPulseControl Ancillary Speech Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper; best medical treatment for management of impulse control in Parkinson\\u00b4s disease according to widely accepted expert consensus paper&quot;, &quot;sponsor&quot;: &quot;Steffen Paschen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06561919&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 54.32133, &quot;lng&quot;: 10.13489, &quot;nct&quot;: &quot;NCT06561919&quot;, &quot;color&quot;: &quot;#0c0674&quot;, &quot;title&quot;: &quot;STIMPulseControl Ancillary Speech Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper; best medical treatment for management of impulse control in Parkinson\\u00b4s disease according to widely accepted expert consensus paper&quot;, &quot;sponsor&quot;: &quot;Steffen Paschen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06561919&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.80904, &quot;lng&quot;: 8.77069, &quot;nct&quot;: &quot;NCT06561919&quot;, &quot;color&quot;: &quot;#0c0674&quot;, &quot;title&quot;: &quot;STIMPulseControl Ancillary Speech Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper; best medical treatment for management of impulse control in Parkinson\\u00b4s disease according to widely accepted expert consensus paper&quot;, &quot;sponsor&quot;: &quot;Steffen Paschen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06561919&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.52003, &quot;lng&quot;: 13.40489, &quot;nct&quot;: &quot;NCT06561919&quot;, &quot;color&quot;: &quot;#0c0674&quot;, &quot;title&quot;: &quot;STIMPulseControl Ancillary Speech Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper; best medical treatment for management of impulse control in Parkinson\\u00b4s disease according to widely accepted expert consensus paper&quot;, &quot;sponsor&quot;: &quot;Steffen Paschen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06561919&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.52266, &quot;lng&quot;: 9.05222, &quot;nct&quot;: &quot;NCT06561919&quot;, &quot;color&quot;: &quot;#0c0674&quot;, &quot;title&quot;: &quot;STIMPulseControl Ancillary Speech Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper; best medical treatment for management of impulse control in Parkinson\\u00b4s disease according to widely accepted expert consensus paper&quot;, &quot;sponsor&quot;: &quot;Steffen Paschen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06561919&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 49.79391, &quot;lng&quot;: 9.95121, &quot;nct&quot;: &quot;NCT06561919&quot;, &quot;color&quot;: &quot;#0c0674&quot;, &quot;title&quot;: &quot;STIMPulseControl Ancillary Speech Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper; best medical treatment for management of impulse control in Parkinson\\u00b4s disease according to widely accepted expert consensus paper&quot;, &quot;sponsor&quot;: &quot;Steffen Paschen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06561919&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.37403, &quot;lng&quot;: 4.88969, &quot;nct&quot;: &quot;NCT06561919&quot;, &quot;color&quot;: &quot;#0c0674&quot;, &quot;title&quot;: &quot;STIMPulseControl Ancillary Speech Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper; best medical treatment for management of impulse control in Parkinson\\u00b4s disease according to widely accepted expert consensus paper&quot;, &quot;sponsor&quot;: &quot;Steffen Paschen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06561919&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 46.94809, &quot;lng&quot;: 7.44744, &quot;nct&quot;: &quot;NCT06561919&quot;, &quot;color&quot;: &quot;#0c0674&quot;, &quot;title&quot;: &quot;STIMPulseControl Ancillary Speech Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper; best medical treatment for management of impulse control in Parkinson\\u00b4s disease according to widely accepted expert consensus paper&quot;, &quot;sponsor&quot;: &quot;Steffen Paschen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06561919&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.36667, &quot;lng&quot;: 8.55, &quot;nct&quot;: &quot;NCT06561919&quot;, &quot;color&quot;: &quot;#0c0674&quot;, &quot;title&quot;: &quot;STIMPulseControl Ancillary Speech Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper; best medical treatment for management of impulse control in Parkinson\\u00b4s disease according to widely accepted expert consensus paper&quot;, &quot;sponsor&quot;: &quot;Steffen Paschen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06561919&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.65163, &quot;lng&quot;: -82.32483, &quot;nct&quot;: &quot;NCT07026734&quot;, &quot;color&quot;: &quot;#964c48&quot;, &quot;title&quot;: &quot;The Impact of Deep Brain Stimulation on Speech and Swallow Function in Parkinson Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Deep brain stimulation surgery - GPi; Deep Brain Stimulation Surgery - STN&quot;, &quot;sponsor&quot;: &quot;University of Florida&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07026734&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.46427, &quot;lng&quot;: 9.18951, &quot;nct&quot;: &quot;NCT04681534&quot;, &quot;color&quot;: &quot;#53f2b7&quot;, &quot;title&quot;: &quot;Safety and Efficacy of Adaptive Deep Brain Stimulation&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;AlphaDBS System&quot;, &quot;sponsor&quot;: &quot;Newronika&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04681534&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.40797, &quot;lng&quot;: 11.88586, &quot;nct&quot;: &quot;NCT04681534&quot;, &quot;color&quot;: &quot;#53f2b7&quot;, &quot;title&quot;: &quot;Safety and Efficacy of Adaptive Deep Brain Stimulation&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;AlphaDBS System&quot;, &quot;sponsor&quot;: &quot;Newronika&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04681534&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.89193, &quot;lng&quot;: 12.51133, &quot;nct&quot;: &quot;NCT04681534&quot;, &quot;color&quot;: &quot;#53f2b7&quot;, &quot;title&quot;: &quot;Safety and Efficacy of Adaptive Deep Brain Stimulation&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;AlphaDBS System&quot;, &quot;sponsor&quot;: &quot;Newronika&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04681534&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.07049, &quot;lng&quot;: 7.68682, &quot;nct&quot;: &quot;NCT04681534&quot;, &quot;color&quot;: &quot;#53f2b7&quot;, &quot;title&quot;: &quot;Safety and Efficacy of Adaptive Deep Brain Stimulation&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;AlphaDBS System&quot;, &quot;sponsor&quot;: &quot;Newronika&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04681534&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.84833, &quot;lng&quot;: 5.68889, &quot;nct&quot;: &quot;NCT04681534&quot;, &quot;color&quot;: &quot;#53f2b7&quot;, &quot;title&quot;: &quot;Safety and Efficacy of Adaptive Deep Brain Stimulation&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;AlphaDBS System&quot;, &quot;sponsor&quot;: &quot;Newronika&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04681534&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 54.35227, &quot;lng&quot;: 18.64912, &quot;nct&quot;: &quot;NCT04681534&quot;, &quot;color&quot;: &quot;#53f2b7&quot;, &quot;title&quot;: &quot;Safety and Efficacy of Adaptive Deep Brain Stimulation&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;AlphaDBS System&quot;, &quot;sponsor&quot;: &quot;Newronika&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04681534&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.22977, &quot;lng&quot;: 21.01178, &quot;nct&quot;: &quot;NCT04681534&quot;, &quot;color&quot;: &quot;#53f2b7&quot;, &quot;title&quot;: &quot;Safety and Efficacy of Adaptive Deep Brain Stimulation&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;AlphaDBS System&quot;, &quot;sponsor&quot;: &quot;Newronika&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04681534&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.78235, &quot;lng&quot;: 12.59836, &quot;nct&quot;: &quot;NCT05871359&quot;, &quot;color&quot;: &quot;#b36c15&quot;, &quot;title&quot;: &quot;Transcranial Direct Current Stimulation and Dual Tasks&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Transcranial Direct Current Stimulation; Dual task&quot;, &quot;sponsor&quot;: &quot;Casa di Cura Privata del Policlinico SpA&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05871359&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.15478, &quot;lng&quot;: -77.61556, &quot;nct&quot;: &quot;NCT06993142&quot;, &quot;color&quot;: &quot;#e22742&quot;, &quot;title&quot;: &quot;Slow-SPEED: Slowing Parkinson&#x27;s Early Through Exercise Dosage&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Increase of physical activity volume and intensity with the use of a motivational smartphone application&quot;, &quot;sponsor&quot;: &quot;Radboud University Medical Center&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06993142&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.8425, &quot;lng&quot;: 5.85278, &quot;nct&quot;: &quot;NCT06993142&quot;, &quot;color&quot;: &quot;#e22742&quot;, &quot;title&quot;: &quot;Slow-SPEED: Slowing Parkinson&#x27;s Early Through Exercise Dosage&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Increase of physical activity volume and intensity with the use of a motivational smartphone application&quot;, &quot;sponsor&quot;: &quot;Radboud University Medical Center&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06993142&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.12066, &quot;lng&quot;: 16.86982, &quot;nct&quot;: &quot;NCT06685744&quot;, &quot;color&quot;: &quot;#964666&quot;, &quot;title&quot;: &quot;TeleNEURO-Rehabilitation Systems for Neurodegenerative Conditions: the FIT4TeleNEURO Pragmatic Trial&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Telerehabilitation_TRsA; Educational treatment; Telerehabilitation_TRcA&quot;, &quot;sponsor&quot;: &quot;Fondazione Don Carlo Gnocchi Onlus&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06685744&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.21604, &quot;lng&quot;: 11.87211, &quot;nct&quot;: &quot;NCT06685744&quot;, &quot;color&quot;: &quot;#964666&quot;, &quot;title&quot;: &quot;TeleNEURO-Rehabilitation Systems for Neurodegenerative Conditions: the FIT4TeleNEURO Pragmatic Trial&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Telerehabilitation_TRsA; Educational treatment; Telerehabilitation_TRcA&quot;, &quot;sponsor&quot;: &quot;Fondazione Don Carlo Gnocchi Onlus&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06685744&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.85589, &quot;lng&quot;: 9.39704, &quot;nct&quot;: &quot;NCT06685744&quot;, &quot;color&quot;: &quot;#964666&quot;, &quot;title&quot;: &quot;TeleNEURO-Rehabilitation Systems for Neurodegenerative Conditions: the FIT4TeleNEURO Pragmatic Trial&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Telerehabilitation_TRsA; Educational treatment; Telerehabilitation_TRcA&quot;, &quot;sponsor&quot;: &quot;Fondazione Don Carlo Gnocchi Onlus&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06685744&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.46427, &quot;lng&quot;: 9.18951, &quot;nct&quot;: &quot;NCT06685744&quot;, &quot;color&quot;: &quot;#964666&quot;, &quot;title&quot;: &quot;TeleNEURO-Rehabilitation Systems for Neurodegenerative Conditions: the FIT4TeleNEURO Pragmatic Trial&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Telerehabilitation_TRsA; Educational treatment; Telerehabilitation_TRcA&quot;, &quot;sponsor&quot;: &quot;Fondazione Don Carlo Gnocchi Onlus&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06685744&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 44.64783, &quot;lng&quot;: 10.92539, &quot;nct&quot;: &quot;NCT06685744&quot;, &quot;color&quot;: &quot;#964666&quot;, &quot;title&quot;: &quot;TeleNEURO-Rehabilitation Systems for Neurodegenerative Conditions: the FIT4TeleNEURO Pragmatic Trial&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Telerehabilitation_TRsA; Educational treatment; Telerehabilitation_TRcA&quot;, &quot;sponsor&quot;: &quot;Fondazione Don Carlo Gnocchi Onlus&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06685744&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.19205, &quot;lng&quot;: 9.15917, &quot;nct&quot;: &quot;NCT06685744&quot;, &quot;color&quot;: &quot;#964666&quot;, &quot;title&quot;: &quot;TeleNEURO-Rehabilitation Systems for Neurodegenerative Conditions: the FIT4TeleNEURO Pragmatic Trial&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Telerehabilitation_TRsA; Educational treatment; Telerehabilitation_TRcA&quot;, &quot;sponsor&quot;: &quot;Fondazione Don Carlo Gnocchi Onlus&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06685744&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 49.24966, &quot;lng&quot;: -123.11934, &quot;nct&quot;: &quot;NCT06518824&quot;, &quot;color&quot;: &quot;#a92f46&quot;, &quot;title&quot;: &quot;Theta Deep Brain Stimulation for Cognitive Enhancement in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;DBS On; DBS Off&quot;, &quot;sponsor&quot;: &quot;University of British Columbia&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06518824&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 31.86389, &quot;lng&quot;: 117.28083, &quot;nct&quot;: &quot;NCT06542991&quot;, &quot;color&quot;: &quot;#fcb059&quot;, &quot;title&quot;: &quot;An Open-label Study on the Clinical Efficacy of rTMS Intervention in PD&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;transcranial magnetic stimulation&quot;, &quot;sponsor&quot;: &quot;Anhui Medical University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06542991&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: -7.115, &quot;lng&quot;: -34.86306, &quot;nct&quot;: &quot;NCT06145776&quot;, &quot;color&quot;: &quot;#4a92ad&quot;, &quot;title&quot;: &quot;The Role of EEG in Identifying Cognitive Changes in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;tDCS + tredmill training (Standart trehab training); Cognitite-motor Dual Task Training (DT training)&quot;, &quot;sponsor&quot;: &quot;Federal University of Para\\u00edba&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06145776&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 46.516, &quot;lng&quot;: 6.63282, &quot;nct&quot;: &quot;NCT06831500&quot;, &quot;color&quot;: &quot;#ff1f71&quot;, &quot;title&quot;: &quot;Feasibility Study Assessing the Effect of Carbidopa/levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease.&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Administration of Carbidopa/levodopa&quot;, &quot;sponsor&quot;: &quot;Julien Bally&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06831500&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.15833, &quot;lng&quot;: 4.49306, &quot;nct&quot;: &quot;NCT05814614&quot;, &quot;color&quot;: &quot;#70f8e5&quot;, &quot;title&quot;: &quot;Bladder Complaints in Parkinson&#x27;s Disease Effectiveness of Pelvic Floor Muscle Exercises and Electrical Stimulation&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;pelvic physical therapy&quot;, &quot;sponsor&quot;: &quot;Leiden University Medical Center&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05814614&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 31.558, &quot;lng&quot;: 74.35071, &quot;nct&quot;: &quot;NCT07129304&quot;, &quot;color&quot;: &quot;#3abb68&quot;, &quot;title&quot;: &quot;Design And Analysis of The Effectiveness of CVRE VS Non-Immersive VR in the Rehabilitation of Parkinson&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Collaborative Virtual Reality with Routine Physical Therapy; Non-Immersive Virtual Reality with Routine Physical Therapy&quot;, &quot;sponsor&quot;: &quot;Superior University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07129304&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.73583, &quot;lng&quot;: 31.60611, &quot;nct&quot;: &quot;NCT04941326&quot;, &quot;color&quot;: &quot;#d9d9b4&quot;, &quot;title&quot;: &quot;The Effect of Spinal Mobilization on Respiratory Parameters in Parkinson&#x27;s Disease Patients&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Diaphragmatic stimulation treatment with PNF techniques; Costal mobilization; Breathing exercises; Spinal mobilization; Sham mobilization&quot;, &quot;sponsor&quot;: &quot;Abant Izzet Baysal University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04941326&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.52066, &quot;lng&quot;: -86.80249, &quot;nct&quot;: &quot;NCT06289582&quot;, &quot;color&quot;: &quot;#d4de56&quot;, &quot;title&quot;: &quot;Longitudinal TSPO PET Imaging with [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;EARLY_PHASE1&quot;], &quot;interventions&quot;: &quot;[F-18]DPA714 administration IV&quot;, &quot;sponsor&quot;: &quot;University of Alabama at Birmingham&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06289582&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.95238, &quot;lng&quot;: -75.16362, &quot;nct&quot;: &quot;NCT04459052&quot;, &quot;color&quot;: &quot;#4a1285&quot;, &quot;title&quot;: &quot;FDOPA PET and Nutritional Support in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;N acetyl cysteine; [F-18] Fluorodopa Positron Emission Tomography&quot;, &quot;sponsor&quot;: &quot;Thomas Jefferson University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04459052&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.11109, &quot;lng&quot;: -1.67431, &quot;nct&quot;: &quot;NCT05808504&quot;, &quot;color&quot;: &quot;#977325&quot;, &quot;title&quot;: &quot;Investigation of the Benefits of Electrical Non-invasive Stimulation on Cognitive Symptoms in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Neuropsychological assessment; Neurological assessment; Cognitive task; EEG; tACS (real or sham)&quot;, &quot;sponsor&quot;: &quot;Institut National de la Sant\\u00e9 Et de la Recherche M\\u00e9dicale, France&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05808504&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.4105, &quot;lng&quot;: 12.36649, &quot;nct&quot;: &quot;NCT05826548&quot;, &quot;color&quot;: &quot;#6c4d9a&quot;, &quot;title&quot;: &quot;Financial Abilities in Neurological Diseases. Development of a Telerehabilitation Program: FINAGE&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Telerehabilitation group; Conventioanl treatment group&quot;, &quot;sponsor&quot;: &quot;IRCCS San Camillo, Venezia, Italy&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05826548&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: -37.814, &quot;lng&quot;: 144.96332, &quot;nct&quot;: &quot;NCT06466525&quot;, &quot;color&quot;: &quot;#626c62&quot;, &quot;title&quot;: &quot;A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson&#x27;s Disease.&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;LBT-3627; Placebo&quot;, &quot;sponsor&quot;: &quot;Longevity Biotech Australia Pty Ltd (subsidiary)&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06466525&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.08804, &quot;lng&quot;: 14.42076, &quot;nct&quot;: &quot;NCT06481540&quot;, &quot;color&quot;: &quot;#6a37aa&quot;, &quot;title&quot;: &quot;SpiroGym App-Aided Cough Rehabilitation&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Expiratory muscle strength training + SpiroGym application; Expiratory muscle strength training&quot;, &quot;sponsor&quot;: &quot;General University Hospital, Prague&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06481540&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.87959, &quot;lng&quot;: 4.70093, &quot;nct&quot;: &quot;NCT04269590&quot;, &quot;color&quot;: &quot;#f3c8ad&quot;, &quot;title&quot;: &quot;Triggering Motor Memory Consolidation in PD: Complex Practice of Fine Motor Tasks and Brain Activity During Learning&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Dual Task (DT) training; Single Task (ST) training&quot;, &quot;sponsor&quot;: &quot;KU Leuven&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04269590&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 30.78847, &quot;lng&quot;: 31.00192, &quot;nct&quot;: &quot;NCT07001150&quot;, &quot;color&quot;: &quot;#3262a5&quot;, &quot;title&quot;: &quot;Role of Silymarin in Neuroprotection and Symptom Management in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;levodopa-carbidopa; Silymarin&quot;, &quot;sponsor&quot;: &quot;Tanta University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07001150&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.77493, &quot;lng&quot;: -122.41942, &quot;nct&quot;: &quot;NCT03582891&quot;, &quot;color&quot;: &quot;#0474f9&quot;, &quot;title&quot;: &quot;The Motor Network in Parkinson&#x27;s Disease and Dystonia: Mechanisms of Therapy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Summit RC+S for Motor; 8-week pilot trial of Closed-loop vs. Open-loop Stimulation; Summit RC+S for Sleep&quot;, &quot;sponsor&quot;: &quot;University of California, San Francisco&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03582891&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.16589, &quot;lng&quot;: -86.78444, &quot;nct&quot;: &quot;NCT02897063&quot;, &quot;color&quot;: &quot;#0249fe&quot;, &quot;title&quot;: &quot;Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;Droxidopa; Midodrine; Placebo&quot;, &quot;sponsor&quot;: &quot;Vanderbilt University Medical Center&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT02897063&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 39.14583, &quot;lng&quot;: 34.16389, &quot;nct&quot;: &quot;NCT06272838&quot;, &quot;color&quot;: &quot;#a40be3&quot;, &quot;title&quot;: &quot;Biodex Balance System in Patients With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Biodex balance system; The conventional balance exercise program&quot;, &quot;sponsor&quot;: &quot;Kirsehir Ahi Evran Universitesi&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06272838&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.70643, &quot;lng&quot;: -79.39864, &quot;nct&quot;: &quot;NCT05402163&quot;, &quot;color&quot;: &quot;#2e4792&quot;, &quot;title&quot;: &quot;CANadian Adaptive DBS TriAl&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Adaptive DBS; Continuous DBS&quot;, &quot;sponsor&quot;: &quot;University of Toronto&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05402163&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.48622, &quot;lng&quot;: -74.45182, &quot;nct&quot;: &quot;NCT04976959&quot;, &quot;color&quot;: &quot;#533535&quot;, &quot;title&quot;: &quot;High Fiber in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;High Fiber supplement&quot;, &quot;sponsor&quot;: &quot;Rutgers, The State University of New Jersey&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04976959&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.52066, &quot;lng&quot;: -86.80249, &quot;nct&quot;: &quot;NCT06553027&quot;, &quot;color&quot;: &quot;#020e9d&quot;, &quot;title&quot;: &quot;To Evaluate the Efficacy of CVN424 in Parkinson&#x27;s Disease Participants With Motor Complications&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;CVN424 75 mg; CVN424 150 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Cerevance&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06553027&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.44188, &quot;lng&quot;: -122.14302, &quot;nct&quot;: &quot;NCT06553027&quot;, &quot;color&quot;: &quot;#020e9d&quot;, &quot;title&quot;: &quot;To Evaluate the Efficacy of CVN424 in Parkinson&#x27;s Disease Participants With Motor Complications&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;CVN424 75 mg; CVN424 150 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Cerevance&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06553027&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.64777, &quot;lng&quot;: -104.98776, &quot;nct&quot;: &quot;NCT06553027&quot;, &quot;color&quot;: &quot;#020e9d&quot;, &quot;title&quot;: &quot;To Evaluate the Efficacy of CVN424 in Parkinson&#x27;s Disease Participants With Motor Complications&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;CVN424 75 mg; CVN424 150 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Cerevance&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06553027&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.35869, &quot;lng&quot;: -80.0831, &quot;nct&quot;: &quot;NCT06553027&quot;, &quot;color&quot;: &quot;#020e9d&quot;, &quot;title&quot;: &quot;To Evaluate the Efficacy of CVN424 in Parkinson&#x27;s Disease Participants With Motor Complications&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;CVN424 75 mg; CVN424 150 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Cerevance&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06553027&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 28.62778, &quot;lng&quot;: -81.36312, &quot;nct&quot;: &quot;NCT06553027&quot;, &quot;color&quot;: &quot;#020e9d&quot;, &quot;title&quot;: &quot;To Evaluate the Efficacy of CVN424 in Parkinson&#x27;s Disease Participants With Motor Complications&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;CVN424 75 mg; CVN424 150 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Cerevance&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06553027&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.1872, &quot;lng&quot;: -82.14009, &quot;nct&quot;: &quot;NCT06553027&quot;, &quot;color&quot;: &quot;#020e9d&quot;, &quot;title&quot;: &quot;To Evaluate the Efficacy of CVN424 in Parkinson&#x27;s Disease Participants With Motor Complications&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;CVN424 75 mg; CVN424 150 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Cerevance&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06553027&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 28.53834, &quot;lng&quot;: -81.37924, &quot;nct&quot;: &quot;NCT06553027&quot;, &quot;color&quot;: &quot;#020e9d&quot;, &quot;title&quot;: &quot;To Evaluate the Efficacy of CVN424 in Parkinson&#x27;s Disease Participants With Motor Complications&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;CVN424 75 mg; CVN424 150 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Cerevance&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06553027&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.97617, &quot;lng&quot;: -82.09064, &quot;nct&quot;: &quot;NCT06553027&quot;, &quot;color&quot;: &quot;#020e9d&quot;, &quot;title&quot;: &quot;To Evaluate the Efficacy of CVN424 in Parkinson&#x27;s Disease Participants With Motor Complications&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;CVN424 75 mg; CVN424 150 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Cerevance&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06553027&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.13832, &quot;lng&quot;: -80.99561, &quot;nct&quot;: &quot;NCT06553027&quot;, &quot;color&quot;: &quot;#020e9d&quot;, &quot;title&quot;: &quot;To Evaluate the Efficacy of CVN424 in Parkinson&#x27;s Disease Participants With Motor Complications&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;CVN424 75 mg; CVN424 150 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Cerevance&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06553027&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.11417, &quot;lng&quot;: -94.62746, &quot;nct&quot;: &quot;NCT06553027&quot;, &quot;color&quot;: &quot;#020e9d&quot;, &quot;title&quot;: &quot;To Evaluate the Efficacy of CVN424 in Parkinson&#x27;s Disease Participants With Motor Complications&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;CVN424 75 mg; CVN424 150 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Cerevance&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06553027&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.98869, &quot;lng&quot;: -84.47772, &quot;nct&quot;: &quot;NCT06553027&quot;, &quot;color&quot;: &quot;#020e9d&quot;, &quot;title&quot;: &quot;To Evaluate the Efficacy of CVN424 in Parkinson&#x27;s Disease Participants With Motor Complications&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;CVN424 75 mg; CVN424 150 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Cerevance&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06553027&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.35843, &quot;lng&quot;: -71.05977, &quot;nct&quot;: &quot;NCT06553027&quot;, &quot;color&quot;: &quot;#020e9d&quot;, &quot;title&quot;: &quot;To Evaluate the Efficacy of CVN424 in Parkinson&#x27;s Disease Participants With Motor Complications&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;CVN424 75 mg; CVN424 150 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Cerevance&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06553027&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.27756, &quot;lng&quot;: -83.74088, &quot;nct&quot;: &quot;NCT06553027&quot;, &quot;color&quot;: &quot;#020e9d&quot;, &quot;title&quot;: &quot;To Evaluate the Efficacy of CVN424 in Parkinson&#x27;s Disease Participants With Motor Complications&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;CVN424 75 mg; CVN424 150 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Cerevance&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06553027&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.48531, &quot;lng&quot;: -83.37716, &quot;nct&quot;: &quot;NCT06553027&quot;, &quot;color&quot;: &quot;#020e9d&quot;, &quot;title&quot;: &quot;To Evaluate the Efficacy of CVN424 in Parkinson&#x27;s Disease Participants With Motor Complications&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;CVN424 75 mg; CVN424 150 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Cerevance&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06553027&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.38927, &quot;lng&quot;: -74.76183, &quot;nct&quot;: &quot;NCT06553027&quot;, &quot;color&quot;: &quot;#020e9d&quot;, &quot;title&quot;: &quot;To Evaluate the Efficacy of CVN424 in Parkinson&#x27;s Disease Participants With Motor Complications&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;CVN424 75 mg; CVN424 150 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Cerevance&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06553027&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.84288, &quot;lng&quot;: -73.29289, &quot;nct&quot;: &quot;NCT06553027&quot;, &quot;color&quot;: &quot;#020e9d&quot;, &quot;title&quot;: &quot;To Evaluate the Efficacy of CVN424 in Parkinson&#x27;s Disease Participants With Motor Complications&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;CVN424 75 mg; CVN424 150 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Cerevance&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06553027&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.71427, &quot;lng&quot;: -74.00597, &quot;nct&quot;: &quot;NCT06553027&quot;, &quot;color&quot;: &quot;#020e9d&quot;, &quot;title&quot;: &quot;To Evaluate the Efficacy of CVN424 in Parkinson&#x27;s Disease Participants With Motor Complications&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;CVN424 75 mg; CVN424 150 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Cerevance&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06553027&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 35.99403, &quot;lng&quot;: -78.89862, &quot;nct&quot;: &quot;NCT06553027&quot;, &quot;color&quot;: &quot;#020e9d&quot;, &quot;title&quot;: &quot;To Evaluate the Efficacy of CVN424 in Parkinson&#x27;s Disease Participants With Motor Complications&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;CVN424 75 mg; CVN424 150 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Cerevance&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06553027&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 35.7721, &quot;lng&quot;: -78.63861, &quot;nct&quot;: &quot;NCT06553027&quot;, &quot;color&quot;: &quot;#020e9d&quot;, &quot;title&quot;: &quot;To Evaluate the Efficacy of CVN424 in Parkinson&#x27;s Disease Participants With Motor Complications&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;CVN424 75 mg; CVN424 150 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Cerevance&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06553027&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.12711, &quot;lng&quot;: -84.51439, &quot;nct&quot;: &quot;NCT06553027&quot;, &quot;color&quot;: &quot;#020e9d&quot;, &quot;title&quot;: &quot;To Evaluate the Efficacy of CVN424 in Parkinson&#x27;s Disease Participants With Motor Complications&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;CVN424 75 mg; CVN424 150 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Cerevance&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06553027&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.96118, &quot;lng&quot;: -82.99879, &quot;nct&quot;: &quot;NCT06553027&quot;, &quot;color&quot;: &quot;#020e9d&quot;, &quot;title&quot;: &quot;To Evaluate the Efficacy of CVN424 in Parkinson&#x27;s Disease Participants With Motor Complications&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;CVN424 75 mg; CVN424 150 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Cerevance&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06553027&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.15398, &quot;lng&quot;: -95.99277, &quot;nct&quot;: &quot;NCT06553027&quot;, &quot;color&quot;: &quot;#020e9d&quot;, &quot;title&quot;: &quot;To Evaluate the Efficacy of CVN424 in Parkinson&#x27;s Disease Participants With Motor Complications&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;CVN424 75 mg; CVN424 150 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Cerevance&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06553027&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 35.14953, &quot;lng&quot;: -90.04898, &quot;nct&quot;: &quot;NCT06553027&quot;, &quot;color&quot;: &quot;#020e9d&quot;, &quot;title&quot;: &quot;To Evaluate the Efficacy of CVN424 in Parkinson&#x27;s Disease Participants With Motor Complications&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;CVN424 75 mg; CVN424 150 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Cerevance&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06553027&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.96911, &quot;lng&quot;: -95.69717, &quot;nct&quot;: &quot;NCT06553027&quot;, &quot;color&quot;: &quot;#020e9d&quot;, &quot;title&quot;: &quot;To Evaluate the Efficacy of CVN424 in Parkinson&#x27;s Disease Participants With Motor Complications&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;CVN424 75 mg; CVN424 150 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Cerevance&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06553027&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 30.63269, &quot;lng&quot;: -97.67723, &quot;nct&quot;: &quot;NCT06553027&quot;, &quot;color&quot;: &quot;#020e9d&quot;, &quot;title&quot;: &quot;To Evaluate the Efficacy of CVN424 in Parkinson&#x27;s Disease Participants With Motor Complications&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;CVN424 75 mg; CVN424 150 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Cerevance&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06553027&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.76328, &quot;lng&quot;: -95.36327, &quot;nct&quot;: &quot;NCT06553027&quot;, &quot;color&quot;: &quot;#020e9d&quot;, &quot;title&quot;: &quot;To Evaluate the Efficacy of CVN424 in Parkinson&#x27;s Disease Participants With Motor Complications&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;CVN424 75 mg; CVN424 150 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Cerevance&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06553027&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 30.50826, &quot;lng&quot;: -97.6789, &quot;nct&quot;: &quot;NCT06553027&quot;, &quot;color&quot;: &quot;#020e9d&quot;, &quot;title&quot;: &quot;To Evaluate the Efficacy of CVN424 in Parkinson&#x27;s Disease Participants With Motor Complications&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;CVN424 75 mg; CVN424 150 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Cerevance&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06553027&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 38.84622, &quot;lng&quot;: -77.30637, &quot;nct&quot;: &quot;NCT06553027&quot;, &quot;color&quot;: &quot;#020e9d&quot;, &quot;title&quot;: &quot;To Evaluate the Efficacy of CVN424 in Parkinson&#x27;s Disease Participants With Motor Complications&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;CVN424 75 mg; CVN424 150 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Cerevance&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06553027&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 38.88233, &quot;lng&quot;: -77.17109, &quot;nct&quot;: &quot;NCT06553027&quot;, &quot;color&quot;: &quot;#020e9d&quot;, &quot;title&quot;: &quot;To Evaluate the Efficacy of CVN424 in Parkinson&#x27;s Disease Participants With Motor Complications&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;CVN424 75 mg; CVN424 150 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Cerevance&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06553027&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.55376, &quot;lng&quot;: -77.46026, &quot;nct&quot;: &quot;NCT06553027&quot;, &quot;color&quot;: &quot;#020e9d&quot;, &quot;title&quot;: &quot;To Evaluate the Efficacy of CVN424 in Parkinson&#x27;s Disease Participants With Motor Complications&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;CVN424 75 mg; CVN424 150 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Cerevance&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06553027&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.65966, &quot;lng&quot;: -117.42908, &quot;nct&quot;: &quot;NCT06553027&quot;, &quot;color&quot;: &quot;#020e9d&quot;, &quot;title&quot;: &quot;To Evaluate the Efficacy of CVN424 in Parkinson&#x27;s Disease Participants With Motor Complications&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;CVN424 75 mg; CVN424 150 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Cerevance&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06553027&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.0389, &quot;lng&quot;: -87.90647, &quot;nct&quot;: &quot;NCT06553027&quot;, &quot;color&quot;: &quot;#020e9d&quot;, &quot;title&quot;: &quot;To Evaluate the Efficacy of CVN424 in Parkinson&#x27;s Disease Participants With Motor Complications&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;CVN424 75 mg; CVN424 150 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Cerevance&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06553027&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.5283, &quot;lng&quot;: 5.44973, &quot;nct&quot;: &quot;NCT06155942&quot;, &quot;color&quot;: &quot;#17e7d1&quot;, &quot;title&quot;: &quot;Early Biomarkers of Neurodegeneration in Parkinsonian Syndromes&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;7 Tesla MRI&quot;, &quot;sponsor&quot;: &quot;Assistance Publique Hopitaux De Marseille&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06155942&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.29276, &quot;lng&quot;: 5.57067, &quot;nct&quot;: &quot;NCT06155942&quot;, &quot;color&quot;: &quot;#17e7d1&quot;, &quot;title&quot;: &quot;Early Biomarkers of Neurodegeneration in Parkinsonian Syndromes&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;7 Tesla MRI&quot;, &quot;sponsor&quot;: &quot;Assistance Publique Hopitaux De Marseille&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06155942&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.94834, &quot;lng&quot;: 4.80892, &quot;nct&quot;: &quot;NCT06155942&quot;, &quot;color&quot;: &quot;#17e7d1&quot;, &quot;title&quot;: &quot;Early Biomarkers of Neurodegeneration in Parkinsonian Syndromes&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;7 Tesla MRI&quot;, &quot;sponsor&quot;: &quot;Assistance Publique Hopitaux De Marseille&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06155942&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.70313, &quot;lng&quot;: 7.26608, &quot;nct&quot;: &quot;NCT06155942&quot;, &quot;color&quot;: &quot;#17e7d1&quot;, &quot;title&quot;: &quot;Early Biomarkers of Neurodegeneration in Parkinsonian Syndromes&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;7 Tesla MRI&quot;, &quot;sponsor&quot;: &quot;Assistance Publique Hopitaux De Marseille&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06155942&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.83665, &quot;lng&quot;: 4.35788, &quot;nct&quot;: &quot;NCT06155942&quot;, &quot;color&quot;: &quot;#17e7d1&quot;, &quot;title&quot;: &quot;Early Biomarkers of Neurodegeneration in Parkinsonian Syndromes&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;7 Tesla MRI&quot;, &quot;sponsor&quot;: &quot;Assistance Publique Hopitaux De Marseille&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06155942&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.12442, &quot;lng&quot;: 5.92836, &quot;nct&quot;: &quot;NCT06155942&quot;, &quot;color&quot;: &quot;#17e7d1&quot;, &quot;title&quot;: &quot;Early Biomarkers of Neurodegeneration in Parkinsonian Syndromes&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;7 Tesla MRI&quot;, &quot;sponsor&quot;: &quot;Assistance Publique Hopitaux De Marseille&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06155942&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.3264, &quot;lng&quot;: 8.79779, &quot;nct&quot;: &quot;NCT06631742&quot;, &quot;color&quot;: &quot;#f9a788&quot;, &quot;title&quot;: &quot;Exergaming Revolution in Dementia&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Exergaming on Dividat Senso; Usual Care&quot;, &quot;sponsor&quot;: &quot;Eastern Switzerland University of Applied Sciences&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06631742&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.17497, &quot;lng&quot;: -115.13722, &quot;nct&quot;: &quot;NCT06605183&quot;, &quot;color&quot;: &quot;#9657ea&quot;, &quot;title&quot;: &quot;10,000 Step Club: Community Walking Program for People with Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Community walking program using Nordic walking poles&quot;, &quot;sponsor&quot;: &quot;University of Nevada, Las Vegas&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06605183&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.85003, &quot;lng&quot;: -87.65005, &quot;nct&quot;: &quot;NCT06306768&quot;, &quot;color&quot;: &quot;#a40371&quot;, &quot;title&quot;: &quot;Remote Therapeutic Monitoring Exercise Tracking&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Activity Monitoring&quot;, &quot;sponsor&quot;: &quot;Shirley Ryan AbilityLab&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06306768&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.38193, &quot;lng&quot;: 9.1559, &quot;nct&quot;: &quot;NCT06814782&quot;, &quot;color&quot;: &quot;#3884fe&quot;, &quot;title&quot;: &quot;Effects of Action Observation Training and Motor Imagery Delivered by Telerehabilitation in Patients with Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Action Observation Training; Action Observation and Motor Imagery; Exercise&quot;, &quot;sponsor&quot;: &quot;Istituto Clinico Humanitas&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06814782&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 30.29365, &quot;lng&quot;: 120.16142, &quot;nct&quot;: &quot;NCT05882487&quot;, &quot;color&quot;: &quot;#abd3a3&quot;, &quot;title&quot;: &quot;Safety and Efficacy Study of KL002 in the Treatment of Advanced Primary PD&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;EARLY_PHASE1&quot;], &quot;interventions&quot;: &quot;KL002 injection solution&quot;, &quot;sponsor&quot;: &quot;Second Affiliated Hospital, School of Medicine, Zhejiang University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05882487&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.47391, &quot;lng&quot;: -0.37966, &quot;nct&quot;: &quot;NCT06879821&quot;, &quot;color&quot;: &quot;#e05acf&quot;, &quot;title&quot;: &quot;High-intensity Functional Training on Functional and Cognitive Performance in People with Parkinson&#x27;s Disease.&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;high intensity functional training&quot;, &quot;sponsor&quot;: &quot;Fundacion Para La Investigacion Hospital La Fe&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06879821&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 49.9, &quot;lng&quot;: 2.3, &quot;nct&quot;: &quot;NCT04884412&quot;, &quot;color&quot;: &quot;#bf1ebd&quot;, &quot;title&quot;: &quot;Deep Brain Stimulation for Parkinson&#x27;s Disease: Probabilistic STN Targeting Under General Anaesthesia Without Micro-electrode Recordings vs Current Targeting Procedure&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Surgery under general anesthesia with experimental targeting; Usual Surgery&quot;, &quot;sponsor&quot;: &quot;University Hospital, Bordeaux&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04884412&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 44.84124, &quot;lng&quot;: -0.58046, &quot;nct&quot;: &quot;NCT04884412&quot;, &quot;color&quot;: &quot;#bf1ebd&quot;, &quot;title&quot;: &quot;Deep Brain Stimulation for Parkinson&#x27;s Disease: Probabilistic STN Targeting Under General Anaesthesia Without Micro-electrode Recordings vs Current Targeting Procedure&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Surgery under general anesthesia with experimental targeting; Usual Surgery&quot;, &quot;sponsor&quot;: &quot;University Hospital, Bordeaux&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04884412&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.17869, &quot;lng&quot;: 5.71479, &quot;nct&quot;: &quot;NCT04884412&quot;, &quot;color&quot;: &quot;#bf1ebd&quot;, &quot;title&quot;: &quot;Deep Brain Stimulation for Parkinson&#x27;s Disease: Probabilistic STN Targeting Under General Anaesthesia Without Micro-electrode Recordings vs Current Targeting Procedure&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Surgery under general anesthesia with experimental targeting; Usual Surgery&quot;, &quot;sponsor&quot;: &quot;University Hospital, Bordeaux&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04884412&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.74906, &quot;lng&quot;: 4.84789, &quot;nct&quot;: &quot;NCT04884412&quot;, &quot;color&quot;: &quot;#bf1ebd&quot;, &quot;title&quot;: &quot;Deep Brain Stimulation for Parkinson&#x27;s Disease: Probabilistic STN Targeting Under General Anaesthesia Without Micro-electrode Recordings vs Current Targeting Procedure&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Surgery under general anesthesia with experimental targeting; Usual Surgery&quot;, &quot;sponsor&quot;: &quot;University Hospital, Bordeaux&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04884412&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.29695, &quot;lng&quot;: 5.38107, &quot;nct&quot;: &quot;NCT04884412&quot;, &quot;color&quot;: &quot;#bf1ebd&quot;, &quot;title&quot;: &quot;Deep Brain Stimulation for Parkinson&#x27;s Disease: Probabilistic STN Targeting Under General Anaesthesia Without Micro-electrode Recordings vs Current Targeting Procedure&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Surgery under general anesthesia with experimental targeting; Usual Surgery&quot;, &quot;sponsor&quot;: &quot;University Hospital, Bordeaux&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04884412&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.68439, &quot;lng&quot;: 6.18496, &quot;nct&quot;: &quot;NCT04884412&quot;, &quot;color&quot;: &quot;#bf1ebd&quot;, &quot;title&quot;: &quot;Deep Brain Stimulation for Parkinson&#x27;s Disease: Probabilistic STN Targeting Under General Anaesthesia Without Micro-electrode Recordings vs Current Targeting Procedure&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Surgery under general anesthesia with experimental targeting; Usual Surgery&quot;, &quot;sponsor&quot;: &quot;University Hospital, Bordeaux&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04884412&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.70313, &quot;lng&quot;: 7.26608, &quot;nct&quot;: &quot;NCT04884412&quot;, &quot;color&quot;: &quot;#bf1ebd&quot;, &quot;title&quot;: &quot;Deep Brain Stimulation for Parkinson&#x27;s Disease: Probabilistic STN Targeting Under General Anaesthesia Without Micro-electrode Recordings vs Current Targeting Procedure&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Surgery under general anesthesia with experimental targeting; Usual Surgery&quot;, &quot;sponsor&quot;: &quot;University Hospital, Bordeaux&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04884412&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 49.44313, &quot;lng&quot;: 1.09932, &quot;nct&quot;: &quot;NCT04884412&quot;, &quot;color&quot;: &quot;#bf1ebd&quot;, &quot;title&quot;: &quot;Deep Brain Stimulation for Parkinson&#x27;s Disease: Probabilistic STN Targeting Under General Anaesthesia Without Micro-electrode Recordings vs Current Targeting Procedure&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Surgery under general anesthesia with experimental targeting; Usual Surgery&quot;, &quot;sponsor&quot;: &quot;University Hospital, Bordeaux&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04884412&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.58392, &quot;lng&quot;: 7.74553, &quot;nct&quot;: &quot;NCT04884412&quot;, &quot;color&quot;: &quot;#bf1ebd&quot;, &quot;title&quot;: &quot;Deep Brain Stimulation for Parkinson&#x27;s Disease: Probabilistic STN Targeting Under General Anaesthesia Without Micro-electrode Recordings vs Current Targeting Procedure&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Surgery under general anesthesia with experimental targeting; Usual Surgery&quot;, &quot;sponsor&quot;: &quot;University Hospital, Bordeaux&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04884412&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.60426, &quot;lng&quot;: 1.44367, &quot;nct&quot;: &quot;NCT04884412&quot;, &quot;color&quot;: &quot;#bf1ebd&quot;, &quot;title&quot;: &quot;Deep Brain Stimulation for Parkinson&#x27;s Disease: Probabilistic STN Targeting Under General Anaesthesia Without Micro-electrode Recordings vs Current Targeting Procedure&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Surgery under general anesthesia with experimental targeting; Usual Surgery&quot;, &quot;sponsor&quot;: &quot;University Hospital, Bordeaux&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04884412&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.08804, &quot;lng&quot;: 14.42076, &quot;nct&quot;: &quot;NCT05238545&quot;, &quot;color&quot;: &quot;#1f2c72&quot;, &quot;title&quot;: &quot;The Effect of Gluten-free Diet on Parkinsonism&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;gluten-free diet&quot;, &quot;sponsor&quot;: &quot;General University Hospital, Prague&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05238545&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.73566, &quot;lng&quot;: -74.17237, &quot;nct&quot;: &quot;NCT04804202&quot;, &quot;color&quot;: &quot;#02a210&quot;, &quot;title&quot;: &quot;Virtual Cycling Environments for Persons With Parkinson Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Bicycling with and without virtual reality&quot;, &quot;sponsor&quot;: &quot;Rutgers, The State University of New Jersey&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04804202&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.78871, &quot;lng&quot;: -73.59957, &quot;nct&quot;: &quot;NCT04804202&quot;, &quot;color&quot;: &quot;#02a210&quot;, &quot;title&quot;: &quot;Virtual Cycling Environments for Persons With Parkinson Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Bicycling with and without virtual reality&quot;, &quot;sponsor&quot;: &quot;Rutgers, The State University of New Jersey&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04804202&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.16589, &quot;lng&quot;: -86.78444, &quot;nct&quot;: &quot;NCT04246437&quot;, &quot;color&quot;: &quot;#475ed9&quot;, &quot;title&quot;: &quot;[18F]F-DOPA Imaging in Patients with Autonomic Failure&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;[18F]FDOPA; Carbidopa 200mg oral dose; Entacapone 400mg oral dose&quot;, &quot;sponsor&quot;: &quot;Daniel Claassen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04246437&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 45.53329, &quot;lng&quot;: 9.22585, &quot;nct&quot;: &quot;NCT05273957&quot;, &quot;color&quot;: &quot;#64c0cc&quot;, &quot;title&quot;: &quot;A Model of Hospital-Territory Management Coordinated by a Case Manager to Improve the Care of Patients With Parkinsonism.&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Case Manager; Standard-of-care&quot;, &quot;sponsor&quot;: &quot;Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05273957&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.46427, &quot;lng&quot;: 9.18951, &quot;nct&quot;: &quot;NCT05273957&quot;, &quot;color&quot;: &quot;#64c0cc&quot;, &quot;title&quot;: &quot;A Model of Hospital-Territory Management Coordinated by a Case Manager to Improve the Care of Patients With Parkinsonism.&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Case Manager; Standard-of-care&quot;, &quot;sponsor&quot;: &quot;Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05273957&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.87959, &quot;lng&quot;: 4.70093, &quot;nct&quot;: &quot;NCT06875765&quot;, &quot;color&quot;: &quot;#364abe&quot;, &quot;title&quot;: &quot;Long-term Longitudinal Imaging of Presynaptic Terminals in PD&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;11C-UCB-J PET-CT; 18F-PE2I PET-CT; MRI brain&quot;, &quot;sponsor&quot;: &quot;Universitaire Ziekenhuizen KU Leuven&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06875765&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 44.33352, &quot;lng&quot;: 10.83544, &quot;nct&quot;: &quot;NCT07010328&quot;, &quot;color&quot;: &quot;#dd2ce8&quot;, &quot;title&quot;: &quot;Integrating AI in Postural Rehabilitation for Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Neurorehabilitation; AI-based home rehabilitation for postural disorders&quot;, &quot;sponsor&quot;: &quot;IRCCS National Neurological Institute \\&quot;C. Mondino\\&quot; Foundation&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07010328&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: -30.03283, &quot;lng&quot;: -51.23019, &quot;nct&quot;: &quot;NCT04863118&quot;, &quot;color&quot;: &quot;#6ac5d8&quot;, &quot;title&quot;: &quot;Acute Effects of Strength Training and High Intensity Training on Functional and Biochemical Measurements of Individuals With Parkinson&#x27;s Disease in Different Environments and Depths&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Strength training in shallow water and dry land; High-intensity training in shallow and deep water&quot;, &quot;sponsor&quot;: &quot;Federal University of Health Science of Porto Alegre&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04863118&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 21.30694, &quot;lng&quot;: -157.85833, &quot;nct&quot;: &quot;NCT06543810&quot;, &quot;color&quot;: &quot;#d34254&quot;, &quot;title&quot;: &quot;Parkinson&#x27;s Improvement Activated by Hula Understanding&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Hula for Parkinson&#x27;s&quot;, &quot;sponsor&quot;: &quot;University of Hawaii&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06543810&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.9075, &quot;lng&quot;: 116.39723, &quot;nct&quot;: &quot;NCT06196242&quot;, &quot;color&quot;: &quot;#d2ff04&quot;, &quot;title&quot;: &quot;Deep Brain Stimulation Lead Localization After Implantation&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;MRI and CT scan&quot;, &quot;sponsor&quot;: &quot;Tsinghua University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06196242&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.52065, &quot;lng&quot;: 9.25736, &quot;nct&quot;: &quot;NCT04459559&quot;, &quot;color&quot;: &quot;#547622&quot;, &quot;title&quot;: &quot;Usability of a Novel Cueing Device for Patients With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Tactile Cueing Device&quot;, &quot;sponsor&quot;: &quot;Swiss Federal Institute of Technology&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04459559&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 44.97997, &quot;lng&quot;: -93.26384, &quot;nct&quot;: &quot;NCT06467461&quot;, &quot;color&quot;: &quot;#832ab9&quot;, &quot;title&quot;: &quot;Identification of Prodromal Neurodegeneration in Serotonergic-Induced REM Sleep Behavior Disorder&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Skin biopsy; Speech testing; Ultra high field 7T MRI&quot;, &quot;sponsor&quot;: &quot;University of Minnesota&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06467461&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.95238, &quot;lng&quot;: -75.16362, &quot;nct&quot;: &quot;NCT05103618&quot;, &quot;color&quot;: &quot;#6f5d2d&quot;, &quot;title&quot;: &quot;Effect of Meditation and Controls and Subjects With Parkinson&#x27;s Disease on Brain Activity Measured by fMRI With FDOPA&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;[F-18] Fluorodopa Positron Emission Tomography; OM Meditation&quot;, &quot;sponsor&quot;: &quot;Andrew Newberg&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05103618&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.8425, &quot;lng&quot;: 5.85278, &quot;nct&quot;: &quot;NCT06573866&quot;, &quot;color&quot;: &quot;#ac736e&quot;, &quot;title&quot;: &quot;Enhancement of Quality of Work And Life&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Preventive Participatory workplace intervention&quot;, &quot;sponsor&quot;: &quot;Radboud University Medical Center&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06573866&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.66113, &quot;lng&quot;: -91.53017, &quot;nct&quot;: &quot;NCT03217110&quot;, &quot;color&quot;: &quot;#f54906&quot;, &quot;title&quot;: &quot;Cerebellar Stimulation and Cognitive Control&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Repetitive Transcranial Magnetic Stimulation (rTMS); Sham Repetitive Transcranial Magnetic Stimulation (rTMS)&quot;, &quot;sponsor&quot;: &quot;Krystal Parker, PhD&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03217110&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.41477, &quot;lng&quot;: -111.90931, &quot;nct&quot;: &quot;NCT06815302&quot;, &quot;color&quot;: &quot;#9d19cc&quot;, &quot;title&quot;: &quot;TURN-IT FOG: Improving Turning and Freezing of Gait in People With PD&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Experimental intervention; Active intervention&quot;, &quot;sponsor&quot;: &quot;Oregon Health and Science University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06815302&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.52345, &quot;lng&quot;: -122.67621, &quot;nct&quot;: &quot;NCT06815302&quot;, &quot;color&quot;: &quot;#9d19cc&quot;, &quot;title&quot;: &quot;TURN-IT FOG: Improving Turning and Freezing of Gait in People With PD&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Experimental intervention; Active intervention&quot;, &quot;sponsor&quot;: &quot;Oregon Health and Science University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06815302&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: -22.31472, &quot;lng&quot;: -49.06056, &quot;nct&quot;: &quot;NCT06815302&quot;, &quot;color&quot;: &quot;#9d19cc&quot;, &quot;title&quot;: &quot;TURN-IT FOG: Improving Turning and Freezing of Gait in People With PD&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Experimental intervention; Active intervention&quot;, &quot;sponsor&quot;: &quot;Oregon Health and Science University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06815302&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.3925, &quot;lng&quot;: 126.92694, &quot;nct&quot;: &quot;NCT06329141&quot;, &quot;color&quot;: &quot;#d2c10f&quot;, &quot;title&quot;: &quot;A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson&#x27;s Disease Patients&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Vutiglabridin; Placebo&quot;, &quot;sponsor&quot;: &quot;Glaceum&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06329141&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.7415, &quot;lng&quot;: 127.0474, &quot;nct&quot;: &quot;NCT06329141&quot;, &quot;color&quot;: &quot;#d2c10f&quot;, &quot;title&quot;: &quot;A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson&#x27;s Disease Patients&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Vutiglabridin; Placebo&quot;, &quot;sponsor&quot;: &quot;Glaceum&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06329141&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 35.10168, &quot;lng&quot;: 129.03004, &quot;nct&quot;: &quot;NCT06329141&quot;, &quot;color&quot;: &quot;#d2c10f&quot;, &quot;title&quot;: &quot;A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson&#x27;s Disease Patients&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Vutiglabridin; Placebo&quot;, &quot;sponsor&quot;: &quot;Glaceum&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06329141&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.566, &quot;lng&quot;: 126.9784, &quot;nct&quot;: &quot;NCT06329141&quot;, &quot;color&quot;: &quot;#d2c10f&quot;, &quot;title&quot;: &quot;A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson&#x27;s Disease Patients&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Vutiglabridin; Placebo&quot;, &quot;sponsor&quot;: &quot;Glaceum&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06329141&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 38.58157, &quot;lng&quot;: -121.4944, &quot;nct&quot;: &quot;NCT04650932&quot;, &quot;color&quot;: &quot;#875bbc&quot;, &quot;title&quot;: &quot;Dual Frequency Stimulation in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Deep brain stimulation&quot;, &quot;sponsor&quot;: &quot;University of California, Davis&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04650932&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 46.516, &quot;lng&quot;: 6.63282, &quot;nct&quot;: &quot;NCT06295614&quot;, &quot;color&quot;: &quot;#9897eb&quot;, &quot;title&quot;: &quot;Study on Preliminary Safety and Efficacy of the ARC-IM Therapy to Alleviate Locomotor Deficits in People With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;ARC-IM System implantation&quot;, &quot;sponsor&quot;: &quot;Ecole Polytechnique F\\u00e9d\\u00e9rale de Lausanne&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06295614&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.66946, &quot;lng&quot;: -117.82311, &quot;nct&quot;: &quot;NCT06285643&quot;, &quot;color&quot;: &quot;#838eb8&quot;, &quot;title&quot;: &quot;A Study of AAV2-GDNF in Adults With Moderate Parkinson&#x27;s Disease (REGENERATE-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF Gene therapy; Control Surgery&quot;, &quot;sponsor&quot;: &quot;AskBio Inc&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06285643&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 34.04835, &quot;lng&quot;: -117.26115, &quot;nct&quot;: &quot;NCT06285643&quot;, &quot;color&quot;: &quot;#838eb8&quot;, &quot;title&quot;: &quot;A Study of AAV2-GDNF in Adults With Moderate Parkinson&#x27;s Disease (REGENERATE-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF Gene therapy; Control Surgery&quot;, &quot;sponsor&quot;: &quot;AskBio Inc&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06285643&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.77493, &quot;lng&quot;: -122.41942, &quot;nct&quot;: &quot;NCT06285643&quot;, &quot;color&quot;: &quot;#838eb8&quot;, &quot;title&quot;: &quot;A Study of AAV2-GDNF in Adults With Moderate Parkinson&#x27;s Disease (REGENERATE-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF Gene therapy; Control Surgery&quot;, &quot;sponsor&quot;: &quot;AskBio Inc&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06285643&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.64777, &quot;lng&quot;: -104.98776, &quot;nct&quot;: &quot;NCT06285643&quot;, &quot;color&quot;: &quot;#838eb8&quot;, &quot;title&quot;: &quot;A Study of AAV2-GDNF in Adults With Moderate Parkinson&#x27;s Disease (REGENERATE-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF Gene therapy; Control Surgery&quot;, &quot;sponsor&quot;: &quot;AskBio Inc&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06285643&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 38.89511, &quot;lng&quot;: -77.03637, &quot;nct&quot;: &quot;NCT06285643&quot;, &quot;color&quot;: &quot;#838eb8&quot;, &quot;title&quot;: &quot;A Study of AAV2-GDNF in Adults With Moderate Parkinson&#x27;s Disease (REGENERATE-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF Gene therapy; Control Surgery&quot;, &quot;sponsor&quot;: &quot;AskBio Inc&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06285643&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.35869, &quot;lng&quot;: -80.0831, &quot;nct&quot;: &quot;NCT06285643&quot;, &quot;color&quot;: &quot;#838eb8&quot;, &quot;title&quot;: &quot;A Study of AAV2-GDNF in Adults With Moderate Parkinson&#x27;s Disease (REGENERATE-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF Gene therapy; Control Surgery&quot;, &quot;sponsor&quot;: &quot;AskBio Inc&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06285643&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.97617, &quot;lng&quot;: -82.09064, &quot;nct&quot;: &quot;NCT06285643&quot;, &quot;color&quot;: &quot;#838eb8&quot;, &quot;title&quot;: &quot;A Study of AAV2-GDNF in Adults With Moderate Parkinson&#x27;s Disease (REGENERATE-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF Gene therapy; Control Surgery&quot;, &quot;sponsor&quot;: &quot;AskBio Inc&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06285643&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.749, &quot;lng&quot;: -84.38798, &quot;nct&quot;: &quot;NCT06285643&quot;, &quot;color&quot;: &quot;#838eb8&quot;, &quot;title&quot;: &quot;A Study of AAV2-GDNF in Adults With Moderate Parkinson&#x27;s Disease (REGENERATE-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF Gene therapy; Control Surgery&quot;, &quot;sponsor&quot;: &quot;AskBio Inc&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06285643&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.85003, &quot;lng&quot;: -87.65005, &quot;nct&quot;: &quot;NCT06285643&quot;, &quot;color&quot;: &quot;#838eb8&quot;, &quot;title&quot;: &quot;A Study of AAV2-GDNF in Adults With Moderate Parkinson&#x27;s Disease (REGENERATE-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF Gene therapy; Control Surgery&quot;, &quot;sponsor&quot;: &quot;AskBio Inc&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06285643&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.11417, &quot;lng&quot;: -94.62746, &quot;nct&quot;: &quot;NCT06285643&quot;, &quot;color&quot;: &quot;#838eb8&quot;, &quot;title&quot;: &quot;A Study of AAV2-GDNF in Adults With Moderate Parkinson&#x27;s Disease (REGENERATE-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF Gene therapy; Control Surgery&quot;, &quot;sponsor&quot;: &quot;AskBio Inc&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06285643&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.35843, &quot;lng&quot;: -71.05977, &quot;nct&quot;: &quot;NCT06285643&quot;, &quot;color&quot;: &quot;#838eb8&quot;, &quot;title&quot;: &quot;A Study of AAV2-GDNF in Adults With Moderate Parkinson&#x27;s Disease (REGENERATE-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF Gene therapy; Control Surgery&quot;, &quot;sponsor&quot;: &quot;AskBio Inc&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06285643&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.73698, &quot;lng&quot;: -84.48387, &quot;nct&quot;: &quot;NCT06285643&quot;, &quot;color&quot;: &quot;#838eb8&quot;, &quot;title&quot;: &quot;A Study of AAV2-GDNF in Adults With Moderate Parkinson&#x27;s Disease (REGENERATE-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF Gene therapy; Control Surgery&quot;, &quot;sponsor&quot;: &quot;AskBio Inc&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06285643&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.48531, &quot;lng&quot;: -83.37716, &quot;nct&quot;: &quot;NCT06285643&quot;, &quot;color&quot;: &quot;#838eb8&quot;, &quot;title&quot;: &quot;A Study of AAV2-GDNF in Adults With Moderate Parkinson&#x27;s Disease (REGENERATE-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF Gene therapy; Control Surgery&quot;, &quot;sponsor&quot;: &quot;AskBio Inc&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06285643&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.17497, &quot;lng&quot;: -115.13722, &quot;nct&quot;: &quot;NCT06285643&quot;, &quot;color&quot;: &quot;#838eb8&quot;, &quot;title&quot;: &quot;A Study of AAV2-GDNF in Adults With Moderate Parkinson&#x27;s Disease (REGENERATE-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF Gene therapy; Control Surgery&quot;, &quot;sponsor&quot;: &quot;AskBio Inc&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06285643&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 35.9132, &quot;lng&quot;: -79.05584, &quot;nct&quot;: &quot;NCT06285643&quot;, &quot;color&quot;: &quot;#838eb8&quot;, &quot;title&quot;: &quot;A Study of AAV2-GDNF in Adults With Moderate Parkinson&#x27;s Disease (REGENERATE-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF Gene therapy; Control Surgery&quot;, &quot;sponsor&quot;: &quot;AskBio Inc&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06285643&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 35.99403, &quot;lng&quot;: -78.89862, &quot;nct&quot;: &quot;NCT06285643&quot;, &quot;color&quot;: &quot;#838eb8&quot;, &quot;title&quot;: &quot;A Study of AAV2-GDNF in Adults With Moderate Parkinson&#x27;s Disease (REGENERATE-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF Gene therapy; Control Surgery&quot;, &quot;sponsor&quot;: &quot;AskBio Inc&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06285643&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.96118, &quot;lng&quot;: -82.99879, &quot;nct&quot;: &quot;NCT06285643&quot;, &quot;color&quot;: &quot;#838eb8&quot;, &quot;title&quot;: &quot;A Study of AAV2-GDNF in Adults With Moderate Parkinson&#x27;s Disease (REGENERATE-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF Gene therapy; Control Surgery&quot;, &quot;sponsor&quot;: &quot;AskBio Inc&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06285643&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.95238, &quot;lng&quot;: -75.16362, &quot;nct&quot;: &quot;NCT06285643&quot;, &quot;color&quot;: &quot;#838eb8&quot;, &quot;title&quot;: &quot;A Study of AAV2-GDNF in Adults With Moderate Parkinson&#x27;s Disease (REGENERATE-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF Gene therapy; Control Surgery&quot;, &quot;sponsor&quot;: &quot;AskBio Inc&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06285643&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.16589, &quot;lng&quot;: -86.78444, &quot;nct&quot;: &quot;NCT06285643&quot;, &quot;color&quot;: &quot;#838eb8&quot;, &quot;title&quot;: &quot;A Study of AAV2-GDNF in Adults With Moderate Parkinson&#x27;s Disease (REGENERATE-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF Gene therapy; Control Surgery&quot;, &quot;sponsor&quot;: &quot;AskBio Inc&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06285643&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.76328, &quot;lng&quot;: -95.36327, &quot;nct&quot;: &quot;NCT06285643&quot;, &quot;color&quot;: &quot;#838eb8&quot;, &quot;title&quot;: &quot;A Study of AAV2-GDNF in Adults With Moderate Parkinson&#x27;s Disease (REGENERATE-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF Gene therapy; Control Surgery&quot;, &quot;sponsor&quot;: &quot;AskBio Inc&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06285643&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.68149, &quot;lng&quot;: -122.20874, &quot;nct&quot;: &quot;NCT06285643&quot;, &quot;color&quot;: &quot;#838eb8&quot;, &quot;title&quot;: &quot;A Study of AAV2-GDNF in Adults With Moderate Parkinson&#x27;s Disease (REGENERATE-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF Gene therapy; Control Surgery&quot;, &quot;sponsor&quot;: &quot;AskBio Inc&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06285643&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.07305, &quot;lng&quot;: -89.40123, &quot;nct&quot;: &quot;NCT06285643&quot;, &quot;color&quot;: &quot;#838eb8&quot;, &quot;title&quot;: &quot;A Study of AAV2-GDNF in Adults With Moderate Parkinson&#x27;s Disease (REGENERATE-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF Gene therapy; Control Surgery&quot;, &quot;sponsor&quot;: &quot;AskBio Inc&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06285643&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.52437, &quot;lng&quot;: 13.41053, &quot;nct&quot;: &quot;NCT06285643&quot;, &quot;color&quot;: &quot;#838eb8&quot;, &quot;title&quot;: &quot;A Study of AAV2-GDNF in Adults With Moderate Parkinson&#x27;s Disease (REGENERATE-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF Gene therapy; Control Surgery&quot;, &quot;sponsor&quot;: &quot;AskBio Inc&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06285643&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.80904, &quot;lng&quot;: 8.77069, &quot;nct&quot;: &quot;NCT06285643&quot;, &quot;color&quot;: &quot;#838eb8&quot;, &quot;title&quot;: &quot;A Study of AAV2-GDNF in Adults With Moderate Parkinson&#x27;s Disease (REGENERATE-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF Gene therapy; Control Surgery&quot;, &quot;sponsor&quot;: &quot;AskBio Inc&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06285643&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.52266, &quot;lng&quot;: 9.05222, &quot;nct&quot;: &quot;NCT06285643&quot;, &quot;color&quot;: &quot;#838eb8&quot;, &quot;title&quot;: &quot;A Study of AAV2-GDNF in Adults With Moderate Parkinson&#x27;s Disease (REGENERATE-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF Gene therapy; Control Surgery&quot;, &quot;sponsor&quot;: &quot;AskBio Inc&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06285643&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 49.79391, &quot;lng&quot;: 9.95121, &quot;nct&quot;: &quot;NCT06285643&quot;, &quot;color&quot;: &quot;#838eb8&quot;, &quot;title&quot;: &quot;A Study of AAV2-GDNF in Adults With Moderate Parkinson&#x27;s Disease (REGENERATE-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF Gene therapy; Control Surgery&quot;, &quot;sponsor&quot;: &quot;AskBio Inc&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06285643&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 54.35227, &quot;lng&quot;: 18.64912, &quot;nct&quot;: &quot;NCT06285643&quot;, &quot;color&quot;: &quot;#838eb8&quot;, &quot;title&quot;: &quot;A Study of AAV2-GDNF in Adults With Moderate Parkinson&#x27;s Disease (REGENERATE-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF Gene therapy; Control Surgery&quot;, &quot;sponsor&quot;: &quot;AskBio Inc&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06285643&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.2597, &quot;lng&quot;: 19.02173, &quot;nct&quot;: &quot;NCT06285643&quot;, &quot;color&quot;: &quot;#838eb8&quot;, &quot;title&quot;: &quot;A Study of AAV2-GDNF in Adults With Moderate Parkinson&#x27;s Disease (REGENERATE-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF Gene therapy; Control Surgery&quot;, &quot;sponsor&quot;: &quot;AskBio Inc&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06285643&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.22977, &quot;lng&quot;: 21.01178, &quot;nct&quot;: &quot;NCT06285643&quot;, &quot;color&quot;: &quot;#838eb8&quot;, &quot;title&quot;: &quot;A Study of AAV2-GDNF in Adults With Moderate Parkinson&#x27;s Disease (REGENERATE-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF Gene therapy; Control Surgery&quot;, &quot;sponsor&quot;: &quot;AskBio Inc&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06285643&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.45523, &quot;lng&quot;: -2.59665, &quot;nct&quot;: &quot;NCT06285643&quot;, &quot;color&quot;: &quot;#838eb8&quot;, &quot;title&quot;: &quot;A Study of AAV2-GDNF in Adults With Moderate Parkinson&#x27;s Disease (REGENERATE-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF Gene therapy; Control Surgery&quot;, &quot;sponsor&quot;: &quot;AskBio Inc&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06285643&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.48, &quot;lng&quot;: -3.18, &quot;nct&quot;: &quot;NCT06285643&quot;, &quot;color&quot;: &quot;#838eb8&quot;, &quot;title&quot;: &quot;A Study of AAV2-GDNF in Adults With Moderate Parkinson&#x27;s Disease (REGENERATE-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF Gene therapy; Control Surgery&quot;, &quot;sponsor&quot;: &quot;AskBio Inc&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06285643&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.16589, &quot;lng&quot;: -86.78444, &quot;nct&quot;: &quot;NCT04715984&quot;, &quot;color&quot;: &quot;#96bc4a&quot;, &quot;title&quot;: &quot;Corticostriatal Contributions to Parkinson&#x27;s Disease Cognitive Impairment&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Neurophysiology recordings; Neural stimulation&quot;, &quot;sponsor&quot;: &quot;Vanderbilt University Medical Center&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04715984&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.2, &quot;lng&quot;: 0.11667, &quot;nct&quot;: &quot;NCT07157735&quot;, &quot;color&quot;: &quot;#6d32d4&quot;, &quot;title&quot;: &quot;A Trial to Test the Use of Dapansutrile, an Anti-inflammatory Medication, in People With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;dapansutrile; placebo&quot;, &quot;sponsor&quot;: &quot;Cambridge University Hospitals NHS Foundation Trust&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07157735&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 35.69439, &quot;lng&quot;: 51.42151, &quot;nct&quot;: &quot;NCT06530290&quot;, &quot;color&quot;: &quot;#58c3a1&quot;, &quot;title&quot;: &quot;Evaluating the Effect of Mirtazapine on Anxiety in Parkinson&#x27;s Disease Patients&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Mirtazapine 15 MG; Placebo&quot;, &quot;sponsor&quot;: &quot;Leila Dargahi. PharmD PhD&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06530290&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: -7.115, &quot;lng&quot;: -34.86306, &quot;nct&quot;: &quot;NCT04581590&quot;, &quot;color&quot;: &quot;#bd63b6&quot;, &quot;title&quot;: &quot;The Impact TDCS-linked Motor and Cognitive Training Gains in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Cognitive training&quot;, &quot;sponsor&quot;: &quot;Federal University of Para\\u00edba&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04581590&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.16589, &quot;lng&quot;: -86.78444, &quot;nct&quot;: &quot;NCT04620382&quot;, &quot;color&quot;: &quot;#9852e4&quot;, &quot;title&quot;: &quot;Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;EARLY_PHASE1&quot;], &quot;interventions&quot;: &quot;Midodrine; Placebo pill; Abdominal compression; sham compression&quot;, &quot;sponsor&quot;: &quot;Vanderbilt University Medical Center&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04620382&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.42587, &quot;lng&quot;: -86.90807, &quot;nct&quot;: &quot;NCT05700825&quot;, &quot;color&quot;: &quot;#59370b&quot;, &quot;title&quot;: &quot;Rehabilitation of Airway Protection in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Expiratory Muscle Strength Training + Cough Skill Training&quot;, &quot;sponsor&quot;: &quot;Teachers College, Columbia University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05700825&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.71427, &quot;lng&quot;: -74.00597, &quot;nct&quot;: &quot;NCT05700825&quot;, &quot;color&quot;: &quot;#59370b&quot;, &quot;title&quot;: &quot;Rehabilitation of Airway Protection in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Expiratory Muscle Strength Training + Cough Skill Training&quot;, &quot;sponsor&quot;: &quot;Teachers College, Columbia University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05700825&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 31.22222, &quot;lng&quot;: 121.45806, &quot;nct&quot;: &quot;NCT06388863&quot;, &quot;color&quot;: &quot;#597f05&quot;, &quot;title&quot;: &quot;Evaluation of the Efficacy and Safety of Fecal Microbiota Transplantation for Constipation in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Healthy donor-derived FMT capsule; Placebo capsule&quot;, &quot;sponsor&quot;: &quot;Shanghai Zhongshan Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06388863&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 46.94809, &quot;lng&quot;: 7.44744, &quot;nct&quot;: &quot;NCT06386497&quot;, &quot;color&quot;: &quot;#61cec7&quot;, &quot;title&quot;: &quot;Acceptability of the Somnomat Casa for the Treatment of Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Nocturnal translational vestibular stimulation&quot;, &quot;sponsor&quot;: &quot;Insel Gruppe AG, University Hospital Bern&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06386497&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.36667, &quot;lng&quot;: 8.55, &quot;nct&quot;: &quot;NCT06386497&quot;, &quot;color&quot;: &quot;#61cec7&quot;, &quot;title&quot;: &quot;Acceptability of the Somnomat Casa for the Treatment of Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Nocturnal translational vestibular stimulation&quot;, &quot;sponsor&quot;: &quot;Insel Gruppe AG, University Hospital Bern&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06386497&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 44.84124, &quot;lng&quot;: -0.58046, &quot;nct&quot;: &quot;NCT06241924&quot;, &quot;color&quot;: &quot;#327b51&quot;, &quot;title&quot;: &quot;Oscillatory Activity in Basal Ganglia Circuits During Normal and Pathological Movement&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;High Resolution Electroencephalogram (EEG-HR); Stereo-electro-encephalography (SEEG)&quot;, &quot;sponsor&quot;: &quot;University Hospital, Bordeaux&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06241924&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 46.96658, &quot;lng&quot;: 9.47705, &quot;nct&quot;: &quot;NCT04108741&quot;, &quot;color&quot;: &quot;#1029ac&quot;, &quot;title&quot;: &quot;Augmented Reality Treadmill Training in Patients With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;C-Mill augmented reality treadmill training&quot;, &quot;sponsor&quot;: &quot;Klinik Valens&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04108741&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 55.67594, &quot;lng&quot;: 12.56553, &quot;nct&quot;: &quot;NCT04229056&quot;, &quot;color&quot;: &quot;#b43646&quot;, &quot;title&quot;: &quot;COMPuter-assisted Self-training to Improve EXecutive Function&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Computer-based cognitive rehabilitation (CBCR); General computer-based cognitive stimulation&quot;, &quot;sponsor&quot;: &quot;Bispebjerg Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04229056&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 46.516, &quot;lng&quot;: 6.63282, &quot;nct&quot;: &quot;NCT04956770&quot;, &quot;color&quot;: &quot;#ca9a50&quot;, &quot;title&quot;: &quot;Study on Feasibility of Targeted Epidural Spinal Stimulation (TESS) to Improve Mobility in Patients With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Implantation surgery&quot;, &quot;sponsor&quot;: &quot;Jocelyne Bloch&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04956770&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.87959, &quot;lng&quot;: 4.70093, &quot;nct&quot;: &quot;NCT06798844&quot;, &quot;color&quot;: &quot;#8ff43f&quot;, &quot;title&quot;: &quot;Spinal Cord Stimulation for Freezing of Gait in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Spinal Cord Stimulation; Spinal electrophysiological recordings&quot;, &quot;sponsor&quot;: &quot;Universitaire Ziekenhuizen KU Leuven&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06798844&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.76838, &quot;lng&quot;: -86.15804, &quot;nct&quot;: &quot;NCT05218187&quot;, &quot;color&quot;: &quot;#6b65fa&quot;, &quot;title&quot;: &quot;Robotic Gait Rehabilitation in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;G-EO End-Effector Gait Trainer; Conventional Physical Therapy Treatment&quot;, &quot;sponsor&quot;: &quot;Indiana University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05218187&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.41675, &quot;lng&quot;: -71.06573, &quot;nct&quot;: &quot;NCT06175871&quot;, &quot;color&quot;: &quot;#820d0b&quot;, &quot;title&quot;: &quot;New Clinical Rehabilitation Approach for the Management of Falls Risks&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;OTAGO exercises; Conventional therapy&quot;, &quot;sponsor&quot;: &quot;Universit\\u00e9 du Qu\\u00e9bec \\u00e0 Chicoutimi&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06175871&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 34.05223, &quot;lng&quot;: -118.24368, &quot;nct&quot;: &quot;NCT05179187&quot;, &quot;color&quot;: &quot;#77fca5&quot;, &quot;title&quot;: &quot;Non-invasive Brain Mapping of Movement Facilitation in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Movement task&quot;, &quot;sponsor&quot;: &quot;University of California, Los Angeles&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05179187&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.59754, &quot;lng&quot;: -112.27182, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 34.74648, &quot;lng&quot;: -92.28959, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.74773, &quot;lng&quot;: -119.77237, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.66946, &quot;lng&quot;: -117.82311, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 34.05223, &quot;lng&quot;: -118.24368, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.55391, &quot;lng&quot;: -117.21392, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.44188, &quot;lng&quot;: -122.14302, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.72943, &quot;lng&quot;: -104.83192, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.30815, &quot;lng&quot;: -72.92816, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.35869, &quot;lng&quot;: -80.0831, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.65163, &quot;lng&quot;: -82.32483, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 28.53834, &quot;lng&quot;: -81.37924, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 27.94752, &quot;lng&quot;: -82.45843, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.749, &quot;lng&quot;: -84.38798, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.47097, &quot;lng&quot;: -81.97484, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.85003, &quot;lng&quot;: -87.65005, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.11417, &quot;lng&quot;: -94.62746, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.98869, &quot;lng&quot;: -84.47772, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.95465, &quot;lng&quot;: -90.07507, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.29038, &quot;lng&quot;: -76.61219, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.35843, &quot;lng&quot;: -71.05977, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.48531, &quot;lng&quot;: -83.37716, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.00969, &quot;lng&quot;: -93.34912, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.17497, &quot;lng&quot;: -115.13722, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.80066, &quot;lng&quot;: -73.72846, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.71427, &quot;lng&quot;: -74.00597, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.15478, &quot;lng&quot;: -77.61556, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 35.9132, &quot;lng&quot;: -79.05584, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 35.7721, &quot;lng&quot;: -78.63861, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.96118, &quot;lng&quot;: -82.99879, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.15398, &quot;lng&quot;: -95.99277, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.52345, &quot;lng&quot;: -122.67621, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.95238, &quot;lng&quot;: -75.16362, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 32.77632, &quot;lng&quot;: -79.93275, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.16589, &quot;lng&quot;: -86.78444, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 32.78306, &quot;lng&quot;: -96.80667, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.76328, &quot;lng&quot;: -95.36327, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 30.50826, &quot;lng&quot;: -97.6789, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.76078, &quot;lng&quot;: -111.89105, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 38.02931, &quot;lng&quot;: -78.47668, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.68149, &quot;lng&quot;: -122.20874, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.0389, &quot;lng&quot;: -87.90647, &quot;nct&quot;: &quot;NCT06680830&quot;, &quot;color&quot;: &quot;#cf0195&quot;, &quot;title&quot;: &quot;A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;NEU-411; Placebo&quot;, &quot;sponsor&quot;: &quot;Neuron23 Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06680830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.93333, &quot;lng&quot;: 6.95, &quot;nct&quot;: &quot;NCT06498349&quot;, &quot;color&quot;: &quot;#d3d0e2&quot;, &quot;title&quot;: &quot;Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment; best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations&quot;, &quot;sponsor&quot;: &quot;University of Kiel&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06498349&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.05089, &quot;lng&quot;: 13.73832, &quot;nct&quot;: &quot;NCT06498349&quot;, &quot;color&quot;: &quot;#d3d0e2&quot;, &quot;title&quot;: &quot;Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment; best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations&quot;, &quot;sponsor&quot;: &quot;University of Kiel&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06498349&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.22172, &quot;lng&quot;: 6.77616, &quot;nct&quot;: &quot;NCT06498349&quot;, &quot;color&quot;: &quot;#d3d0e2&quot;, &quot;title&quot;: &quot;Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment; best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations&quot;, &quot;sponsor&quot;: &quot;University of Kiel&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06498349&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 53.55073, &quot;lng&quot;: 9.99302, &quot;nct&quot;: &quot;NCT06498349&quot;, &quot;color&quot;: &quot;#d3d0e2&quot;, &quot;title&quot;: &quot;Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment; best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations&quot;, &quot;sponsor&quot;: &quot;University of Kiel&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06498349&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 54.32133, &quot;lng&quot;: 10.13489, &quot;nct&quot;: &quot;NCT06498349&quot;, &quot;color&quot;: &quot;#d3d0e2&quot;, &quot;title&quot;: &quot;Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment; best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations&quot;, &quot;sponsor&quot;: &quot;University of Kiel&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06498349&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.80904, &quot;lng&quot;: 8.77069, &quot;nct&quot;: &quot;NCT06498349&quot;, &quot;color&quot;: &quot;#d3d0e2&quot;, &quot;title&quot;: &quot;Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment; best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations&quot;, &quot;sponsor&quot;: &quot;University of Kiel&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06498349&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.52003, &quot;lng&quot;: 13.40489, &quot;nct&quot;: &quot;NCT06498349&quot;, &quot;color&quot;: &quot;#d3d0e2&quot;, &quot;title&quot;: &quot;Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment; best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations&quot;, &quot;sponsor&quot;: &quot;University of Kiel&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06498349&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.52266, &quot;lng&quot;: 9.05222, &quot;nct&quot;: &quot;NCT06498349&quot;, &quot;color&quot;: &quot;#d3d0e2&quot;, &quot;title&quot;: &quot;Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment; best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations&quot;, &quot;sponsor&quot;: &quot;University of Kiel&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06498349&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 49.79391, &quot;lng&quot;: 9.95121, &quot;nct&quot;: &quot;NCT06498349&quot;, &quot;color&quot;: &quot;#d3d0e2&quot;, &quot;title&quot;: &quot;Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment; best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations&quot;, &quot;sponsor&quot;: &quot;University of Kiel&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06498349&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.37403, &quot;lng&quot;: 4.88969, &quot;nct&quot;: &quot;NCT06498349&quot;, &quot;color&quot;: &quot;#d3d0e2&quot;, &quot;title&quot;: &quot;Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment; best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations&quot;, &quot;sponsor&quot;: &quot;University of Kiel&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06498349&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 46.94809, &quot;lng&quot;: 7.44744, &quot;nct&quot;: &quot;NCT06498349&quot;, &quot;color&quot;: &quot;#d3d0e2&quot;, &quot;title&quot;: &quot;Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment; best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations&quot;, &quot;sponsor&quot;: &quot;University of Kiel&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06498349&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.36667, &quot;lng&quot;: 8.55, &quot;nct&quot;: &quot;NCT06498349&quot;, &quot;color&quot;: &quot;#d3d0e2&quot;, &quot;title&quot;: &quot;Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment; best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations&quot;, &quot;sponsor&quot;: &quot;University of Kiel&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06498349&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 31.22222, &quot;lng&quot;: 121.45806, &quot;nct&quot;: &quot;NCT06236230&quot;, &quot;color&quot;: &quot;#1a6805&quot;, &quot;title&quot;: &quot;Basic and Clinical Studies of Levodopa/Carbidopa/Entacapone in the Treatment of Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;levodopa/carbidopa/entacapone&quot;, &quot;sponsor&quot;: &quot;Second Affiliated Hospital of Soochow University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06236230&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.53558, &quot;lng&quot;: 10.21472, &quot;nct&quot;: &quot;NCT06657274&quot;, &quot;color&quot;: &quot;#bc7983&quot;, &quot;title&quot;: &quot;EARLY-COGN^3 - Smart Digital Solutions for EARLY Treatment of COGnitive Disability: a Neuropsychological, Neurophysiological and Neurobiological Perspective in Chronic Neurological Diseases - PNRR-MCNT2-2023-12377069&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;RICORDO-DTx; Home-based unstructured cognitive stimulation&quot;, &quot;sponsor&quot;: &quot;IRCCS Centro San Giovanni di Dio Fatebenefratelli&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06657274&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 38.19394, &quot;lng&quot;: 15.55256, &quot;nct&quot;: &quot;NCT06657274&quot;, &quot;color&quot;: &quot;#bc7983&quot;, &quot;title&quot;: &quot;EARLY-COGN^3 - Smart Digital Solutions for EARLY Treatment of COGnitive Disability: a Neuropsychological, Neurophysiological and Neurobiological Perspective in Chronic Neurological Diseases - PNRR-MCNT2-2023-12377069&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;RICORDO-DTx; Home-based unstructured cognitive stimulation&quot;, &quot;sponsor&quot;: &quot;IRCCS Centro San Giovanni di Dio Fatebenefratelli&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06657274&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.46427, &quot;lng&quot;: 9.18951, &quot;nct&quot;: &quot;NCT06657274&quot;, &quot;color&quot;: &quot;#bc7983&quot;, &quot;title&quot;: &quot;EARLY-COGN^3 - Smart Digital Solutions for EARLY Treatment of COGnitive Disability: a Neuropsychological, Neurophysiological and Neurobiological Perspective in Chronic Neurological Diseases - PNRR-MCNT2-2023-12377069&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;RICORDO-DTx; Home-based unstructured cognitive stimulation&quot;, &quot;sponsor&quot;: &quot;IRCCS Centro San Giovanni di Dio Fatebenefratelli&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06657274&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 24.9896, &quot;lng&quot;: 121.3187, &quot;nct&quot;: &quot;NCT06367101&quot;, &quot;color&quot;: &quot;#e07d5e&quot;, &quot;title&quot;: &quot;AR Stimulation Effects on Gait, Anxiety, and Brain Connectivity in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;AR training with gait and HRV feedback&quot;, &quot;sponsor&quot;: &quot;Chang Gung University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06367101&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.72943, &quot;lng&quot;: -104.83192, &quot;nct&quot;: &quot;NCT06446505&quot;, &quot;color&quot;: &quot;#58c232&quot;, &quot;title&quot;: &quot;Evaluation of a Decision Aid for Deep Brain Stimulation Surgery for Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Deep Brain Stimulation Decision Aid&quot;, &quot;sponsor&quot;: &quot;University of Colorado, Denver&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06446505&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 30.29365, &quot;lng&quot;: 120.16142, &quot;nct&quot;: &quot;NCT06596005&quot;, &quot;color&quot;: &quot;#32b13f&quot;, &quot;title&quot;: &quot;Efficacy and Safety of TJ0113 Capsule in Patients With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TJ0113; Placebo&quot;, &quot;sponsor&quot;: &quot;Second Affiliated Hospital, School of Medicine, Zhejiang University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06596005&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.73865, &quot;lng&quot;: 4.91303, &quot;nct&quot;: &quot;NCT07127146&quot;, &quot;color&quot;: &quot;#4e5891&quot;, &quot;title&quot;: &quot;Opioidergic and Noradrenergic Systems in Central Parkisonian Pain&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;PET-MRI exam with administration of [11C]Carfentanil; PET-MRI exam with administration of [11C]Yohimbine&quot;, &quot;sponsor&quot;: &quot;Hospices Civils de Lyon&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07127146&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.77969, &quot;lng&quot;: 3.08682, &quot;nct&quot;: &quot;NCT07127146&quot;, &quot;color&quot;: &quot;#4e5891&quot;, &quot;title&quot;: &quot;Opioidergic and Noradrenergic Systems in Central Parkisonian Pain&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;PET-MRI exam with administration of [11C]Carfentanil; PET-MRI exam with administration of [11C]Yohimbine&quot;, &quot;sponsor&quot;: &quot;Hospices Civils de Lyon&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07127146&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.60426, &quot;lng&quot;: 1.44367, &quot;nct&quot;: &quot;NCT07127146&quot;, &quot;color&quot;: &quot;#4e5891&quot;, &quot;title&quot;: &quot;Opioidergic and Noradrenergic Systems in Central Parkisonian Pain&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;PET-MRI exam with administration of [11C]Carfentanil; PET-MRI exam with administration of [11C]Yohimbine&quot;, &quot;sponsor&quot;: &quot;Hospices Civils de Lyon&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07127146&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.46427, &quot;lng&quot;: 9.18951, &quot;nct&quot;: &quot;NCT06868160&quot;, &quot;color&quot;: &quot;#cba622&quot;, &quot;title&quot;: &quot;Comparison of Different Non-invasive Electrical Stimulation Protocols to Facilitate Rehabilitation in Parkinson&#x27;s Disease Subjects With Postural Instability and Gait Disorders&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Rehabilitation; SHAM tDCS; tDCS; tsDCS (first cycle); tsDCS (second cycle); SHAM tsDCS (first cycle); SHAM tsDCS (second cycle); SHAM tsDCS&quot;, &quot;sponsor&quot;: &quot;IRCCS San Raffaele&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06868160&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.42411, &quot;lng&quot;: -122.16608, &quot;nct&quot;: &quot;NCT06028477&quot;, &quot;color&quot;: &quot;#33ff19&quot;, &quot;title&quot;: &quot;Vibrotactile Coordinated Reset in Parkinson&#x27;s Disease - Proof of Concept Study&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Stanford Glove&quot;, &quot;sponsor&quot;: &quot;Stanford University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06028477&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.77493, &quot;lng&quot;: -122.41942, &quot;nct&quot;: &quot;NCT05395624&quot;, &quot;color&quot;: &quot;#6e534d&quot;, &quot;title&quot;: &quot;Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;18F-OP-801&quot;, &quot;sponsor&quot;: &quot;Ashvattha Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05395624&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.42411, &quot;lng&quot;: -122.16608, &quot;nct&quot;: &quot;NCT05395624&quot;, &quot;color&quot;: &quot;#6e534d&quot;, &quot;title&quot;: &quot;Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;18F-OP-801&quot;, &quot;sponsor&quot;: &quot;Ashvattha Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05395624&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 30.33218, &quot;lng&quot;: -81.65565, &quot;nct&quot;: &quot;NCT05395624&quot;, &quot;color&quot;: &quot;#6e534d&quot;, &quot;title&quot;: &quot;Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;18F-OP-801&quot;, &quot;sponsor&quot;: &quot;Ashvattha Therapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05395624&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.36667, &quot;lng&quot;: 8.55, &quot;nct&quot;: &quot;NCT07082595&quot;, &quot;color&quot;: &quot;#a9462d&quot;, &quot;title&quot;: &quot;Personalized Stimulation Loop for Neurorehabilitation in Parkinson: a Proof-of-principle Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;TASS Intervention (Sham); TASS Intervention (Verum)&quot;, &quot;sponsor&quot;: &quot;University of Zurich&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07082595&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.64953, &quot;lng&quot;: 13.77678, &quot;nct&quot;: &quot;NCT06835595&quot;, &quot;color&quot;: &quot;#b29b85&quot;, &quot;title&quot;: &quot;TMS-related Measures As Biomarker of Cognitive Impairment in PD&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Transcranial Magnetic Stimulation&quot;, &quot;sponsor&quot;: &quot;Azienda Provinciale per i Servizi Sanitari, Provincia Autonoma di Trento&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06835595&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 46.89313, &quot;lng&quot;: 11.42961, &quot;nct&quot;: &quot;NCT06835595&quot;, &quot;color&quot;: &quot;#b29b85&quot;, &quot;title&quot;: &quot;TMS-related Measures As Biomarker of Cognitive Impairment in PD&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Transcranial Magnetic Stimulation&quot;, &quot;sponsor&quot;: &quot;Azienda Provinciale per i Servizi Sanitari, Provincia Autonoma di Trento&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06835595&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 46.06787, &quot;lng&quot;: 11.12108, &quot;nct&quot;: &quot;NCT06835595&quot;, &quot;color&quot;: &quot;#b29b85&quot;, &quot;title&quot;: &quot;TMS-related Measures As Biomarker of Cognitive Impairment in PD&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Transcranial Magnetic Stimulation&quot;, &quot;sponsor&quot;: &quot;Azienda Provinciale per i Servizi Sanitari, Provincia Autonoma di Trento&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06835595&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 49.8844, &quot;lng&quot;: -97.14704, &quot;nct&quot;: &quot;NCT03025334&quot;, &quot;color&quot;: &quot;#3865aa&quot;, &quot;title&quot;: &quot;tDCS on Parkinson&#x27;s Disease Cognition&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;High-definition transcranial direct current stimulation&quot;, &quot;sponsor&quot;: &quot;University of Manitoba&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03025334&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 46.87909, &quot;lng&quot;: 7.62013, &quot;nct&quot;: &quot;NCT04976127&quot;, &quot;color&quot;: &quot;#831f92&quot;, &quot;title&quot;: &quot;Safety Evaluation of Intravenous Talineuren (TLN) in Parkinson&#x27;s Disease-affected Patients&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;Talineuren&quot;, &quot;sponsor&quot;: &quot;InnoMedica Schweiz AG&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04976127&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 31.86389, &quot;lng&quot;: 117.28083, &quot;nct&quot;: &quot;NCT06642454&quot;, &quot;color&quot;: &quot;#472561&quot;, &quot;title&quot;: &quot;A Comparative Open-Label Crossover Study of Respiratory-Gated Versus Non-Respiratory-Gated Transcutaneous Auricular Vagus Nerve Stimulation for the Treatment of Non-Motor Symptoms in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Transcutaneous auricular vagus nerve stimulation&quot;, &quot;sponsor&quot;: &quot;Anhui Medical University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06642454&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 46.87909, &quot;lng&quot;: 7.62013, &quot;nct&quot;: &quot;NCT06431971&quot;, &quot;color&quot;: &quot;#be368e&quot;, &quot;title&quot;: &quot;Estimates of the Short-term Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Talineuren; Placebo&quot;, &quot;sponsor&quot;: &quot;InnoMedica Schweiz AG&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06431971&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.35843, &quot;lng&quot;: -71.05977, &quot;nct&quot;: &quot;NCT06687837&quot;, &quot;color&quot;: &quot;#8543d1&quot;, &quot;title&quot;: &quot;Treating Parkinson&#x27;s Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;autologous dopaminergic cell implantation&quot;, &quot;sponsor&quot;: &quot;Jeffrey S. Schweitzer, MD, PhD&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06687837&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.80307, &quot;lng&quot;: -118.07256, &quot;nct&quot;: &quot;NCT04291859&quot;, &quot;color&quot;: &quot;#0d7201&quot;, &quot;title&quot;: &quot;Lu AF28996 in Participants With Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;Lu AF28996&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04291859&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 38.89511, &quot;lng&quot;: -77.03637, &quot;nct&quot;: &quot;NCT04291859&quot;, &quot;color&quot;: &quot;#0d7201&quot;, &quot;title&quot;: &quot;Lu AF28996 in Participants With Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;Lu AF28996&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04291859&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 25.9812, &quot;lng&quot;: -80.14838, &quot;nct&quot;: &quot;NCT04291859&quot;, &quot;color&quot;: &quot;#0d7201&quot;, &quot;title&quot;: &quot;Lu AF28996 in Participants With Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;Lu AF28996&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04291859&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.97617, &quot;lng&quot;: -82.09064, &quot;nct&quot;: &quot;NCT04291859&quot;, &quot;color&quot;: &quot;#0d7201&quot;, &quot;title&quot;: &quot;Lu AF28996 in Participants With Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;Lu AF28996&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04291859&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.749, &quot;lng&quot;: -84.38798, &quot;nct&quot;: &quot;NCT04291859&quot;, &quot;color&quot;: &quot;#0d7201&quot;, &quot;title&quot;: &quot;Lu AF28996 in Participants With Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;Lu AF28996&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04291859&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 21.30694, &quot;lng&quot;: -157.85833, &quot;nct&quot;: &quot;NCT04291859&quot;, &quot;color&quot;: &quot;#0d7201&quot;, &quot;title&quot;: &quot;Lu AF28996 in Participants With Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;Lu AF28996&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04291859&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.48531, &quot;lng&quot;: -83.37716, &quot;nct&quot;: &quot;NCT04291859&quot;, &quot;color&quot;: &quot;#0d7201&quot;, &quot;title&quot;: &quot;Lu AF28996 in Participants With Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;Lu AF28996&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04291859&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.25626, &quot;lng&quot;: -95.94043, &quot;nct&quot;: &quot;NCT04291859&quot;, &quot;color&quot;: &quot;#0d7201&quot;, &quot;title&quot;: &quot;Lu AF28996 in Participants With Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;Lu AF28996&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04291859&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.65966, &quot;lng&quot;: -117.42908, &quot;nct&quot;: &quot;NCT04291859&quot;, &quot;color&quot;: &quot;#0d7201&quot;, &quot;title&quot;: &quot;Lu AF28996 in Participants With Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;Lu AF28996&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04291859&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 49.18585, &quot;lng&quot;: -0.35912, &quot;nct&quot;: &quot;NCT04291859&quot;, &quot;color&quot;: &quot;#0d7201&quot;, &quot;title&quot;: &quot;Lu AF28996 in Participants With Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;Lu AF28996&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04291859&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 53.55073, &quot;lng&quot;: 9.99302, &quot;nct&quot;: &quot;NCT04291859&quot;, &quot;color&quot;: &quot;#0d7201&quot;, &quot;title&quot;: &quot;Lu AF28996 in Participants With Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;Lu AF28996&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04291859&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 53.20271, &quot;lng&quot;: 5.80973, &quot;nct&quot;: &quot;NCT04291859&quot;, &quot;color&quot;: &quot;#0d7201&quot;, &quot;title&quot;: &quot;Lu AF28996 in Participants With Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;Lu AF28996&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04291859&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.38879, &quot;lng&quot;: 2.15899, &quot;nct&quot;: &quot;NCT04291859&quot;, &quot;color&quot;: &quot;#0d7201&quot;, &quot;title&quot;: &quot;Lu AF28996 in Participants With Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;Lu AF28996&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04291859&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.38283, &quot;lng&quot;: -5.97317, &quot;nct&quot;: &quot;NCT04291859&quot;, &quot;color&quot;: &quot;#0d7201&quot;, &quot;title&quot;: &quot;Lu AF28996 in Participants With Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;Lu AF28996&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04291859&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.9075, &quot;lng&quot;: 116.39723, &quot;nct&quot;: &quot;NCT07022522&quot;, &quot;color&quot;: &quot;#0b01c2&quot;, &quot;title&quot;: &quot;Impact of Frequency-specific Subthalamic Nucleus Subregion Stimulation on Inhibitory Control in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;5Hz stimulation on the STN motor subregion; 5Hz stimulation on the STN associative subregion; 130Hz stimulation on the STN motor subregion; 130Hz stimulation on the STN associative subregion; No stimulation&quot;, &quot;sponsor&quot;: &quot;Beijing Tiantan Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07022522&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.42411, &quot;lng&quot;: -122.16608, &quot;nct&quot;: &quot;NCT05558189&quot;, &quot;color&quot;: &quot;#062cb1&quot;, &quot;title&quot;: &quot;Vibrotactile Coordinated Reset for the Treatment of Post Surgery Refractory Parkinson&#x27;s Disease Patients&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Vibrotactile Coordinated Reset (vCR)&quot;, &quot;sponsor&quot;: &quot;Stanford University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05558189&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 22.27832, &quot;lng&quot;: 114.17469, &quot;nct&quot;: &quot;NCT06078046&quot;, &quot;color&quot;: &quot;#ef3e2c&quot;, &quot;title&quot;: &quot;MOVIN&#x27; CARE for PD (Mind-body Interventions)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Mind-body interventions&quot;, &quot;sponsor&quot;: &quot;The University of Hong Kong&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06078046&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 25.77427, &quot;lng&quot;: -80.19366, &quot;nct&quot;: &quot;NCT05773612&quot;, &quot;color&quot;: &quot;#f672b6&quot;, &quot;title&quot;: &quot;Rock Steady Boxing: A Community Based In Person Class&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Rock Steady Boxing Class&quot;, &quot;sponsor&quot;: &quot;University of St. Augustine for Health Sciences&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05773612&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.749, &quot;lng&quot;: -84.38798, &quot;nct&quot;: &quot;NCT06234995&quot;, &quot;color&quot;: &quot;#928f5c&quot;, &quot;title&quot;: &quot;Cortical Electrophysiology of Response Inhibition in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Levodopa; Clinical DBS Setting; Sham DBS; DBS Setting Maximizing Prefrontal Activation; DBS Setting Minimizing Prefrontal Activation&quot;, &quot;sponsor&quot;: &quot;Emory University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06234995&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 25.05306, &quot;lng&quot;: 121.52639, &quot;nct&quot;: &quot;NCT06588439&quot;, &quot;color&quot;: &quot;#c786db&quot;, &quot;title&quot;: &quot;Cognitive-motor Training in Parkinson Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Cognitive-motor training; Conventional physiotherapy&quot;, &quot;sponsor&quot;: &quot;National Yang Ming Chiao Tung University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06588439&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 31.22222, &quot;lng&quot;: 121.45806, &quot;nct&quot;: &quot;NCT07085195&quot;, &quot;color&quot;: &quot;#0e138a&quot;, &quot;title&quot;: &quot;A Clinical Study of the Safety and Efficacy of Chemogenetics Therapy in the Treatment of Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;EARLY_PHASE1&quot;], &quot;interventions&quot;: &quot;gene therapy; clozapine&quot;, &quot;sponsor&quot;: &quot;Ruijin Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07085195&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 49.83465, &quot;lng&quot;: 18.28204, &quot;nct&quot;: &quot;NCT06570421&quot;, &quot;color&quot;: &quot;#5de6ea&quot;, &quot;title&quot;: &quot;24-months Study to Evaluate Safety and Efficacy of Peroneal Transcutaneous NeuroModulation in Subjects With Parkinson&#x27;s Disease and Essential Tremor&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Peroneal electrical transcutaneous neuromodulation (peroneal eTNM\\u00ae)&quot;, &quot;sponsor&quot;: &quot;Stimvia s.r.o.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06570421&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.52066, &quot;lng&quot;: -86.80249, &quot;nct&quot;: &quot;NCT06169852&quot;, &quot;color&quot;: &quot;#1b7eea&quot;, &quot;title&quot;: &quot;Stimulus-Evoked Directional Field Potentials to Guide Subthalamic and Pallidal DBS for PD&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Unilateral dual-target (STN/GPi) DBS&quot;, &quot;sponsor&quot;: &quot;University of Alabama at Birmingham&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06169852&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.95238, &quot;lng&quot;: -75.16362, &quot;nct&quot;: &quot;NCT04062526&quot;, &quot;color&quot;: &quot;#eb332c&quot;, &quot;title&quot;: &quot;Evaluation of Neuroinflammation in Parkinson&#x27;s Disease Using 18F-NOS PET/CT&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;EARLY_PHASE1&quot;], &quot;interventions&quot;: &quot;[18F]NOS&quot;, &quot;sponsor&quot;: &quot;University of Pennsylvania&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04062526&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.4995, &quot;lng&quot;: -81.69541, &quot;nct&quot;: &quot;NCT05022147&quot;, &quot;color&quot;: &quot;#6a9a3d&quot;, &quot;title&quot;: &quot;Enhancing Gait Using Alternating-Frequency DBS in Parkinson Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;High-Frequency-Only Stimulation; Low-Frequency-Only Stimulation; Alternating, 50 sec High-Frequency, 10 sec Low-Frequency Stimulation; Alternating, 50 sec High-Frequency, 50 sec Low-Frequency Stimulation; Alternating, 10 sec High-Frequency, 50 sec Low-Frequency Stimulation; Alternating, 10 sec High-Frequency, 10 sec Low-Frequency Stimulation; OFF Dopaminergic Medication; ON Dopaminergic Medication&quot;, &quot;sponsor&quot;: &quot;James Liao&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05022147&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.25626, &quot;lng&quot;: -95.94043, &quot;nct&quot;: &quot;NCT04620551&quot;, &quot;color&quot;: &quot;#16cd34&quot;, &quot;title&quot;: &quot;Adaptive Neurostimulation to Restore Sleep in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Sub-clinical stimulation&quot;, &quot;sponsor&quot;: &quot;University of Nebraska&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04620551&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 55.70584, &quot;lng&quot;: 13.19321, &quot;nct&quot;: &quot;NCT05635409&quot;, &quot;color&quot;: &quot;#ddcaf1&quot;, &quot;title&quot;: &quot;A Trial to Determine the Safety and Tolerability of Transplanted Stem Cell Derived Dopamine Neurons to the Brains of Individuals With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;STEM-PD&quot;, &quot;sponsor&quot;: &quot;Region Skane&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05635409&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.2, &quot;lng&quot;: 0.11667, &quot;nct&quot;: &quot;NCT05635409&quot;, &quot;color&quot;: &quot;#ddcaf1&quot;, &quot;title&quot;: &quot;A Trial to Determine the Safety and Tolerability of Transplanted Stem Cell Derived Dopamine Neurons to the Brains of Individuals With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;STEM-PD&quot;, &quot;sponsor&quot;: &quot;Region Skane&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05635409&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 34.25833, &quot;lng&quot;: 108.92861, &quot;nct&quot;: &quot;NCT06390761&quot;, &quot;color&quot;: &quot;#4f73a7&quot;, &quot;title&quot;: &quot;Efficacy of Acupuncture for the Treatment of Parkinson&#x27;s Disease Related Constipation&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Acupuncture&quot;, &quot;sponsor&quot;: &quot;Xi&#x27;an No.3 Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06390761&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.155, &quot;lng&quot;: 5.3875, &quot;nct&quot;: &quot;NCT05164783&quot;, &quot;color&quot;: &quot;#c0c5ab&quot;, &quot;title&quot;: &quot;Multicenter Implementation of E-monitoring in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Sanacoach Parkinson (SCP)&quot;, &quot;sponsor&quot;: &quot;Zuyderland Medisch Centrum&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05164783&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.37403, &quot;lng&quot;: 4.88969, &quot;nct&quot;: &quot;NCT05164783&quot;, &quot;color&quot;: &quot;#c0c5ab&quot;, &quot;title&quot;: &quot;Multicenter Implementation of E-monitoring in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Sanacoach Parkinson (SCP)&quot;, &quot;sponsor&quot;: &quot;Zuyderland Medisch Centrum&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05164783&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.48333, &quot;lng&quot;: 4.65694, &quot;nct&quot;: &quot;NCT05164783&quot;, &quot;color&quot;: &quot;#c0c5ab&quot;, &quot;title&quot;: &quot;Multicenter Implementation of E-monitoring in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Sanacoach Parkinson (SCP)&quot;, &quot;sponsor&quot;: &quot;Zuyderland Medisch Centrum&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05164783&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.97417, &quot;lng&quot;: 5.82917, &quot;nct&quot;: &quot;NCT05164783&quot;, &quot;color&quot;: &quot;#c0c5ab&quot;, &quot;title&quot;: &quot;Multicenter Implementation of E-monitoring in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Sanacoach Parkinson (SCP)&quot;, &quot;sponsor&quot;: &quot;Zuyderland Medisch Centrum&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05164783&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.88365, &quot;lng&quot;: 5.98154, &quot;nct&quot;: &quot;NCT05164783&quot;, &quot;color&quot;: &quot;#c0c5ab&quot;, &quot;title&quot;: &quot;Multicenter Implementation of E-monitoring in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Sanacoach Parkinson (SCP)&quot;, &quot;sponsor&quot;: &quot;Zuyderland Medisch Centrum&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05164783&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.48167, &quot;lng&quot;: 5.66111, &quot;nct&quot;: &quot;NCT05164783&quot;, &quot;color&quot;: &quot;#c0c5ab&quot;, &quot;title&quot;: &quot;Multicenter Implementation of E-monitoring in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Sanacoach Parkinson (SCP)&quot;, &quot;sponsor&quot;: &quot;Zuyderland Medisch Centrum&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05164783&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.27756, &quot;lng&quot;: -83.74088, &quot;nct&quot;: &quot;NCT04497168&quot;, &quot;color&quot;: &quot;#1760d3&quot;, &quot;title&quot;: &quot;Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Citalopram 20mg; Placebo&quot;, &quot;sponsor&quot;: &quot;University of Michigan&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04497168&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 44.64269, &quot;lng&quot;: -63.57688, &quot;nct&quot;: &quot;NCT06572150&quot;, &quot;color&quot;: &quot;#5e9687&quot;, &quot;title&quot;: &quot;Minimal Electrophysiology and Imaging Enhanced Deep Brain Stimulation&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Deep Brain Stimulation - Minimal Electrophysiology; Deep Brain Stimulation - Standard&quot;, &quot;sponsor&quot;: &quot;Nova Scotia Health Authority&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06572150&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 38.02931, &quot;lng&quot;: -78.47668, &quot;nct&quot;: &quot;NCT06903910&quot;, &quot;color&quot;: &quot;#0aa436&quot;, &quot;title&quot;: &quot;Investigating the Cholinergic Contribution to Gait Dysfunction in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Donepezil (Aricept)&quot;, &quot;sponsor&quot;: &quot;University of Virginia&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06903910&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.9075, &quot;lng&quot;: 116.39723, &quot;nct&quot;: &quot;NCT06710574&quot;, &quot;color&quot;: &quot;#7ddcc7&quot;, &quot;title&quot;: &quot;Multimodal Image Technologies Investigate the Role and Mechanism of Probiotics in Improving RBD with Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;PD-RBD; iRBD&quot;, &quot;sponsor&quot;: &quot;Beijing Friendship Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06710574&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 30.43826, &quot;lng&quot;: -84.28073, &quot;nct&quot;: &quot;NCT06593860&quot;, &quot;color&quot;: &quot;#a1a3ab&quot;, &quot;title&quot;: &quot;Dysarthria Management for Minor Groups&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Remote speech rehabilitation&quot;, &quot;sponsor&quot;: &quot;Florida State University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06593860&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.4668, &quot;lng&quot;: -80.51639, &quot;nct&quot;: &quot;NCT05971459&quot;, &quot;color&quot;: &quot;#036eac&quot;, &quot;title&quot;: &quot;A Study of the Efficacy of IAMT as an Assessment Tool for Prediction of Progression of Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Improvised Active Music Therapy&quot;, &quot;sponsor&quot;: &quot;Wilfrid Laurier University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05971459&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 30.29365, &quot;lng&quot;: 120.16142, &quot;nct&quot;: &quot;NCT06356662&quot;, &quot;color&quot;: &quot;#20afa1&quot;, &quot;title&quot;: &quot;Tenofovir Disoproxil Fumarate in the Treatment of Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;Tenofovir Disoproxil Fumarate&quot;, &quot;sponsor&quot;: &quot;The Fourth Affiliated Hospital of Zhejiang University School of Medicine&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06356662&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 32.71571, &quot;lng&quot;: -117.16472, &quot;nct&quot;: &quot;NCT04735627&quot;, &quot;color&quot;: &quot;#baaf5c&quot;, &quot;title&quot;: &quot;Real-Time Levodopa Level Monitoring in Parkinson Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Levodopameter&quot;, &quot;sponsor&quot;: &quot;University of California, San Diego&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04735627&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 44.97997, &quot;lng&quot;: -93.26384, &quot;nct&quot;: &quot;NCT06998303&quot;, &quot;color&quot;: &quot;#ff5ee4&quot;, &quot;title&quot;: &quot;Imaging Core Aim 2, and Udall Project 2 Aim 2&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Bipolar DBS stimulation&quot;, &quot;sponsor&quot;: &quot;University of Minnesota&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06998303&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 38.62727, &quot;lng&quot;: -90.19789, &quot;nct&quot;: &quot;NCT06115382&quot;, &quot;color&quot;: &quot;#c737e9&quot;, &quot;title&quot;: &quot;Sing For Your Saunter Part 2 R33&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Self Cueing Training; External Cueing Training&quot;, &quot;sponsor&quot;: &quot;Washington University School of Medicine&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06115382&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.48531, &quot;lng&quot;: -83.37716, &quot;nct&quot;: &quot;NCT03683225&quot;, &quot;color&quot;: &quot;#6b690a&quot;, &quot;title&quot;: &quot;A Study to Evaluate in Patients With Parkinsonian Type Disorders&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;CTC-413&quot;, &quot;sponsor&quot;: &quot;Chase Therapeutics Corporation&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03683225&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.70643, &quot;lng&quot;: -79.39864, &quot;nct&quot;: &quot;NCT06090292&quot;, &quot;color&quot;: &quot;#5b763e&quot;, &quot;title&quot;: &quot;Effects of Peripheral Electrical Stimulation With Focused Ultrasound on Motor Symptoms in Parkinson&#x27;s Patients&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Real TUS; Real FES; Sham TUS; Sham FES&quot;, &quot;sponsor&quot;: &quot;University Health Network, Toronto&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06090292&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 55.6666, &quot;lng&quot;: 12.40377, &quot;nct&quot;: &quot;NCT06284629&quot;, &quot;color&quot;: &quot;#92134d&quot;, &quot;title&quot;: &quot;Enhancing Referral Decision-making for Advanced Treatment in Parkinson&#x27;s Disease Through Objective Measurements and Patient Reported Outcomes.&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Neptune; Standard clinical care&quot;, &quot;sponsor&quot;: &quot;Rigshospitalet, Denmark&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06284629&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 55.39594, &quot;lng&quot;: 10.38831, &quot;nct&quot;: &quot;NCT06284629&quot;, &quot;color&quot;: &quot;#92134d&quot;, &quot;title&quot;: &quot;Enhancing Referral Decision-making for Advanced Treatment in Parkinson&#x27;s Disease Through Objective Measurements and Patient Reported Outcomes.&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Neptune; Standard clinical care&quot;, &quot;sponsor&quot;: &quot;Rigshospitalet, Denmark&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06284629&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 49.24966, &quot;lng&quot;: -123.11934, &quot;nct&quot;: &quot;NCT04426786&quot;, &quot;color&quot;: &quot;#dc1b64&quot;, &quot;title&quot;: &quot;Exercise &amp; Brain Energetics in PD&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Active exercise; Passive exercise&quot;, &quot;sponsor&quot;: &quot;Pacific Parkinson&#x27;s Research Centre&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04426786&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 31.22222, &quot;lng&quot;: 121.45806, &quot;nct&quot;: &quot;NCT06388551&quot;, &quot;color&quot;: &quot;#d0c6a5&quot;, &quot;title&quot;: &quot;A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;LY03017; LY03017-Placebo&quot;, &quot;sponsor&quot;: &quot;Luye Pharma Group Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06388551&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 31.86389, &quot;lng&quot;: 117.28083, &quot;nct&quot;: &quot;NCT06607653&quot;, &quot;color&quot;: &quot;#52c269&quot;, &quot;title&quot;: &quot;The Efficacy of Olfactory Training Intervention on Olfactory and Other Non-motor Symptoms in PD&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Olfactory training&quot;, &quot;sponsor&quot;: &quot;Anhui Medical University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06607653&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.36667, &quot;lng&quot;: 8.55, &quot;nct&quot;: &quot;NCT06608875&quot;, &quot;color&quot;: &quot;#7681e5&quot;, &quot;title&quot;: &quot;Precision Sensorimotor Neurorehabilitation Through Personalized Stimulation Loops&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Hyper-personalized feedback (HPF intervention); Targeted auditory stimulation during sleep (TASS verum intervention); Control targeted auditory stimulation during sleep (TASS sham intervention)&quot;, &quot;sponsor&quot;: &quot;University of Zurich&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06608875&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 31.22222, &quot;lng&quot;: 121.45806, &quot;nct&quot;: &quot;NCT06980207&quot;, &quot;color&quot;: &quot;#bd54d2&quot;, &quot;title&quot;: &quot;A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;LY03017; LY03017-Placebo&quot;, &quot;sponsor&quot;: &quot;Luye Pharma Group Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06980207&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.15367, &quot;lng&quot;: -81.35789, &quot;nct&quot;: &quot;NCT05361200&quot;, &quot;color&quot;: &quot;#e3ad0d&quot;, &quot;title&quot;: &quot;Speed Manipulated Adaptive Rehabilitation Therapy Bike for Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Dynamic high-cadence cycling&quot;, &quot;sponsor&quot;: &quot;Kent State University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05361200&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.52066, &quot;lng&quot;: -86.80249, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.50921, &quot;lng&quot;: -111.89903, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.59754, &quot;lng&quot;: -112.27182, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 34.74648, &quot;lng&quot;: -92.28959, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 32.84727, &quot;lng&quot;: -117.2742, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 34.05223, &quot;lng&quot;: -118.24368, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.78779, &quot;lng&quot;: -117.85311, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.44188, &quot;lng&quot;: -122.14302, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 34.09751, &quot;lng&quot;: -117.64839, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.72943, &quot;lng&quot;: -104.83192, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.64777, &quot;lng&quot;: -104.98776, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.71982, &quot;lng&quot;: -72.83204, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.30815, &quot;lng&quot;: -72.92816, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.39093, &quot;lng&quot;: -72.85954, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.05343, &quot;lng&quot;: -73.53873, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.5909, &quot;lng&quot;: -80.10088, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.35869, &quot;lng&quot;: -80.0831, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.65163, &quot;lng&quot;: -82.32483, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 30.33218, &quot;lng&quot;: -81.65565, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 28.62778, &quot;lng&quot;: -81.36312, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 25.77427, &quot;lng&quot;: -80.19366, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 27.94752, &quot;lng&quot;: -82.45843, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.10037, &quot;lng&quot;: -80.39977, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.11417, &quot;lng&quot;: -94.62746, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.29038, &quot;lng&quot;: -76.61219, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.35843, &quot;lng&quot;: -71.05977, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.50482, &quot;lng&quot;: -71.19561, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.06538, &quot;lng&quot;: -71.24783, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.27756, &quot;lng&quot;: -83.74088, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.48531, &quot;lng&quot;: -83.37716, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.00969, &quot;lng&quot;: -93.34912, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 44.97997, &quot;lng&quot;: -93.26384, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 44.94441, &quot;lng&quot;: -93.09327, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 38.66311, &quot;lng&quot;: -90.57707, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.17497, &quot;lng&quot;: -115.13722, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.64229, &quot;lng&quot;: -72.25176, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.30428, &quot;lng&quot;: -73.99236, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.48622, &quot;lng&quot;: -74.45182, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 35.08449, &quot;lng&quot;: -106.65114, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.65258, &quot;lng&quot;: -73.75623, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.84288, &quot;lng&quot;: -73.29289, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.71427, &quot;lng&quot;: -74.00597, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.15478, &quot;lng&quot;: -77.61556, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.79895, &quot;lng&quot;: -81.37845, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.4995, &quot;lng&quot;: -81.69541, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.15398, &quot;lng&quot;: -95.99277, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.52345, &quot;lng&quot;: -122.67621, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.95238, &quot;lng&quot;: -75.16362, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 32.77632, &quot;lng&quot;: -79.93275, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 35.14953, &quot;lng&quot;: -90.04898, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.76328, &quot;lng&quot;: -95.36327, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 30.50826, &quot;lng&quot;: -97.6789, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.42412, &quot;lng&quot;: -98.49363, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.76078, &quot;lng&quot;: -111.89105, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 44.47588, &quot;lng&quot;: -73.21207, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 38.02931, &quot;lng&quot;: -78.47668, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.59264, &quot;lng&quot;: -78.61611, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.98038, &quot;lng&quot;: -76.42975, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.61038, &quot;lng&quot;: -122.20068, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.60621, &quot;lng&quot;: -122.33207, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.65966, &quot;lng&quot;: -117.42908, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.0389, &quot;lng&quot;: -87.90647, &quot;nct&quot;: &quot;NCT06976268&quot;, &quot;color&quot;: &quot;#dcd030&quot;, &quot;title&quot;: &quot;A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;BHV-8000; Placebo&quot;, &quot;sponsor&quot;: &quot;Biohaven Therapeutics Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06976268&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.4995, &quot;lng&quot;: -81.69541, &quot;nct&quot;: &quot;NCT05972759&quot;, &quot;color&quot;: &quot;#f5fc01&quot;, &quot;title&quot;: &quot;Identifying the Neural Signature of Exercise to Advance Treatment of PD Cognitive Declines&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Forced and voluntary exercise&quot;, &quot;sponsor&quot;: &quot;The Cleveland Clinic&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05972759&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.71427, &quot;lng&quot;: -74.00597, &quot;nct&quot;: &quot;NCT04922190&quot;, &quot;color&quot;: &quot;#30accd&quot;, &quot;title&quot;: &quot;Promoting Physical Activity Engagement for People With Early-mid Stage Parkinson&#x27;s Disease (Engage-PD)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;Physical Activity Coaching&quot;, &quot;sponsor&quot;: &quot;Teachers College, Columbia University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04922190&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.27756, &quot;lng&quot;: -83.74088, &quot;nct&quot;: &quot;NCT05446194&quot;, &quot;color&quot;: &quot;#b45169&quot;, &quot;title&quot;: &quot;Vestibulopathy, Imbalance, and Gait Disturbances in Parkinson Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Non invasive neuromodulation device pattern 1; Non invasive neuromodulation device pattern 2&quot;, &quot;sponsor&quot;: &quot;University of Michigan&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05446194&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.35843, &quot;lng&quot;: -71.05977, &quot;nct&quot;: &quot;NCT06425731&quot;, &quot;color&quot;: &quot;#70521b&quot;, &quot;title&quot;: &quot;Dance and Energy Expenditure Among Adults With Parkinson&#x27;s&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Fasting; No Intervention&quot;, &quot;sponsor&quot;: &quot;Northeastern University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06425731&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 1.28967, &quot;lng&quot;: 103.85007, &quot;nct&quot;: &quot;NCT04491383&quot;, &quot;color&quot;: &quot;#99a32a&quot;, &quot;title&quot;: &quot;Tocotrienols in Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Tocovid Suprabio (HOV-12020); Placebo&quot;, &quot;sponsor&quot;: &quot;National Neuroscience Institute&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04491383&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.52345, &quot;lng&quot;: -122.67621, &quot;nct&quot;: &quot;NCT05680597&quot;, &quot;color&quot;: &quot;#835ca7&quot;, &quot;title&quot;: &quot;Balance Tele-Rehab in Parkinson&#x27;s Disease Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Balance Tele-Rehabilitation Agility Boot Camp (ABC)&quot;, &quot;sponsor&quot;: &quot;Oregon Health and Science University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05680597&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.09115, &quot;lng&quot;: 14.26352, &quot;nct&quot;: &quot;NCT06690931&quot;, &quot;color&quot;: &quot;#0b1b22&quot;, &quot;title&quot;: &quot;Neurofeedback Rehabilitation With FES and VR for PD&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Brain-Computer Interface with FES and VR; Motor imagery with Functional Electrical Stimulation and Virtual Reality feedback&quot;, &quot;sponsor&quot;: &quot;g.tec medical engineering GmbH&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06690931&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.04114, &quot;lng&quot;: -87.69006, &quot;nct&quot;: &quot;NCT04664634&quot;, &quot;color&quot;: &quot;#027512&quot;, &quot;title&quot;: &quot;A Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson&#x27;s&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Aria Sensor&quot;, &quot;sponsor&quot;: &quot;Northwestern University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04664634&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 30.00944, &quot;lng&quot;: 31.20861, &quot;nct&quot;: &quot;NCT05198076&quot;, &quot;color&quot;: &quot;#cbdbd9&quot;, &quot;title&quot;: &quot;6 Month Follow up Study on the Changes of Postural Stability in Parkinsonian Patients in Response to High Frequency TMS.&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;High Frequency Repetitive Transcranial Magnetic Stimulation&quot;, &quot;sponsor&quot;: &quot;Cairo University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05198076&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.42411, &quot;lng&quot;: -122.16608, &quot;nct&quot;: &quot;NCT05545826&quot;, &quot;color&quot;: &quot;#44932e&quot;, &quot;title&quot;: &quot;Vibrotactile Coordinated Reset (VCR): A Treatment for Early Stage Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Vibrotactile coordinated reset&quot;, &quot;sponsor&quot;: &quot;Stanford University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05545826&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.37787, &quot;lng&quot;: -71.062, &quot;nct&quot;: &quot;NCT03981055&quot;, &quot;color&quot;: &quot;#810d7c&quot;, &quot;title&quot;: &quot;Parkinson&#x27;s Disease: Enhancing Physical Therapy With Brain Stimulation for Treating Postural Instability.&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Active Comparator: Active tDCS and Active TUS; Sham Comparator: Sham TDCS and Sham TUS; Physical Therapy&quot;, &quot;sponsor&quot;: &quot;Spaulding Rehabilitation Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03981055&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.61093, &quot;lng&quot;: 3.87635, &quot;nct&quot;: &quot;NCT07083089&quot;, &quot;color&quot;: &quot;#deeb27&quot;, &quot;title&quot;: &quot;Early Stage of Alzheimer&#x27;s and Parkinson&#x27;s Diseases, HearIng Relevance (SAPHIR)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Thorough Hearing assessment&quot;, &quot;sponsor&quot;: &quot;Cilcare SAS&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07083089&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.70313, &quot;lng&quot;: 7.26608, &quot;nct&quot;: &quot;NCT07083089&quot;, &quot;color&quot;: &quot;#deeb27&quot;, &quot;title&quot;: &quot;Early Stage of Alzheimer&#x27;s and Parkinson&#x27;s Diseases, HearIng Relevance (SAPHIR)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Thorough Hearing assessment&quot;, &quot;sponsor&quot;: &quot;Cilcare SAS&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07083089&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.83665, &quot;lng&quot;: 4.35788, &quot;nct&quot;: &quot;NCT07083089&quot;, &quot;color&quot;: &quot;#deeb27&quot;, &quot;title&quot;: &quot;Early Stage of Alzheimer&#x27;s and Parkinson&#x27;s Diseases, HearIng Relevance (SAPHIR)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Thorough Hearing assessment&quot;, &quot;sponsor&quot;: &quot;Cilcare SAS&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07083089&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.76601, &quot;lng&quot;: 4.8795, &quot;nct&quot;: &quot;NCT07083089&quot;, &quot;color&quot;: &quot;#deeb27&quot;, &quot;title&quot;: &quot;Early Stage of Alzheimer&#x27;s and Parkinson&#x27;s Diseases, HearIng Relevance (SAPHIR)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Thorough Hearing assessment&quot;, &quot;sponsor&quot;: &quot;Cilcare SAS&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07083089&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 49.19522, &quot;lng&quot;: 16.60796, &quot;nct&quot;: &quot;NCT06416553&quot;, &quot;color&quot;: &quot;#1f2240&quot;, &quot;title&quot;: &quot;Effect of Speech Therapy in Combination With Non-invasive Brain Stimulation on Speech of Patients With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Home-based transcranial direct current stimulation- real tDCS; Home-based transcranial direct current stimulation- sham tDCS; Lee-Silverman voice treatment&quot;, &quot;sponsor&quot;: &quot;Masaryk University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06416553&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.52266, &quot;lng&quot;: 9.05222, &quot;nct&quot;: &quot;NCT07151378&quot;, &quot;color&quot;: &quot;#5a416d&quot;, &quot;title&quot;: &quot;Intestinal Levodopa + Entacapone Therapy (Lecigon\\u00ae) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;LECIG (levodopa, carbidopa, entacapone intestinal gel); Best oral medication&quot;, &quot;sponsor&quot;: &quot;University Hospital Tuebingen&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07151378&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.35869, &quot;lng&quot;: -80.0831, &quot;nct&quot;: &quot;NCT03944447&quot;, &quot;color&quot;: &quot;#92f4f2&quot;, &quot;title&quot;: &quot;Outcomes Mandate National Integration With Cannabis as Medicine&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Cannabis, Medical; RYAH-Medtech Inhaler&quot;, &quot;sponsor&quot;: &quot;OMNI Medical Services, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03944447&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 27.49893, &quot;lng&quot;: -82.57482, &quot;nct&quot;: &quot;NCT03944447&quot;, &quot;color&quot;: &quot;#92f4f2&quot;, &quot;title&quot;: &quot;Outcomes Mandate National Integration With Cannabis as Medicine&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Cannabis, Medical; RYAH-Medtech Inhaler&quot;, &quot;sponsor&quot;: &quot;OMNI Medical Services, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03944447&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.12231, &quot;lng&quot;: -80.14338, &quot;nct&quot;: &quot;NCT03944447&quot;, &quot;color&quot;: &quot;#92f4f2&quot;, &quot;title&quot;: &quot;Outcomes Mandate National Integration With Cannabis as Medicine&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Cannabis, Medical; RYAH-Medtech Inhaler&quot;, &quot;sponsor&quot;: &quot;OMNI Medical Services, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03944447&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.62168, &quot;lng&quot;: -81.84059, &quot;nct&quot;: &quot;NCT03944447&quot;, &quot;color&quot;: &quot;#92f4f2&quot;, &quot;title&quot;: &quot;Outcomes Mandate National Integration With Cannabis as Medicine&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Cannabis, Medical; RYAH-Medtech Inhaler&quot;, &quot;sponsor&quot;: &quot;OMNI Medical Services, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03944447&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.65163, &quot;lng&quot;: -82.32483, &quot;nct&quot;: &quot;NCT03944447&quot;, &quot;color&quot;: &quot;#92f4f2&quot;, &quot;title&quot;: &quot;Outcomes Mandate National Integration With Cannabis as Medicine&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Cannabis, Medical; RYAH-Medtech Inhaler&quot;, &quot;sponsor&quot;: &quot;OMNI Medical Services, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03944447&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 28.359, &quot;lng&quot;: -80.69, &quot;nct&quot;: &quot;NCT03944447&quot;, &quot;color&quot;: &quot;#92f4f2&quot;, &quot;title&quot;: &quot;Outcomes Mandate National Integration With Cannabis as Medicine&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Cannabis, Medical; RYAH-Medtech Inhaler&quot;, &quot;sponsor&quot;: &quot;OMNI Medical Services, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03944447&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 25.77427, &quot;lng&quot;: -80.19366, &quot;nct&quot;: &quot;NCT03944447&quot;, &quot;color&quot;: &quot;#92f4f2&quot;, &quot;title&quot;: &quot;Outcomes Mandate National Integration With Cannabis as Medicine&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Cannabis, Medical; RYAH-Medtech Inhaler&quot;, &quot;sponsor&quot;: &quot;OMNI Medical Services, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03944447&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 28.56917, &quot;lng&quot;: -81.54396, &quot;nct&quot;: &quot;NCT03944447&quot;, &quot;color&quot;: &quot;#92f4f2&quot;, &quot;title&quot;: &quot;Outcomes Mandate National Integration With Cannabis as Medicine&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Cannabis, Medical; RYAH-Medtech Inhaler&quot;, &quot;sponsor&quot;: &quot;OMNI Medical Services, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03944447&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 30.42131, &quot;lng&quot;: -87.21691, &quot;nct&quot;: &quot;NCT03944447&quot;, &quot;color&quot;: &quot;#92f4f2&quot;, &quot;title&quot;: &quot;Outcomes Mandate National Integration With Cannabis as Medicine&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Cannabis, Medical; RYAH-Medtech Inhaler&quot;, &quot;sponsor&quot;: &quot;OMNI Medical Services, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03944447&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.23786, &quot;lng&quot;: -80.12477, &quot;nct&quot;: &quot;NCT03944447&quot;, &quot;color&quot;: &quot;#92f4f2&quot;, &quot;title&quot;: &quot;Outcomes Mandate National Integration With Cannabis as Medicine&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Cannabis, Medical; RYAH-Medtech Inhaler&quot;, &quot;sponsor&quot;: &quot;OMNI Medical Services, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03944447&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 27.94752, &quot;lng&quot;: -82.45843, &quot;nct&quot;: &quot;NCT03944447&quot;, &quot;color&quot;: &quot;#92f4f2&quot;, &quot;title&quot;: &quot;Outcomes Mandate National Integration With Cannabis as Medicine&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Cannabis, Medical; RYAH-Medtech Inhaler&quot;, &quot;sponsor&quot;: &quot;OMNI Medical Services, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03944447&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 28.23973, &quot;lng&quot;: -82.32787, &quot;nct&quot;: &quot;NCT03944447&quot;, &quot;color&quot;: &quot;#92f4f2&quot;, &quot;title&quot;: &quot;Outcomes Mandate National Integration With Cannabis as Medicine&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Cannabis, Medical; RYAH-Medtech Inhaler&quot;, &quot;sponsor&quot;: &quot;OMNI Medical Services, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03944447&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.20839, &quot;lng&quot;: -84.39911, &quot;nct&quot;: &quot;NCT03944447&quot;, &quot;color&quot;: &quot;#92f4f2&quot;, &quot;title&quot;: &quot;Outcomes Mandate National Integration With Cannabis as Medicine&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Cannabis, Medical; RYAH-Medtech Inhaler&quot;, &quot;sponsor&quot;: &quot;OMNI Medical Services, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03944447&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.37477, &quot;lng&quot;: -83.65132, &quot;nct&quot;: &quot;NCT03944447&quot;, &quot;color&quot;: &quot;#92f4f2&quot;, &quot;title&quot;: &quot;Outcomes Mandate National Integration With Cannabis as Medicine&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Cannabis, Medical; RYAH-Medtech Inhaler&quot;, &quot;sponsor&quot;: &quot;OMNI Medical Services, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03944447&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.44894, &quot;lng&quot;: -82.70796, &quot;nct&quot;: &quot;NCT03944447&quot;, &quot;color&quot;: &quot;#92f4f2&quot;, &quot;title&quot;: &quot;Outcomes Mandate National Integration With Cannabis as Medicine&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Cannabis, Medical; RYAH-Medtech Inhaler&quot;, &quot;sponsor&quot;: &quot;OMNI Medical Services, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03944447&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.66394, &quot;lng&quot;: -83.55521, &quot;nct&quot;: &quot;NCT03944447&quot;, &quot;color&quot;: &quot;#92f4f2&quot;, &quot;title&quot;: &quot;Outcomes Mandate National Integration With Cannabis as Medicine&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Cannabis, Medical; RYAH-Medtech Inhaler&quot;, &quot;sponsor&quot;: &quot;OMNI Medical Services, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03944447&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.4995, &quot;lng&quot;: -81.69541, &quot;nct&quot;: &quot;NCT06442033&quot;, &quot;color&quot;: &quot;#9df4b4&quot;, &quot;title&quot;: &quot;Genetics and Aerobic Exercise to Slow Parkinson&#x27;s Disease Trial&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;High intensity stationary cycling&quot;, &quot;sponsor&quot;: &quot;Jay Alberts&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06442033&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.46427, &quot;lng&quot;: 9.18951, &quot;nct&quot;: &quot;NCT04607174&quot;, &quot;color&quot;: &quot;#8b5650&quot;, &quot;title&quot;: &quot;Voluntary Activation During Isokinetic Contractions in Subjects with Neuromotor Disorders&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Pathologic group&quot;, &quot;sponsor&quot;: &quot;Istituto Auxologico Italiano&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04607174&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.75115, &quot;lng&quot;: 11.32252, &quot;nct&quot;: &quot;NCT06907589&quot;, &quot;color&quot;: &quot;#fcb887&quot;, &quot;title&quot;: &quot;A Novel Accessible and Widespread Healthcare Service Model Based on Technology Innovation for Objective (Early) Diagnosis and Therapeutic Monitoring of Parkinson&#x27;s Disease Promoting Continuity of Care&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Motor Data Analysis&quot;, &quot;sponsor&quot;: &quot;Scuola Superiore di Studi Universitari e di Perfezionamento Sant&#x27;Anna&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06907589&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.77925, &quot;lng&quot;: 11.24626, &quot;nct&quot;: &quot;NCT06907589&quot;, &quot;color&quot;: &quot;#fcb887&quot;, &quot;title&quot;: &quot;A Novel Accessible and Widespread Healthcare Service Model Based on Technology Innovation for Objective (Early) Diagnosis and Therapeutic Monitoring of Parkinson&#x27;s Disease Promoting Continuity of Care&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Motor Data Analysis&quot;, &quot;sponsor&quot;: &quot;Scuola Superiore di Studi Universitari e di Perfezionamento Sant&#x27;Anna&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06907589&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 44.03541, &quot;lng&quot;: 10.13927, &quot;nct&quot;: &quot;NCT06907589&quot;, &quot;color&quot;: &quot;#fcb887&quot;, &quot;title&quot;: &quot;A Novel Accessible and Widespread Healthcare Service Model Based on Technology Innovation for Objective (Early) Diagnosis and Therapeutic Monitoring of Parkinson&#x27;s Disease Promoting Continuity of Care&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Motor Data Analysis&quot;, &quot;sponsor&quot;: &quot;Scuola Superiore di Studi Universitari e di Perfezionamento Sant&#x27;Anna&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06907589&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.78235, &quot;lng&quot;: 12.59836, &quot;nct&quot;: &quot;NCT06907589&quot;, &quot;color&quot;: &quot;#fcb887&quot;, &quot;title&quot;: &quot;A Novel Accessible and Widespread Healthcare Service Model Based on Technology Innovation for Objective (Early) Diagnosis and Therapeutic Monitoring of Parkinson&#x27;s Disease Promoting Continuity of Care&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Motor Data Analysis&quot;, &quot;sponsor&quot;: &quot;Scuola Superiore di Studi Universitari e di Perfezionamento Sant&#x27;Anna&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06907589&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.48581, &quot;lng&quot;: 13.82835, &quot;nct&quot;: &quot;NCT06906679&quot;, &quot;color&quot;: &quot;#ef5e94&quot;, &quot;title&quot;: &quot;Upper Limb Rehabilitation in People With Parkinson&#x27;s Disease:&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Experimental Group; control group&quot;, &quot;sponsor&quot;: &quot;IRCCS San Raffaele Roma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06906679&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.89193, &quot;lng&quot;: 12.51133, &quot;nct&quot;: &quot;NCT06906679&quot;, &quot;color&quot;: &quot;#ef5e94&quot;, &quot;title&quot;: &quot;Upper Limb Rehabilitation in People With Parkinson&#x27;s Disease:&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Experimental Group; control group&quot;, &quot;sponsor&quot;: &quot;IRCCS San Raffaele Roma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06906679&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 46.94809, &quot;lng&quot;: 7.44744, &quot;nct&quot;: &quot;NCT06629207&quot;, &quot;color&quot;: &quot;#aff225&quot;, &quot;title&quot;: &quot;Artificial Intelligence in Molecular Imaging: Predicting Parkinson&#x27;s Risk in REM Sleep Behavior Disorder&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;PET/CT with 18-FDG; SPECT : 123 I-FP-CIT (DATSCAN); MRI&quot;, &quot;sponsor&quot;: &quot;Insel Gruppe AG, University Hospital Bern&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06629207&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.08804, &quot;lng&quot;: 14.42076, &quot;nct&quot;: &quot;NCT05182892&quot;, &quot;color&quot;: &quot;#39bf26&quot;, &quot;title&quot;: &quot;REducing SPEECH-related Side-effects of Deep Brain Stimulation in Parkinson&#x27;s Disease Via Automated Speech Analysis&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Change of stimulation amplitudes in dopaminergic OFF drug state&quot;, &quot;sponsor&quot;: &quot;Insel Gruppe AG, University Hospital Bern&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05182892&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 46.94809, &quot;lng&quot;: 7.44744, &quot;nct&quot;: &quot;NCT05182892&quot;, &quot;color&quot;: &quot;#39bf26&quot;, &quot;title&quot;: &quot;REducing SPEECH-related Side-effects of Deep Brain Stimulation in Parkinson&#x27;s Disease Via Automated Speech Analysis&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Change of stimulation amplitudes in dopaminergic OFF drug state&quot;, &quot;sponsor&quot;: &quot;Insel Gruppe AG, University Hospital Bern&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05182892&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 49.24966, &quot;lng&quot;: -123.11934, &quot;nct&quot;: &quot;NCT05505019&quot;, &quot;color&quot;: &quot;#c98800&quot;, &quot;title&quot;: &quot;Targeting Apathy With Music in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Music listening; Podcast listening&quot;, &quot;sponsor&quot;: &quot;University of British Columbia&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05505019&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.61093, &quot;lng&quot;: 3.87635, &quot;nct&quot;: &quot;NCT05626608&quot;, &quot;color&quot;: &quot;#65d2a6&quot;, &quot;title&quot;: &quot;Continuous Electrical Neuromodulation of the Globus Pallidus Intern in Parkinson&#x27;s Disease by the Directional Electrode CARTESIA\\u2122&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Classical ring stimulation; Stimulation in directional mode&quot;, &quot;sponsor&quot;: &quot;University Hospital, Montpellier&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05626608&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.71427, &quot;lng&quot;: -74.00597, &quot;nct&quot;: &quot;NCT03526991&quot;, &quot;color&quot;: &quot;#4b835b&quot;, &quot;title&quot;: &quot;Exploring the Effects of Spinal Cord Stimulation in Parkinson&#x27;s Disease.&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Spinal Cord Stimulator (SCS)&quot;, &quot;sponsor&quot;: &quot;Nora Vanegas&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03526991&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.76328, &quot;lng&quot;: -95.36327, &quot;nct&quot;: &quot;NCT03526991&quot;, &quot;color&quot;: &quot;#4b835b&quot;, &quot;title&quot;: &quot;Exploring the Effects of Spinal Cord Stimulation in Parkinson&#x27;s Disease.&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Spinal Cord Stimulator (SCS)&quot;, &quot;sponsor&quot;: &quot;Nora Vanegas&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03526991&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.72943, &quot;lng&quot;: -104.83192, &quot;nct&quot;: &quot;NCT03049033&quot;, &quot;color&quot;: &quot;#2e6a2f&quot;, &quot;title&quot;: &quot;NMT for Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Neurologic Music Therapy; Occupational Therapy; Music Supported Therapy&quot;, &quot;sponsor&quot;: &quot;University of Colorado, Denver&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03049033&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.08804, &quot;lng&quot;: 14.42076, &quot;nct&quot;: &quot;NCT06963918&quot;, &quot;color&quot;: &quot;#2208d0&quot;, &quot;title&quot;: &quot;Expiratory Muscle Training and Trunk Flexion in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Expiratory muscle strength training&quot;, &quot;sponsor&quot;: &quot;General University Hospital, Prague&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06963918&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.44838, &quot;lng&quot;: -112.07404, &quot;nct&quot;: &quot;NCT06765668&quot;, &quot;color&quot;: &quot;#faf841&quot;, &quot;title&quot;: &quot;A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;CREXONT ER&quot;, &quot;sponsor&quot;: &quot;Impax Laboratories, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06765668&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 34.74648, &quot;lng&quot;: -92.28959, &quot;nct&quot;: &quot;NCT06765668&quot;, &quot;color&quot;: &quot;#faf841&quot;, &quot;title&quot;: &quot;A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;CREXONT ER&quot;, &quot;sponsor&quot;: &quot;Impax Laboratories, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06765668&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.56504, &quot;lng&quot;: -117.72712, &quot;nct&quot;: &quot;NCT06765668&quot;, &quot;color&quot;: &quot;#faf841&quot;, &quot;title&quot;: &quot;A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;CREXONT ER&quot;, &quot;sponsor&quot;: &quot;Impax Laboratories, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06765668&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.44188, &quot;lng&quot;: -122.14302, &quot;nct&quot;: &quot;NCT06765668&quot;, &quot;color&quot;: &quot;#faf841&quot;, &quot;title&quot;: &quot;A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;CREXONT ER&quot;, &quot;sponsor&quot;: &quot;Impax Laboratories, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06765668&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 25.95648, &quot;lng&quot;: -80.13921, &quot;nct&quot;: &quot;NCT06765668&quot;, &quot;color&quot;: &quot;#faf841&quot;, &quot;title&quot;: &quot;A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;CREXONT ER&quot;, &quot;sponsor&quot;: &quot;Impax Laboratories, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06765668&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.35869, &quot;lng&quot;: -80.0831, &quot;nct&quot;: &quot;NCT06765668&quot;, &quot;color&quot;: &quot;#faf841&quot;, &quot;title&quot;: &quot;A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;CREXONT ER&quot;, &quot;sponsor&quot;: &quot;Impax Laboratories, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06765668&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 25.77427, &quot;lng&quot;: -80.19366, &quot;nct&quot;: &quot;NCT06765668&quot;, &quot;color&quot;: &quot;#faf841&quot;, &quot;title&quot;: &quot;A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;CREXONT ER&quot;, &quot;sponsor&quot;: &quot;Impax Laboratories, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06765668&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 28.53834, &quot;lng&quot;: -81.37924, &quot;nct&quot;: &quot;NCT06765668&quot;, &quot;color&quot;: &quot;#faf841&quot;, &quot;title&quot;: &quot;A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;CREXONT ER&quot;, &quot;sponsor&quot;: &quot;Impax Laboratories, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06765668&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 27.94752, &quot;lng&quot;: -82.45843, &quot;nct&quot;: &quot;NCT06765668&quot;, &quot;color&quot;: &quot;#faf841&quot;, &quot;title&quot;: &quot;A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;CREXONT ER&quot;, &quot;sponsor&quot;: &quot;Impax Laboratories, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06765668&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.8617, &quot;lng&quot;: -88.1609, &quot;nct&quot;: &quot;NCT06765668&quot;, &quot;color&quot;: &quot;#faf841&quot;, &quot;title&quot;: &quot;A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;CREXONT ER&quot;, &quot;sponsor&quot;: &quot;Impax Laboratories, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06765668&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.11417, &quot;lng&quot;: -94.62746, &quot;nct&quot;: &quot;NCT06765668&quot;, &quot;color&quot;: &quot;#faf841&quot;, &quot;title&quot;: &quot;A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;CREXONT ER&quot;, &quot;sponsor&quot;: &quot;Impax Laboratories, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06765668&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.48531, &quot;lng&quot;: -83.37716, &quot;nct&quot;: &quot;NCT06765668&quot;, &quot;color&quot;: &quot;#faf841&quot;, &quot;title&quot;: &quot;A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;CREXONT ER&quot;, &quot;sponsor&quot;: &quot;Impax Laboratories, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06765668&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.17497, &quot;lng&quot;: -115.13722, &quot;nct&quot;: &quot;NCT06765668&quot;, &quot;color&quot;: &quot;#faf841&quot;, &quot;title&quot;: &quot;A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;CREXONT ER&quot;, &quot;sponsor&quot;: &quot;Impax Laboratories, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06765668&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.84288, &quot;lng&quot;: -73.29289, &quot;nct&quot;: &quot;NCT06765668&quot;, &quot;color&quot;: &quot;#faf841&quot;, &quot;title&quot;: &quot;A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;CREXONT ER&quot;, &quot;sponsor&quot;: &quot;Impax Laboratories, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06765668&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.09986, &quot;lng&quot;: -80.24422, &quot;nct&quot;: &quot;NCT06765668&quot;, &quot;color&quot;: &quot;#faf841&quot;, &quot;title&quot;: &quot;A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;CREXONT ER&quot;, &quot;sponsor&quot;: &quot;Impax Laboratories, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06765668&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.79895, &quot;lng&quot;: -81.37845, &quot;nct&quot;: &quot;NCT06765668&quot;, &quot;color&quot;: &quot;#faf841&quot;, &quot;title&quot;: &quot;A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;CREXONT ER&quot;, &quot;sponsor&quot;: &quot;Impax Laboratories, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06765668&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.12711, &quot;lng&quot;: -84.51439, &quot;nct&quot;: &quot;NCT06765668&quot;, &quot;color&quot;: &quot;#faf841&quot;, &quot;title&quot;: &quot;A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;CREXONT ER&quot;, &quot;sponsor&quot;: &quot;Impax Laboratories, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06765668&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.4995, &quot;lng&quot;: -81.69541, &quot;nct&quot;: &quot;NCT06765668&quot;, &quot;color&quot;: &quot;#faf841&quot;, &quot;title&quot;: &quot;A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;CREXONT ER&quot;, &quot;sponsor&quot;: &quot;Impax Laboratories, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06765668&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.15398, &quot;lng&quot;: -95.99277, &quot;nct&quot;: &quot;NCT06765668&quot;, &quot;color&quot;: &quot;#faf841&quot;, &quot;title&quot;: &quot;A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;CREXONT ER&quot;, &quot;sponsor&quot;: &quot;Impax Laboratories, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06765668&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 32.78306, &quot;lng&quot;: -96.80667, &quot;nct&quot;: &quot;NCT06765668&quot;, &quot;color&quot;: &quot;#faf841&quot;, &quot;title&quot;: &quot;A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;CREXONT ER&quot;, &quot;sponsor&quot;: &quot;Impax Laboratories, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06765668&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 30.63269, &quot;lng&quot;: -97.67723, &quot;nct&quot;: &quot;NCT06765668&quot;, &quot;color&quot;: &quot;#faf841&quot;, &quot;title&quot;: &quot;A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;CREXONT ER&quot;, &quot;sponsor&quot;: &quot;Impax Laboratories, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06765668&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.76328, &quot;lng&quot;: -95.36327, &quot;nct&quot;: &quot;NCT06765668&quot;, &quot;color&quot;: &quot;#faf841&quot;, &quot;title&quot;: &quot;A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;CREXONT ER&quot;, &quot;sponsor&quot;: &quot;Impax Laboratories, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06765668&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 38.84622, &quot;lng&quot;: -77.30637, &quot;nct&quot;: &quot;NCT06765668&quot;, &quot;color&quot;: &quot;#faf841&quot;, &quot;title&quot;: &quot;A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;CREXONT ER&quot;, &quot;sponsor&quot;: &quot;Impax Laboratories, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06765668&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.59264, &quot;lng&quot;: -78.61611, &quot;nct&quot;: &quot;NCT06765668&quot;, &quot;color&quot;: &quot;#faf841&quot;, &quot;title&quot;: &quot;A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;CREXONT ER&quot;, &quot;sponsor&quot;: &quot;Impax Laboratories, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06765668&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 38.93428, &quot;lng&quot;: -77.17748, &quot;nct&quot;: &quot;NCT06765668&quot;, &quot;color&quot;: &quot;#faf841&quot;, &quot;title&quot;: &quot;A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;CREXONT ER&quot;, &quot;sponsor&quot;: &quot;Impax Laboratories, LLC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06765668&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.77493, &quot;lng&quot;: -122.41942, &quot;nct&quot;: &quot;NCT05720468&quot;, &quot;color&quot;: &quot;#9a3364&quot;, &quot;title&quot;: &quot;Exercise for Cognitive Excellence in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Exercise; No Exercise&quot;, &quot;sponsor&quot;: &quot;University of California, San Francisco&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05720468&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.22172, &quot;lng&quot;: 6.77616, &quot;nct&quot;: &quot;NCT06617884&quot;, &quot;color&quot;: &quot;#602e74&quot;, &quot;title&quot;: &quot;Home-based Gait and Balance Training in Patients With Movement Disorders&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Gait and balance training&quot;, &quot;sponsor&quot;: &quot;Forschungszentrum Juelich&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06617884&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 25.06199, &quot;lng&quot;: 121.45703, &quot;nct&quot;: &quot;NCT07143006&quot;, &quot;color&quot;: &quot;#f44a41&quot;, &quot;title&quot;: &quot;Application of Smart Electric Vehicles in Analyzing Gait Abnormalities in Patients With Neurodegenerative Diseases&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;BestShape Go Intelligent Generation Transformable Electric Vehicle&quot;, &quot;sponsor&quot;: &quot;Taipei Medical University Shuang Ho Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07143006&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.52066, &quot;lng&quot;: -86.80249, &quot;nct&quot;: &quot;NCT04735458&quot;, &quot;color&quot;: &quot;#39d8b3&quot;, &quot;title&quot;: &quot;Investigating Inhibitory Control Networks in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Procedure/Surgery: Response Inhibition and Deep Brain Stimulation in Parkinson&#x27;s disease&quot;, &quot;sponsor&quot;: &quot;University of Alabama at Birmingham&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04735458&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.21725, &quot;lng&quot;: -1.55336, &quot;nct&quot;: &quot;NCT03230526&quot;, &quot;color&quot;: &quot;#f82107&quot;, &quot;title&quot;: &quot;Identification of a Biomarker Predictive of Evolution of Parkinson Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;[18F]DPA-714 PET scan&quot;, &quot;sponsor&quot;: &quot;Nantes University Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03230526&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.11109, &quot;lng&quot;: -1.67431, &quot;nct&quot;: &quot;NCT03230526&quot;, &quot;color&quot;: &quot;#f82107&quot;, &quot;title&quot;: &quot;Identification of a Biomarker Predictive of Evolution of Parkinson Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;[18F]DPA-714 PET scan&quot;, &quot;sponsor&quot;: &quot;Nantes University Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03230526&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.39484, &quot;lng&quot;: 0.70398, &quot;nct&quot;: &quot;NCT03230526&quot;, &quot;color&quot;: &quot;#f82107&quot;, &quot;title&quot;: &quot;Identification of a Biomarker Predictive of Evolution of Parkinson Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;[18F]DPA-714 PET scan&quot;, &quot;sponsor&quot;: &quot;Nantes University Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03230526&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.14583, &quot;lng&quot;: 34.16389, &quot;nct&quot;: &quot;NCT07165106&quot;, &quot;color&quot;: &quot;#444899&quot;, &quot;title&quot;: &quot;Effects of Resistance and Aerobic Exercises on Walking and Sarcopenic Parameters in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Aerobic Exercise; Resistance Exercise; Conventional Rehabilitation&quot;, &quot;sponsor&quot;: &quot;Ahi Evran University Education and Research Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07165106&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 38.19394, &quot;lng&quot;: 15.55256, &quot;nct&quot;: &quot;NCT06793735&quot;, &quot;color&quot;: &quot;#d17913&quot;, &quot;title&quot;: &quot;Effectiveness of TeleVR App in Cognitive Decline and MCI Patients&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Telerehabilitation with Virtual Reality; Traditional Cognitive Rehabilitation&quot;, &quot;sponsor&quot;: &quot;IRCCS Centro Neurolesi Bonino Pulejo&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06793735&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.50853, &quot;lng&quot;: -0.12574, &quot;nct&quot;: &quot;NCT06005584&quot;, &quot;color&quot;: &quot;#cdf13b&quot;, &quot;title&quot;: &quot;Spinal Cord Stimulation for Gait Dysfunction in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Spinal Cord Stimulation - High Frequency SCS; Spinal Cord Stimulation - Burst SCS; Spinal Cord Stimulation - Sham SCS&quot;, &quot;sponsor&quot;: &quot;Imperial College London&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06005584&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 31.86389, &quot;lng&quot;: 117.28083, &quot;nct&quot;: &quot;NCT06383247&quot;, &quot;color&quot;: &quot;#89e2fe&quot;, &quot;title&quot;: &quot;The Efficacy and Safety of Precision REpetitive Transcranial Magnetic Stimulation in Alleviating Motor Symptom in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;transcranial magnetic stimulation&quot;, &quot;sponsor&quot;: &quot;Anhui Medical University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06383247&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 35.99403, &quot;lng&quot;: -78.89862, &quot;nct&quot;: &quot;NCT06309147&quot;, &quot;color&quot;: &quot;#91893f&quot;, &quot;title&quot;: &quot;A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson&#x27;s&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;BMS-9894923&quot;, &quot;sponsor&quot;: &quot;Allyx Therapeutics&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06309147&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 49.88307, &quot;lng&quot;: -119.48568, &quot;nct&quot;: &quot;NCT06915987&quot;, &quot;color&quot;: &quot;#025973&quot;, &quot;title&quot;: &quot;Parkinson Disease and Exercise Snacks&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Exercise Intervention&quot;, &quot;sponsor&quot;: &quot;University of British Columbia&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06915987&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.80843, &quot;lng&quot;: -72.24952, &quot;nct&quot;: &quot;NCT07115563&quot;, &quot;color&quot;: &quot;#b651a1&quot;, &quot;title&quot;: &quot;Daily Amino Acid Supplementation for People With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Targeted Amino Acid Supplement; Control (placebo)&quot;, &quot;sponsor&quot;: &quot;Cristina Colon-Semenza&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07115563&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.96395, &quot;lng&quot;: -78.73781, &quot;nct&quot;: &quot;NCT06339034&quot;, &quot;color&quot;: &quot;#e62df2&quot;, &quot;title&quot;: &quot;Repurposing Lithium for Parkinson&#x27;s Disease: a RCT&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lithium; Placebo&quot;, &quot;sponsor&quot;: &quot;State University of New York at Buffalo&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06339034&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.29038, &quot;lng&quot;: -76.61219, &quot;nct&quot;: &quot;NCT05763732&quot;, &quot;color&quot;: &quot;#ce6809&quot;, &quot;title&quot;: &quot;Effects of RAS on Gait in PD Patients With DBS&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Rhythmic Auditory Stimulation (RAS)&quot;, &quot;sponsor&quot;: &quot;Johns Hopkins University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05763732&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.48142, &quot;lng&quot;: -1.89983, &quot;nct&quot;: &quot;NCT05778617&quot;, &quot;color&quot;: &quot;#ec3cfd&quot;, &quot;title&quot;: &quot;Ambroxol to Slow Progression in Parkinson Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ambroxol Hydrochloride (420mg); Placebo&quot;, &quot;sponsor&quot;: &quot;University College, London&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05778617&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.45523, &quot;lng&quot;: -2.59665, &quot;nct&quot;: &quot;NCT05778617&quot;, &quot;color&quot;: &quot;#ec3cfd&quot;, &quot;title&quot;: &quot;Ambroxol to Slow Progression in Parkinson Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ambroxol Hydrochloride (420mg); Placebo&quot;, &quot;sponsor&quot;: &quot;University College, London&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05778617&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.2, &quot;lng&quot;: 0.11667, &quot;nct&quot;: &quot;NCT05778617&quot;, &quot;color&quot;: &quot;#ec3cfd&quot;, &quot;title&quot;: &quot;Ambroxol to Slow Progression in Parkinson Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ambroxol Hydrochloride (420mg); Placebo&quot;, &quot;sponsor&quot;: &quot;University College, London&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05778617&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 55.95206, &quot;lng&quot;: -3.19648, &quot;nct&quot;: &quot;NCT05778617&quot;, &quot;color&quot;: &quot;#ec3cfd&quot;, &quot;title&quot;: &quot;Ambroxol to Slow Progression in Parkinson Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ambroxol Hydrochloride (420mg); Placebo&quot;, &quot;sponsor&quot;: &quot;University College, London&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05778617&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.50853, &quot;lng&quot;: -0.12574, &quot;nct&quot;: &quot;NCT05778617&quot;, &quot;color&quot;: &quot;#ec3cfd&quot;, &quot;title&quot;: &quot;Ambroxol to Slow Progression in Parkinson Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ambroxol Hydrochloride (420mg); Placebo&quot;, &quot;sponsor&quot;: &quot;University College, London&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05778617&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 54.21804, &quot;lng&quot;: -5.88979, &quot;nct&quot;: &quot;NCT05778617&quot;, &quot;color&quot;: &quot;#ec3cfd&quot;, &quot;title&quot;: &quot;Ambroxol to Slow Progression in Parkinson Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ambroxol Hydrochloride (420mg); Placebo&quot;, &quot;sponsor&quot;: &quot;University College, London&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05778617&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 54.97328, &quot;lng&quot;: -1.61396, &quot;nct&quot;: &quot;NCT05778617&quot;, &quot;color&quot;: &quot;#ec3cfd&quot;, &quot;title&quot;: &quot;Ambroxol to Slow Progression in Parkinson Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ambroxol Hydrochloride (420mg); Placebo&quot;, &quot;sponsor&quot;: &quot;University College, London&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05778617&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.75222, &quot;lng&quot;: -1.25596, &quot;nct&quot;: &quot;NCT05778617&quot;, &quot;color&quot;: &quot;#ec3cfd&quot;, &quot;title&quot;: &quot;Ambroxol to Slow Progression in Parkinson Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ambroxol Hydrochloride (420mg); Placebo&quot;, &quot;sponsor&quot;: &quot;University College, London&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05778617&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.37153, &quot;lng&quot;: -4.14305, &quot;nct&quot;: &quot;NCT05778617&quot;, &quot;color&quot;: &quot;#ec3cfd&quot;, &quot;title&quot;: &quot;Ambroxol to Slow Progression in Parkinson Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ambroxol Hydrochloride (420mg); Placebo&quot;, &quot;sponsor&quot;: &quot;University College, London&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05778617&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 53.48771, &quot;lng&quot;: -2.29042, &quot;nct&quot;: &quot;NCT05778617&quot;, &quot;color&quot;: &quot;#ec3cfd&quot;, &quot;title&quot;: &quot;Ambroxol to Slow Progression in Parkinson Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ambroxol Hydrochloride (420mg); Placebo&quot;, &quot;sponsor&quot;: &quot;University College, London&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05778617&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.90395, &quot;lng&quot;: -1.40428, &quot;nct&quot;: &quot;NCT05778617&quot;, &quot;color&quot;: &quot;#ec3cfd&quot;, &quot;title&quot;: &quot;Ambroxol to Slow Progression in Parkinson Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ambroxol Hydrochloride (420mg); Placebo&quot;, &quot;sponsor&quot;: &quot;University College, London&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05778617&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 53.34061, &quot;lng&quot;: -1.28162, &quot;nct&quot;: &quot;NCT05778617&quot;, &quot;color&quot;: &quot;#ec3cfd&quot;, &quot;title&quot;: &quot;Ambroxol to Slow Progression in Parkinson Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ambroxol Hydrochloride (420mg); Placebo&quot;, &quot;sponsor&quot;: &quot;University College, London&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05778617&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.42411, &quot;lng&quot;: -122.16608, &quot;nct&quot;: &quot;NCT03319485&quot;, &quot;color&quot;: &quot;#2fcfe0&quot;, &quot;title&quot;: &quot;ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;ExAblate Pallidotomy; Sham ExAblate Pallidotomy&quot;, &quot;sponsor&quot;: &quot;InSightec&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03319485&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.52535, &quot;lng&quot;: -80.06643, &quot;nct&quot;: &quot;NCT03319485&quot;, &quot;color&quot;: &quot;#2fcfe0&quot;, &quot;title&quot;: &quot;ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;ExAblate Pallidotomy; Sham ExAblate Pallidotomy&quot;, &quot;sponsor&quot;: &quot;InSightec&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03319485&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.29038, &quot;lng&quot;: -76.61219, &quot;nct&quot;: &quot;NCT03319485&quot;, &quot;color&quot;: &quot;#2fcfe0&quot;, &quot;title&quot;: &quot;ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;ExAblate Pallidotomy; Sham ExAblate Pallidotomy&quot;, &quot;sponsor&quot;: &quot;InSightec&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03319485&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.35843, &quot;lng&quot;: -71.05977, &quot;nct&quot;: &quot;NCT03319485&quot;, &quot;color&quot;: &quot;#2fcfe0&quot;, &quot;title&quot;: &quot;ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;ExAblate Pallidotomy; Sham ExAblate Pallidotomy&quot;, &quot;sponsor&quot;: &quot;InSightec&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03319485&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 44.02163, &quot;lng&quot;: -92.4699, &quot;nct&quot;: &quot;NCT03319485&quot;, &quot;color&quot;: &quot;#2fcfe0&quot;, &quot;title&quot;: &quot;ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;ExAblate Pallidotomy; Sham ExAblate Pallidotomy&quot;, &quot;sponsor&quot;: &quot;InSightec&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03319485&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.71427, &quot;lng&quot;: -74.00597, &quot;nct&quot;: &quot;NCT03319485&quot;, &quot;color&quot;: &quot;#2fcfe0&quot;, &quot;title&quot;: &quot;ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;ExAblate Pallidotomy; Sham ExAblate Pallidotomy&quot;, &quot;sponsor&quot;: &quot;InSightec&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03319485&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.96118, &quot;lng&quot;: -82.99879, &quot;nct&quot;: &quot;NCT03319485&quot;, &quot;color&quot;: &quot;#2fcfe0&quot;, &quot;title&quot;: &quot;ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;ExAblate Pallidotomy; Sham ExAblate Pallidotomy&quot;, &quot;sponsor&quot;: &quot;InSightec&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03319485&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.95238, &quot;lng&quot;: -75.16362, &quot;nct&quot;: &quot;NCT03319485&quot;, &quot;color&quot;: &quot;#2fcfe0&quot;, &quot;title&quot;: &quot;ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;ExAblate Pallidotomy; Sham ExAblate Pallidotomy&quot;, &quot;sponsor&quot;: &quot;InSightec&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03319485&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 38.02931, &quot;lng&quot;: -78.47668, &quot;nct&quot;: &quot;NCT03319485&quot;, &quot;color&quot;: &quot;#2fcfe0&quot;, &quot;title&quot;: &quot;ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;ExAblate Pallidotomy; Sham ExAblate Pallidotomy&quot;, &quot;sponsor&quot;: &quot;InSightec&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03319485&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.60621, &quot;lng&quot;: -122.33207, &quot;nct&quot;: &quot;NCT03319485&quot;, &quot;color&quot;: &quot;#2fcfe0&quot;, &quot;title&quot;: &quot;ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;ExAblate Pallidotomy; Sham ExAblate Pallidotomy&quot;, &quot;sponsor&quot;: &quot;InSightec&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03319485&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.70643, &quot;lng&quot;: -79.39864, &quot;nct&quot;: &quot;NCT03319485&quot;, &quot;color&quot;: &quot;#2fcfe0&quot;, &quot;title&quot;: &quot;ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;ExAblate Pallidotomy; Sham ExAblate Pallidotomy&quot;, &quot;sponsor&quot;: &quot;InSightec&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03319485&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 32.81303, &quot;lng&quot;: 34.99928, &quot;nct&quot;: &quot;NCT03319485&quot;, &quot;color&quot;: &quot;#2fcfe0&quot;, &quot;title&quot;: &quot;ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;ExAblate Pallidotomy; Sham ExAblate Pallidotomy&quot;, &quot;sponsor&quot;: &quot;InSightec&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03319485&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.46427, &quot;lng&quot;: 9.18951, &quot;nct&quot;: &quot;NCT03319485&quot;, &quot;color&quot;: &quot;#2fcfe0&quot;, &quot;title&quot;: &quot;ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;ExAblate Pallidotomy; Sham ExAblate Pallidotomy&quot;, &quot;sponsor&quot;: &quot;InSightec&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03319485&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.43854, &quot;lng&quot;: 10.9938, &quot;nct&quot;: &quot;NCT03319485&quot;, &quot;color&quot;: &quot;#2fcfe0&quot;, &quot;title&quot;: &quot;ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;ExAblate Pallidotomy; Sham ExAblate Pallidotomy&quot;, &quot;sponsor&quot;: &quot;InSightec&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03319485&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.566, &quot;lng&quot;: 126.9784, &quot;nct&quot;: &quot;NCT03319485&quot;, &quot;color&quot;: &quot;#2fcfe0&quot;, &quot;title&quot;: &quot;ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;ExAblate Pallidotomy; Sham ExAblate Pallidotomy&quot;, &quot;sponsor&quot;: &quot;InSightec&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03319485&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.32234, &quot;lng&quot;: -3.86496, &quot;nct&quot;: &quot;NCT03319485&quot;, &quot;color&quot;: &quot;#2fcfe0&quot;, &quot;title&quot;: &quot;ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;ExAblate Pallidotomy; Sham ExAblate Pallidotomy&quot;, &quot;sponsor&quot;: &quot;InSightec&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03319485&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.81687, &quot;lng&quot;: -1.64323, &quot;nct&quot;: &quot;NCT03319485&quot;, &quot;color&quot;: &quot;#2fcfe0&quot;, &quot;title&quot;: &quot;ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;ExAblate Pallidotomy; Sham ExAblate Pallidotomy&quot;, &quot;sponsor&quot;: &quot;InSightec&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03319485&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 24.0692, &quot;lng&quot;: 120.5512, &quot;nct&quot;: &quot;NCT03319485&quot;, &quot;color&quot;: &quot;#2fcfe0&quot;, &quot;title&quot;: &quot;ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;ExAblate Pallidotomy; Sham ExAblate Pallidotomy&quot;, &quot;sponsor&quot;: &quot;InSightec&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03319485&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.50853, &quot;lng&quot;: -0.12574, &quot;nct&quot;: &quot;NCT03319485&quot;, &quot;color&quot;: &quot;#2fcfe0&quot;, &quot;title&quot;: &quot;ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;ExAblate Pallidotomy; Sham ExAblate Pallidotomy&quot;, &quot;sponsor&quot;: &quot;InSightec&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03319485&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.749, &quot;lng&quot;: -84.38798, &quot;nct&quot;: &quot;NCT06295458&quot;, &quot;color&quot;: &quot;#d54aae&quot;, &quot;title&quot;: &quot;Gamma Sensory Flicker for Parkinson&#x27;s Disease Patients With Freezing of Gait&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;David Delight Plus Device; Sham Therapy&quot;, &quot;sponsor&quot;: &quot;Emory University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06295458&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.73583, &quot;lng&quot;: 31.60611, &quot;nct&quot;: &quot;NCT06147726&quot;, &quot;color&quot;: &quot;#9981e6&quot;, &quot;title&quot;: &quot;Upper Extremity Rehabilitation With Virtual Reality in Parkinson&#x27;s Disease Patients&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Upper extremity position matching exercises in virtual reality; Conventional physiotherapy&quot;, &quot;sponsor&quot;: &quot;Ramazan KURUL&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06147726&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.06287, &quot;lng&quot;: -80.2331, &quot;nct&quot;: &quot;NCT05266417&quot;, &quot;color&quot;: &quot;#a17c6a&quot;, &quot;title&quot;: &quot;Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;INS-GSH; Matched Placebos&quot;, &quot;sponsor&quot;: &quot;Gateway Institute for Brain Research&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05266417&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 25.8576, &quot;lng&quot;: -80.27811, &quot;nct&quot;: &quot;NCT05266417&quot;, &quot;color&quot;: &quot;#a17c6a&quot;, &quot;title&quot;: &quot;Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;INS-GSH; Matched Placebos&quot;, &quot;sponsor&quot;: &quot;Gateway Institute for Brain Research&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05266417&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.98339, &quot;lng&quot;: -81.23304, &quot;nct&quot;: &quot;NCT07066163&quot;, &quot;color&quot;: &quot;#d94c5c&quot;, &quot;title&quot;: &quot;SMART-PD: Evaluating the Impact of Smartphone-Based Wearable Technology on Motor Symptoms and Quality of Life in People With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Kinesia U; Standard of care treatment&quot;, &quot;sponsor&quot;: &quot;Western University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07066163&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.77969, &quot;lng&quot;: 3.08682, &quot;nct&quot;: &quot;NCT04375280&quot;, &quot;color&quot;: &quot;#11eea5&quot;, &quot;title&quot;: &quot;Evaluation of Impaired Mobility in Chronic Illness Constitution of a Cohort&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Development of a screening algorithm designed to determine a \\&quot;dysmobility\\&quot; profile in patients with chronic illness.&quot;, &quot;sponsor&quot;: &quot;University Hospital, Clermont-Ferrand&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04375280&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.85003, &quot;lng&quot;: -87.65005, &quot;nct&quot;: &quot;NCT07011771&quot;, &quot;color&quot;: &quot;#341431&quot;, &quot;title&quot;: &quot;A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;gene therapy&quot;, &quot;sponsor&quot;: &quot;Capsida Biotherapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07011771&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.11417, &quot;lng&quot;: -94.62746, &quot;nct&quot;: &quot;NCT07011771&quot;, &quot;color&quot;: &quot;#341431&quot;, &quot;title&quot;: &quot;A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;gene therapy&quot;, &quot;sponsor&quot;: &quot;Capsida Biotherapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07011771&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.71427, &quot;lng&quot;: -74.00597, &quot;nct&quot;: &quot;NCT07011771&quot;, &quot;color&quot;: &quot;#341431&quot;, &quot;title&quot;: &quot;A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;gene therapy&quot;, &quot;sponsor&quot;: &quot;Capsida Biotherapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07011771&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.76328, &quot;lng&quot;: -95.36327, &quot;nct&quot;: &quot;NCT07011771&quot;, &quot;color&quot;: &quot;#341431&quot;, &quot;title&quot;: &quot;A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;gene therapy&quot;, &quot;sponsor&quot;: &quot;Capsida Biotherapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07011771&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.68149, &quot;lng&quot;: -122.20874, &quot;nct&quot;: &quot;NCT07011771&quot;, &quot;color&quot;: &quot;#341431&quot;, &quot;title&quot;: &quot;A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;gene therapy&quot;, &quot;sponsor&quot;: &quot;Capsida Biotherapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07011771&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.65966, &quot;lng&quot;: -117.42908, &quot;nct&quot;: &quot;NCT07011771&quot;, &quot;color&quot;: &quot;#341431&quot;, &quot;title&quot;: &quot;A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;gene therapy&quot;, &quot;sponsor&quot;: &quot;Capsida Biotherapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07011771&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 31.558, &quot;lng&quot;: 74.35071, &quot;nct&quot;: &quot;NCT06111924&quot;, &quot;color&quot;: &quot;#b705ec&quot;, &quot;title&quot;: &quot;Effects of Telerehabilitation Versus Clinic-based Task-oriented Circuit Training in Parkinson&#x27;s Patients&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Task oriented circuit training based telerehabilitation; Clinic based Task oriented circuit training&quot;, &quot;sponsor&quot;: &quot;Riphah International University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06111924&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 23.7104, &quot;lng&quot;: 90.40744, &quot;nct&quot;: &quot;NCT07055958&quot;, &quot;color&quot;: &quot;#489f9b&quot;, &quot;title&quot;: &quot;Effect of Metformin as Add-on Therapy in Levodopa Treated Parkinson&#x27;s Disease Patients&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Metformin; placebo&quot;, &quot;sponsor&quot;: &quot;Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07055958&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.4584, &quot;lng&quot;: 14.20283, &quot;nct&quot;: &quot;NCT07013214&quot;, &quot;color&quot;: &quot;#82893a&quot;, &quot;title&quot;: &quot;Rehabilitation With Dual-task Exercises to Improve Balance in Patients With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Dual-Task Exercise; Standard Rehabilitation&quot;, &quot;sponsor&quot;: &quot;G. d&#x27;Annunzio University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07013214&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 46.60207, &quot;lng&quot;: -120.5059, &quot;nct&quot;: &quot;NCT06576817&quot;, &quot;color&quot;: &quot;#775188&quot;, &quot;title&quot;: &quot;High-intensity Interval Circuit Training in People With Parkinson Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;High intensity circuit exercise class - Lower and upper extremity; High intensity circuit exercise class - Lower extremity alone&quot;, &quot;sponsor&quot;: &quot;Pacific Northwest University of Health Sciences&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06576817&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.58526, &quot;lng&quot;: -105.08442, &quot;nct&quot;: &quot;NCT06447207&quot;, &quot;color&quot;: &quot;#6462f3&quot;, &quot;title&quot;: &quot;Occupational Therapy Led Social Prescription for People With Parkinson Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Occupational Therapy Led Social Prescription&quot;, &quot;sponsor&quot;: &quot;Colorado State University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06447207&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.08804, &quot;lng&quot;: 14.42076, &quot;nct&quot;: &quot;NCT06942533&quot;, &quot;color&quot;: &quot;#2cbfa6&quot;, &quot;title&quot;: &quot;Effect of Visual Feedback From the SpiroGym Mobile Application&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;EMST with SpiroGym app; EMST without SpiroGym app&quot;, &quot;sponsor&quot;: &quot;General University Hospital, Prague&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06942533&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 31.22222, &quot;lng&quot;: 121.45806, &quot;nct&quot;: &quot;NCT06793995&quot;, &quot;color&quot;: &quot;#240751&quot;, &quot;title&quot;: &quot;Effect of Food and Age on the Pharmacokinetics of LY03017&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;LY03017&quot;, &quot;sponsor&quot;: &quot;Luye Pharma Group Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06793995&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 44.49381, &quot;lng&quot;: 11.33875, &quot;nct&quot;: &quot;NCT06316232&quot;, &quot;color&quot;: &quot;#250c74&quot;, &quot;title&quot;: &quot;DBS and Levodopa for Treating Freezing of Gait in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;STIM ON plus; MED ON plus&quot;, &quot;sponsor&quot;: &quot;IRCCS Istituto delle Scienze Neurologiche di Bologna&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06316232&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.11109, &quot;lng&quot;: -1.67431, &quot;nct&quot;: &quot;NCT05822258&quot;, &quot;color&quot;: &quot;#d05fb4&quot;, &quot;title&quot;: &quot;DetectFoG : Detection of Gait Freezing Episodes in Parkinsonian Patients Using Inertial Measurement Units&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Walk under 3 conditions (normal, physical tasks, verbal tasks)&quot;, &quot;sponsor&quot;: &quot;Rennes University Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05822258&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 32.06167, &quot;lng&quot;: 118.77778, &quot;nct&quot;: &quot;NCT06665113&quot;, &quot;color&quot;: &quot;#199c85&quot;, &quot;title&quot;: &quot;Neuroprotective Effects of Long-term TaVNS in Early Parkinson&#x27;s Disease Patients&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;taVNS real stimulation; taVNS sham stimulation&quot;, &quot;sponsor&quot;: &quot;Kezhong Zhang&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06665113&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.07706, &quot;lng&quot;: -75.12684, &quot;nct&quot;: &quot;NCT06225830&quot;, &quot;color&quot;: &quot;#d99974&quot;, &quot;title&quot;: &quot;Unlocking Movement Potential: Enhancing Parkinson&#x27;s Disease Treatment With Robotic EksoSkeleton&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Eksobionics Eksoskeleton NR&quot;, &quot;sponsor&quot;: &quot;Albert Einstein Healthcare Network&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06225830&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 19.07283, &quot;lng&quot;: 72.88261, &quot;nct&quot;: &quot;NCT06205043&quot;, &quot;color&quot;: &quot;#3e5228&quot;, &quot;title&quot;: &quot;Algorithm Guided DBS Programming in Parkinson&#x27;s Patients&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;StimSearch programming algorithm software; Clinician based programming&quot;, &quot;sponsor&quot;: &quot;Jaslok Hospital and Research Centre&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06205043&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 38.25424, &quot;lng&quot;: -85.75941, &quot;nct&quot;: &quot;NCT06804642&quot;, &quot;color&quot;: &quot;#cc42c0&quot;, &quot;title&quot;: &quot;Spinal Cord Stimulation for Parkinson&#x27;s Disease Rehabilitation&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Spinal cord transcutaneous stimulation (scTS)&quot;, &quot;sponsor&quot;: &quot;University of Louisville&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06804642&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.89193, &quot;lng&quot;: 12.51133, &quot;nct&quot;: &quot;NCT05741151&quot;, &quot;color&quot;: &quot;#7c3a61&quot;, &quot;title&quot;: &quot;Superior Cervical Ganglion in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;PET-Neck Parkinsonian patients&quot;, &quot;sponsor&quot;: &quot;Fondazione Policlinico Universitario Agostino Gemelli IRCCS&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05741151&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 35.7721, &quot;lng&quot;: -78.63861, &quot;nct&quot;: &quot;NCT05308368&quot;, &quot;color&quot;: &quot;#88807b&quot;, &quot;title&quot;: &quot;Analysis and Suppression of Tremor During Grasp Using Ultrasound Imaging and Electrical Stimulation&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Ultrasound Imaging; Electromyography; Inertial Measurement Units (IMU); Functional Electrical Stimulation (FES)&quot;, &quot;sponsor&quot;: &quot;North Carolina State University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05308368&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.52345, &quot;lng&quot;: -122.67621, &quot;nct&quot;: &quot;NCT05818189&quot;, &quot;color&quot;: &quot;#5426e2&quot;, &quot;title&quot;: &quot;Cortical Correlates of Gait in Parkinson&#x27;s Disease: Impact of Medication and Cueing&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Personalized tactile cueing; Fixed tactile cueing&quot;, &quot;sponsor&quot;: &quot;Oregon Health and Science University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05818189&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 34.25833, &quot;lng&quot;: 108.92861, &quot;nct&quot;: &quot;NCT06914427&quot;, &quot;color&quot;: &quot;#fddfa2&quot;, &quot;title&quot;: &quot;PET/CT Imaging Study With Simultaneous Dual-nuclide Imaging Technique&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;PET/CT&quot;, &quot;sponsor&quot;: &quot;Xijing Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06914427&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.63391, &quot;lng&quot;: 3.05512, &quot;nct&quot;: &quot;NCT04691661&quot;, &quot;color&quot;: &quot;#508d12&quot;, &quot;title&quot;: &quot;Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Radotinib HCl 50 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Il-Yang Pharm. Co., Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04691661&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.83362, &quot;lng&quot;: 1.24759, &quot;nct&quot;: &quot;NCT04691661&quot;, &quot;color&quot;: &quot;#508d12&quot;, &quot;title&quot;: &quot;Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Radotinib HCl 50 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Il-Yang Pharm. Co., Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04691661&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.74906, &quot;lng&quot;: 4.84789, &quot;nct&quot;: &quot;NCT04691661&quot;, &quot;color&quot;: &quot;#508d12&quot;, &quot;title&quot;: &quot;Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Radotinib HCl 50 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Il-Yang Pharm. Co., Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04691661&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.21725, &quot;lng&quot;: -1.55336, &quot;nct&quot;: &quot;NCT04691661&quot;, &quot;color&quot;: &quot;#508d12&quot;, &quot;title&quot;: &quot;Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Radotinib HCl 50 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Il-Yang Pharm. Co., Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04691661&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.85341, &quot;lng&quot;: 2.3488, &quot;nct&quot;: &quot;NCT04691661&quot;, &quot;color&quot;: &quot;#508d12&quot;, &quot;title&quot;: &quot;Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Radotinib HCl 50 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Il-Yang Pharm. Co., Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04691661&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 46.58261, &quot;lng&quot;: 0.34348, &quot;nct&quot;: &quot;NCT04691661&quot;, &quot;color&quot;: &quot;#508d12&quot;, &quot;title&quot;: &quot;Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Radotinib HCl 50 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Il-Yang Pharm. Co., Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04691661&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 49.44313, &quot;lng&quot;: 1.09932, &quot;nct&quot;: &quot;NCT04691661&quot;, &quot;color&quot;: &quot;#508d12&quot;, &quot;title&quot;: &quot;Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Radotinib HCl 50 mg; Placebo&quot;, &quot;sponsor&quot;: &quot;Il-Yang Pharm. Co., Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04691661&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.82058, &quot;lng&quot;: 8.82511, &quot;nct&quot;: &quot;NCT06705517&quot;, &quot;color&quot;: &quot;#c3d1a8&quot;, &quot;title&quot;: &quot;Mediterranean Diet Effects on Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Mediterranean Diet&quot;, &quot;sponsor&quot;: &quot;Universit\\u00e0 degli Studi dell&#x27;Insubria&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06705517&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 46.60207, &quot;lng&quot;: -120.5059, &quot;nct&quot;: &quot;NCT06908135&quot;, &quot;color&quot;: &quot;#43f684&quot;, &quot;title&quot;: &quot;Effects of an Independent Walking Program With Walking Poles in People With Parkinson Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Independent walking program using walking poles; Independent walking program without walking poles&quot;, &quot;sponsor&quot;: &quot;Pacific Northwest University of Health Sciences&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06908135&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.98339, &quot;lng&quot;: -81.23304, &quot;nct&quot;: &quot;NCT03343574&quot;, &quot;color&quot;: &quot;#936ad5&quot;, &quot;title&quot;: &quot;Cardiovascular Effects of Exercise in Patients With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Abdominal Strengthening Exercise&quot;, &quot;sponsor&quot;: &quot;Faizan Ahmed&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03343574&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 34.05223, &quot;lng&quot;: -118.24368, &quot;nct&quot;: &quot;NCT05166655&quot;, &quot;color&quot;: &quot;#cd75e3&quot;, &quot;title&quot;: &quot;DBS Recordings to Characterize Movement Facilitation in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Movement task&quot;, &quot;sponsor&quot;: &quot;University of California, Los Angeles&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05166655&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 46.01008, &quot;lng&quot;: 8.96004, &quot;nct&quot;: &quot;NCT07097298&quot;, &quot;color&quot;: &quot;#b14639&quot;, &quot;title&quot;: &quot;Empathy and (Self-)Compassion in Parkinson&#x27;s Disease Patients and Caregivers&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;empathy and compassion training&quot;, &quot;sponsor&quot;: &quot;Alain Kaelin&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07097298&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 31.03637, &quot;lng&quot;: 31.38069, &quot;nct&quot;: &quot;NCT06113640&quot;, &quot;color&quot;: &quot;#961b87&quot;, &quot;title&quot;: &quot;Montelukast in Parkinson Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;levodopa-carbidopa; Montelukast&quot;, &quot;sponsor&quot;: &quot;Mostafa Bahaa&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06113640&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 23.7104, &quot;lng&quot;: 90.40744, &quot;nct&quot;: &quot;NCT07084597&quot;, &quot;color&quot;: &quot;#4330f6&quot;, &quot;title&quot;: &quot;Effect of Vitamin D3 Supplementation on Cardiac Autonomic Nerve Function in Male Parkinson&#x27;s Disease Patients With Hypovitaminosis D&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Vitamin D&quot;, &quot;sponsor&quot;: &quot;Bangladesh Medical University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07084597&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 32.22174, &quot;lng&quot;: -110.92648, &quot;nct&quot;: &quot;NCT05269862&quot;, &quot;color&quot;: &quot;#0bbc55&quot;, &quot;title&quot;: &quot;Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)&quot;, &quot;sponsor&quot;: &quot;Abbott Medical Devices&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05269862&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 38.58157, &quot;lng&quot;: -121.4944, &quot;nct&quot;: &quot;NCT05269862&quot;, &quot;color&quot;: &quot;#0bbc55&quot;, &quot;title&quot;: &quot;Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)&quot;, &quot;sponsor&quot;: &quot;Abbott Medical Devices&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05269862&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 25.77427, &quot;lng&quot;: -80.19366, &quot;nct&quot;: &quot;NCT05269862&quot;, &quot;color&quot;: &quot;#0bbc55&quot;, &quot;title&quot;: &quot;Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)&quot;, &quot;sponsor&quot;: &quot;Abbott Medical Devices&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05269862&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.85003, &quot;lng&quot;: -87.65005, &quot;nct&quot;: &quot;NCT05269862&quot;, &quot;color&quot;: &quot;#0bbc55&quot;, &quot;title&quot;: &quot;Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)&quot;, &quot;sponsor&quot;: &quot;Abbott Medical Devices&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05269862&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.76838, &quot;lng&quot;: -86.15804, &quot;nct&quot;: &quot;NCT05269862&quot;, &quot;color&quot;: &quot;#0bbc55&quot;, &quot;title&quot;: &quot;Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)&quot;, &quot;sponsor&quot;: &quot;Abbott Medical Devices&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05269862&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.35843, &quot;lng&quot;: -71.05977, &quot;nct&quot;: &quot;NCT05269862&quot;, &quot;color&quot;: &quot;#0bbc55&quot;, &quot;title&quot;: &quot;Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)&quot;, &quot;sponsor&quot;: &quot;Abbott Medical Devices&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05269862&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.64229, &quot;lng&quot;: -72.25176, &quot;nct&quot;: &quot;NCT05269862&quot;, &quot;color&quot;: &quot;#0bbc55&quot;, &quot;title&quot;: &quot;Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)&quot;, &quot;sponsor&quot;: &quot;Abbott Medical Devices&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05269862&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.4995, &quot;lng&quot;: -81.69541, &quot;nct&quot;: &quot;NCT05269862&quot;, &quot;color&quot;: &quot;#0bbc55&quot;, &quot;title&quot;: &quot;Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)&quot;, &quot;sponsor&quot;: &quot;Abbott Medical Devices&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05269862&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.96118, &quot;lng&quot;: -82.99879, &quot;nct&quot;: &quot;NCT05269862&quot;, &quot;color&quot;: &quot;#0bbc55&quot;, &quot;title&quot;: &quot;Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)&quot;, &quot;sponsor&quot;: &quot;Abbott Medical Devices&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05269862&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.95238, &quot;lng&quot;: -75.16362, &quot;nct&quot;: &quot;NCT05269862&quot;, &quot;color&quot;: &quot;#0bbc55&quot;, &quot;title&quot;: &quot;Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)&quot;, &quot;sponsor&quot;: &quot;Abbott Medical Devices&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05269862&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 30.63269, &quot;lng&quot;: -97.67723, &quot;nct&quot;: &quot;NCT05269862&quot;, &quot;color&quot;: &quot;#0bbc55&quot;, &quot;title&quot;: &quot;Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)&quot;, &quot;sponsor&quot;: &quot;Abbott Medical Devices&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05269862&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.52266, &quot;lng&quot;: 9.05222, &quot;nct&quot;: &quot;NCT05269862&quot;, &quot;color&quot;: &quot;#0bbc55&quot;, &quot;title&quot;: &quot;Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)&quot;, &quot;sponsor&quot;: &quot;Abbott Medical Devices&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05269862&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.22172, &quot;lng&quot;: 6.77616, &quot;nct&quot;: &quot;NCT05269862&quot;, &quot;color&quot;: &quot;#0bbc55&quot;, &quot;title&quot;: &quot;Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)&quot;, &quot;sponsor&quot;: &quot;Abbott Medical Devices&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05269862&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 49.98185, &quot;lng&quot;: 8.28008, &quot;nct&quot;: &quot;NCT05269862&quot;, &quot;color&quot;: &quot;#0bbc55&quot;, &quot;title&quot;: &quot;Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)&quot;, &quot;sponsor&quot;: &quot;Abbott Medical Devices&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05269862&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.45004, &quot;lng&quot;: 2.24741, &quot;nct&quot;: &quot;NCT05269862&quot;, &quot;color&quot;: &quot;#0bbc55&quot;, &quot;title&quot;: &quot;Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)&quot;, &quot;sponsor&quot;: &quot;Abbott Medical Devices&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05269862&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.4165, &quot;lng&quot;: -3.70256, &quot;nct&quot;: &quot;NCT05269862&quot;, &quot;color&quot;: &quot;#0bbc55&quot;, &quot;title&quot;: &quot;Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)&quot;, &quot;sponsor&quot;: &quot;Abbott Medical Devices&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05269862&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.38283, &quot;lng&quot;: -5.97317, &quot;nct&quot;: &quot;NCT05269862&quot;, &quot;color&quot;: &quot;#0bbc55&quot;, &quot;title&quot;: &quot;Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)&quot;, &quot;sponsor&quot;: &quot;Abbott Medical Devices&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05269862&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 55.86515, &quot;lng&quot;: -4.25763, &quot;nct&quot;: &quot;NCT05269862&quot;, &quot;color&quot;: &quot;#0bbc55&quot;, &quot;title&quot;: &quot;Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature; Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)&quot;, &quot;sponsor&quot;: &quot;Abbott Medical Devices&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05269862&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.90812, &quot;lng&quot;: 30.69556, &quot;nct&quot;: &quot;NCT05919485&quot;, &quot;color&quot;: &quot;#1a56bb&quot;, &quot;title&quot;: &quot;The Effects of Specific tDCS on Cognition in MCI&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;tDCS&quot;, &quot;sponsor&quot;: &quot;Istanbul Medipol University Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05919485&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 49.01096, &quot;lng&quot;: 1.0873, &quot;nct&quot;: &quot;NCT06695455&quot;, &quot;color&quot;: &quot;#b61b4c&quot;, &quot;title&quot;: &quot;The Effect of an Auditory Rhythmic Cue on the Frequency of Rolling in Patients with Dysphagia and Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Swallowing rehabilitation by rhythmic auditory cue&quot;, &quot;sponsor&quot;: &quot;Hopital La Musse&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06695455&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.85003, &quot;lng&quot;: -87.65005, &quot;nct&quot;: &quot;NCT03667404&quot;, &quot;color&quot;: &quot;#57e5dd&quot;, &quot;title&quot;: &quot;Resistant Maltodextrin for Gut Microbiome in Parkinson&#x27;s Disease: Safety and Tolerability Study&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Resistant maltodextrin; maltodextrin&quot;, &quot;sponsor&quot;: &quot;Northwestern University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03667404&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 54.32133, &quot;lng&quot;: 10.13489, &quot;nct&quot;: &quot;NCT06463769&quot;, &quot;color&quot;: &quot;#cb0070&quot;, &quot;title&quot;: &quot;Impact of Diet on the Microbiome-Immune-Brain Axis in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;8 week predominantly plant-based New Nordic LPF-diet program; maintenance of the predominantly plant-based New Nordic LPF-diet&quot;, &quot;sponsor&quot;: &quot;University of Kiel&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06463769&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 44.97997, &quot;lng&quot;: -93.26384, &quot;nct&quot;: &quot;NCT06848205&quot;, &quot;color&quot;: &quot;#9018ca&quot;, &quot;title&quot;: &quot;Percept Transitions in FOG and PD&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;OFF Parkinson&#x27;s Medication(s); OFF Deep Brain Stimulation&quot;, &quot;sponsor&quot;: &quot;University of Minnesota&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06848205&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 31.30408, &quot;lng&quot;: 120.59538, &quot;nct&quot;: &quot;NCT06129942&quot;, &quot;color&quot;: &quot;#a3c4bc&quot;, &quot;title&quot;: &quot;Light Therapy in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Bright light box; Dim Light box&quot;, &quot;sponsor&quot;: &quot;Second Affiliated Hospital of Soochow University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06129942&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.60717, &quot;lng&quot;: 13.5103, &quot;nct&quot;: &quot;NCT04087031&quot;, &quot;color&quot;: &quot;#08b905&quot;, &quot;title&quot;: &quot;Innovative Models in the Rehabilitation of the Elderly With Parkinson&#x27;s Disease Through Technological Innovation&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;control arm; virtual reality games; robotic treadmill&quot;, &quot;sponsor&quot;: &quot;Istituto Nazionale di Ricovero e Cura per Anziani&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04087031&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.16296, &quot;lng&quot;: 13.72274, &quot;nct&quot;: &quot;NCT04087031&quot;, &quot;color&quot;: &quot;#08b905&quot;, &quot;title&quot;: &quot;Innovative Models in the Rehabilitation of the Elderly With Parkinson&#x27;s Disease Through Technological Innovation&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;control arm; virtual reality games; robotic treadmill&quot;, &quot;sponsor&quot;: &quot;Istituto Nazionale di Ricovero e Cura per Anziani&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04087031&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.05048, &quot;lng&quot;: 8.30635, &quot;nct&quot;: &quot;NCT06062693&quot;, &quot;color&quot;: &quot;#46df88&quot;, &quot;title&quot;: &quot;New Interactive Sensor-home-based Hand Training to Improve Dexterity&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;smart sensor egg training&quot;, &quot;sponsor&quot;: &quot;Luzerner Kantonsspital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06062693&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 49.24966, &quot;lng&quot;: -123.11934, &quot;nct&quot;: &quot;NCT05469997&quot;, &quot;color&quot;: &quot;#e71323&quot;, &quot;title&quot;: &quot;Ketogenic Diet Interventions in Parkinson&#x27;s Disease: Safeguarding the Gut Microbiome&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Mediterranean-Ketogenic Diet; Mediterranean diet supplemented with medium-chain triglyceride oil&quot;, &quot;sponsor&quot;: &quot;University of British Columbia&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05469997&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.37403, &quot;lng&quot;: 4.88969, &quot;nct&quot;: &quot;NCT06909045&quot;, &quot;color&quot;: &quot;#f2cf63&quot;, &quot;title&quot;: &quot;Adaptive vs. Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Adaptive DBS; Continue DBS&quot;, &quot;sponsor&quot;: &quot;Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06909045&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.84833, &quot;lng&quot;: 5.68889, &quot;nct&quot;: &quot;NCT06909045&quot;, &quot;color&quot;: &quot;#f2cf63&quot;, &quot;title&quot;: &quot;Adaptive vs. Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Adaptive DBS; Continue DBS&quot;, &quot;sponsor&quot;: &quot;Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06909045&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.07667, &quot;lng&quot;: 4.29861, &quot;nct&quot;: &quot;NCT06909045&quot;, &quot;color&quot;: &quot;#f2cf63&quot;, &quot;title&quot;: &quot;Adaptive vs. Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Adaptive DBS; Continue DBS&quot;, &quot;sponsor&quot;: &quot;Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06909045&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 32.78306, &quot;lng&quot;: -96.80667, &quot;nct&quot;: &quot;NCT05982730&quot;, &quot;color&quot;: &quot;#efc480&quot;, &quot;title&quot;: &quot;SegwayPD: The Effect of Sensory-augmented Postural Training Using Segway on Motor and Cognitive Function in Individuals With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Sensory-Augmented Postural Training&quot;, &quot;sponsor&quot;: &quot;University of Texas Southwestern Medical Center&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05982730&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.9075, &quot;lng&quot;: 116.39723, &quot;nct&quot;: &quot;NCT06607900&quot;, &quot;color&quot;: &quot;#42aeef&quot;, &quot;title&quot;: &quot;hUC-MSC-sEV-001 Nasal Drops for Neurodegenerative Diseases&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;hUC-MSC-sEV-001 nasal drops&quot;, &quot;sponsor&quot;: &quot;Xuanwu Hospital, Beijing&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06607900&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 30.78847, &quot;lng&quot;: 31.00192, &quot;nct&quot;: &quot;NCT05781711&quot;, &quot;color&quot;: &quot;#9182a7&quot;, &quot;title&quot;: &quot;Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;levodopa-carbidopa; Metformin&quot;, &quot;sponsor&quot;: &quot;Tanta University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05781711&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 24.9896, &quot;lng&quot;: 121.3187, &quot;nct&quot;: &quot;NCT06363071&quot;, &quot;color&quot;: &quot;#1c7e11&quot;, &quot;title&quot;: &quot;APA and PAS Training for Gait Initiation in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Weight shift training and APA feedback; Paired associative stimulation&quot;, &quot;sponsor&quot;: &quot;Chang Gung University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06363071&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 53.1235, &quot;lng&quot;: 18.00762, &quot;nct&quot;: &quot;NCT06671938&quot;, &quot;color&quot;: &quot;#e01f7a&quot;, &quot;title&quot;: &quot;Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson&#x27;s Disease and Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;exidavnemab; Placebo Comparator&quot;, &quot;sponsor&quot;: &quot;BioArctic AB&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06671938&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 50.06143, &quot;lng&quot;: 19.93658, &quot;nct&quot;: &quot;NCT06671938&quot;, &quot;color&quot;: &quot;#e01f7a&quot;, &quot;title&quot;: &quot;Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson&#x27;s Disease and Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;exidavnemab; Placebo Comparator&quot;, &quot;sponsor&quot;: &quot;BioArctic AB&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06671938&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 37.38283, &quot;lng&quot;: -5.97317, &quot;nct&quot;: &quot;NCT06671938&quot;, &quot;color&quot;: &quot;#e01f7a&quot;, &quot;title&quot;: &quot;Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson&#x27;s Disease and Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;exidavnemab; Placebo Comparator&quot;, &quot;sponsor&quot;: &quot;BioArctic AB&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06671938&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 41.38879, &quot;lng&quot;: 2.15899, &quot;nct&quot;: &quot;NCT06671938&quot;, &quot;color&quot;: &quot;#e01f7a&quot;, &quot;title&quot;: &quot;Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson&#x27;s Disease and Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;exidavnemab; Placebo Comparator&quot;, &quot;sponsor&quot;: &quot;BioArctic AB&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06671938&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 41.47063, &quot;lng&quot;: 2.08611, &quot;nct&quot;: &quot;NCT06671938&quot;, &quot;color&quot;: &quot;#e01f7a&quot;, &quot;title&quot;: &quot;Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson&#x27;s Disease and Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;exidavnemab; Placebo Comparator&quot;, &quot;sponsor&quot;: &quot;BioArctic AB&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06671938&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.4165, &quot;lng&quot;: -3.70256, &quot;nct&quot;: &quot;NCT06671938&quot;, &quot;color&quot;: &quot;#e01f7a&quot;, &quot;title&quot;: &quot;Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson&#x27;s Disease and Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;exidavnemab; Placebo Comparator&quot;, &quot;sponsor&quot;: &quot;BioArctic AB&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06671938&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 43.56667, &quot;lng&quot;: -5.9, &quot;nct&quot;: &quot;NCT06671938&quot;, &quot;color&quot;: &quot;#e01f7a&quot;, &quot;title&quot;: &quot;Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson&#x27;s Disease and Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;exidavnemab; Placebo Comparator&quot;, &quot;sponsor&quot;: &quot;BioArctic AB&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06671938&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.78871, &quot;lng&quot;: -73.59957, &quot;nct&quot;: &quot;NCT05884944&quot;, &quot;color&quot;: &quot;#8c60ad&quot;, &quot;title&quot;: &quot;Effects Of Osteopathic Manipulative Medicine(OMM) On Lower Extremity Muscle Characteristics In Parkinson&#x27;s Disease(PD) Patients&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Sham- Light touch, not reaching restrictive barrier; Experimental: Interventional Group- OMM- Muscle energy&quot;, &quot;sponsor&quot;: &quot;New York Institute of Technology&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05884944&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 44.99364, &quot;lng&quot;: 11.10642, &quot;nct&quot;: &quot;NCT05769699&quot;, &quot;color&quot;: &quot;#f13bbd&quot;, &quot;title&quot;: &quot;Serum Biomarkers in Parkinson&#x27;s Disease at Different Stages&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;blood sample&quot;, &quot;sponsor&quot;: &quot;Fondazione Policlinico Universitario Agostino Gemelli IRCCS&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05769699&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 34.27834, &quot;lng&quot;: -119.29317, &quot;nct&quot;: &quot;NCT06647277&quot;, &quot;color&quot;: &quot;#e74c2d&quot;, &quot;title&quot;: &quot;Fecal MicrobiotaTransplant for the Treatment of Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;Fecal Microbiota Transplant&quot;, &quot;sponsor&quot;: &quot;ProgenaBiome&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06647277&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.52066, &quot;lng&quot;: -86.80249, &quot;nct&quot;: &quot;NCT04284436&quot;, &quot;color&quot;: &quot;#47f2ea&quot;, &quot;title&quot;: &quot;Study in Parkinson Disease of Exercise&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Treadmill walking&quot;, &quot;sponsor&quot;: &quot;Northwestern University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04284436&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.77493, &quot;lng&quot;: -122.41942, &quot;nct&quot;: &quot;NCT04284436&quot;, &quot;color&quot;: &quot;#47f2ea&quot;, &quot;title&quot;: &quot;Study in Parkinson Disease of Exercise&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Treadmill walking&quot;, &quot;sponsor&quot;: &quot;Northwestern University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04284436&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.72943, &quot;lng&quot;: -104.83192, &quot;nct&quot;: &quot;NCT04284436&quot;, &quot;color&quot;: &quot;#47f2ea&quot;, &quot;title&quot;: &quot;Study in Parkinson Disease of Exercise&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Treadmill walking&quot;, &quot;sponsor&quot;: &quot;Northwestern University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04284436&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.65163, &quot;lng&quot;: -82.32483, &quot;nct&quot;: &quot;NCT04284436&quot;, &quot;color&quot;: &quot;#47f2ea&quot;, &quot;title&quot;: &quot;Study in Parkinson Disease of Exercise&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Treadmill walking&quot;, &quot;sponsor&quot;: &quot;Northwestern University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04284436&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.749, &quot;lng&quot;: -84.38798, &quot;nct&quot;: &quot;NCT04284436&quot;, &quot;color&quot;: &quot;#47f2ea&quot;, &quot;title&quot;: &quot;Study in Parkinson Disease of Exercise&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Treadmill walking&quot;, &quot;sponsor&quot;: &quot;Northwestern University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04284436&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.85003, &quot;lng&quot;: -87.65005, &quot;nct&quot;: &quot;NCT04284436&quot;, &quot;color&quot;: &quot;#47f2ea&quot;, &quot;title&quot;: &quot;Study in Parkinson Disease of Exercise&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Treadmill walking&quot;, &quot;sponsor&quot;: &quot;Northwestern University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04284436&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.03471, &quot;lng&quot;: -93.61994, &quot;nct&quot;: &quot;NCT04284436&quot;, &quot;color&quot;: &quot;#47f2ea&quot;, &quot;title&quot;: &quot;Study in Parkinson Disease of Exercise&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Treadmill walking&quot;, &quot;sponsor&quot;: &quot;Northwestern University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04284436&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 30.44332, &quot;lng&quot;: -91.18747, &quot;nct&quot;: &quot;NCT04284436&quot;, &quot;color&quot;: &quot;#47f2ea&quot;, &quot;title&quot;: &quot;Study in Parkinson Disease of Exercise&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Treadmill walking&quot;, &quot;sponsor&quot;: &quot;Northwestern University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04284436&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.35843, &quot;lng&quot;: -71.05977, &quot;nct&quot;: &quot;NCT04284436&quot;, &quot;color&quot;: &quot;#47f2ea&quot;, &quot;title&quot;: &quot;Study in Parkinson Disease of Exercise&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Treadmill walking&quot;, &quot;sponsor&quot;: &quot;Northwestern University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04284436&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.27756, &quot;lng&quot;: -83.74088, &quot;nct&quot;: &quot;NCT04284436&quot;, &quot;color&quot;: &quot;#47f2ea&quot;, &quot;title&quot;: &quot;Study in Parkinson Disease of Exercise&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Treadmill walking&quot;, &quot;sponsor&quot;: &quot;Northwestern University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04284436&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 44.97997, &quot;lng&quot;: -93.26384, &quot;nct&quot;: &quot;NCT04284436&quot;, &quot;color&quot;: &quot;#47f2ea&quot;, &quot;title&quot;: &quot;Study in Parkinson Disease of Exercise&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Treadmill walking&quot;, &quot;sponsor&quot;: &quot;Northwestern University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04284436&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 38.62727, &quot;lng&quot;: -90.19789, &quot;nct&quot;: &quot;NCT04284436&quot;, &quot;color&quot;: &quot;#47f2ea&quot;, &quot;title&quot;: &quot;Study in Parkinson Disease of Exercise&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Treadmill walking&quot;, &quot;sponsor&quot;: &quot;Northwestern University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04284436&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.71427, &quot;lng&quot;: -74.00597, &quot;nct&quot;: &quot;NCT04284436&quot;, &quot;color&quot;: &quot;#47f2ea&quot;, &quot;title&quot;: &quot;Study in Parkinson Disease of Exercise&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Treadmill walking&quot;, &quot;sponsor&quot;: &quot;Northwestern University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04284436&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.12711, &quot;lng&quot;: -84.51439, &quot;nct&quot;: &quot;NCT04284436&quot;, &quot;color&quot;: &quot;#47f2ea&quot;, &quot;title&quot;: &quot;Study in Parkinson Disease of Exercise&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Treadmill walking&quot;, &quot;sponsor&quot;: &quot;Northwestern University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04284436&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.4995, &quot;lng&quot;: -81.69541, &quot;nct&quot;: &quot;NCT04284436&quot;, &quot;color&quot;: &quot;#47f2ea&quot;, &quot;title&quot;: &quot;Study in Parkinson Disease of Exercise&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Treadmill walking&quot;, &quot;sponsor&quot;: &quot;Northwestern University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04284436&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.96118, &quot;lng&quot;: -82.99879, &quot;nct&quot;: &quot;NCT04284436&quot;, &quot;color&quot;: &quot;#47f2ea&quot;, &quot;title&quot;: &quot;Study in Parkinson Disease of Exercise&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Treadmill walking&quot;, &quot;sponsor&quot;: &quot;Northwestern University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04284436&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.15367, &quot;lng&quot;: -81.35789, &quot;nct&quot;: &quot;NCT04284436&quot;, &quot;color&quot;: &quot;#47f2ea&quot;, &quot;title&quot;: &quot;Study in Parkinson Disease of Exercise&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Treadmill walking&quot;, &quot;sponsor&quot;: &quot;Northwestern University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04284436&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.52345, &quot;lng&quot;: -122.67621, &quot;nct&quot;: &quot;NCT04284436&quot;, &quot;color&quot;: &quot;#47f2ea&quot;, &quot;title&quot;: &quot;Study in Parkinson Disease of Exercise&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Treadmill walking&quot;, &quot;sponsor&quot;: &quot;Northwestern University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04284436&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.95238, &quot;lng&quot;: -75.16362, &quot;nct&quot;: &quot;NCT04284436&quot;, &quot;color&quot;: &quot;#47f2ea&quot;, &quot;title&quot;: &quot;Study in Parkinson Disease of Exercise&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Treadmill walking&quot;, &quot;sponsor&quot;: &quot;Northwestern University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04284436&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.44062, &quot;lng&quot;: -79.99589, &quot;nct&quot;: &quot;NCT04284436&quot;, &quot;color&quot;: &quot;#47f2ea&quot;, &quot;title&quot;: &quot;Study in Parkinson Disease of Exercise&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Treadmill walking&quot;, &quot;sponsor&quot;: &quot;Northwestern University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04284436&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.42412, &quot;lng&quot;: -98.49363, &quot;nct&quot;: &quot;NCT04284436&quot;, &quot;color&quot;: &quot;#47f2ea&quot;, &quot;title&quot;: &quot;Study in Parkinson Disease of Exercise&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Treadmill walking&quot;, &quot;sponsor&quot;: &quot;Northwestern University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04284436&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.76078, &quot;lng&quot;: -111.89105, &quot;nct&quot;: &quot;NCT04284436&quot;, &quot;color&quot;: &quot;#47f2ea&quot;, &quot;title&quot;: &quot;Study in Parkinson Disease of Exercise&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Treadmill walking&quot;, &quot;sponsor&quot;: &quot;Northwestern University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04284436&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 53.55014, &quot;lng&quot;: -113.46871, &quot;nct&quot;: &quot;NCT04284436&quot;, &quot;color&quot;: &quot;#47f2ea&quot;, &quot;title&quot;: &quot;Study in Parkinson Disease of Exercise&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Treadmill walking&quot;, &quot;sponsor&quot;: &quot;Northwestern University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04284436&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.77493, &quot;lng&quot;: -122.41942, &quot;nct&quot;: &quot;NCT06455293&quot;, &quot;color&quot;: &quot;#2621d8&quot;, &quot;title&quot;: &quot;Psilocybin Therapy for Depression in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Psilocybin&quot;, &quot;sponsor&quot;: &quot;Joshua Woolley, MD, PhD&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06455293&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 30.33218, &quot;lng&quot;: -81.65565, &quot;nct&quot;: &quot;NCT06263673&quot;, &quot;color&quot;: &quot;#6e7d77&quot;, &quot;title&quot;: &quot;Anti-Diabetic Medications to Fight PD and LBD&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Sitagliptin; Dapagliflozin; Placebo&quot;, &quot;sponsor&quot;: &quot;Mayo Clinic&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06263673&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.27756, &quot;lng&quot;: -83.74088, &quot;nct&quot;: &quot;NCT05459753&quot;, &quot;color&quot;: &quot;#55b086&quot;, &quot;title&quot;: &quot;Cholinergic Mechanisms of Attentional-motor Integration and Gait Dysfunction in Parkinson Disease (UDALL)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;(18)F]fluoroethoxybenzovesamicol ([(18)F (FEOBV) PET; Dihydrotetrabenazine (DTBZ) PET&quot;, &quot;sponsor&quot;: &quot;University of Michigan&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05459753&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 38.62727, &quot;lng&quot;: -90.19789, &quot;nct&quot;: &quot;NCT06859528&quot;, &quot;color&quot;: &quot;#6669af&quot;, &quot;title&quot;: &quot;Step Up to PD: A Community-based Walking Program for People With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Community Walking Program&quot;, &quot;sponsor&quot;: &quot;St. Louis University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06859528&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 44.97997, &quot;lng&quot;: -93.26384, &quot;nct&quot;: &quot;NCT05893186&quot;, &quot;color&quot;: &quot;#3d89b8&quot;, &quot;title&quot;: &quot;Multiple Objective Particle Swarm Optimization Postural Instability Gait Disorder&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;EARLY_PHASE1&quot;], &quot;interventions&quot;: &quot;Deep Brain Stimulation, STN; GP Deep Brain Stimulation&quot;, &quot;sponsor&quot;: &quot;University of Minnesota&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05893186&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 58.97005, &quot;lng&quot;: 5.73332, &quot;nct&quot;: &quot;NCT06487975&quot;, &quot;color&quot;: &quot;#0e4bdd&quot;, &quot;title&quot;: &quot;Bacillus Subtilis in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Bacillus Subtilis; Placebo&quot;, &quot;sponsor&quot;: &quot;University of Edinburgh&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06487975&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 55.95206, &quot;lng&quot;: -3.19648, &quot;nct&quot;: &quot;NCT06487975&quot;, &quot;color&quot;: &quot;#0e4bdd&quot;, &quot;title&quot;: &quot;Bacillus Subtilis in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Bacillus Subtilis; Placebo&quot;, &quot;sponsor&quot;: &quot;University of Edinburgh&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06487975&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 25.05306, &quot;lng&quot;: 121.52639, &quot;nct&quot;: &quot;NCT05800470&quot;, &quot;color&quot;: &quot;#849c5c&quot;, &quot;title&quot;: &quot;The Effects of fNIRS-based Neurofeedback Training on Balance and Gait in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;fNIRS-based neurofeedback with motor imagery; Kinesthetic motor imagery; Motor training&quot;, &quot;sponsor&quot;: &quot;National Yang Ming Chiao Tung University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05800470&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.91987, &quot;lng&quot;: 32.85427, &quot;nct&quot;: &quot;NCT05900934&quot;, &quot;color&quot;: &quot;#fc12cd&quot;, &quot;title&quot;: &quot;The Effects Of Myofascial Release In Combined With Task-Oriented Circuit Training On Balance And Gait In People With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Myofascial Releasing Group; Sham Myofascial Releasing Group&quot;, &quot;sponsor&quot;: &quot;Hacettepe University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05900934&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.44188, &quot;lng&quot;: -122.14302, &quot;nct&quot;: &quot;NCT07001072&quot;, &quot;color&quot;: &quot;#bd20ab&quot;, &quot;title&quot;: &quot;Smartshoes for Freezing of Gait in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Smartshoes with haptic vibration feedback&quot;, &quot;sponsor&quot;: &quot;Stanford University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07001072&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.05048, &quot;lng&quot;: 8.30635, &quot;nct&quot;: &quot;NCT05965661&quot;, &quot;color&quot;: &quot;#280127&quot;, &quot;title&quot;: &quot;A New 3D Virtual Reality-based Upper Limb Training to Improve Dexterity in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;virtual reality upper limb hand training; virtual reality control training&quot;, &quot;sponsor&quot;: &quot;Luzerner Kantonsspital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05965661&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.48165, &quot;lng&quot;: 7.21648, &quot;nct&quot;: &quot;NCT06015841&quot;, &quot;color&quot;: &quot;#bf1988&quot;, &quot;title&quot;: &quot;A Study to Evaluate the Effects of ACI-7104.056 Vaccination in Patients With Early Stages of Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo; ACI-7104.056 at Dose A; ACI-7104.056 at Dose B (optional); ACI-7104.056 at Dose C (optional)&quot;, &quot;sponsor&quot;: &quot;AC Immune SA&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06015841&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.31667, &quot;lng&quot;: 9.5, &quot;nct&quot;: &quot;NCT06015841&quot;, &quot;color&quot;: &quot;#bf1988&quot;, &quot;title&quot;: &quot;A Study to Evaluate the Effects of ACI-7104.056 Vaccination in Patients With Early Stages of Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo; ACI-7104.056 at Dose A; ACI-7104.056 at Dose B (optional); ACI-7104.056 at Dose C (optional)&quot;, &quot;sponsor&quot;: &quot;AC Immune SA&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06015841&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 54.32133, &quot;lng&quot;: 10.13489, &quot;nct&quot;: &quot;NCT06015841&quot;, &quot;color&quot;: &quot;#bf1988&quot;, &quot;title&quot;: &quot;A Study to Evaluate the Effects of ACI-7104.056 Vaccination in Patients With Early Stages of Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo; ACI-7104.056 at Dose A; ACI-7104.056 at Dose B (optional); ACI-7104.056 at Dose C (optional)&quot;, &quot;sponsor&quot;: &quot;AC Immune SA&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06015841&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.38879, &quot;lng&quot;: 2.15899, &quot;nct&quot;: &quot;NCT06015841&quot;, &quot;color&quot;: &quot;#bf1988&quot;, &quot;title&quot;: &quot;A Study to Evaluate the Effects of ACI-7104.056 Vaccination in Patients With Early Stages of Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo; ACI-7104.056 at Dose A; ACI-7104.056 at Dose B (optional); ACI-7104.056 at Dose C (optional)&quot;, &quot;sponsor&quot;: &quot;AC Immune SA&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06015841&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.31283, &quot;lng&quot;: -1.97499, &quot;nct&quot;: &quot;NCT06015841&quot;, &quot;color&quot;: &quot;#bf1988&quot;, &quot;title&quot;: &quot;A Study to Evaluate the Effects of ACI-7104.056 Vaccination in Patients With Early Stages of Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo; ACI-7104.056 at Dose A; ACI-7104.056 at Dose B (optional); ACI-7104.056 at Dose C (optional)&quot;, &quot;sponsor&quot;: &quot;AC Immune SA&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06015841&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.4165, &quot;lng&quot;: -3.70256, &quot;nct&quot;: &quot;NCT06015841&quot;, &quot;color&quot;: &quot;#bf1988&quot;, &quot;title&quot;: &quot;A Study to Evaluate the Effects of ACI-7104.056 Vaccination in Patients With Early Stages of Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo; ACI-7104.056 at Dose A; ACI-7104.056 at Dose B (optional); ACI-7104.056 at Dose C (optional)&quot;, &quot;sponsor&quot;: &quot;AC Immune SA&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06015841&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.47353, &quot;lng&quot;: -3.87182, &quot;nct&quot;: &quot;NCT06015841&quot;, &quot;color&quot;: &quot;#bf1988&quot;, &quot;title&quot;: &quot;A Study to Evaluate the Effects of ACI-7104.056 Vaccination in Patients With Early Stages of Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo; ACI-7104.056 at Dose A; ACI-7104.056 at Dose B (optional); ACI-7104.056 at Dose C (optional)&quot;, &quot;sponsor&quot;: &quot;AC Immune SA&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06015841&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.43293, &quot;lng&quot;: -3.81338, &quot;nct&quot;: &quot;NCT06015841&quot;, &quot;color&quot;: &quot;#bf1988&quot;, &quot;title&quot;: &quot;A Study to Evaluate the Effects of ACI-7104.056 Vaccination in Patients With Early Stages of Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo; ACI-7104.056 at Dose A; ACI-7104.056 at Dose B (optional); ACI-7104.056 at Dose C (optional)&quot;, &quot;sponsor&quot;: &quot;AC Immune SA&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06015841&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.50853, &quot;lng&quot;: -0.12574, &quot;nct&quot;: &quot;NCT06015841&quot;, &quot;color&quot;: &quot;#bf1988&quot;, &quot;title&quot;: &quot;A Study to Evaluate the Effects of ACI-7104.056 Vaccination in Patients With Early Stages of Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo; ACI-7104.056 at Dose A; ACI-7104.056 at Dose B (optional); ACI-7104.056 at Dose C (optional)&quot;, &quot;sponsor&quot;: &quot;AC Immune SA&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06015841&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 53.48771, &quot;lng&quot;: -2.29042, &quot;nct&quot;: &quot;NCT06015841&quot;, &quot;color&quot;: &quot;#bf1988&quot;, &quot;title&quot;: &quot;A Study to Evaluate the Effects of ACI-7104.056 Vaccination in Patients With Early Stages of Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Placebo; ACI-7104.056 at Dose A; ACI-7104.056 at Dose B (optional); ACI-7104.056 at Dose C (optional)&quot;, &quot;sponsor&quot;: &quot;AC Immune SA&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06015841&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: -19.92083, &quot;lng&quot;: -43.93778, &quot;nct&quot;: &quot;NCT06646523&quot;, &quot;color&quot;: &quot;#e39c6c&quot;, &quot;title&quot;: &quot;Effects of Home-based High-speed Bodyweight Resistance Training in Individual with Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;High-speed bodyweight resistance training; Control group (Bodyweight intervention, usual speed)&quot;, &quot;sponsor&quot;: &quot;Federal University of Minas Gerais&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06646523&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.566, &quot;lng&quot;: 126.9784, &quot;nct&quot;: &quot;NCT05995782&quot;, &quot;color&quot;: &quot;#f3aa20&quot;, &quot;title&quot;: &quot;A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;FB418&quot;, &quot;sponsor&quot;: &quot;1ST Biotherapeutics, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05995782&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.60621, &quot;lng&quot;: -122.33207, &quot;nct&quot;: &quot;NCT02696603&quot;, &quot;color&quot;: &quot;#9d6e8d&quot;, &quot;title&quot;: &quot;Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Participant self-assessment surveys; Phonation; Gait and balance; Memory; Dexterity; Participant open-response writing; Parkinson mPower mobile application&quot;, &quot;sponsor&quot;: &quot;Sage Bionetworks&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT02696603&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 56.15674, &quot;lng&quot;: 10.21076, &quot;nct&quot;: &quot;NCT05981261&quot;, &quot;color&quot;: &quot;#7422ae&quot;, &quot;title&quot;: &quot;Experimental Pain in Parkinsons&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;inducement of experimental pain&quot;, &quot;sponsor&quot;: &quot;University of Aarhus&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05981261&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 44.02163, &quot;lng&quot;: -92.4699, &quot;nct&quot;: &quot;NCT05779839&quot;, &quot;color&quot;: &quot;#2ce3c5&quot;, &quot;title&quot;: &quot;A Study of Caregiver Connections Via Technology in Dementia&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Algorithm; Random Match&quot;, &quot;sponsor&quot;: &quot;Mayo Clinic&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05779839&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.71427, &quot;lng&quot;: -74.00597, &quot;nct&quot;: &quot;NCT06540989&quot;, &quot;color&quot;: &quot;#66314c&quot;, &quot;title&quot;: &quot;Noise-augmented Automatic Speech Recognition for Speech Treatment in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;EARLY_PHASE1&quot;], &quot;interventions&quot;: &quot;Immediate treatment; Deferred treatment&quot;, &quot;sponsor&quot;: &quot;Teachers College, Columbia University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06540989&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 38.19394, &quot;lng&quot;: 15.55256, &quot;nct&quot;: &quot;NCT04045080&quot;, &quot;color&quot;: &quot;#1446ca&quot;, &quot;title&quot;: &quot;Hand Rehab Using AMADEO in PD Patients&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;AMADEO; Training; OT Training&quot;, &quot;sponsor&quot;: &quot;IRCCS Centro Neurolesi Bonino Pulejo&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04045080&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.52066, &quot;lng&quot;: -86.80249, &quot;nct&quot;: &quot;NCT03797378&quot;, &quot;color&quot;: &quot;#a1f437&quot;, &quot;title&quot;: &quot;Movement-2-Music: Lakeshore Examination of Activity, Disability, and Exercise Response Study&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;eM2M&quot;, &quot;sponsor&quot;: &quot;University of Alabama at Birmingham&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03797378&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 34.05223, &quot;lng&quot;: -118.24368, &quot;nct&quot;: &quot;NCT04386317&quot;, &quot;color&quot;: &quot;#d01bc7&quot;, &quot;title&quot;: &quot;Terazosin Effect on Cardiac Changes in Early Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Terazosin&quot;, &quot;sponsor&quot;: &quot;Cedars-Sinai Medical Center&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04386317&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 35.9132, &quot;lng&quot;: -79.05584, &quot;nct&quot;: &quot;NCT06087926&quot;, &quot;color&quot;: &quot;#7f738a&quot;, &quot;title&quot;: &quot;Apathy in Parkinson Disease TMS Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Transcranial Magnetic Stimulation (TMS)&quot;, &quot;sponsor&quot;: &quot;University of North Carolina, Chapel Hill&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06087926&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.77969, &quot;lng&quot;: 3.08682, &quot;nct&quot;: &quot;NCT06582121&quot;, &quot;color&quot;: &quot;#ffa76a&quot;, &quot;title&quot;: &quot;Study of Sleep Disorders in Prodromal and Definite Parkinsons Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Polysomnography&quot;, &quot;sponsor&quot;: &quot;Assistance Publique - H\\u00f4pitaux de Paris&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06582121&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.63391, &quot;lng&quot;: 3.05512, &quot;nct&quot;: &quot;NCT06582121&quot;, &quot;color&quot;: &quot;#ffa76a&quot;, &quot;title&quot;: &quot;Study of Sleep Disorders in Prodromal and Definite Parkinsons Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Polysomnography&quot;, &quot;sponsor&quot;: &quot;Assistance Publique - H\\u00f4pitaux de Paris&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06582121&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.74906, &quot;lng&quot;: 4.84789, &quot;nct&quot;: &quot;NCT06582121&quot;, &quot;color&quot;: &quot;#ffa76a&quot;, &quot;title&quot;: &quot;Study of Sleep Disorders in Prodromal and Definite Parkinsons Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Polysomnography&quot;, &quot;sponsor&quot;: &quot;Assistance Publique - H\\u00f4pitaux de Paris&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06582121&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.21725, &quot;lng&quot;: -1.55336, &quot;nct&quot;: &quot;NCT06582121&quot;, &quot;color&quot;: &quot;#ffa76a&quot;, &quot;title&quot;: &quot;Study of Sleep Disorders in Prodromal and Definite Parkinsons Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Polysomnography&quot;, &quot;sponsor&quot;: &quot;Assistance Publique - H\\u00f4pitaux de Paris&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06582121&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.83665, &quot;lng&quot;: 4.35788, &quot;nct&quot;: &quot;NCT06582121&quot;, &quot;color&quot;: &quot;#ffa76a&quot;, &quot;title&quot;: &quot;Study of Sleep Disorders in Prodromal and Definite Parkinsons Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Polysomnography&quot;, &quot;sponsor&quot;: &quot;Assistance Publique - H\\u00f4pitaux de Paris&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06582121&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.85341, &quot;lng&quot;: 2.3488, &quot;nct&quot;: &quot;NCT06582121&quot;, &quot;color&quot;: &quot;#ffa76a&quot;, &quot;title&quot;: &quot;Study of Sleep Disorders in Prodromal and Definite Parkinsons Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Polysomnography&quot;, &quot;sponsor&quot;: &quot;Assistance Publique - H\\u00f4pitaux de Paris&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06582121&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.44062, &quot;lng&quot;: -79.99589, &quot;nct&quot;: &quot;NCT07056361&quot;, &quot;color&quot;: &quot;#8b1f11&quot;, &quot;title&quot;: &quot;Stimulating Specific Brain Areas (VOP/VIM) With Electricity to Improve Movement and Muscle Control&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Direct cortical stimulation and deep brain stimulation of motor thalamus&quot;, &quot;sponsor&quot;: &quot;University of Pittsburgh&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07056361&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 56.16558, &quot;lng&quot;: 10.21231, &quot;nct&quot;: &quot;NCT06707402&quot;, &quot;color&quot;: &quot;#87087e&quot;, &quot;title&quot;: &quot;The Effects of 24-Weeks Community-based Brisk Walking in People With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;WALK; ACTIVE; CON&quot;, &quot;sponsor&quot;: &quot;University of Aarhus&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06707402&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: -19.92083, &quot;lng&quot;: -43.93778, &quot;nct&quot;: &quot;NCT06950255&quot;, &quot;color&quot;: &quot;#1df3fe&quot;, &quot;title&quot;: &quot;Effect of Training and Use of Cane on Gait in Individuals With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Cane; static stretching and health education&quot;, &quot;sponsor&quot;: &quot;Federal University of Minas Gerais&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06950255&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.17497, &quot;lng&quot;: -115.13722, &quot;nct&quot;: &quot;NCT05854524&quot;, &quot;color&quot;: &quot;#fc3bd9&quot;, &quot;title&quot;: &quot;Exercise Neuroprotection in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Aerobic exercise&quot;, &quot;sponsor&quot;: &quot;University of Nevada, Las Vegas&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05854524&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 53.79648, &quot;lng&quot;: -1.54785, &quot;nct&quot;: &quot;NCT05794542&quot;, &quot;color&quot;: &quot;#bb5910&quot;, &quot;title&quot;: &quot;Cue X as a Treatment for People With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Cue X&quot;, &quot;sponsor&quot;: &quot;University of Leeds&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05794542&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.4995, &quot;lng&quot;: -81.69541, &quot;nct&quot;: &quot;NCT07138560&quot;, &quot;color&quot;: &quot;#1f6daa&quot;, &quot;title&quot;: &quot;BOOST-PD A Naturalistic Study on IPX-203 for Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;CREXONT ER&quot;, &quot;sponsor&quot;: &quot;The Cleveland Clinic&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07138560&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 55.13333, &quot;lng&quot;: -6.66667, &quot;nct&quot;: &quot;NCT06697626&quot;, &quot;color&quot;: &quot;#2ba79e&quot;, &quot;title&quot;: &quot;Validation of a Novel Functional Food Designed to Meet the Nutritional Needs of People Living With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Inulin, B-vitamins and vitamin D; Placebo group&quot;, &quot;sponsor&quot;: &quot;University of Ulster&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06697626&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.11417, &quot;lng&quot;: -94.62746, &quot;nct&quot;: &quot;NCT03969927&quot;, &quot;color&quot;: &quot;#0e8a90&quot;, &quot;title&quot;: &quot;User-friendliness of a Portable Driving Simulator&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Low-Fidelity PDS; High Fidelity Fixed-Base Simulator&quot;, &quot;sponsor&quot;: &quot;University of Kansas Medical Center&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03969927&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.16589, &quot;lng&quot;: -86.78444, &quot;nct&quot;: &quot;NCT05357612&quot;, &quot;color&quot;: &quot;#ea528a&quot;, &quot;title&quot;: &quot;Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE4&quot;], &quot;interventions&quot;: &quot;Pimavanserin&quot;, &quot;sponsor&quot;: &quot;Vanderbilt University Medical Center&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05357612&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.42412, &quot;lng&quot;: -98.49363, &quot;nct&quot;: &quot;NCT06133283&quot;, &quot;color&quot;: &quot;#6f7002&quot;, &quot;title&quot;: &quot;Endurance Exercise &amp; Virtual Reality for Optimizing Cortical Excitability and Neuroplasticity in PD&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;High intensity endurance exercise; Stretching exercise; Virtual reality (VR)-based gaming&quot;, &quot;sponsor&quot;: &quot;The University of Texas Health Science Center at San Antonio&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06133283&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 35.99403, &quot;lng&quot;: -78.89862, &quot;nct&quot;: &quot;NCT03815656&quot;, &quot;color&quot;: &quot;#89f137&quot;, &quot;title&quot;: &quot;Closed Loop DBS Implanted RC+S Study&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;STN alone; GPi alone; STN + GPi; Closed-loop stimulation&quot;, &quot;sponsor&quot;: &quot;Dennis Turner, M.D.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03815656&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 25.07777, &quot;lng&quot;: 121.39348, &quot;nct&quot;: &quot;NCT06248073&quot;, &quot;color&quot;: &quot;#3f8f3b&quot;, &quot;title&quot;: &quot;Effectiveness of Online Program and Task-related Training for Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;on-line self-management training; onsite task-related training&quot;, &quot;sponsor&quot;: &quot;Chang Gung University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06248073&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.4165, &quot;lng&quot;: -3.70256, &quot;nct&quot;: &quot;NCT06490861&quot;, &quot;color&quot;: &quot;#1362be&quot;, &quot;title&quot;: &quot;Performance of the Paragit Sleeve to Measure and Monitor Motor Symptoms in Patients With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Paragit&quot;, &quot;sponsor&quot;: &quot;Paragit ApS&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06490861&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 46.516, &quot;lng&quot;: 6.63282, &quot;nct&quot;: &quot;NCT06791902&quot;, &quot;color&quot;: &quot;#a53836&quot;, &quot;title&quot;: &quot;Study on Preliminary Safety and Efficacy of Adaptive DBS Aligned to Locomotor States to Improve Locomotor Functions in Parkinson&#x27;s Patients&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Adaptive DBS&quot;, &quot;sponsor&quot;: &quot;Jocelyne Bloch&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06791902&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 49.32637, &quot;lng&quot;: 7.33867, &quot;nct&quot;: &quot;NCT06479083&quot;, &quot;color&quot;: &quot;#95feb8&quot;, &quot;title&quot;: &quot;Interdisciplinary + Intersectoral Telemedicine Evaluation, Coordination + Treatment in RhineMain+ Parkinson&#x27;s Network&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;New Intervention form including; Standard treatment&quot;, &quot;sponsor&quot;: &quot;Johannes Gutenberg University Mainz&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06479083&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 49.98185, &quot;lng&quot;: 8.28008, &quot;nct&quot;: &quot;NCT06479083&quot;, &quot;color&quot;: &quot;#95feb8&quot;, &quot;title&quot;: &quot;Interdisciplinary + Intersectoral Telemedicine Evaluation, Coordination + Treatment in RhineMain+ Parkinson&#x27;s Network&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;New Intervention form including; Standard treatment&quot;, &quot;sponsor&quot;: &quot;Johannes Gutenberg University Mainz&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06479083&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 14.61341, &quot;lng&quot;: -60.99964, &quot;nct&quot;: &quot;NCT04492345&quot;, &quot;color&quot;: &quot;#7f2cd2&quot;, &quot;title&quot;: &quot;Assessment of a Special Modality of Back Muscles Strengthening for Postural Deformations in Parkinsonian Patient&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Isokinetic reeducation; Conventional reeducation&quot;, &quot;sponsor&quot;: &quot;University Hospital Center of Martinique&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04492345&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.6386, &quot;lng&quot;: -1.13169, &quot;nct&quot;: &quot;NCT05986643&quot;, &quot;color&quot;: &quot;#955115&quot;, &quot;title&quot;: &quot;Brain Training to Improve Balance in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Exergame+Neurofeedback; Exergame [alone]&quot;, &quot;sponsor&quot;: &quot;University of Leicester&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05986643&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.3751, &quot;lng&quot;: -71.10561, &quot;nct&quot;: &quot;NCT05268887&quot;, &quot;color&quot;: &quot;#9b13ff&quot;, &quot;title&quot;: &quot;High Frequency Light, Sound, and Tactile Stimulation to Improve Motor and Cognitive Deficits in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;GENUS device (Active Settings); GENUS device (Sham settings)&quot;, &quot;sponsor&quot;: &quot;Massachusetts Institute of Technology&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05268887&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.9075, &quot;lng&quot;: 116.39723, &quot;nct&quot;: &quot;NCT06167681&quot;, &quot;color&quot;: &quot;#ef1a4b&quot;, &quot;title&quot;: &quot;The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Human Dopaminergic Progenitor Cells&quot;, &quot;sponsor&quot;: &quot;iRegene Therapeutics Co., Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06167681&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 30.58333, &quot;lng&quot;: 114.26667, &quot;nct&quot;: &quot;NCT06167681&quot;, &quot;color&quot;: &quot;#ef1a4b&quot;, &quot;title&quot;: &quot;The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Human Dopaminergic Progenitor Cells&quot;, &quot;sponsor&quot;: &quot;iRegene Therapeutics Co., Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06167681&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.70643, &quot;lng&quot;: -79.39864, &quot;nct&quot;: &quot;NCT06436313&quot;, &quot;color&quot;: &quot;#d4274a&quot;, &quot;title&quot;: &quot;DBS Virtual Learning Experience&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Educational Sessions&quot;, &quot;sponsor&quot;: &quot;University of Toronto&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06436313&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 32.78306, &quot;lng&quot;: -96.80667, &quot;nct&quot;: &quot;NCT06489483&quot;, &quot;color&quot;: &quot;#99f29c&quot;, &quot;title&quot;: &quot;Action Regulation Behavioral&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Action Regulation Movement Task&quot;, &quot;sponsor&quot;: &quot;University of Texas Southwestern Medical Center&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06489483&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.71427, &quot;lng&quot;: -74.00597, &quot;nct&quot;: &quot;NCT07102342&quot;, &quot;color&quot;: &quot;#bf956e&quot;, &quot;title&quot;: &quot;This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson&#x27;s Disease.&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;Human Dopaminergic Progenitor Cells&quot;, &quot;sponsor&quot;: &quot;iRegene Therapeutics Co., Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07102342&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 23.11667, &quot;lng&quot;: 113.25, &quot;nct&quot;: &quot;NCT06112392&quot;, &quot;color&quot;: &quot;#b47d30&quot;, &quot;title&quot;: &quot;Clinical Study of Stellate Ganglion Block in Treatment of Patients With Advanced Primary Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Treatment \\uff08Stellate ganglion block\\uff1bOral standard anti-Parkinson&#x27;s drugs\\uff09; Treatment \\uff08Oral standard anti-Parkinson&#x27;s drugs\\uff09&quot;, &quot;sponsor&quot;: &quot;Zhujiang Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06112392&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.17869, &quot;lng&quot;: 5.71479, &quot;nct&quot;: &quot;NCT06582212&quot;, &quot;color&quot;: &quot;#fdbb81&quot;, &quot;title&quot;: &quot;Enabling Women with Parkinson&#x27;s Disease to Identify and Better Manage Hormonal Triggers of Parkinsonian Symptoms&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Mymovesmatter mobile application&quot;, &quot;sponsor&quot;: &quot;University Hospital, Grenoble&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06582212&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.21725, &quot;lng&quot;: -1.55336, &quot;nct&quot;: &quot;NCT06582212&quot;, &quot;color&quot;: &quot;#fdbb81&quot;, &quot;title&quot;: &quot;Enabling Women with Parkinson&#x27;s Disease to Identify and Better Manage Hormonal Triggers of Parkinsonian Symptoms&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Mymovesmatter mobile application&quot;, &quot;sponsor&quot;: &quot;University Hospital, Grenoble&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06582212&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.11109, &quot;lng&quot;: -1.67431, &quot;nct&quot;: &quot;NCT06582212&quot;, &quot;color&quot;: &quot;#fdbb81&quot;, &quot;title&quot;: &quot;Enabling Women with Parkinson&#x27;s Disease to Identify and Better Manage Hormonal Triggers of Parkinsonian Symptoms&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Mymovesmatter mobile application&quot;, &quot;sponsor&quot;: &quot;University Hospital, Grenoble&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06582212&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.60426, &quot;lng&quot;: 1.44367, &quot;nct&quot;: &quot;NCT06582212&quot;, &quot;color&quot;: &quot;#fdbb81&quot;, &quot;title&quot;: &quot;Enabling Women with Parkinson&#x27;s Disease to Identify and Better Manage Hormonal Triggers of Parkinsonian Symptoms&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Mymovesmatter mobile application&quot;, &quot;sponsor&quot;: &quot;University Hospital, Grenoble&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06582212&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.85003, &quot;lng&quot;: -87.65005, &quot;nct&quot;: &quot;NCT06603012&quot;, &quot;color&quot;: &quot;#8114db&quot;, &quot;title&quot;: &quot;Behavioral Intervention for Lifestyle Physical Activity in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;GET Up PD; Stretching and Flexibility&quot;, &quot;sponsor&quot;: &quot;University of Illinois at Chicago&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06603012&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 30.29365, &quot;lng&quot;: 120.16142, &quot;nct&quot;: &quot;NCT06852352&quot;, &quot;color&quot;: &quot;#fa2b19&quot;, &quot;title&quot;: &quot;An Exploratory Study to Confirm Efficacy of Modified Deep Cervical Lymphovenous Anastomosis (LVA) in Alzheimer&#x27;s Disease/ Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Modified deep cervical Lymphatic-Venous Anastomosis&quot;, &quot;sponsor&quot;: &quot;Zhejiang Provincial People&#x27;s Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06852352&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.01384, &quot;lng&quot;: 28.94966, &quot;nct&quot;: &quot;NCT06615115&quot;, &quot;color&quot;: &quot;#534ab2&quot;, &quot;title&quot;: &quot;The Effect of Different Types of Focus Instructions in Parkinson&#x27;s Rehabilitation&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Exercise&quot;, &quot;sponsor&quot;: &quot;Bah\\u00e7e\\u015fehir University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06615115&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 54.32133, &quot;lng&quot;: 10.13489, &quot;nct&quot;: &quot;NCT07058285&quot;, &quot;color&quot;: &quot;#c5a999&quot;, &quot;title&quot;: &quot;Steps Against the Burden of Parkinson&#x27;s Disease - RCT Kiel&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Speed-dependent treadmill training (SDTT); SDTT+ anteroposterior perturbations&quot;, &quot;sponsor&quot;: &quot;University of Kiel&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07058285&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.60717, &quot;lng&quot;: 13.5103, &quot;nct&quot;: &quot;NCT05005208&quot;, &quot;color&quot;: &quot;#427e5f&quot;, &quot;title&quot;: &quot;SocIal ROBOTics for Active and Healthy Ageing&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;rehabilitation program with the support of the technological platform SI-ROBOTICS&quot;, &quot;sponsor&quot;: &quot;Istituto Nazionale di Ricovero e Cura per Anziani&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05005208&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.07305, &quot;lng&quot;: -89.40123, &quot;nct&quot;: &quot;NCT06616948&quot;, &quot;color&quot;: &quot;#aedc5f&quot;, &quot;title&quot;: &quot;In-home Cycling for Individuals With PD: Effectiveness&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Social Cycling Group; coaching calls; No coaching calls&quot;, &quot;sponsor&quot;: &quot;University of Wisconsin, Madison&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06616948&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 44.97997, &quot;lng&quot;: -93.26384, &quot;nct&quot;: &quot;NCT06506058&quot;, &quot;color&quot;: &quot;#20b955&quot;, &quot;title&quot;: &quot;Vestibular and Cortical Contributions to Transitions in Freezing of Gait in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;EVS and EEG&quot;, &quot;sponsor&quot;: &quot;University of Minnesota&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06506058&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 49.24966, &quot;lng&quot;: -123.11934, &quot;nct&quot;: &quot;NCT06207136&quot;, &quot;color&quot;: &quot;#c549e1&quot;, &quot;title&quot;: &quot;Microbiome and Diet in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Mediterranean-style diet&quot;, &quot;sponsor&quot;: &quot;University of British Columbia&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06207136&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 32.22174, &quot;lng&quot;: -110.92648, &quot;nct&quot;: &quot;NCT06263010&quot;, &quot;color&quot;: &quot;#12bb14&quot;, &quot;title&quot;: &quot;Allopregnanolone As a Regenerative Treatment for Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;Allopregnanolone&quot;, &quot;sponsor&quot;: &quot;Roberta Brinton&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06263010&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: -27.46794, &quot;lng&quot;: 153.02809, &quot;nct&quot;: &quot;NCT04643327&quot;, &quot;color&quot;: &quot;#1613b2&quot;, &quot;title&quot;: &quot;Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Levetiracetam; Placebo&quot;, &quot;sponsor&quot;: &quot;The University of Queensland&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04643327&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.08804, &quot;lng&quot;: 14.42076, &quot;nct&quot;: &quot;NCT05765110&quot;, &quot;color&quot;: &quot;#7c4be9&quot;, &quot;title&quot;: &quot;SPEECH as Biomarker for Emotion, Movement and cOgnition in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Dopaminergic OFF drug state; DBS OFF state; Dopaminergic ON drug state; DBS ON state&quot;, &quot;sponsor&quot;: &quot;Insel Gruppe AG, University Hospital Bern&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05765110&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 46.94809, &quot;lng&quot;: 7.44744, &quot;nct&quot;: &quot;NCT05765110&quot;, &quot;color&quot;: &quot;#7c4be9&quot;, &quot;title&quot;: &quot;SPEECH as Biomarker for Emotion, Movement and cOgnition in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Dopaminergic OFF drug state; DBS OFF state; Dopaminergic ON drug state; DBS ON state&quot;, &quot;sponsor&quot;: &quot;Insel Gruppe AG, University Hospital Bern&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05765110&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.60717, &quot;lng&quot;: 13.5103, &quot;nct&quot;: &quot;NCT06984393&quot;, &quot;color&quot;: &quot;#563b04&quot;, &quot;title&quot;: &quot;Tele-Rehabilitation Intervention in Community-Based Healthcare for Patients With Parkinson&#x27;s Disease (DHEAL-COM-PD)&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;home tele-rehabilitation; Usual care&quot;, &quot;sponsor&quot;: &quot;Istituto Nazionale di Ricovero e Cura per Anziani&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06984393&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.27756, &quot;lng&quot;: -83.74088, &quot;nct&quot;: &quot;NCT07154511&quot;, &quot;color&quot;: &quot;#9d893b&quot;, &quot;title&quot;: &quot;Phase 2 Trial of Tributyrin in People With Parkinson&#x27;s Disease and Cognitive Impairments&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Tributyrin; Placebo&quot;, &quot;sponsor&quot;: &quot;Prabesh Kanel&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07154511&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: -1.29389, &quot;lng&quot;: -47.92639, &quot;nct&quot;: &quot;NCT06967493&quot;, &quot;color&quot;: &quot;#6f5fe0&quot;, &quot;title&quot;: &quot;Effects of Amazonian Dance on Motor and Non-motor Symptoms of People With Parkinson&#x27;s: Study Protocol&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Amazonian Dance; Nordic Walking&quot;, &quot;sponsor&quot;: &quot;Federal University of Rio Grande do Sul&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06967493&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: -30.03283, &quot;lng&quot;: -51.23019, &quot;nct&quot;: &quot;NCT06967493&quot;, &quot;color&quot;: &quot;#6f5fe0&quot;, &quot;title&quot;: &quot;Effects of Amazonian Dance on Motor and Non-motor Symptoms of People With Parkinson&#x27;s: Study Protocol&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Amazonian Dance; Nordic Walking&quot;, &quot;sponsor&quot;: &quot;Federal University of Rio Grande do Sul&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06967493&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.93333, &quot;lng&quot;: 6.95, &quot;nct&quot;: &quot;NCT06582355&quot;, &quot;color&quot;: &quot;#39bf87&quot;, &quot;title&quot;: &quot;FMRI-neurofeedback in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Neurofeedback; Kinesthetic imagery&quot;, &quot;sponsor&quot;: &quot;Maastricht University Medical Center&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06582355&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.84833, &quot;lng&quot;: 5.68889, &quot;nct&quot;: &quot;NCT06582355&quot;, &quot;color&quot;: &quot;#39bf87&quot;, &quot;title&quot;: &quot;FMRI-neurofeedback in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Neurofeedback; Kinesthetic imagery&quot;, &quot;sponsor&quot;: &quot;Maastricht University Medical Center&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06582355&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.35843, &quot;lng&quot;: -71.05977, &quot;nct&quot;: &quot;NCT05317390&quot;, &quot;color&quot;: &quot;#051487&quot;, &quot;title&quot;: &quot;Clinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated Dystonia&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;DystoniaNet-based diagnosis of isolated dystonia&quot;, &quot;sponsor&quot;: &quot;Massachusetts Eye and Ear Infirmary&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05317390&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 59.32938, &quot;lng&quot;: 18.06871, &quot;nct&quot;: &quot;NCT05510739&quot;, &quot;color&quot;: &quot;#a7441f&quot;, &quot;title&quot;: &quot;Support for Physical Activity in Everyday Life With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Motor-cognitive home exercise supported by eHealth technology; Individualized home exercise program&quot;, &quot;sponsor&quot;: &quot;Stiftelsen Stockholms Sjukhem&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05510739&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.27756, &quot;lng&quot;: -83.74088, &quot;nct&quot;: &quot;NCT05509842&quot;, &quot;color&quot;: &quot;#750aec&quot;, &quot;title&quot;: &quot;Function-based Accelerated Stimulation Therapy (FAST-therapy) for Freezing of Gait (FOG) After Parkinson&#x27;s Disease (PD)&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;rTMS&quot;, &quot;sponsor&quot;: &quot;University of Michigan&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05509842&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.70643, &quot;lng&quot;: -79.39864, &quot;nct&quot;: &quot;NCT06232629&quot;, &quot;color&quot;: &quot;#2663e0&quot;, &quot;title&quot;: &quot;Towards Noninvasive DBS of the Basal Ganglia in Parkinson&#x27;s Disease Using TUS&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;TUS Active; TUS Sham&quot;, &quot;sponsor&quot;: &quot;University Health Network, Toronto&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06232629&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 49.84889, &quot;lng&quot;: 3.28757, &quot;nct&quot;: &quot;NCT06500182&quot;, &quot;color&quot;: &quot;#77cfcd&quot;, &quot;title&quot;: &quot;The Benefits of Hippotherapy for Patients With Parkinson&#x27;s Disease of 75 Years&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;hippotherapy sessions&quot;, &quot;sponsor&quot;: &quot;Central Hospital Saint Quentin&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06500182&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 55.64297, &quot;lng&quot;: 12.47708, &quot;nct&quot;: &quot;NCT06570824&quot;, &quot;color&quot;: &quot;#68c5ab&quot;, &quot;title&quot;: &quot;rTMS as an Intervention for Levodopa-induced Dyskinesia&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;active TMS; sham TMS&quot;, &quot;sponsor&quot;: &quot;Danish Research Centre for Magnetic Resonance&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06570824&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.47156, &quot;lng&quot;: -0.55202, &quot;nct&quot;: &quot;NCT06401395&quot;, &quot;color&quot;: &quot;#5930f5&quot;, &quot;title&quot;: &quot;Clinical Evaluation of A neW Management Strategy for Patients With pArKinson&#x27;s disEase usiNg an Innovative telemonitorING (AWAKENING)&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;DIGIPARK MONITOR&quot;, &quot;sponsor&quot;: &quot;DIAMPARK&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06401395&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 46.20574, &quot;lng&quot;: 5.2258, &quot;nct&quot;: &quot;NCT06401395&quot;, &quot;color&quot;: &quot;#5930f5&quot;, &quot;title&quot;: &quot;Clinical Evaluation of A neW Management Strategy for Patients With pArKinson&#x27;s disEase usiNg an Innovative telemonitorING (AWAKENING)&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;DIGIPARK MONITOR&quot;, &quot;sponsor&quot;: &quot;DIAMPARK&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06401395&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 49.18585, &quot;lng&quot;: -0.35912, &quot;nct&quot;: &quot;NCT06401395&quot;, &quot;color&quot;: &quot;#5930f5&quot;, &quot;title&quot;: &quot;Clinical Evaluation of A neW Management Strategy for Patients With pArKinson&#x27;s disEase usiNg an Innovative telemonitorING (AWAKENING)&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;DIGIPARK MONITOR&quot;, &quot;sponsor&quot;: &quot;DIAMPARK&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06401395&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.80299, &quot;lng&quot;: 2.26692, &quot;nct&quot;: &quot;NCT06401395&quot;, &quot;color&quot;: &quot;#5930f5&quot;, &quot;title&quot;: &quot;Clinical Evaluation of A neW Management Strategy for Patients With pArKinson&#x27;s disEase usiNg an Innovative telemonitorING (AWAKENING)&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;DIGIPARK MONITOR&quot;, &quot;sponsor&quot;: &quot;DIAMPARK&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06401395&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.04366, &quot;lng&quot;: 3.88523, &quot;nct&quot;: &quot;NCT06401395&quot;, &quot;color&quot;: &quot;#5930f5&quot;, &quot;title&quot;: &quot;Clinical Evaluation of A neW Management Strategy for Patients With pArKinson&#x27;s disEase usiNg an Innovative telemonitorING (AWAKENING)&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;DIGIPARK MONITOR&quot;, &quot;sponsor&quot;: &quot;DIAMPARK&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06401395&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.61093, &quot;lng&quot;: 3.87635, &quot;nct&quot;: &quot;NCT06401395&quot;, &quot;color&quot;: &quot;#5930f5&quot;, &quot;title&quot;: &quot;Clinical Evaluation of A neW Management Strategy for Patients With pArKinson&#x27;s disEase usiNg an Innovative telemonitorING (AWAKENING)&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;DIGIPARK MONITOR&quot;, &quot;sponsor&quot;: &quot;DIAMPARK&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06401395&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.70313, &quot;lng&quot;: 7.26608, &quot;nct&quot;: &quot;NCT06401395&quot;, &quot;color&quot;: &quot;#5930f5&quot;, &quot;title&quot;: &quot;Clinical Evaluation of A neW Management Strategy for Patients With pArKinson&#x27;s disEase usiNg an Innovative telemonitorING (AWAKENING)&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;DIGIPARK MONITOR&quot;, &quot;sponsor&quot;: &quot;DIAMPARK&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06401395&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.30073, &quot;lng&quot;: 4.08524, &quot;nct&quot;: &quot;NCT06401395&quot;, &quot;color&quot;: &quot;#5930f5&quot;, &quot;title&quot;: &quot;Clinical Evaluation of A neW Management Strategy for Patients With pArKinson&#x27;s disEase usiNg an Innovative telemonitorING (AWAKENING)&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;DIGIPARK MONITOR&quot;, &quot;sponsor&quot;: &quot;DIAMPARK&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06401395&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 50.35909, &quot;lng&quot;: 3.52506, &quot;nct&quot;: &quot;NCT06401395&quot;, &quot;color&quot;: &quot;#5930f5&quot;, &quot;title&quot;: &quot;Clinical Evaluation of A neW Management Strategy for Patients With pArKinson&#x27;s disEase usiNg an Innovative telemonitorING (AWAKENING)&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;DIGIPARK MONITOR&quot;, &quot;sponsor&quot;: &quot;DIAMPARK&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06401395&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 45.76601, &quot;lng&quot;: 4.8795, &quot;nct&quot;: &quot;NCT06401395&quot;, &quot;color&quot;: &quot;#5930f5&quot;, &quot;title&quot;: &quot;Clinical Evaluation of A neW Management Strategy for Patients With pArKinson&#x27;s disEase usiNg an Innovative telemonitorING (AWAKENING)&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;DIGIPARK MONITOR&quot;, &quot;sponsor&quot;: &quot;DIAMPARK&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06401395&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.85341, &quot;lng&quot;: 2.3488, &quot;nct&quot;: &quot;NCT07074119&quot;, &quot;color&quot;: &quot;#0359f9&quot;, &quot;title&quot;: &quot;Sensor-Based Optimization of Therapy for Parkinson&#x27;s Disease Patients With Motor Fluctuations&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;wearable-based adjustment therapy&quot;, &quot;sponsor&quot;: &quot;Assistance Publique - H\\u00f4pitaux de Paris&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07074119&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.60426, &quot;lng&quot;: 1.44367, &quot;nct&quot;: &quot;NCT06817200&quot;, &quot;color&quot;: &quot;#3cb71b&quot;, &quot;title&quot;: &quot;The Effect of Amantadine as add-on Therapy for Motor Fluctuations in Advanced Parkinson&#x27;s Disease: a Randomized Double-blinded Placebo-controlled Trial&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Amantadine (100mg) as add on therapy.; Placebo&quot;, &quot;sponsor&quot;: &quot;University Hospital, Toulouse&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06817200&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 23.7104, &quot;lng&quot;: 90.40744, &quot;nct&quot;: &quot;NCT07096336&quot;, &quot;color&quot;: &quot;#6259bb&quot;, &quot;title&quot;: &quot;Effect of Vitamin D3 on Brain Waves in Male Parkinson&#x27;s Patients With Low Vitamin D: A qEEG Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;vitamin D3 capsule&quot;, &quot;sponsor&quot;: &quot;Bangladesh Medical University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07096336&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 29.65163, &quot;lng&quot;: -82.32483, &quot;nct&quot;: &quot;NCT06911229&quot;, &quot;color&quot;: &quot;#62d878&quot;, &quot;title&quot;: &quot;Neurophysiology of Locomotor Adaptation and Freezing of Gait in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Deep Brain Stimulation (DBS)&quot;, &quot;sponsor&quot;: &quot;University of Florida&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06911229&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 23.70944, &quot;lng&quot;: 120.54333, &quot;nct&quot;: &quot;NCT06197698&quot;, &quot;color&quot;: &quot;#62e2b0&quot;, &quot;title&quot;: &quot;A Proof-of-concept Study Evaluating the Microbiota-gut-brain Axis&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;F18-FDG, Tc-99m TRODAT-1&quot;, &quot;sponsor&quot;: &quot;National Taiwan University Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06197698&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 39.95238, &quot;lng&quot;: -75.16362, &quot;nct&quot;: &quot;NCT06377033&quot;, &quot;color&quot;: &quot;#8193f5&quot;, &quot;title&quot;: &quot;Using the EHR to Advance Genomic Medicine Across a Diverse Health System&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Behavioral nudge&quot;, &quot;sponsor&quot;: &quot;University of Pennsylvania&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06377033&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 36.16589, &quot;lng&quot;: -86.78444, &quot;nct&quot;: &quot;NCT05489575&quot;, &quot;color&quot;: &quot;#40bfc3&quot;, &quot;title&quot;: &quot;CPAP for the Treatment of Supine Hypertension&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Active CPAP; Sham CPAP; Sleeping in a head-up tilt (HUT) position&quot;, &quot;sponsor&quot;: &quot;Vanderbilt University Medical Center&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05489575&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 38.62727, &quot;lng&quot;: -90.19789, &quot;nct&quot;: &quot;NCT04922411&quot;, &quot;color&quot;: &quot;#661aad&quot;, &quot;title&quot;: &quot;Cortical Network Modulation by Subthalamic Nucleus DBS&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;STN DBS&quot;, &quot;sponsor&quot;: &quot;Washington University School of Medicine&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04922411&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 34.05223, &quot;lng&quot;: -118.24368, &quot;nct&quot;: &quot;NCT06602193&quot;, &quot;color&quot;: &quot;#2d991b&quot;, &quot;title&quot;: &quot;Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson&#x27;s Disease (LRRK2-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122 225 mg; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Denali Therapeutics Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06602193&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.77493, &quot;lng&quot;: -122.41942, &quot;nct&quot;: &quot;NCT06602193&quot;, &quot;color&quot;: &quot;#2d991b&quot;, &quot;title&quot;: &quot;Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson&#x27;s Disease (LRRK2-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122 225 mg; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Denali Therapeutics Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06602193&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 26.35869, &quot;lng&quot;: -80.0831, &quot;nct&quot;: &quot;NCT06602193&quot;, &quot;color&quot;: &quot;#2d991b&quot;, &quot;title&quot;: &quot;Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson&#x27;s Disease (LRRK2-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122 225 mg; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Denali Therapeutics Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06602193&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 42.35843, &quot;lng&quot;: -71.05977, &quot;nct&quot;: &quot;NCT06602193&quot;, &quot;color&quot;: &quot;#2d991b&quot;, &quot;title&quot;: &quot;Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson&#x27;s Disease (LRRK2-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122 225 mg; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Denali Therapeutics Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06602193&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.71427, &quot;lng&quot;: -74.00597, &quot;nct&quot;: &quot;NCT06602193&quot;, &quot;color&quot;: &quot;#2d991b&quot;, &quot;title&quot;: &quot;Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson&#x27;s Disease (LRRK2-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122 225 mg; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Denali Therapeutics Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06602193&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.68149, &quot;lng&quot;: -122.20874, &quot;nct&quot;: &quot;NCT06602193&quot;, &quot;color&quot;: &quot;#2d991b&quot;, &quot;title&quot;: &quot;Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson&#x27;s Disease (LRRK2-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122 225 mg; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Denali Therapeutics Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06602193&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 47.65966, &quot;lng&quot;: -117.42908, &quot;nct&quot;: &quot;NCT06602193&quot;, &quot;color&quot;: &quot;#2d991b&quot;, &quot;title&quot;: &quot;Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson&#x27;s Disease (LRRK2-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122 225 mg; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Denali Therapeutics Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06602193&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.05089, &quot;lng&quot;: 13.73832, &quot;nct&quot;: &quot;NCT06602193&quot;, &quot;color&quot;: &quot;#2d991b&quot;, &quot;title&quot;: &quot;Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson&#x27;s Disease (LRRK2-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122 225 mg; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Denali Therapeutics Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06602193&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 53.86893, &quot;lng&quot;: 10.68729, &quot;nct&quot;: &quot;NCT06602193&quot;, &quot;color&quot;: &quot;#2d991b&quot;, &quot;title&quot;: &quot;Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson&#x27;s Disease (LRRK2-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122 225 mg; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Denali Therapeutics Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06602193&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 48.52266, &quot;lng&quot;: 9.05222, &quot;nct&quot;: &quot;NCT06602193&quot;, &quot;color&quot;: &quot;#2d991b&quot;, &quot;title&quot;: &quot;Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson&#x27;s Disease (LRRK2-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122 225 mg; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Denali Therapeutics Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06602193&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 41.38879, &quot;lng&quot;: 2.15899, &quot;nct&quot;: &quot;NCT06602193&quot;, &quot;color&quot;: &quot;#2d991b&quot;, &quot;title&quot;: &quot;Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson&#x27;s Disease (LRRK2-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122 225 mg; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Denali Therapeutics Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06602193&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.31283, &quot;lng&quot;: -1.97499, &quot;nct&quot;: &quot;NCT06602193&quot;, &quot;color&quot;: &quot;#2d991b&quot;, &quot;title&quot;: &quot;Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson&#x27;s Disease (LRRK2-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122 225 mg; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Denali Therapeutics Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06602193&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 40.4165, &quot;lng&quot;: -3.70256, &quot;nct&quot;: &quot;NCT06602193&quot;, &quot;color&quot;: &quot;#2d991b&quot;, &quot;title&quot;: &quot;Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson&#x27;s Disease (LRRK2-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122 225 mg; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Denali Therapeutics Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06602193&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.46589, &quot;lng&quot;: -3.80493, &quot;nct&quot;: &quot;NCT06602193&quot;, &quot;color&quot;: &quot;#2d991b&quot;, &quot;title&quot;: &quot;Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson&#x27;s Disease (LRRK2-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122 225 mg; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Denali Therapeutics Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06602193&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.38283, &quot;lng&quot;: -5.97317, &quot;nct&quot;: &quot;NCT06602193&quot;, &quot;color&quot;: &quot;#2d991b&quot;, &quot;title&quot;: &quot;Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson&#x27;s Disease (LRRK2-PD)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;BIIB122 225 mg; BIIB122-Matching Placebo&quot;, &quot;sponsor&quot;: &quot;Denali Therapeutics Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06602193&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.566, &quot;lng&quot;: 126.9784, &quot;nct&quot;: &quot;NCT02018406&quot;, &quot;color&quot;: &quot;#ffb55e&quot;, &quot;title&quot;: &quot;Establishment of Clinical Basis for Hematopoietic Growth Factors Therapy in Brain Injury&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Combination injection of EPO and G-CSF; Injection of normal saline&quot;, &quot;sponsor&quot;: &quot;Yonsei University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT02018406&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 34.27834, &quot;lng&quot;: -119.29317, &quot;nct&quot;: &quot;NCT06538298&quot;, &quot;color&quot;: &quot;#b6e079&quot;, &quot;title&quot;: &quot;Title: A Multimodal Exercise Program With Gamification for Parkinson Disease (MEP+G)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;EARLY_PHASE1&quot;], &quot;interventions&quot;: &quot;Multimodal Exercise Program with Gamification&quot;, &quot;sponsor&quot;: &quot;California State University, Northridge&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06538298&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 51.05, &quot;lng&quot;: 3.71667, &quot;nct&quot;: &quot;NCT06120049&quot;, &quot;color&quot;: &quot;#2bcba0&quot;, &quot;title&quot;: &quot;[18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;[18F]-MFBG PET CT; [18F]-FE-PE2I PET CT or PET MRI; [123I]-MIBG SPECT CT; [18F]-MFBG PET dosimetry scans&quot;, &quot;sponsor&quot;: &quot;prof. dr. Koen Van Laere&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06120049&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 50.87959, &quot;lng&quot;: 4.70093, &quot;nct&quot;: &quot;NCT06120049&quot;, &quot;color&quot;: &quot;#2bcba0&quot;, &quot;title&quot;: &quot;[18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;[18F]-MFBG PET CT; [18F]-FE-PE2I PET CT or PET MRI; [123I]-MIBG SPECT CT; [18F]-MFBG PET dosimetry scans&quot;, &quot;sponsor&quot;: &quot;prof. dr. Koen Van Laere&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06120049&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;, &quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 30.78847, &quot;lng&quot;: 31.00192, &quot;nct&quot;: &quot;NCT06785298&quot;, &quot;color&quot;: &quot;#ada722&quot;, &quot;title&quot;: &quot;Fexofenadine As Adjuvant Therapy in Parkinson Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;, &quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Levodopa/carbidopa; Fexofenadine&quot;, &quot;sponsor&quot;: &quot;Tanta University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06785298&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 43.73718, &quot;lng&quot;: 7.42145, &quot;nct&quot;: &quot;NCT04731246&quot;, &quot;color&quot;: &quot;#681f60&quot;, &quot;title&quot;: &quot;Video-oculography and Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Video-oculography / Neuropsychological evaluations&quot;, &quot;sponsor&quot;: &quot;Association de Recherche Bibliographique pour les Neurosciences&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04731246&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 52.37403, &quot;lng&quot;: 4.88969, &quot;nct&quot;: &quot;NCT06399731&quot;, &quot;color&quot;: &quot;#52678d&quot;, &quot;title&quot;: &quot;Non-invasive Brain Stimulation for the Treatment of Mild Cognitive Impairment in Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;High-frequency (10Hz) rTMS; Anodal tDCS&quot;, &quot;sponsor&quot;: &quot;Amsterdam UMC&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06399731&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 23.11667, &quot;lng&quot;: 113.25, &quot;nct&quot;: &quot;NCT07156773&quot;, &quot;color&quot;: &quot;#ffde6b&quot;, &quot;title&quot;: &quot;The Study is Being Conducted to Evaluate the Safety and Efficacy of XJN010 Nasal Spray in Patients With Parkinson&#x27;s Disease Experiencing Off Episodes&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;XJN010 Nasal Spray; Placebo&quot;, &quot;sponsor&quot;: &quot;Guangzhou Novaken Pharm Co., Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07156773&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 35.17284, &quot;lng&quot;: 33.35397, &quot;nct&quot;: &quot;NCT06459154&quot;, &quot;color&quot;: &quot;#07ed11&quot;, &quot;title&quot;: &quot;The Effectiveness of Mixed Reality as Interventional Tool for the Improvement on Quality of Life for People With Parkinson\\u00b4s Disease.&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Mixed Reality; Traditional Physiotherapy&quot;, &quot;sponsor&quot;: &quot;University of Nicosia&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06459154&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 25.28545, &quot;lng&quot;: 51.53096, &quot;nct&quot;: &quot;NCT06962930&quot;, &quot;color&quot;: &quot;#1b00df&quot;, &quot;title&quot;: &quot;An Online Physical Activity Coaching Intervention for People With PD in Qatar&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;8-week personalized self-management program tailored to their individual needs using Engage-Qatar PD. participants will be invited to one face-to-face coaching session and 7 online sessions&quot;, &quot;sponsor&quot;: &quot;Qatar University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06962930&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 37.566, &quot;lng&quot;: 126.9784, &quot;nct&quot;: &quot;NCT06324448&quot;, &quot;color&quot;: &quot;#c963f2&quot;, &quot;title&quot;: &quot;Self-administered tDCS for Improving Single- and Dual-task Gait in Patients With PD&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Transcranial direct current stimulation&quot;, &quot;sponsor&quot;: &quot;Seoul National University Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06324448&quot;, &quot;diseases&quot;: [&quot;Parkinson Disease&quot;]}, {&quot;lat&quot;: 33.66946, &quot;lng&quot;: -117.82311, &quot;nct&quot;: &quot;NCT04680065&quot;, &quot;color&quot;: &quot;#b65bd2&quot;, &quot;title&quot;: &quot;GDNF Gene Therapy for Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF gene therapy; Sham (Placebo) Surgery&quot;, &quot;sponsor&quot;: &quot;Brain Neurotherapy Bio, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04680065&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 26.35869, &quot;lng&quot;: -80.0831, &quot;nct&quot;: &quot;NCT04680065&quot;, &quot;color&quot;: &quot;#b65bd2&quot;, &quot;title&quot;: &quot;GDNF Gene Therapy for Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF gene therapy; Sham (Placebo) Surgery&quot;, &quot;sponsor&quot;: &quot;Brain Neurotherapy Bio, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04680065&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 42.35843, &quot;lng&quot;: -71.05977, &quot;nct&quot;: &quot;NCT04680065&quot;, &quot;color&quot;: &quot;#b65bd2&quot;, &quot;title&quot;: &quot;GDNF Gene Therapy for Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF gene therapy; Sham (Placebo) Surgery&quot;, &quot;sponsor&quot;: &quot;Brain Neurotherapy Bio, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04680065&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 42.48531, &quot;lng&quot;: -83.37716, &quot;nct&quot;: &quot;NCT04680065&quot;, &quot;color&quot;: &quot;#b65bd2&quot;, &quot;title&quot;: &quot;GDNF Gene Therapy for Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF gene therapy; Sham (Placebo) Surgery&quot;, &quot;sponsor&quot;: &quot;Brain Neurotherapy Bio, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04680065&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.71427, &quot;lng&quot;: -74.00597, &quot;nct&quot;: &quot;NCT04680065&quot;, &quot;color&quot;: &quot;#b65bd2&quot;, &quot;title&quot;: &quot;GDNF Gene Therapy for Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF gene therapy; Sham (Placebo) Surgery&quot;, &quot;sponsor&quot;: &quot;Brain Neurotherapy Bio, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04680065&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 39.96118, &quot;lng&quot;: -82.99879, &quot;nct&quot;: &quot;NCT04680065&quot;, &quot;color&quot;: &quot;#b65bd2&quot;, &quot;title&quot;: &quot;GDNF Gene Therapy for Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF gene therapy; Sham (Placebo) Surgery&quot;, &quot;sponsor&quot;: &quot;Brain Neurotherapy Bio, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04680065&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 36.16589, &quot;lng&quot;: -86.78444, &quot;nct&quot;: &quot;NCT04680065&quot;, &quot;color&quot;: &quot;#b65bd2&quot;, &quot;title&quot;: &quot;GDNF Gene Therapy for Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;AAV2-GDNF gene therapy; Sham (Placebo) Surgery&quot;, &quot;sponsor&quot;: &quot;Brain Neurotherapy Bio, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04680065&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 31.22222, &quot;lng&quot;: 121.45806, &quot;nct&quot;: &quot;NCT07036939&quot;, &quot;color&quot;: &quot;#cecbdf&quot;, &quot;title&quot;: &quot;Efficacy and Safety of Bilateral Cervical Lymphatic-Venous Anastomosis in the Treatment of Multiple System Atrophy&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Immediate LVA; Delayed LVA&quot;, &quot;sponsor&quot;: &quot;Ruijin Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT07036939&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 36.16589, &quot;lng&quot;: -86.78444, &quot;nct&quot;: &quot;NCT03042988&quot;, &quot;color&quot;: &quot;#f0ded7&quot;, &quot;title&quot;: &quot;Overnight Trials with Heat Stress in Autonomic Failure Patients with Supine Hypertension&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Heating pad; Sham control&quot;, &quot;sponsor&quot;: &quot;Vanderbilt University Medical Center&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03042988&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.67545, &quot;lng&quot;: 14.79328, &quot;nct&quot;: &quot;NCT06821256&quot;, &quot;color&quot;: &quot;#12707e&quot;, &quot;title&quot;: &quot;Efficacy and Safety of Transcranial dIrect Current stiMulation in Multiple System Atrophy-Cerebellar Variant&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Anodal transcranial direct current stimulation (a-tDCS); Sham stimulation&quot;, &quot;sponsor&quot;: &quot;University of Salerno&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06821256&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 38.19394, &quot;lng&quot;: 15.55256, &quot;nct&quot;: &quot;NCT05792332&quot;, &quot;color&quot;: &quot;#b8000a&quot;, &quot;title&quot;: &quot;Integrated Management of Atypical Parkinsonism: A Home-based Patient-Centered Healthcare Delivery Based on Telenursing (IMPACT Study)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Telemonitoring; Standard-of-care&quot;, &quot;sponsor&quot;: &quot;Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05792332&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 45.46427, &quot;lng&quot;: 9.18951, &quot;nct&quot;: &quot;NCT05792332&quot;, &quot;color&quot;: &quot;#b8000a&quot;, &quot;title&quot;: &quot;Integrated Management of Atypical Parkinsonism: A Home-based Patient-Centered Healthcare Delivery Based on Telenursing (IMPACT Study)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Telemonitoring; Standard-of-care&quot;, &quot;sponsor&quot;: &quot;Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05792332&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 45.19205, &quot;lng&quot;: 9.15917, &quot;nct&quot;: &quot;NCT05792332&quot;, &quot;color&quot;: &quot;#b8000a&quot;, &quot;title&quot;: &quot;Integrated Management of Atypical Parkinsonism: A Home-based Patient-Centered Healthcare Delivery Based on Telenursing (IMPACT Study)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Telemonitoring; Standard-of-care&quot;, &quot;sponsor&quot;: &quot;Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05792332&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 41.51142, &quot;lng&quot;: 14.06252, &quot;nct&quot;: &quot;NCT05792332&quot;, &quot;color&quot;: &quot;#b8000a&quot;, &quot;title&quot;: &quot;Integrated Management of Atypical Parkinsonism: A Home-based Patient-Centered Healthcare Delivery Based on Telenursing (IMPACT Study)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Telemonitoring; Standard-of-care&quot;, &quot;sponsor&quot;: &quot;Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05792332&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 59.36004, &quot;lng&quot;: 18.00086, &quot;nct&quot;: &quot;NCT06891703&quot;, &quot;color&quot;: &quot;#bfc0a7&quot;, &quot;title&quot;: &quot;[18F]ACI-15916 PET in \\u03b1-synucleinopathies&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;EARLY_PHASE1&quot;], &quot;interventions&quot;: &quot;[18F]ACI-15916&quot;, &quot;sponsor&quot;: &quot;AC Immune SA&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06891703&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 33.50921, &quot;lng&quot;: -111.89903, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 34.74648, &quot;lng&quot;: -92.28959, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 37.77493, &quot;lng&quot;: -122.41942, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 39.64777, &quot;lng&quot;: -104.98776, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 41.39093, &quot;lng&quot;: -72.85954, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 26.35869, &quot;lng&quot;: -80.0831, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 29.65163, &quot;lng&quot;: -82.32483, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 39.76838, &quot;lng&quot;: -86.15804, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 42.48531, &quot;lng&quot;: -83.37716, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 44.02163, &quot;lng&quot;: -92.4699, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 41.25626, &quot;lng&quot;: -95.94043, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.71427, &quot;lng&quot;: -74.00597, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 41.4995, &quot;lng&quot;: -81.69541, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 39.95238, &quot;lng&quot;: -75.16362, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.44062, &quot;lng&quot;: -79.99589, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 36.16589, &quot;lng&quot;: -86.78444, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 29.76328, &quot;lng&quot;: -95.36327, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 47.65966, &quot;lng&quot;: -117.42908, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: -33.91938, &quot;lng&quot;: 150.92588, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: -33.80383, &quot;lng&quot;: 150.98768, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: -27.96724, &quot;lng&quot;: 153.39796, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: -37.814, &quot;lng&quot;: 144.96332, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 44.84124, &quot;lng&quot;: -0.58046, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 50.63391, &quot;lng&quot;: 3.05512, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 43.61093, &quot;lng&quot;: 3.87635, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 48.85341, &quot;lng&quot;: 2.3488, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 43.60426, &quot;lng&quot;: 1.44367, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 52.25965, &quot;lng&quot;: 12.92662, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 49.59099, &quot;lng&quot;: 11.00783, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 48.16196, &quot;lng&quot;: 12.17942, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 48.52266, &quot;lng&quot;: 9.05222, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 44.49381, &quot;lng&quot;: 11.33875, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 45.46427, &quot;lng&quot;: 9.18951, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 43.70853, &quot;lng&quot;: 10.4036, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.67545, &quot;lng&quot;: 14.79328, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 35.42291, &quot;lng&quot;: 136.76039, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 43.06667, &quot;lng&quot;: 141.35, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 38.26667, &quot;lng&quot;: 140.86667, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 37.92259, &quot;lng&quot;: 139.04125, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 35.6895, &quot;lng&quot;: 139.69171, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 37.566, &quot;lng&quot;: 126.9784, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 41.38879, &quot;lng&quot;: 2.15899, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.4165, &quot;lng&quot;: -3.70256, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 37.38283, &quot;lng&quot;: -5.97317, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 39.47391, &quot;lng&quot;: -0.37966, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 53.48771, &quot;lng&quot;: -2.29042, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 55.86515, &quot;lng&quot;: -4.25763, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 54.97328, &quot;lng&quot;: -1.61396, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 51.50853, &quot;lng&quot;: -0.12574, &quot;nct&quot;: &quot;NCT06706622&quot;, &quot;color&quot;: &quot;#c7de68&quot;, &quot;title&quot;: &quot;A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06706622&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 37.566, &quot;lng&quot;: 126.9784, &quot;nct&quot;: &quot;NCT04782284&quot;, &quot;color&quot;: &quot;#e7b7b0&quot;, &quot;title&quot;: &quot;Comprehensive Swallowing Rehabilitation in Patients With MSA&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Comprehensive swallowing rehabilitation; Swallowing education&quot;, &quot;sponsor&quot;: &quot;Seoul National University Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04782284&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 39.9075, &quot;lng&quot;: 116.39723, &quot;nct&quot;: &quot;NCT06765733&quot;, &quot;color&quot;: &quot;#47c5bb&quot;, &quot;title&quot;: &quot;The Study of Safety and Preliminary Efficacy of Aleeto in Patients With MultIple System Atrophy&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;EARLY_PHASE1&quot;], &quot;interventions&quot;: &quot;Aleeto&quot;, &quot;sponsor&quot;: &quot;Beijing Tiantan Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06765733&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 36.16589, &quot;lng&quot;: -86.78444, &quot;nct&quot;: &quot;NCT03482297&quot;, &quot;color&quot;: &quot;#730f78&quot;, &quot;title&quot;: &quot;Automated Abdominal Binder for Orthostatic Hypotension&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;, &quot;PHASE2&quot;], &quot;interventions&quot;: &quot;automated abdominal binder; Sham binder; Placebo; Midodrine&quot;, &quot;sponsor&quot;: &quot;Vanderbilt University Medical Center&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT03482297&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 36.16589, &quot;lng&quot;: -86.78444, &quot;nct&quot;: &quot;NCT02726711&quot;, &quot;color&quot;: &quot;#5fe124&quot;, &quot;title&quot;: &quot;Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;Trimethaphan; Placebo&quot;, &quot;sponsor&quot;: &quot;Vanderbilt University&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT02726711&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 43.60426, &quot;lng&quot;: 1.44367, &quot;nct&quot;: &quot;NCT05819957&quot;, &quot;color&quot;: &quot;#ef5a81&quot;, &quot;title&quot;: &quot;Therapeutic Education for Multiple System Atrophy (MSA) Patients and Their Caregivers&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Therapeutic Education Program (TEP)&quot;, &quot;sponsor&quot;: &quot;University Hospital, Toulouse&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05819957&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 33.70918, &quot;lng&quot;: -117.95367, &quot;nct&quot;: &quot;NCT05104476&quot;, &quot;color&quot;: &quot;#41c2c7&quot;, &quot;title&quot;: &quot;A Study of Lu AF82422 in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05104476&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 32.84727, &quot;lng&quot;: -117.2742, &quot;nct&quot;: &quot;NCT05104476&quot;, &quot;color&quot;: &quot;#41c2c7&quot;, &quot;title&quot;: &quot;A Study of Lu AF82422 in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05104476&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 37.77493, &quot;lng&quot;: -122.41942, &quot;nct&quot;: &quot;NCT05104476&quot;, &quot;color&quot;: &quot;#41c2c7&quot;, &quot;title&quot;: &quot;A Study of Lu AF82422 in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05104476&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 39.64777, &quot;lng&quot;: -104.98776, &quot;nct&quot;: &quot;NCT05104476&quot;, &quot;color&quot;: &quot;#41c2c7&quot;, &quot;title&quot;: &quot;A Study of Lu AF82422 in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05104476&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 26.35869, &quot;lng&quot;: -80.0831, &quot;nct&quot;: &quot;NCT05104476&quot;, &quot;color&quot;: &quot;#41c2c7&quot;, &quot;title&quot;: &quot;A Study of Lu AF82422 in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05104476&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 29.65163, &quot;lng&quot;: -82.32483, &quot;nct&quot;: &quot;NCT05104476&quot;, &quot;color&quot;: &quot;#41c2c7&quot;, &quot;title&quot;: &quot;A Study of Lu AF82422 in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05104476&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 41.85003, &quot;lng&quot;: -87.65005, &quot;nct&quot;: &quot;NCT05104476&quot;, &quot;color&quot;: &quot;#41c2c7&quot;, &quot;title&quot;: &quot;A Study of Lu AF82422 in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05104476&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 42.06975, &quot;lng&quot;: -87.78784, &quot;nct&quot;: &quot;NCT05104476&quot;, &quot;color&quot;: &quot;#41c2c7&quot;, &quot;title&quot;: &quot;A Study of Lu AF82422 in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05104476&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 42.35843, &quot;lng&quot;: -71.05977, &quot;nct&quot;: &quot;NCT05104476&quot;, &quot;color&quot;: &quot;#41c2c7&quot;, &quot;title&quot;: &quot;A Study of Lu AF82422 in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05104476&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 44.02163, &quot;lng&quot;: -92.4699, &quot;nct&quot;: &quot;NCT05104476&quot;, &quot;color&quot;: &quot;#41c2c7&quot;, &quot;title&quot;: &quot;A Study of Lu AF82422 in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05104476&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 41.25626, &quot;lng&quot;: -95.94043, &quot;nct&quot;: &quot;NCT05104476&quot;, &quot;color&quot;: &quot;#41c2c7&quot;, &quot;title&quot;: &quot;A Study of Lu AF82422 in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05104476&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.71427, &quot;lng&quot;: -74.00597, &quot;nct&quot;: &quot;NCT05104476&quot;, &quot;color&quot;: &quot;#41c2c7&quot;, &quot;title&quot;: &quot;A Study of Lu AF82422 in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05104476&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.28592, &quot;lng&quot;: -76.65025, &quot;nct&quot;: &quot;NCT05104476&quot;, &quot;color&quot;: &quot;#41c2c7&quot;, &quot;title&quot;: &quot;A Study of Lu AF82422 in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05104476&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 39.95238, &quot;lng&quot;: -75.16362, &quot;nct&quot;: &quot;NCT05104476&quot;, &quot;color&quot;: &quot;#41c2c7&quot;, &quot;title&quot;: &quot;A Study of Lu AF82422 in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05104476&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.44062, &quot;lng&quot;: -79.99589, &quot;nct&quot;: &quot;NCT05104476&quot;, &quot;color&quot;: &quot;#41c2c7&quot;, &quot;title&quot;: &quot;A Study of Lu AF82422 in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05104476&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 35.038, &quot;lng&quot;: 136.99931, &quot;nct&quot;: &quot;NCT05104476&quot;, &quot;color&quot;: &quot;#41c2c7&quot;, &quot;title&quot;: &quot;A Study of Lu AF82422 in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05104476&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 35.42291, &quot;lng&quot;: 136.76039, &quot;nct&quot;: &quot;NCT05104476&quot;, &quot;color&quot;: &quot;#41c2c7&quot;, &quot;title&quot;: &quot;A Study of Lu AF82422 in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05104476&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 38.26667, &quot;lng&quot;: 140.86667, &quot;nct&quot;: &quot;NCT05104476&quot;, &quot;color&quot;: &quot;#41c2c7&quot;, &quot;title&quot;: &quot;A Study of Lu AF82422 in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Lu AF82422; Placebo&quot;, &quot;sponsor&quot;: &quot;H. Lundbeck A/S&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05104476&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 51.50853, &quot;lng&quot;: -0.12574, &quot;nct&quot;: &quot;NCT06174948&quot;, &quot;color&quot;: &quot;#f43c26&quot;, &quot;title&quot;: &quot;The Use of the CUE1/CUE1+ in People With Parkinson&#x27;s Disease and Related Disorders&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;CUE1 non-invasive device; CUE1+ device active vs sham CUE1+ device&quot;, &quot;sponsor&quot;: &quot;Queen Mary University of London&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06174948&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 32.08088, &quot;lng&quot;: 34.78057, &quot;nct&quot;: &quot;NCT05698017&quot;, &quot;color&quot;: &quot;#977e8d&quot;, &quot;title&quot;: &quot;Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early to Moderate Stage Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;hOMSC300&quot;, &quot;sponsor&quot;: &quot;Cytora Ltd.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05698017&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 47.26266, &quot;lng&quot;: 11.39454, &quot;nct&quot;: &quot;NCT06072105&quot;, &quot;color&quot;: &quot;#849a48&quot;, &quot;title&quot;: &quot;Medical Decision Making in Multiple System Atrophy&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Telemedicine visits; Multidisciplinary, personalized symptomatic treatment&quot;, &quot;sponsor&quot;: &quot;Medical University Innsbruck&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06072105&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 32.84727, &quot;lng&quot;: -117.2742, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 34.05223, &quot;lng&quot;: -118.24368, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 38.89511, &quot;lng&quot;: -77.03637, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 26.35869, &quot;lng&quot;: -80.0831, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 27.94752, &quot;lng&quot;: -82.45843, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 41.85003, &quot;lng&quot;: -87.65005, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 39.11417, &quot;lng&quot;: -94.62746, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 42.35843, &quot;lng&quot;: -71.05977, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 42.48531, &quot;lng&quot;: -83.37716, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 44.02163, &quot;lng&quot;: -92.4699, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.71427, &quot;lng&quot;: -74.00597, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 35.99403, &quot;lng&quot;: -78.89862, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.28592, &quot;lng&quot;: -76.65025, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.44062, &quot;lng&quot;: -79.99589, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 38.80484, &quot;lng&quot;: -77.04692, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 47.65966, &quot;lng&quot;: -117.42908, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 44.84124, &quot;lng&quot;: -0.58046, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 43.29695, &quot;lng&quot;: 5.38107, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 48.83732, &quot;lng&quot;: 2.35823, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 43.60426, &quot;lng&quot;: 1.44367, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 52.25965, &quot;lng&quot;: 12.92662, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 51.05089, &quot;lng&quot;: 13.73832, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 51.22172, &quot;lng&quot;: 6.77616, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 51.31667, &quot;lng&quot;: 9.5, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 51.33962, &quot;lng&quot;: 12.37129, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 50.80904, &quot;lng&quot;: 8.77069, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 51.60698, &quot;lng&quot;: 13.31243, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 51.96236, &quot;lng&quot;: 7.62571, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 48.39841, &quot;lng&quot;: 9.99155, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 32.81303, &quot;lng&quot;: 34.99928, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 32.08088, &quot;lng&quot;: 34.78057, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 44.49381, &quot;lng&quot;: 11.33875, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 37.49223, &quot;lng&quot;: 15.07041, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 42.78235, &quot;lng&quot;: 12.59836, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 45.40797, &quot;lng&quot;: 11.88586, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 44.99364, &quot;lng&quot;: 11.10642, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.67545, &quot;lng&quot;: 14.79328, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 35.67452, &quot;lng&quot;: 139.48216, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 35.42291, &quot;lng&quot;: 136.76039, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 37.92259, &quot;lng&quot;: 139.04125, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 35.56707, &quot;lng&quot;: 139.24167, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 38.26667, &quot;lng&quot;: 140.86667, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 41.38879, &quot;lng&quot;: 2.15899, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 42.81687, &quot;lng&quot;: -1.64323, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 37.38283, &quot;lng&quot;: -5.97317, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 39.47391, &quot;lng&quot;: -0.37966, &quot;nct&quot;: &quot;NCT06568237&quot;, &quot;color&quot;: &quot;#7c3043&quot;, &quot;title&quot;: &quot;A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;TEV-56286; Placebo&quot;, &quot;sponsor&quot;: &quot;Teva Branded Pharmaceutical Products R&amp;D, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06568237&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 34.05223, &quot;lng&quot;: -118.24368, &quot;nct&quot;: &quot;NCT06848231&quot;, &quot;color&quot;: &quot;#bed2ec&quot;, &quot;title&quot;: &quot;A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;YA-101; Placebo&quot;, &quot;sponsor&quot;: &quot;Yoda Therapeutics Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06848231&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 42.35843, &quot;lng&quot;: -71.05977, &quot;nct&quot;: &quot;NCT06848231&quot;, &quot;color&quot;: &quot;#bed2ec&quot;, &quot;title&quot;: &quot;A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;YA-101; Placebo&quot;, &quot;sponsor&quot;: &quot;Yoda Therapeutics Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06848231&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 44.02163, &quot;lng&quot;: -92.4699, &quot;nct&quot;: &quot;NCT06848231&quot;, &quot;color&quot;: &quot;#bed2ec&quot;, &quot;title&quot;: &quot;A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;YA-101; Placebo&quot;, &quot;sponsor&quot;: &quot;Yoda Therapeutics Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06848231&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.71427, &quot;lng&quot;: -74.00597, &quot;nct&quot;: &quot;NCT06848231&quot;, &quot;color&quot;: &quot;#bed2ec&quot;, &quot;title&quot;: &quot;A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;YA-101; Placebo&quot;, &quot;sponsor&quot;: &quot;Yoda Therapeutics Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06848231&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 36.16589, &quot;lng&quot;: -86.78444, &quot;nct&quot;: &quot;NCT06848231&quot;, &quot;color&quot;: &quot;#bed2ec&quot;, &quot;title&quot;: &quot;A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;YA-101; Placebo&quot;, &quot;sponsor&quot;: &quot;Yoda Therapeutics Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06848231&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 29.76328, &quot;lng&quot;: -95.36327, &quot;nct&quot;: &quot;NCT06848231&quot;, &quot;color&quot;: &quot;#bed2ec&quot;, &quot;title&quot;: &quot;A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;YA-101; Placebo&quot;, &quot;sponsor&quot;: &quot;Yoda Therapeutics Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06848231&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 35.6895, &quot;lng&quot;: 139.69171, &quot;nct&quot;: &quot;NCT06848231&quot;, &quot;color&quot;: &quot;#bed2ec&quot;, &quot;title&quot;: &quot;A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;YA-101; Placebo&quot;, &quot;sponsor&quot;: &quot;Yoda Therapeutics Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06848231&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 25.05306, &quot;lng&quot;: 121.52639, &quot;nct&quot;: &quot;NCT06848231&quot;, &quot;color&quot;: &quot;#bed2ec&quot;, &quot;title&quot;: &quot;A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;YA-101; Placebo&quot;, &quot;sponsor&quot;: &quot;Yoda Therapeutics Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06848231&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 46.516, &quot;lng&quot;: 6.63282, &quot;nct&quot;: &quot;NCT06920134&quot;, &quot;color&quot;: &quot;#d93152&quot;, &quot;title&quot;: &quot;Epidural Electrical Stimulation to Support Hemodynamic Management in Individuals With Parkinson&#x27;s Disease&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;ARC-IM Investigational System&quot;, &quot;sponsor&quot;: &quot;Ecole Polytechnique F\\u00e9d\\u00e9rale de Lausanne&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06920134&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 42.37787, &quot;lng&quot;: -71.062, &quot;nct&quot;: &quot;NCT06098612&quot;, &quot;color&quot;: &quot;#e9e57c&quot;, &quot;title&quot;: &quot;PET Imaging Evaluation of [11C]SY08&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;EARLY_PHASE1&quot;], &quot;interventions&quot;: &quot;C11-SY08&quot;, &quot;sponsor&quot;: &quot;Massachusetts General Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06098612&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 49.24966, &quot;lng&quot;: -123.11934, &quot;nct&quot;: &quot;NCT06838637&quot;, &quot;color&quot;: &quot;#7bd798&quot;, &quot;title&quot;: &quot;Transcutaneous Spinal Cord Stimulation Home Study&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Spinal COrd NEuromodulation (\\&quot;SCONE\\&quot;) Device&quot;, &quot;sponsor&quot;: &quot;Michael Berger&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06838637&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 33.70918, &quot;lng&quot;: -117.95367, &quot;nct&quot;: &quot;NCT05923866&quot;, &quot;color&quot;: &quot;#192075&quot;, &quot;title&quot;: &quot;A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;ONO-2808; Placebo&quot;, &quot;sponsor&quot;: &quot;Ono Pharmaceutical Co. Ltd&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05923866&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 34.05223, &quot;lng&quot;: -118.24368, &quot;nct&quot;: &quot;NCT05923866&quot;, &quot;color&quot;: &quot;#192075&quot;, &quot;title&quot;: &quot;A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;ONO-2808; Placebo&quot;, &quot;sponsor&quot;: &quot;Ono Pharmaceutical Co. Ltd&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05923866&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 37.44188, &quot;lng&quot;: -122.14302, &quot;nct&quot;: &quot;NCT05923866&quot;, &quot;color&quot;: &quot;#192075&quot;, &quot;title&quot;: &quot;A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;ONO-2808; Placebo&quot;, &quot;sponsor&quot;: &quot;Ono Pharmaceutical Co. Ltd&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05923866&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 39.64777, &quot;lng&quot;: -104.98776, &quot;nct&quot;: &quot;NCT05923866&quot;, &quot;color&quot;: &quot;#192075&quot;, &quot;title&quot;: &quot;A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;ONO-2808; Placebo&quot;, &quot;sponsor&quot;: &quot;Ono Pharmaceutical Co. Ltd&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05923866&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 41.30815, &quot;lng&quot;: -72.92816, &quot;nct&quot;: &quot;NCT05923866&quot;, &quot;color&quot;: &quot;#192075&quot;, &quot;title&quot;: &quot;A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;ONO-2808; Placebo&quot;, &quot;sponsor&quot;: &quot;Ono Pharmaceutical Co. Ltd&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05923866&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 26.35869, &quot;lng&quot;: -80.0831, &quot;nct&quot;: &quot;NCT05923866&quot;, &quot;color&quot;: &quot;#192075&quot;, &quot;title&quot;: &quot;A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;ONO-2808; Placebo&quot;, &quot;sponsor&quot;: &quot;Ono Pharmaceutical Co. Ltd&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05923866&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 29.65163, &quot;lng&quot;: -82.32483, &quot;nct&quot;: &quot;NCT05923866&quot;, &quot;color&quot;: &quot;#192075&quot;, &quot;title&quot;: &quot;A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;ONO-2808; Placebo&quot;, &quot;sponsor&quot;: &quot;Ono Pharmaceutical Co. Ltd&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05923866&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 30.33218, &quot;lng&quot;: -81.65565, &quot;nct&quot;: &quot;NCT05923866&quot;, &quot;color&quot;: &quot;#192075&quot;, &quot;title&quot;: &quot;A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;ONO-2808; Placebo&quot;, &quot;sponsor&quot;: &quot;Ono Pharmaceutical Co. Ltd&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05923866&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 25.77427, &quot;lng&quot;: -80.19366, &quot;nct&quot;: &quot;NCT05923866&quot;, &quot;color&quot;: &quot;#192075&quot;, &quot;title&quot;: &quot;A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;ONO-2808; Placebo&quot;, &quot;sponsor&quot;: &quot;Ono Pharmaceutical Co. Ltd&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05923866&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 33.749, &quot;lng&quot;: -84.38798, &quot;nct&quot;: &quot;NCT05923866&quot;, &quot;color&quot;: &quot;#192075&quot;, &quot;title&quot;: &quot;A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;ONO-2808; Placebo&quot;, &quot;sponsor&quot;: &quot;Ono Pharmaceutical Co. Ltd&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05923866&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 39.11417, &quot;lng&quot;: -94.62746, &quot;nct&quot;: &quot;NCT05923866&quot;, &quot;color&quot;: &quot;#192075&quot;, &quot;title&quot;: &quot;A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;ONO-2808; Placebo&quot;, &quot;sponsor&quot;: &quot;Ono Pharmaceutical Co. Ltd&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05923866&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 42.35843, &quot;lng&quot;: -71.05977, &quot;nct&quot;: &quot;NCT05923866&quot;, &quot;color&quot;: &quot;#192075&quot;, &quot;title&quot;: &quot;A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;ONO-2808; Placebo&quot;, &quot;sponsor&quot;: &quot;Ono Pharmaceutical Co. Ltd&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05923866&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 42.27756, &quot;lng&quot;: -83.74088, &quot;nct&quot;: &quot;NCT05923866&quot;, &quot;color&quot;: &quot;#192075&quot;, &quot;title&quot;: &quot;A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;ONO-2808; Placebo&quot;, &quot;sponsor&quot;: &quot;Ono Pharmaceutical Co. Ltd&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05923866&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 42.48531, &quot;lng&quot;: -83.37716, &quot;nct&quot;: &quot;NCT05923866&quot;, &quot;color&quot;: &quot;#192075&quot;, &quot;title&quot;: &quot;A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;ONO-2808; Placebo&quot;, &quot;sponsor&quot;: &quot;Ono Pharmaceutical Co. Ltd&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05923866&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 44.02163, &quot;lng&quot;: -92.4699, &quot;nct&quot;: &quot;NCT05923866&quot;, &quot;color&quot;: &quot;#192075&quot;, &quot;title&quot;: &quot;A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;ONO-2808; Placebo&quot;, &quot;sponsor&quot;: &quot;Ono Pharmaceutical Co. Ltd&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05923866&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 41.25626, &quot;lng&quot;: -95.94043, &quot;nct&quot;: &quot;NCT05923866&quot;, &quot;color&quot;: &quot;#192075&quot;, &quot;title&quot;: &quot;A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;ONO-2808; Placebo&quot;, &quot;sponsor&quot;: &quot;Ono Pharmaceutical Co. Ltd&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05923866&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.71427, &quot;lng&quot;: -74.00597, &quot;nct&quot;: &quot;NCT05923866&quot;, &quot;color&quot;: &quot;#192075&quot;, &quot;title&quot;: &quot;A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;ONO-2808; Placebo&quot;, &quot;sponsor&quot;: &quot;Ono Pharmaceutical Co. Ltd&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05923866&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 39.12711, &quot;lng&quot;: -84.51439, &quot;nct&quot;: &quot;NCT05923866&quot;, &quot;color&quot;: &quot;#192075&quot;, &quot;title&quot;: &quot;A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;ONO-2808; Placebo&quot;, &quot;sponsor&quot;: &quot;Ono Pharmaceutical Co. Ltd&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05923866&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 41.4995, &quot;lng&quot;: -81.69541, &quot;nct&quot;: &quot;NCT05923866&quot;, &quot;color&quot;: &quot;#192075&quot;, &quot;title&quot;: &quot;A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;ONO-2808; Placebo&quot;, &quot;sponsor&quot;: &quot;Ono Pharmaceutical Co. Ltd&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05923866&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 39.96118, &quot;lng&quot;: -82.99879, &quot;nct&quot;: &quot;NCT05923866&quot;, &quot;color&quot;: &quot;#192075&quot;, &quot;title&quot;: &quot;A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;ONO-2808; Placebo&quot;, &quot;sponsor&quot;: &quot;Ono Pharmaceutical Co. Ltd&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05923866&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.28592, &quot;lng&quot;: -76.65025, &quot;nct&quot;: &quot;NCT05923866&quot;, &quot;color&quot;: &quot;#192075&quot;, &quot;title&quot;: &quot;A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;ONO-2808; Placebo&quot;, &quot;sponsor&quot;: &quot;Ono Pharmaceutical Co. Ltd&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05923866&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 39.95238, &quot;lng&quot;: -75.16362, &quot;nct&quot;: &quot;NCT05923866&quot;, &quot;color&quot;: &quot;#192075&quot;, &quot;title&quot;: &quot;A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;ONO-2808; Placebo&quot;, &quot;sponsor&quot;: &quot;Ono Pharmaceutical Co. Ltd&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05923866&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 32.78306, &quot;lng&quot;: -96.80667, &quot;nct&quot;: &quot;NCT05923866&quot;, &quot;color&quot;: &quot;#192075&quot;, &quot;title&quot;: &quot;A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;ONO-2808; Placebo&quot;, &quot;sponsor&quot;: &quot;Ono Pharmaceutical Co. Ltd&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05923866&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 37.55376, &quot;lng&quot;: -77.46026, &quot;nct&quot;: &quot;NCT05923866&quot;, &quot;color&quot;: &quot;#192075&quot;, &quot;title&quot;: &quot;A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;ONO-2808; Placebo&quot;, &quot;sponsor&quot;: &quot;Ono Pharmaceutical Co. Ltd&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05923866&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 47.68149, &quot;lng&quot;: -122.20874, &quot;nct&quot;: &quot;NCT05923866&quot;, &quot;color&quot;: &quot;#192075&quot;, &quot;title&quot;: &quot;A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;ONO-2808; Placebo&quot;, &quot;sponsor&quot;: &quot;Ono Pharmaceutical Co. Ltd&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05923866&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 47.60621, &quot;lng&quot;: -122.33207, &quot;nct&quot;: &quot;NCT05923866&quot;, &quot;color&quot;: &quot;#192075&quot;, &quot;title&quot;: &quot;A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;ONO-2808; Placebo&quot;, &quot;sponsor&quot;: &quot;Ono Pharmaceutical Co. Ltd&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05923866&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 35.038, &quot;lng&quot;: 136.99931, &quot;nct&quot;: &quot;NCT05923866&quot;, &quot;color&quot;: &quot;#192075&quot;, &quot;title&quot;: &quot;A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;ONO-2808; Placebo&quot;, &quot;sponsor&quot;: &quot;Ono Pharmaceutical Co. Ltd&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05923866&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 38.26667, &quot;lng&quot;: 140.86667, &quot;nct&quot;: &quot;NCT05923866&quot;, &quot;color&quot;: &quot;#192075&quot;, &quot;title&quot;: &quot;A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;ONO-2808; Placebo&quot;, &quot;sponsor&quot;: &quot;Ono Pharmaceutical Co. Ltd&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05923866&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 34.78244, &quot;lng&quot;: 135.46932, &quot;nct&quot;: &quot;NCT05923866&quot;, &quot;color&quot;: &quot;#192075&quot;, &quot;title&quot;: &quot;A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;ONO-2808; Placebo&quot;, &quot;sponsor&quot;: &quot;Ono Pharmaceutical Co. Ltd&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05923866&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 35.67452, &quot;lng&quot;: 139.48216, &quot;nct&quot;: &quot;NCT05923866&quot;, &quot;color&quot;: &quot;#192075&quot;, &quot;title&quot;: &quot;A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;ONO-2808; Placebo&quot;, &quot;sponsor&quot;: &quot;Ono Pharmaceutical Co. Ltd&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05923866&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 35.02107, &quot;lng&quot;: 135.75385, &quot;nct&quot;: &quot;NCT05923866&quot;, &quot;color&quot;: &quot;#192075&quot;, &quot;title&quot;: &quot;A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;ONO-2808; Placebo&quot;, &quot;sponsor&quot;: &quot;Ono Pharmaceutical Co. Ltd&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05923866&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 33.50921, &quot;lng&quot;: -111.89903, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 33.70918, &quot;lng&quot;: -117.95367, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 32.84727, &quot;lng&quot;: -117.2742, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 34.05223, &quot;lng&quot;: -118.24368, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 37.44188, &quot;lng&quot;: -122.14302, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 38.89511, &quot;lng&quot;: -77.03637, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 26.35869, &quot;lng&quot;: -80.0831, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 26.14234, &quot;lng&quot;: -81.79596, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 26.97617, &quot;lng&quot;: -82.09064, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 27.94752, &quot;lng&quot;: -82.45843, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 33.749, &quot;lng&quot;: -84.38798, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 21.30694, &quot;lng&quot;: -157.85833, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 41.85003, &quot;lng&quot;: -87.65005, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 42.06975, &quot;lng&quot;: -87.78784, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 39.11417, &quot;lng&quot;: -94.62746, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 42.35843, &quot;lng&quot;: -71.05977, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 42.26259, &quot;lng&quot;: -71.80229, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 42.48531, &quot;lng&quot;: -83.37716, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.71427, &quot;lng&quot;: -74.00597, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 39.12711, &quot;lng&quot;: -84.51439, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 36.16589, &quot;lng&quot;: -86.78444, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 32.78306, &quot;lng&quot;: -96.80667, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 29.76328, &quot;lng&quot;: -95.36327, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.76078, &quot;lng&quot;: -111.89105, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: -32.88946, &quot;lng&quot;: -68.84582, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: -37.91667, &quot;lng&quot;: 145.11667, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: -37.814, &quot;lng&quot;: 144.96332, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: -37.78333, &quot;lng&quot;: 144.95, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 47.26266, &quot;lng&quot;: 11.39454, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 48.32829, &quot;lng&quot;: 16.05858, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: -25.42778, &quot;lng&quot;: -49.27306, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: -19.92083, &quot;lng&quot;: -43.93778, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: -30.03283, &quot;lng&quot;: -51.23019, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 51.05011, &quot;lng&quot;: -114.08529, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 55.67594, &quot;lng&quot;: 12.56553, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 59.43696, &quot;lng&quot;: 24.75353, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 58.38062, &quot;lng&quot;: 26.72509, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 43.83665, &quot;lng&quot;: 4.35788, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 44.84124, &quot;lng&quot;: -0.58046, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 43.60426, &quot;lng&quot;: 1.44367, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 50.88029, &quot;lng&quot;: 12.08187, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 52.52437, &quot;lng&quot;: 13.41053, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 47.49835, &quot;lng&quot;: 19.04045, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 32.08088, &quot;lng&quot;: 34.78057, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 44.49381, &quot;lng&quot;: 11.33875, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 42.78235, &quot;lng&quot;: 12.59836, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 41.89193, &quot;lng&quot;: 12.51133, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.67545, &quot;lng&quot;: 14.79328, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 42.56335, &quot;lng&quot;: 12.64329, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 46.06787, &quot;lng&quot;: 11.12108, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 39.93018, &quot;lng&quot;: 18.35421, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: -36.86029, &quot;lng&quot;: 174.76566, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: -43.53333, &quot;lng&quot;: 172.63333, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 54.35227, &quot;lng&quot;: 18.64912, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 50.2597, &quot;lng&quot;: 19.02173, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 50.06143, &quot;lng&quot;: 19.93658, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 50.03437, &quot;lng&quot;: 19.21037, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 39.09109, &quot;lng&quot;: -9.2586, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 44.80401, &quot;lng&quot;: 20.46513, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 41.56667, &quot;lng&quot;: 2.01667, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 43.29639, &quot;lng&quot;: -2.98813, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 40.4165, &quot;lng&quot;: -3.70256, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 25.05306, &quot;lng&quot;: 121.52639, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 52.48142, &quot;lng&quot;: -1.89983, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 51.50853, &quot;lng&quot;: -0.12574, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 53.48771, &quot;lng&quot;: -2.29042, &quot;nct&quot;: &quot;NCT05696717&quot;, &quot;color&quot;: &quot;#0ab456&quot;, &quot;title&quot;: &quot;Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy&quot;, &quot;status&quot;: &quot;ACTIVE_NOT_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE3&quot;], &quot;interventions&quot;: &quot;Ampreloxetine; Placebo&quot;, &quot;sponsor&quot;: &quot;Theravance Biopharma&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05696717&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 36.16589, &quot;lng&quot;: -86.78444, &quot;nct&quot;: &quot;NCT02429557&quot;, &quot;color&quot;: &quot;#b9cbf8&quot;, &quot;title&quot;: &quot;Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;Abdominal compression; Sham abdominal compression; Placebo pill; midodrine&quot;, &quot;sponsor&quot;: &quot;Vanderbilt University Medical Center&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT02429557&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 34.75778, &quot;lng&quot;: 113.64861, &quot;nct&quot;: &quot;NCT06671236&quot;, &quot;color&quot;: &quot;#80a43a&quot;, &quot;title&quot;: &quot;Clinical Study of Regulatory T Cells (Tregs) in the Treatment of Neurodegenerative Diseases&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;Autologous Human Polyclonal Regulatory T Cells Injection (NP001 Cell Injection)&quot;, &quot;sponsor&quot;: &quot;Novabio Therapeutics&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06671236&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 42.35843, &quot;lng&quot;: -71.05977, &quot;nct&quot;: &quot;NCT06868628&quot;, &quot;color&quot;: &quot;#3e036e&quot;, &quot;title&quot;: &quot;A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)&quot;, &quot;status&quot;: &quot;NOT_YET_RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Foralumab Nasal&quot;, &quot;sponsor&quot;: &quot;Brigham and Women&#x27;s Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06868628&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 44.02163, &quot;lng&quot;: -92.4699, &quot;nct&quot;: &quot;NCT05167721&quot;, &quot;color&quot;: &quot;#2c0648&quot;, &quot;title&quot;: &quot;Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Autologous Mesenchymal Stem Cells; Placebo&quot;, &quot;sponsor&quot;: &quot;Mayo Clinic&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05167721&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 44.84124, &quot;lng&quot;: -0.58046, &quot;nct&quot;: &quot;NCT04250493&quot;, &quot;color&quot;: &quot;#cc7f36&quot;, &quot;title&quot;: &quot;Insulin Resistance in Multiple System Atrophy&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Homeostasis Model Assessment of insulin resistance (HOMA); MOntreal Cognitive Assessment (MoCA); Clinical characteristics of AMS patients; Brain Magnetic Resonance Imaging (MRI); Blood sampling&quot;, &quot;sponsor&quot;: &quot;University Hospital, Bordeaux&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04250493&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 51.75222, &quot;lng&quot;: -1.25596, &quot;nct&quot;: &quot;NCT05197816&quot;, &quot;color&quot;: &quot;#b7e49f&quot;, &quot;title&quot;: &quot;MotIoN aDaptive Deep Brain Stimulation for MSA&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Deep brain stimulation&quot;, &quot;sponsor&quot;: &quot;University of Oxford&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT05197816&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 36.16589, &quot;lng&quot;: -86.78444, &quot;nct&quot;: &quot;NCT04782830&quot;, &quot;color&quot;: &quot;#c469f9&quot;, &quot;title&quot;: &quot;Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;NA&quot;], &quot;interventions&quot;: &quot;Accelerometer; placebo pill; Midodrine or atomoxetine pill&quot;, &quot;sponsor&quot;: &quot;Vanderbilt University Medical Center&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04782830&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 59.91273, &quot;lng&quot;: 10.74609, &quot;nct&quot;: &quot;NCT06162013&quot;, &quot;color&quot;: &quot;#0bd023&quot;, &quot;title&quot;: &quot;The NADAPT Study: a Randomized Double-blind Trial of NAD Replenishment Therapy for Atypical Parkinsonism&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Nicotinamide Riboside; Placebo&quot;, &quot;sponsor&quot;: &quot;Haukeland University Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06162013&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 60.39299, &quot;lng&quot;: 5.32415, &quot;nct&quot;: &quot;NCT06162013&quot;, &quot;color&quot;: &quot;#0bd023&quot;, &quot;title&quot;: &quot;The NADAPT Study: a Randomized Double-blind Trial of NAD Replenishment Therapy for Atypical Parkinsonism&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Nicotinamide Riboside; Placebo&quot;, &quot;sponsor&quot;: &quot;Haukeland University Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06162013&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 59.74389, &quot;lng&quot;: 10.20449, &quot;nct&quot;: &quot;NCT06162013&quot;, &quot;color&quot;: &quot;#0bd023&quot;, &quot;title&quot;: &quot;The NADAPT Study: a Randomized Double-blind Trial of NAD Replenishment Therapy for Atypical Parkinsonism&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE2&quot;], &quot;interventions&quot;: &quot;Nicotinamide Riboside; Placebo&quot;, &quot;sponsor&quot;: &quot;Haukeland University Hospital&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06162013&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 47.26266, &quot;lng&quot;: 11.39454, &quot;nct&quot;: &quot;NCT04165486&quot;, &quot;color&quot;: &quot;#7deb26&quot;, &quot;title&quot;: &quot;Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;ION464; Placebo&quot;, &quot;sponsor&quot;: &quot;Ionis Pharmaceuticals, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04165486&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 45.74906, &quot;lng&quot;: 4.84789, &quot;nct&quot;: &quot;NCT04165486&quot;, &quot;color&quot;: &quot;#7deb26&quot;, &quot;title&quot;: &quot;Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;ION464; Placebo&quot;, &quot;sponsor&quot;: &quot;Ionis Pharmaceuticals, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04165486&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 48.85341, &quot;lng&quot;: 2.3488, &quot;nct&quot;: &quot;NCT04165486&quot;, &quot;color&quot;: &quot;#7deb26&quot;, &quot;title&quot;: &quot;Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;ION464; Placebo&quot;, &quot;sponsor&quot;: &quot;Ionis Pharmaceuticals, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04165486&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 43.60426, &quot;lng&quot;: 1.44367, &quot;nct&quot;: &quot;NCT04165486&quot;, &quot;color&quot;: &quot;#7deb26&quot;, &quot;title&quot;: &quot;Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;ION464; Placebo&quot;, &quot;sponsor&quot;: &quot;Ionis Pharmaceuticals, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04165486&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 48.39841, &quot;lng&quot;: 9.99155, &quot;nct&quot;: &quot;NCT04165486&quot;, &quot;color&quot;: &quot;#7deb26&quot;, &quot;title&quot;: &quot;Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;ION464; Placebo&quot;, &quot;sponsor&quot;: &quot;Ionis Pharmaceuticals, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04165486&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 51.22172, &quot;lng&quot;: 6.77616, &quot;nct&quot;: &quot;NCT04165486&quot;, &quot;color&quot;: &quot;#7deb26&quot;, &quot;title&quot;: &quot;Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;ION464; Placebo&quot;, &quot;sponsor&quot;: &quot;Ionis Pharmaceuticals, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04165486&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 52.37052, &quot;lng&quot;: 9.73322, &quot;nct&quot;: &quot;NCT04165486&quot;, &quot;color&quot;: &quot;#7deb26&quot;, &quot;title&quot;: &quot;Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;ION464; Placebo&quot;, &quot;sponsor&quot;: &quot;Ionis Pharmaceuticals, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04165486&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 50.80904, &quot;lng&quot;: 8.77069, &quot;nct&quot;: &quot;NCT04165486&quot;, &quot;color&quot;: &quot;#7deb26&quot;, &quot;title&quot;: &quot;Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;ION464; Placebo&quot;, &quot;sponsor&quot;: &quot;Ionis Pharmaceuticals, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04165486&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 51.60698, &quot;lng&quot;: 13.31243, &quot;nct&quot;: &quot;NCT04165486&quot;, &quot;color&quot;: &quot;#7deb26&quot;, &quot;title&quot;: &quot;Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;ION464; Placebo&quot;, &quot;sponsor&quot;: &quot;Ionis Pharmaceuticals, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04165486&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 38.83091, &quot;lng&quot;: -9.16845, &quot;nct&quot;: &quot;NCT04165486&quot;, &quot;color&quot;: &quot;#7deb26&quot;, &quot;title&quot;: &quot;Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;ION464; Placebo&quot;, &quot;sponsor&quot;: &quot;Ionis Pharmaceuticals, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04165486&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 51.50853, &quot;lng&quot;: -0.12574, &quot;nct&quot;: &quot;NCT04165486&quot;, &quot;color&quot;: &quot;#7deb26&quot;, &quot;title&quot;: &quot;Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;ION464; Placebo&quot;, &quot;sponsor&quot;: &quot;Ionis Pharmaceuticals, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04165486&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 51.75222, &quot;lng&quot;: -1.25596, &quot;nct&quot;: &quot;NCT04165486&quot;, &quot;color&quot;: &quot;#7deb26&quot;, &quot;title&quot;: &quot;Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;ION464; Placebo&quot;, &quot;sponsor&quot;: &quot;Ionis Pharmaceuticals, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04165486&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 53.48771, &quot;lng&quot;: -2.29042, &quot;nct&quot;: &quot;NCT04165486&quot;, &quot;color&quot;: &quot;#7deb26&quot;, &quot;title&quot;: &quot;Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;ION464; Placebo&quot;, &quot;sponsor&quot;: &quot;Ionis Pharmaceuticals, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04165486&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 50.90395, &quot;lng&quot;: -1.40428, &quot;nct&quot;: &quot;NCT04165486&quot;, &quot;color&quot;: &quot;#7deb26&quot;, &quot;title&quot;: &quot;Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;ION464; Placebo&quot;, &quot;sponsor&quot;: &quot;Ionis Pharmaceuticals, Inc.&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT04165486&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}, {&quot;lat&quot;: 37.98869, &quot;lng&quot;: -84.47772, &quot;nct&quot;: &quot;NCT06683365&quot;, &quot;color&quot;: &quot;#6542b0&quot;, &quot;title&quot;: &quot;Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies&quot;, &quot;status&quot;: &quot;RECRUITING&quot;, &quot;phases&quot;: [&quot;PHASE1&quot;], &quot;interventions&quot;: &quot;Sural Nerve Graft to the Substantia Nigra; Sham surgery&quot;, &quot;sponsor&quot;: &quot;Craig van Horne, MD, PhD&quot;, &quot;address&quot;: &quot;&quot;, &quot;url&quot;: &quot;https://clinicaltrials.gov/study/NCT06683365&quot;, &quot;diseases&quot;: [&quot;Multiple System Atrophy&quot;]}];  // array of points with all needed meta\n",
       "\n",
       "      function initWhenReady(tries){\n",
       "        var map = window[MAP_NAME];\n",
       "        if (!map || !map.getContainer) {\n",
       "          if ((tries||0) &lt; 200) return setTimeout(function(){initWhenReady((tries||0)+1)}, 50);\n",
       "          return;\n",
       "        }\n",
       "\n",
       "        // Panel into map\n",
       "        var panel = document.getElementById(&#x27;nct-panel&#x27;);\n",
       "        var mapContainer = map.getContainer();\n",
       "        if (panel.parentNode !== mapContainer) mapContainer.appendChild(panel);\n",
       "\n",
       "        // Build cluster group &amp; markers (in JS, so we fully control them)\n",
       "        var clusterGroup = L.markerClusterGroup();\n",
       "        map.addLayer(clusterGroup);\n",
       "\n",
       "        // Build marker registry\n",
       "        var MARKERS = []; // each: { marker, nct, lat, lng, diseases, color }\n",
       "        DATA.forEach(function(p){\n",
       "          var m = L.circleMarker([p.lat, p.lng], {\n",
       "            radius: 6, color: p.color, fillColor: p.color, fillOpacity: 0.85\n",
       "          });\n",
       "          var phases = (p.phases || []).join(&#x27;, &#x27;);\n",
       "          var html = &#x27;&lt;b&gt;&#x27; + (p.title||&#x27;&#x27;) + &#x27;&lt;/b&gt;&lt;br&gt;&#x27;\n",
       "                   + &#x27;NCT: &lt;a href=&quot;&#x27; + (p.url||&#x27;#&#x27;) + &#x27;&quot; target=&quot;_blank&quot;&gt;&#x27; + p.nct + &#x27;&lt;/a&gt;&lt;br&gt;&#x27;\n",
       "                   + &#x27;Status: &#x27; + (p.status||&#x27;&#x27;) + &#x27; | Phase: &#x27; + (phases||&#x27;&#x27;) + &#x27;&lt;br&gt;&#x27;\n",
       "                   + &#x27;Interventions: &#x27; + (p.interventions||&#x27;n/a&#x27;) + &#x27;&lt;br&gt;&#x27;\n",
       "                   + &#x27;Sponsor: &#x27; + (p.sponsor||&#x27;—&#x27;) + &#x27;&lt;br&gt;&#x27;\n",
       "                   + (p.address||&#x27;&#x27;);\n",
       "          m.bindPopup(html, {maxWidth:350});\n",
       "          MARKERS.push({ marker:m, nct:p.nct, lat:p.lat, lng:p.lng, diseases:(p.diseases||[]), color:p.color });\n",
       "        });\n",
       "\n",
       "        // Add all markers initially\n",
       "        MARKERS.forEach(function(r){ clusterGroup.addLayer(r.marker); });\n",
       "\n",
       "        // ==== Disease selection UI ====\n",
       "        // Universe of diseases\n",
       "        var ALL_DISEASES = [];\n",
       "        (function(){\n",
       "          var seen = new Set();\n",
       "          DATA.forEach(function(p){\n",
       "            (p.diseases||[]).forEach(function(d){ if(!seen.has(d)){seen.add(d); ALL_DISEASES.push(d);} });\n",
       "          });\n",
       "          ALL_DISEASES.sort();\n",
       "        })();\n",
       "        var sel = new Set(ALL_DISEASES);\n",
       "\n",
       "        // Checkboxes\n",
       "        var df = document.getElementById(&#x27;disease-filters&#x27;);\n",
       "        df.innerHTML = &#x27;&#x27;;\n",
       "        ALL_DISEASES.forEach(function(d){\n",
       "          var id = &#x27;dchk_&#x27; + d.replace(/\\W+/g,&#x27;_&#x27;);\n",
       "          var label = document.createElement(&#x27;label&#x27;);\n",
       "          label.innerHTML = &#x27;&lt;input type=&quot;checkbox&quot; id=&quot;&#x27;+id+&#x27;&quot; &#x27;+(sel.has(d)?&#x27;checked&#x27;:&#x27;&#x27;)+&#x27;&gt; &#x27; + d;\n",
       "          df.appendChild(label);\n",
       "          label.querySelector(&#x27;input&#x27;).addEventListener(&#x27;change&#x27;, function(e){\n",
       "            if (e.target.checked) sel.add(d); else sel.delete(d);\n",
       "            applyMarkerFilter();\n",
       "            rerender(currentBounds());\n",
       "          });\n",
       "        });\n",
       "\n",
       "        // Presets\n",
       "        function setSelectionTo(listOrAll){\n",
       "          sel.clear();\n",
       "          if (listOrAll === &quot;ALL&quot;) ALL_DISEASES.forEach(function(d){ sel.add(d); });\n",
       "          else (listOrAll||[]).forEach(function(d){ sel.add(d); });\n",
       "          // sync UI\n",
       "          ALL_DISEASES.forEach(function(d){\n",
       "            var id = &#x27;dchk_&#x27; + d.replace(/\\W+/g,&#x27;_&#x27;);\n",
       "            var el = document.getElementById(id);\n",
       "            if (el) el.checked = sel.has(d);\n",
       "          });\n",
       "          applyMarkerFilter();\n",
       "          rerender(currentBounds());\n",
       "        }\n",
       "        document.querySelectorAll(&#x27;#nct-presets .preset&#x27;).forEach(function(btn){\n",
       "          btn.addEventListener(&#x27;click&#x27;, function(){\n",
       "            var val = btn.getAttribute(&#x27;data-diseases&#x27;);\n",
       "            if (val === &#x27;ALL&#x27;) return setSelectionTo(&#x27;ALL&#x27;);\n",
       "            try { setSelectionTo(JSON.parse(val)); } catch(e) {}\n",
       "          });\n",
       "        });\n",
       "\n",
       "        // ==== Filtering + chart logic ====\n",
       "        function markerIncluded(rec){\n",
       "          if (!ALL_DISEASES.length) return true; // single-disease mode\n",
       "          var ds = rec.diseases || [];\n",
       "          for (var i=0;i&lt;ds.length;i++) if (sel.has(ds[i])) return true;\n",
       "          return false;\n",
       "        }\n",
       "        function applyMarkerFilter(){\n",
       "          MARKERS.forEach(function(rec){\n",
       "            var has = clusterGroup.hasLayer(rec.marker);\n",
       "            var should = markerIncluded(rec);\n",
       "            if (should &amp;&amp; !has) clusterGroup.addLayer(rec.marker);\n",
       "            else if (!should &amp;&amp; has) clusterGroup.removeLayer(rec.marker);\n",
       "          });\n",
       "        }\n",
       "\n",
       "        function withinBounds(lat, lng, bounds) {\n",
       "          return bounds.contains(L.latLng(lat, lng));\n",
       "        }\n",
       "        function currentBounds(){\n",
       "          return map.getBounds ? map.getBounds() : L.latLngBounds([[-90,-180],[90,180]]);\n",
       "        }\n",
       "\n",
       "        function localCounts(bounds){\n",
       "          var counts = {};\n",
       "          MARKERS.forEach(function(r){\n",
       "            if (!markerIncluded(r)) return;\n",
       "            if (!bounds || withinBounds(r.lat, r.lng, bounds)) {\n",
       "              counts[r.nct] = (counts[r.nct]||0) + 1;\n",
       "            }\n",
       "          });\n",
       "          return counts;\n",
       "        }\n",
       "        function globalCountsSelected(){\n",
       "          var counts = {};\n",
       "          MARKERS.forEach(function(r){\n",
       "            if (!markerIncluded(r)) return;\n",
       "            counts[r.nct] = (counts[r.nct]||0) + 1;\n",
       "          });\n",
       "          return counts;\n",
       "        }\n",
       "\n",
       "        function renderBars(local){\n",
       "          var cont = document.getElementById(&#x27;nct-rows&#x27;);\n",
       "          cont.innerHTML = &#x27;&#x27;;\n",
       "          var globalSel = globalCountsSelected();\n",
       "\n",
       "          var keys = Object.keys(local);\n",
       "          if (!keys.length) {\n",
       "            cont.innerHTML = &#x27;&lt;div style=&quot;color:#666;font-size:12px;&quot;&gt;No sites in selection for chosen diseases.&lt;/div&gt;&#x27;;\n",
       "            return;\n",
       "          }\n",
       "\n",
       "          keys.sort(function(a,b){\n",
       "            if (local[b] !== local[a]) return local[b] - local[a];\n",
       "            return (globalSel[b]||0) - (globalSel[a]||0);\n",
       "          });\n",
       "\n",
       "          var maxG = 1;\n",
       "          keys.forEach(function(k){ maxG = Math.max(maxG, globalSel[k]||0); });\n",
       "          keys.forEach(function(nct){\n",
       "            var g = globalSel[nct] || 0;\n",
       "            var l = local[nct] || 0;\n",
       "            var rec = MARKERS.find(function(r){return r.nct===nct;});\n",
       "            var color = (rec &amp;&amp; rec.color) ? rec.color : &#x27;#888&#x27;;\n",
       "            var gPct = Math.max(4, Math.round(100 * g / (maxG||1)));\n",
       "            var lPct = Math.min(gPct, Math.round(gPct * (l / (g||1))));\n",
       "\n",
       "            var row = document.createElement(&#x27;div&#x27;); row.className = &#x27;bar-row&#x27;;\n",
       "\n",
       "            var label = document.createElement(&#x27;div&#x27;); label.className = &#x27;bar-label&#x27;;\n",
       "            label.textContent = nct;\n",
       "            var any = DATA.find(function(p){return p.nct===nct;});\n",
       "            label.title = (any &amp;&amp; any.interventions) ? any.interventions : &#x27;Intervention: n/a&#x27;;\n",
       "\n",
       "            var track = document.createElement(&#x27;div&#x27;); track.className = &#x27;bar-track&#x27;;\n",
       "            track.title = label.title;\n",
       "\n",
       "            var gdiv = document.createElement(&#x27;div&#x27;); gdiv.className=&#x27;bar-global&#x27;;\n",
       "            gdiv.style.width = gPct + &#x27;%&#x27;; gdiv.style.background = color;\n",
       "            var ldiv = document.createElement(&#x27;div&#x27;); ldiv.className=&#x27;bar-local&#x27;;\n",
       "            ldiv.style.width = lPct + &#x27;%&#x27;; ldiv.style.background = color;\n",
       "\n",
       "            var cnt = document.createElement(&#x27;div&#x27;); cnt.className=&#x27;bar-count&#x27;;\n",
       "            cnt.textContent = l + &#x27; / &#x27; + g;\n",
       "\n",
       "            track.appendChild(gdiv); track.appendChild(ldiv);\n",
       "            row.appendChild(label); row.appendChild(track); row.appendChild(cnt);\n",
       "            cont.appendChild(row);\n",
       "          });\n",
       "        }\n",
       "\n",
       "        function rerender(bounds){ renderBars(localCounts(bounds)); }\n",
       "\n",
       "        // Initial sync\n",
       "        applyMarkerFilter();\n",
       "        rerender(L.latLngBounds([[-90,-180],[90,180]]));\n",
       "\n",
       "        // Cluster click → render for that area\n",
       "        clusterGroup.on(&#x27;clusterclick&#x27;, function(e){\n",
       "          rerender(e.layer.getBounds());\n",
       "        });\n",
       "      }\n",
       "      initWhenReady(0);\n",
       "    })();\n",
       "    &lt;/script&gt;\n",
       "    \n",
       "    \n",
       "            &lt;div class=&quot;folium-map&quot; id=&quot;map_0a345331d60a7f95c66cb029a2f6d1e5&quot; &gt;&lt;/div&gt;\n",
       "        \n",
       "&lt;/body&gt;\n",
       "&lt;script&gt;\n",
       "    \n",
       "    \n",
       "            var map_0a345331d60a7f95c66cb029a2f6d1e5 = L.map(\n",
       "                &quot;map_0a345331d60a7f95c66cb029a2f6d1e5&quot;,\n",
       "                {\n",
       "                    center: [20.0, 0.0],\n",
       "                    crs: L.CRS.EPSG3857,\n",
       "                    ...{\n",
       "  &quot;zoom&quot;: 2,\n",
       "  &quot;zoomControl&quot;: true,\n",
       "  &quot;preferCanvas&quot;: false,\n",
       "}\n",
       "\n",
       "                }\n",
       "            );\n",
       "\n",
       "            \n",
       "\n",
       "        \n",
       "    \n",
       "            var tile_layer_800fc8a703d2c15e402338c13f5deaa3 = L.tileLayer(\n",
       "                &quot;https://tile.openstreetmap.org/{z}/{x}/{y}.png&quot;,\n",
       "                {\n",
       "  &quot;minZoom&quot;: 0,\n",
       "  &quot;maxZoom&quot;: 19,\n",
       "  &quot;maxNativeZoom&quot;: 19,\n",
       "  &quot;noWrap&quot;: false,\n",
       "  &quot;attribution&quot;: &quot;\\u0026copy; \\u003ca href=\\&quot;https://www.openstreetmap.org/copyright\\&quot;\\u003eOpenStreetMap\\u003c/a\\u003e contributors&quot;,\n",
       "  &quot;subdomains&quot;: &quot;abc&quot;,\n",
       "  &quot;detectRetina&quot;: false,\n",
       "  &quot;tms&quot;: false,\n",
       "  &quot;opacity&quot;: 1,\n",
       "}\n",
       "\n",
       "            );\n",
       "        \n",
       "    \n",
       "            tile_layer_800fc8a703d2c15e402338c13f5deaa3.addTo(map_0a345331d60a7f95c66cb029a2f6d1e5);\n",
       "        \n",
       "    \n",
       "            var marker_cluster_41f2cb229976ba0f93c42bfa49306634 = L.markerClusterGroup(\n",
       "                {\n",
       "}\n",
       "            );\n",
       "        \n",
       "    \n",
       "            marker_cluster_41f2cb229976ba0f93c42bfa49306634.addTo(map_0a345331d60a7f95c66cb029a2f6d1e5);\n",
       "        \n",
       "    \n",
       "            tile_layer_800fc8a703d2c15e402338c13f5deaa3.addTo(map_0a345331d60a7f95c66cb029a2f6d1e5);\n",
       "        \n",
       "    \n",
       "            marker_cluster_41f2cb229976ba0f93c42bfa49306634.addTo(map_0a345331d60a7f95c66cb029a2f6d1e5);\n",
       "        \n",
       "&lt;/script&gt;\n",
       "&lt;/html&gt;\" style=\"position:absolute;width:100%;height:100%;left:0;top:0;border:none !important;\" allowfullscreen webkitallowfullscreen mozallowfullscreen></iframe></div></div>"
      ],
      "text/plain": [
       "<folium.folium.Map at 0x1d5f3c0c1f0>"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "m = make_map_with_cluster_chart(run_multi([\"Lewy Body Disease\", \"Parkinson Disease\", \"Multiple System Atrophy\"]), outfile=\"C:\\\\Users\\\\robin\\\\Programs\\\\Proteinopathy\\\\reveal.js\\\\trials_map.html\")\n",
    "m  # inline"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "8937f145-5528-4c61-afb4-6830d2e833fb",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(WindowsPath('synuc_trials_graph_data.json'),\n",
       " WindowsPath('C:/Users/robin/Programs/Proteinopathy/reveal.js/synuc_trials_graph.html'))"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "convert_and_render(\n",
    "    geojson_or_path=run_multi([\"Lewy Body Disease\", \"Parkinson Disease\", \"Multiple System Atrophy\"]),  # or pass a dict\n",
    "    out_json=\"synuc_trials_graph_data.json\",\n",
    "    out_html=\"C:\\\\Users\\\\robin\\\\Programs\\\\Proteinopathy\\\\reveal.js\\\\synuc_trials_graph.html\",\n",
    "    title=\"Synucleinopathies\"  # optional\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "8839ece4-8215-4a80-a91a-0ab93bceff2c",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.8"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
